PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"35690723","European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C.","J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x.","Sacco S","J Headache Pain","2022","2022/06/11","PMC9188162","","10.1186/s10194-022-01431-x"
"30681821","Migraine overview and summary of current and emerging treatment options","Peters GL.","Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34.","Peters GL","Am J Manag Care","2019","2019/01/26","","",""
"35027572","Migraine","Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg AMJM, Dodick DW.","Nat Rev Dis Primers. 2022 Jan 13;8(1):2. doi: 10.1038/s41572-021-00328-4.","Ferrari MD","Nat Rev Dis Primers","2022","2022/01/14","","","10.1038/s41572-021-00328-4"
"36454715","CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","Russo AF, Hay DL.","Physiol Rev. 2023 Apr 1;103(2):1565-1644. doi: 10.1152/physrev.00059.2021. Epub 2022 Dec 1.","Russo AF","Physiol Rev","2023","2022/12/01","PMC9988538","","10.1152/physrev.00059.2021"
"32003253","Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting","Wattiez AS, Sowers LP, Russo AF.","Expert Opin Ther Targets. 2020 Feb;24(2):91-100. doi: 10.1080/14728222.2020.1724285. Epub 2020 Feb 13.","Wattiez AS","Expert Opin Ther Targets","2020","2020/02/01","PMC7050542","NIHMS1561651","10.1080/14728222.2020.1724285"
"34160823","The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice","Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society.","Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23.","Ailani J","Headache","2021","2021/06/23","","","10.1111/head.14153"
"35456034","Role of Estrogens in Menstrual Migraine","Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C.","Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355.","Nappi RE","Cells","2022","2022/04/23","PMC9025552","","10.3390/cells11081355"
"33974014","Diagnosis and Management of Headache: A Review","Robbins MS.","JAMA. 2021 May 11;325(18):1874-1885. doi: 10.1001/jama.2021.1640.","Robbins MS","JAMA","2021","2021/05/11","","","10.1001/jama.2021.1640"
"28179394","Pathophysiology of Migraine: A Disorder of Sensory Processing","Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S.","Physiol Rev. 2017 Apr;97(2):553-622. doi: 10.1152/physrev.00034.2015.","Goadsby PJ","Physiol Rev","2017","2017/02/10","PMC5539409","","10.1152/physrev.00034.2015"
"36216384","Management of chronic migraine","Hovaguimian A, Roth J.","BMJ. 2022 Oct 10;379:e067670. doi: 10.1136/bmj-2021-067670.","Hovaguimian A","BMJ","2022","2022/10/10","","","10.1136/bmj-2021-067670"
"31847045","Migraine Aura: Pathophysiology, Mimics, and Treatment Options","Fraser CL, Hepschke JL, Jenkins B, Prasad S.","Semin Neurol. 2019 Dec;39(6):739-748. doi: 10.1055/s-0039-1700525. Epub 2019 Dec 17.","Fraser CL","Semin Neurol","2019","2019/12/18","","","10.1055/s-0039-1700525"
"37029836","Migraine: from pathophysiology to treatment","Puledda F, Silva EM, Suwanlaong K, Goadsby PJ.","J Neurol. 2023 Jul;270(7):3654-3666. doi: 10.1007/s00415-023-11706-1. Epub 2023 Apr 8.","Puledda F","J Neurol","2023","2023/04/08","PMC10267278","","10.1007/s00415-023-11706-1"
"30600979","Migraine Headache Prophylaxis","Ha H, Gonzalez A.","Am Fam Physician. 2019 Jan 1;99(1):17-24.","Ha H","Am Fam Physician","2019","2019/01/03","","",""
"36611935","Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data","Pavelic AR, Wöber C, Riederer F, Zebenholzer K.","Cells. 2022 Dec 29;12(1):143. doi: 10.3390/cells12010143.","Pavelic AR","Cells","2022","2023/01/08","PMC9819019","","10.3390/cells12010143"
"36044103","Vestibular Migraine","Beh SC.","Curr Neurol Neurosci Rep. 2022 Oct;22(10):601-609. doi: 10.1007/s11910-022-01222-6. Epub 2022 Aug 31.","Beh SC","Curr Neurol Neurosci Rep","2022","2022/08/31","","","10.1007/s11910-022-01222-6"
"32192818","Migraine Pathophysiology","Qubty W, Patniyot I.","Pediatr Neurol. 2020 Jun;107:1-6. doi: 10.1016/j.pediatrneurol.2019.12.014. Epub 2020 Feb 4.","Qubty W","Pediatr Neurol","2020","2020/03/21","","","10.1016/j.pediatrneurol.2019.12.014"
"34864754","Vestibular and auditory manifestations of migraine","Benjamin T, Gillard D, Abouzari M, Djalilian HR, Sharon JD.","Curr Opin Neurol. 2022 Feb 1;35(1):84-89. doi: 10.1097/WCO.0000000000001024.","Benjamin T","Curr Opin Neurol","2022","2021/12/05","PMC8755616","NIHMS1759790","10.1097/WCO.0000000000001024"
"36855951","Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P.","Cephalalgia. 2023 Apr;43(4):3331024231159366. doi: 10.1177/03331024231159366.","Haghdoost F","Cephalalgia","2023","2023/03/01","","","10.1177/03331024231159366"
"37278480","Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis","Sun W, Cheng H, Xia B, Liu X, Li Y, Wang X, Liu C.","Clin J Pain. 2023 Oct 1;39(10):560-569. doi: 10.1097/AJP.0000000000001136.","Sun W","Clin J Pain","2023","2023/06/06","","","10.1097/AJP.0000000000001136"
"30203180","The association between migraine and physical exercise","Amin FM, Aristeidou S, Baraldi C, Czapinska-Ciepiela EK, Ariadni DD, Di Lenola D, Fenech C, Kampouris K, Karagiorgis G, Braschinsky M, Linde M; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2018 Sep 10;19(1):83. doi: 10.1186/s10194-018-0902-y.","Amin FM","J Headache Pain","2018","2018/09/12","PMC6134860","","10.1186/s10194-018-0902-y"
"35679008","Sex and Gender Considerations in Episodic Migraine","Ahmad SR, Rosendale N.","Curr Pain Headache Rep. 2022 Jul;26(7):505-516. doi: 10.1007/s11916-022-01052-8. Epub 2022 Jun 9.","Ahmad SR","Curr Pain Headache Rep","2022","2022/06/09","PMC9325838","","10.1007/s11916-022-01052-8"
"36917235","Novel Migraine Treatments: A Review","George N, Tepper SJ.","J Oral Facial Pain Headache. 2023 Winter;37(1):25-32. doi: 10.11607/ofph.3163.","George N","J Oral Facial Pain Headache","2023","2023/03/14","PMC10586574","","10.11607/ofph.3163"
"36786548","Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis","Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC.","Cephalalgia. 2023 Mar;43(3):3331024231152169. doi: 10.1177/03331024231152169.","Messina R","Cephalalgia","2023","2023/02/14","","","10.1177/03331024231152169"
"34048395","Preventive Migraine Treatment","Burch R.","Continuum (Minneap Minn). 2021 Jun 1;27(3):613-632. doi: 10.1212/CON.0000000000000957.","Burch R","Continuum (Minneap Minn)","2021","2021/05/28","","","10.1212/CON.0000000000000957"
"36739335","Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine","Blair HA.","CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007/s40263-023-00988-8. Epub 2023 Feb 4.","Blair HA","CNS Drugs","2023","2023/02/04","PMC10299922","","10.1007/s40263-023-00988-8"
"37254581","A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine","Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R, Russo CV.","Headache. 2023 Jun;63(6):788-794. doi: 10.1111/head.14528. Epub 2023 May 31.","Saccà F","Headache","2023","2023/05/31","","","10.1111/head.14528"
"35190383","What is new in migraine management in children and young people?","Loh NR, Whitehouse WP, Howells R.","Arch Dis Child. 2022 Dec;107(12):1067-1072. doi: 10.1136/archdischild-2021-322373. Epub 2022 Feb 21.","Loh NR","Arch Dis Child","2022","2022/02/22","","","10.1136/archdischild-2021-322373"
"35659086","Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review","Sevivas H, Fresco P.","Eur J Med Res. 2022 Jun 4;27(1):86. doi: 10.1186/s40001-022-00716-w.","Sevivas H","Eur J Med Res","2022","2022/06/06","PMC9167529","","10.1186/s40001-022-00716-w"
"34633423","Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis","Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ.","JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544.","Yang CP","JAMA Netw Open","2021","2021/10/11","PMC8506232","","10.1001/jamanetworkopen.2021.28544"
"37679723","Calcitonin gene-related peptide causes migraine aura","Al-Khazali HM, Ashina H, Wiggers A, Rose K, Iljazi A, Christensen RH, Schytz HW, Amin FM, Ashina M.","J Headache Pain. 2023 Sep 7;24(1):124. doi: 10.1186/s10194-023-01656-4.","Al-Khazali HM","J Headache Pain","2023","2023/09/07","PMC10483878","","10.1186/s10194-023-01656-4"
"36754606","Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine","Giffin NJ.","Pract Neurol. 2023 Jun;23(3):200-207. doi: 10.1136/pn-2022-003592. Epub 2023 Feb 8.","Giffin NJ","Pract Neurol","2023","2023/02/08","","","10.1136/pn-2022-003592"
"35674078","Is calcitonin gene-related peptide a reliable biochemical marker of migraine?","Tesfay B, Karlsson WK, Moreno RD, Hay DL, Hougaard A.","Curr Opin Neurol. 2022 Jun 1;35(3):343-352. doi: 10.1097/WCO.0000000000001053.","Tesfay B","Curr Opin Neurol","2022","2022/06/08","","","10.1097/WCO.0000000000001053"
"36136557","Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches","Kępczyńska K, Domitrz I.","Toxins (Basel). 2022 Sep 5;14(9):619. doi: 10.3390/toxins14090619.","Kępczyńska K","Toxins (Basel)","2022","2022/09/22","PMC9501363","","10.3390/toxins14090619"
"25887765","Calcitonin gene-related peptide and migraine","Karsan N, Goadsby PJ.","Curr Opin Neurol. 2015 Jun;28(3):250-4. doi: 10.1097/WCO.0000000000000191.","Karsan N","Curr Opin Neurol","2015","2015/04/19","","","10.1097/WCO.0000000000000191"
"35066541","Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment","Dominguez-Moreno R, Do TP, Ashina M.","Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):225-231. doi: 10.1097/MED.0000000000000717.","Dominguez-Moreno R","Curr Opin Endocrinol Diabetes Obes","2022","2022/01/23","","","10.1097/MED.0000000000000717"
"37208596","The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis","Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, Reuter U, Uluduz D, Versijpt J, Zeraatkar D, Sacco S.","J Headache Pain. 2023 May 19;24(1):56. doi: 10.1186/s10194-023-01594-1.","Lampl C","J Headache Pain","2023","2023/05/19","PMC10197489","","10.1186/s10194-023-01594-1"
"30648737","Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine","Yuan H, White CS, Silberstein SD.","Clin Pharmacol Ther. 2019 May;105(5):1121-1129. doi: 10.1002/cpt.1356. Epub 2019 Mar 18.","Yuan H","Clin Pharmacol Ther","2019","2019/01/17","","","10.1002/cpt.1356"
"36759320","New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy","Lee MJ, Al-Karagholi MA, Reuter U.","Cephalalgia. 2023 Feb;43(2):3331024221146315. doi: 10.1177/03331024221146315.","Lee MJ","Cephalalgia","2023","2023/02/09","","","10.1177/03331024221146315"
"28234796","Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine","Ramón C, Cernuda-Morollón E, Pascual J.","Curr Opin Neurol. 2017 Jun;30(3):281-286. doi: 10.1097/WCO.0000000000000440.","Ramón C","Curr Opin Neurol","2017","2017/02/25","","","10.1097/WCO.0000000000000440"
"35682830","Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine","Fila M, Sobczuk A, Pawlowska E, Blasiak J.","Int J Mol Sci. 2022 May 30;23(11):6151. doi: 10.3390/ijms23116151.","Fila M","Int J Mol Sci","2022","2022/06/10","PMC9181031","","10.3390/ijms23116151"
"35578182","Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine","Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R.","J Headache Pain. 2022 May 16;23(1):56. doi: 10.1186/s10194-022-01415-x.","Driessen MT","J Headache Pain","2022","2022/05/16","PMC9109352","","10.1186/s10194-022-01415-x"
"33223077","Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine","Caronna E, Starling AJ.","Neurol Clin. 2021 Feb;39(1):1-19. doi: 10.1016/j.ncl.2020.09.001. Epub 2020 Nov 7.","Caronna E","Neurol Clin","2021","2020/11/23","","","10.1016/j.ncl.2020.09.001"
"36127137","Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review","Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, Vélez C, Ramajo AP, Abdrabboh A, Xu C, Rasmussen S, Tepper SJ.","Neurology. 2022 Nov 7;99(19):841-853. doi: 10.1212/WNL.0000000000201332.","Ailani J","Neurology","2022","2022/09/20","PMC9651456","","10.1212/WNL.0000000000201332"
"34003145","Biomarkers in Migraine","Yan BM, Gibson Depoy EM, Ahmad A, Nahas SJ.","Neurol India. 2021 Mar-Apr;69(Supplement):S17-S24. doi: 10.4103/0028-3886.315988.","Yan BM","Neurol India","2021","2021/05/18","","","10.4103/0028-3886.315988"
"36180824","A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine","Wu S, Ren X, Zhu C, Wang W, Zhang K, Li Z, Liu X, Wang Y.","J Headache Pain. 2022 Sep 30;23(1):128. doi: 10.1186/s10194-022-01496-8.","Wu S","J Headache Pain","2022","2022/09/30","PMC9524028","","10.1186/s10194-022-01496-8"
"34743579","Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial","Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M.","Cephalalgia. 2022 Feb;42(2):108-118. doi: 10.1177/03331024211053571. Epub 2021 Nov 7.","Reuter U","Cephalalgia","2022","2021/11/08","PMC8793299","","10.1177/03331024211053571"
"28240610","Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies","Mitsikostas DD, Reuter U.","Curr Opin Neurol. 2017 Jun;30(3):272-280. doi: 10.1097/WCO.0000000000000438.","Mitsikostas DD","Curr Opin Neurol","2017","2017/02/28","","","10.1097/WCO.0000000000000438"
"33322922","Hypersensitivity to calcitonin gene-related peptide in chronic migraine","Iljazi A, Ashina H, Zhuang ZA, Lopez Lopez C, Snellman J, Ashina M, Schytz HW.","Cephalalgia. 2021 May;41(6):701-710. doi: 10.1177/0333102420981666. Epub 2020 Dec 15.","Iljazi A","Cephalalgia","2021","2020/12/16","","","10.1177/0333102420981666"
"36513096","Prevention of Migraine","Holdridge A, Buczyner J, Aymat CC, Le A.","Semin Neurol. 2022 Oct;42(5):558-570. doi: 10.1055/s-0042-1758781. Epub 2022 Dec 13.","Holdridge A","Semin Neurol","2022","2022/12/13","","","10.1055/s-0042-1758781"
"36739516","Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies","de Boer I, Verhagen IE, Souza MNP, Ashina M.","Cephalalgia. 2023 Feb;43(2):3331024221143773. doi: 10.1177/03331024221143773.","de Boer I","Cephalalgia","2023","2023/02/05","","","10.1177/03331024221143773"
"34873692","The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice","Burch RC, Ailani J, Robbins MS.","Headache. 2022 Jan;62(1):111-112. doi: 10.1111/head.14245. Epub 2021 Dec 7.","Burch RC","Headache","2022","2021/12/07","","","10.1111/head.14245"
"32266704","Eptinezumab: First Approval","Dhillon S.","Drugs. 2020 May;80(7):733-739. doi: 10.1007/s40265-020-01300-4.","Dhillon S","Drugs","2020","2020/04/09","","","10.1007/s40265-020-01300-4"
"37665501","Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies","Ferreira VL, Mainka FF, Wiens A, Pontarolo R.","Clin Drug Investig. 2023 Sep;43(9):669-680. doi: 10.1007/s40261-023-01301-7. Epub 2023 Sep 4.","Ferreira VL","Clin Drug Investig","2023","2023/09/04","","","10.1007/s40261-023-01301-7"
"24638916","Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity","Bigal ME, Walter S.","CNS Drugs. 2014 May;28(5):389-99. doi: 10.1007/s40263-014-0156-4.","Bigal ME","CNS Drugs","2014","2014/03/19","","","10.1007/s40263-014-0156-4"
"37569575","Calcitonin Gene-Related Peptide-Mediated Trigeminal Ganglionitis: The Biomolecular Link between Temporomandibular Disorders and Chronic Headaches","Sangalli L, Eli B, Mehrotra S, Sabagh S, Fricton J.","Int J Mol Sci. 2023 Jul 30;24(15):12200. doi: 10.3390/ijms241512200.","Sangalli L","Int J Mol Sci","2023","2023/08/12","PMC10418780","","10.3390/ijms241512200"
"37528353","Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review","Schoenen J, Van Dycke A, Versijpt J, Paemeleire K.","J Headache Pain. 2023 Aug 1;24(1):99. doi: 10.1186/s10194-023-01637-7.","Schoenen J","J Headache Pain","2023","2023/08/01","PMC10391994","","10.1186/s10194-023-01637-7"
"35532284","Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice","Edvinsson L.","J Intern Med. 2022 Oct;292(4):575-586. doi: 10.1111/joim.13506. Epub 2022 May 19.","Edvinsson L","J Intern Med","2022","2022/05/09","PMC9546117","","10.1111/joim.13506"
"36255114","Serum Calcitonin Gene-Related Peptide Is Elevated in Patients With Migraine and Ophthalmoplegia","Takkar A, Kumar KVA, Katoch D, Singh P, Minz R, Anand S, Kathirvel S, Ravishankar K, Lal V, Caplan LR.","J Neuroophthalmol. 2023 Sep 1;43(3):399-405. doi: 10.1097/WNO.0000000000001695. Epub 2022 Oct 18.","Takkar A","J Neuroophthalmol","2023","2022/10/18","","","10.1097/WNO.0000000000001695"
"29848108","Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY.","Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.","Skljarevski V","Cephalalgia","2018","2018/06/01","","","10.1177/0333102418779543"
"34644203","Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study","Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L.","Cephalalgia. 2022 Apr;42(4-5):291-301. doi: 10.1177/03331024211048765. Epub 2021 Oct 13.","Overeem LH","Cephalalgia","2022","2021/10/13","PMC8988456","","10.1177/03331024211048765"
"35713436","Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review","Jiang Y, Huang ZL.","Medicine (Baltimore). 2022 Jun 17;101(24):e29361. doi: 10.1097/MD.0000000000029361.","Jiang Y","Medicine (Baltimore)","2022","2022/06/17","PMC9276107","","10.1097/MD.0000000000029361"
"28645128","[Headache News]","Diener HC, Gaul C, Holle-Lee D, Lazaridis L, Nägel S, Obermann M.","Fortschr Neurol Psychiatr. 2017 Jun;85(6):352-365. doi: 10.1055/s-0043-111118. Epub 2017 Jun 23.","Diener HC","Fortschr Neurol Psychiatr","2017","2017/06/24","","","10.1055/s-0043-111118"
"30409109","Migraine induction with calcitonin gene-related peptide in patients from erenumab trials","Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M.","J Headache Pain. 2018 Nov 8;19(1):105. doi: 10.1186/s10194-018-0927-2.","Christensen CE","J Headache Pain","2018","2018/11/10","PMC6755614","","10.1186/s10194-018-0927-2"
"36941533","Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies","Verhagen IE, de Vries Lentsch S, van der Arend BWH, le Cessie S, MaassenVanDenBrink A, Terwindt GM.","Eur J Neurol. 2023 Jul;30(7):2117-2121. doi: 10.1111/ene.15794. Epub 2023 Apr 6.","Verhagen IE","Eur J Neurol","2023","2023/03/21","","","10.1111/ene.15794"
"33008505","Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants","Chiang CC, Schwedt TJ.","Prog Brain Res. 2020;255:143-170. doi: 10.1016/bs.pbr.2020.06.019. Epub 2020 Jul 22.","Chiang CC","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.06.019"
"16927957","Calcitonin gene-related peptide (CGRP) and migraine","Durham PL.","Headache. 2006 Jun;46 Suppl 1(Suppl 1):S3-8. doi: 10.1111/j.1526-4610.2006.00483.x.","Durham PL","Headache","2006","2006/08/25","PMC3134175","NIHMS307460","10.1111/j.1526-4610.2006.00483.x"
"29987331","Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine","Gelfand AA, Goadsby PJ.","JAMA Neurol. 2018 Oct 1;75(10):1179-1180. doi: 10.1001/jamaneurol.2018.1428.","Gelfand AA","JAMA Neurol","2018","2018/07/11","","","10.1001/jamaneurol.2018.1428"
"30392545","Migraine Headache: Updates and Future Developments","Bohm PE, Stancampiano FF, Rozen TD.","Mayo Clin Proc. 2018 Nov;93(11):1648-1653. doi: 10.1016/j.mayocp.2018.09.006.","Bohm PE","Mayo Clin Proc","2018","2018/11/06","","","10.1016/j.mayocp.2018.09.006"
"34009094","Eptinezumab for the treatment of migraine","Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P.","Expert Opin Biol Ther. 2021 Aug;21(8):999-1011. doi: 10.1080/14712598.2021.1931678. Epub 2021 Jun 1.","Spuntarelli V","Expert Opin Biol Ther","2021","2021/05/19","","","10.1080/14712598.2021.1931678"
"35895308","Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?","Vural S, Albayrak L.","J Recept Signal Transduct Res. 2022 Dec;42(6):562-566. doi: 10.1080/10799893.2022.2097264. Epub 2022 Jul 27.","Vural S","J Recept Signal Transduct Res","2022","2022/07/27","","","10.1080/10799893.2022.2097264"
"37038303","Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome","Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Giné-Ciprés E, Pozo-Rosich P.","Eur J Neurol. 2023 Jul;30(7):1937-1944. doi: 10.1111/ene.15816. Epub 2023 Apr 26.","Torres-Ferrus M","Eur J Neurol","2023","2023/04/11","","","10.1111/ene.15816"
"30311143","From LBR-101 to Fremanezumab for Migraine","Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.","CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4.","Bigal ME","CNS Drugs","2018","2018/10/13","","","10.1007/s40263-018-0579-4"
"15464043","Calcitonin gene-related peptide and its role in migraine pathophysiology","Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR.","Eur J Pharmacol. 2004 Oct 1;500(1-3):315-30. doi: 10.1016/j.ejphar.2004.07.035.","Arulmani U","Eur J Pharmacol","2004","2004/10/07","","","10.1016/j.ejphar.2004.07.035"
"30950844","How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective","Torres-Ferrus M, Alpuente A, Pozo-Rosich P.","Curr Opin Neurol. 2019 Jun;32(3):395-404. doi: 10.1097/WCO.0000000000000689.","Torres-Ferrus M","Curr Opin Neurol","2019","2019/04/06","","","10.1097/WCO.0000000000000689"
"37062749","Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study","Ito Y, Mitsufuji T, Okada M, Fujita S, Yokoyama R, Kawasaki H, Yamamoto T.","Intern Med. 2023 Dec 1;62(23):3455-3460. doi: 10.2169/internalmedicine.1471-22. Epub 2023 Apr 14.","Ito Y","Intern Med","2023","2023/04/16","PMC10749820","","10.2169/internalmedicine.1471-22"
"31989282","Menstrual migraine: what it is and does it matter?","Cupini LM, Corbelli I, Sarchelli P.","J Neurol. 2021 Jul;268(7):2355-2363. doi: 10.1007/s00415-020-09726-2. Epub 2020 Jan 28.","Cupini LM","J Neurol","2021","2020/01/29","","","10.1007/s00415-020-09726-2"
"35505285","Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","Gérard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lantéri-Minet M, Drici MD.","J Headache Pain. 2022 May 3;23(1):53. doi: 10.1186/s10194-022-01424-w.","Gérard AO","J Headache Pain","2022","2022/05/03","PMC9066820","","10.1186/s10194-022-01424-w"
"16392873","Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches","Goadsby PJ.","Drugs. 2005;65(18):2557-67. doi: 10.2165/00003495-200565180-00002.","Goadsby PJ","Drugs","2005","2006/01/06","","","10.2165/00003495-200565180-00002"
"29616494","The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy","Raffaelli B, Reuter U.","Neurotherapeutics. 2018 Apr;15(2):324-335. doi: 10.1007/s13311-018-0622-7.","Raffaelli B","Neurotherapeutics","2018","2018/04/05","PMC5935651","","10.1007/s13311-018-0622-7"
"26898484","Calcitonin Gene-Related Peptide Targeted Therapy for Migraine","Tepper DE.","Headache. 2016 Feb;56(2):447-8. doi: 10.1111/head.12759. Epub 2016 Jan 27.","Tepper DE","Headache","2016","2016/02/23","","","10.1111/head.12759"
"27819404","[Calcitonin gene-related peptide: a key player neuropeptide in migraine]","Ramos-Romero ML, Sobrino-Mejia FE.","Rev Neurol. 2016 Nov 16;63(10):460-468.","Ramos-Romero ML","Rev Neurol","2016","2016/11/08","","",""
"28792865","Migraine","Charles A.","N Engl J Med. 2017 Aug 10;377(6):553-561. doi: 10.1056/NEJMcp1605502.","Charles A","N Engl J Med","2017","2017/08/10","","","10.1056/NEJMcp1605502"
"34003149","Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?","Nagaraj K, Vandenbussche N, Goadsby PJ.","Neurol India. 2021 Mar-Apr;69(Supplement):S59-S66. doi: 10.4103/0028-3886.315997.","Nagaraj K","Neurol India","2021","2021/05/18","","","10.4103/0028-3886.315997"
"18808507","Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine","Durham PL.","Headache. 2008 Sep;48(8):1269-75. doi: 10.1111/j.1526-4610.2008.01215.x.","Durham PL","Headache","2008","2008/09/24","PMC3137656","NIHMS304676","10.1111/j.1526-4610.2008.01215.x"
"30311219","The Future of Migraine Prevention","Cowan RP.","Headache. 2018 Nov;58 Suppl 3:291-297. doi: 10.1111/head.13418. Epub 2018 Oct 12.","Cowan RP","Headache","2018","2018/10/13","","","10.1111/head.13418"
"33799975","Migraine: Calcium Channels and Glia","Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J.","Int J Mol Sci. 2021 Mar 7;22(5):2688. doi: 10.3390/ijms22052688.","Kowalska M","Int J Mol Sci","2021","2021/04/03","PMC7962070","","10.3390/ijms22052688"
"35322292","Photophobia in headache disorders: characteristics and potential mechanisms","Wang Y, Wang S, Qiu T, Xiao Z.","J Neurol. 2022 Aug;269(8):4055-4067. doi: 10.1007/s00415-022-11080-4. Epub 2022 Mar 23.","Wang Y","J Neurol","2022","2022/03/24","","","10.1007/s00415-022-11080-4"
"36651532","Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial","Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM.","Headache. 2023 Jan;63(1):79-88. doi: 10.1111/head.14439. Epub 2023 Jan 18.","Ashina M","Headache","2023","2023/01/18","PMC10107835","","10.1111/head.14439"
"36792981","The sense of stopping migraine prophylaxis","Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A, Waliszewska-Prosół M, Reuter U; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2023 Feb 16;24(1):9. doi: 10.1186/s10194-023-01539-8.","Al-Hassany L","J Headache Pain","2023","2023/02/16","PMC9933401","","10.1186/s10194-023-01539-8"
"36226379","A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond","Garelja ML, Hay DL.","Headache. 2022 Oct;62(9):1093-1104. doi: 10.1111/head.14388. Epub 2022 Oct 13.","Garelja ML","Headache","2022","2022/10/13","PMC9613588","NIHMS1829811","10.1111/head.14388"
"27919795","Current and novel insights into the neurophysiology of migraine and its implications for therapeutics","Akerman S, Romero-Reyes M, Holland PR.","Pharmacol Ther. 2017 Apr;172:151-170. doi: 10.1016/j.pharmthera.2016.12.005. Epub 2016 Dec 2.","Akerman S","Pharmacol Ther","2017","2016/12/07","","","10.1016/j.pharmthera.2016.12.005"
"37656319","Update of Gepants in the Treatment of Chronic Migraine","Cho S, Kim BK.","Curr Pain Headache Rep. 2023 Oct;27(10):561-569. doi: 10.1007/s11916-023-01167-6. Epub 2023 Sep 1.","Cho S","Curr Pain Headache Rep","2023","2023/09/01","","","10.1007/s11916-023-01167-6"
"33280422","Eptinezumab for the preventive treatment of migraine","Villar-Martínez MD, Moreno-Ajona D, Goadsby PJ.","Pain Manag. 2021 Mar;11(2):113-121. doi: 10.2217/pmt-2020-0075. Epub 2020 Dec 7.","Villar-Martínez MD","Pain Manag","2021","2020/12/07","","","10.2217/pmt-2020-0075"
"30242519","Migraine and cluster headache - the common link","Vollesen AL, Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Ashina M, Lampl C; School of Advanced Studies of the European Headache Federation (EHF-SAS).","J Headache Pain. 2018 Sep 21;19(1):89. doi: 10.1186/s10194-018-0909-4.","Vollesen AL","J Headache Pain","2018","2018/09/23","PMC6755613","","10.1186/s10194-018-0909-4"
"31714319","Biochemical Modulation and Pathophysiology of Migraine","Chan C, Wei DY, Goadsby PJ.","J Neuroophthalmol. 2019 Dec;39(4):470-479. doi: 10.1097/WNO.0000000000000875.","Chan C","J Neuroophthalmol","2019","2019/11/13","","","10.1097/WNO.0000000000000875"
"30014208","Emerging Treatments in Episodic Migraine","Grimsrud KW, Halker Singh RB.","Curr Pain Headache Rep. 2018 Jul 16;22(9):61. doi: 10.1007/s11916-018-0716-2.","Grimsrud KW","Curr Pain Headache Rep","2018","2018/07/18","","","10.1007/s11916-018-0716-2"
"32419007","Emerging Treatment Options for Migraine","Zhao YJ, Ong JJY, Goadsby PJ.","Ann Acad Med Singap. 2020 Apr;49(4):226-235.","Zhao YJ","Ann Acad Med Singap","2020","2020/05/19","","",""
"35470321","Update on migraine management","Larkin L.","Menopause. 2022 May 1;29(5):606-608. doi: 10.1097/GME.0000000000001977.","Larkin L","Menopause","2022","2022/04/26","","","10.1097/GME.0000000000001977"
"36306631","Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome?","Suzuki S, Suzuki K, Shiina T, Kobayashi S, Hirata K.","J Neurol Sci. 2022 Dec 15;443:120462. doi: 10.1016/j.jns.2022.120462. Epub 2022 Oct 20.","Suzuki S","J Neurol Sci","2022","2022/10/28","","","10.1016/j.jns.2022.120462"
"35353359","CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects","Evers S.","Curr Pain Headache Rep. 2022 Jun;26(6):475-480. doi: 10.1007/s11916-022-01047-5. Epub 2022 Mar 30.","Evers S","Curr Pain Headache Rep","2022","2022/03/30","PMC9124163","","10.1007/s11916-022-01047-5"
"37366160","Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center","Danno D, Ishizaki K, Kikui S, Takeshima T.","Headache. 2023 Jul-Aug;63(7):984-989. doi: 10.1111/head.14591. Epub 2023 Jun 27.","Danno D","Headache","2023","2023/06/27","","","10.1111/head.14591"
"31686633","Novelty in Inflammation and Immunomodulation in Migraine","Cavestro C, Ferrero M, Mandrino S, Di Tavi M, Rota E.","Curr Pharm Des. 2019;25(27):2919-2936. doi: 10.2174/1381612825666190709204107.","Cavestro C","Curr Pharm Des","2019","2019/11/06","","","10.2174/1381612825666190709204107"
"36481434","Role of PACAP in migraine: An alternative to CGRP?","Guo S, Jansen-Olesen I, Olesen J, Christensen SL.","Neurobiol Dis. 2023 Jan;176:105946. doi: 10.1016/j.nbd.2022.105946. Epub 2022 Dec 5.","Guo S","Neurobiol Dis","2023","2022/12/08","","","10.1016/j.nbd.2022.105946"
"36018499","Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review","Marshall A, Lindsay R, Clementi MA, Gelfand AA, Orr SL.","Curr Neurol Neurosci Rep. 2022 Oct;22(10):611-624. doi: 10.1007/s11910-022-01224-4. Epub 2022 Aug 26.","Marshall A","Curr Neurol Neurosci Rep","2022","2022/08/26","","","10.1007/s11910-022-01224-4"
"32238377","Preventing migraine: The old and the new","Solomon GD.","Cleve Clin J Med. 2020 Apr;87(4):219-221. doi: 10.3949/ccjm.87a.19147.","Solomon GD","Cleve Clin J Med","2020","2020/04/03","","","10.3949/ccjm.87a.19147"
"32145209","Medications Approved for Preventing Migraine Headaches","Spindler BL, Ryan M.","Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.","Spindler BL","Am J Med","2020","2020/03/08","","","10.1016/j.amjmed.2020.01.031"
"19330286","Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review","Tfelt-Hansen P, Le H.","J Headache Pain. 2009 Jun;10(3):137-43. doi: 10.1007/s10194-009-0112-8. Epub 2009 Mar 28.","Tfelt-Hansen P","J Headache Pain","2009","2009/03/31","PMC3451987","","10.1007/s10194-009-0112-8"
"32337726","Gepants","Tepper D.","Headache. 2020 May;60(5):1037-1039. doi: 10.1111/head.13791.","Tepper D","Headache","2020","2020/04/28","","","10.1111/head.13791"
"32956223","Acute Care Treatment of Migraine","Konstantinos S, Vikelis M, Rapoport A.","J Neuroophthalmol. 2020 Dec;40(4):472-484. doi: 10.1097/WNO.0000000000001053.","Konstantinos S","J Neuroophthalmol","2020","2020/09/21","","","10.1097/WNO.0000000000001053"
"35263940","Targeting Calcitonin Gene Related Peptide (CGRP) in Prevention of Migraine: Is it Effective?","Singh A.","Neurol India. 2022 Jan-Feb;70(1):433-434. doi: 10.4103/0028-3886.338712.","Singh A","Neurol India","2022","2022/03/10","","","10.4103/0028-3886.338712"
"27146279","Hypoxic mechanisms in primary headaches","Britze J, Arngrim N, Schytz HW, Ashina M.","Cephalalgia. 2017 Apr;37(4):372-384. doi: 10.1177/0333102416647037. Epub 2016 May 4.","Britze J","Cephalalgia","2017","2016/05/06","","","10.1177/0333102416647037"
"31550937","Monoclonal antibodies for the prevention of migraine","Raffaelli B, Neeb L, Reuter U.","Expert Opin Biol Ther. 2019 Dec;19(12):1307-1317. doi: 10.1080/14712598.2019.1671350. Epub 2019 Oct 3.","Raffaelli B","Expert Opin Biol Ther","2019","2019/09/26","","","10.1080/14712598.2019.1671350"
"31563231","Preventive Treatment for Episodic Migraine","Parikh SK, Silberstein SD.","Neurol Clin. 2019 Nov;37(4):753-770. doi: 10.1016/j.ncl.2019.07.004. Epub 2019 Aug 22.","Parikh SK","Neurol Clin","2019","2019/09/30","","","10.1016/j.ncl.2019.07.004"
"26994300","Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine","Guo S, Christensen AF, Liu ML, Janjooa BN, Olesen J, Ashina M.","Cephalalgia. 2017 Feb;37(2):114-124. doi: 10.1177/0333102416639512. Epub 2016 Jul 11.","Guo S","Cephalalgia","2017","2016/03/20","","","10.1177/0333102416639512"
"32822633","Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial","Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A.","Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9.","Goadsby PJ","Lancet Neurol","2020","2020/08/22","","","10.1016/S1474-4422(20)30234-9"
"30058044","Photophobia: When Light Hurts, a Review","Albilali A, Dilli E.","Curr Neurol Neurosci Rep. 2018 Jul 30;18(9):62. doi: 10.1007/s11910-018-0864-0.","Albilali A","Curr Neurol Neurosci Rep","2018","2018/07/31","","","10.1007/s11910-018-0864-0"
"37605392","New Therapeutic Options for Migraine","Tana C, Cipollone F, Giamberardino MA.","Curr Pharm Des. 2023;29(25):1964-1966. doi: 10.2174/1381612829666230821092238.","Tana C","Curr Pharm Des","2023","2023/08/22","","","10.2174/1381612829666230821092238"
"38091211","Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study","Braca S, Miele A, Stornaiuolo A, Cretella G, De Simone R, Russo CV.","Neurol Sci. 2024 Apr;45(4):1655-1660. doi: 10.1007/s10072-023-07241-6. Epub 2023 Dec 13.","Braca S","Neurol Sci","2024","2023/12/13","","","10.1007/s10072-023-07241-6"
"35138589","Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling","Ashina H, Dodick DW.","Curr Neurol Neurosci Rep. 2022 Feb;22(2):105-111. doi: 10.1007/s11910-022-01175-w. Epub 2022 Feb 9.","Ashina H","Curr Neurol Neurosci Rep","2022","2022/02/09","","","10.1007/s11910-022-01175-w"
"37582724","Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration","Wang K, Fenton BT, Dao VX, Guirguis AB, Anthony SE, Skanderson M, Sico JJ.","J Headache Pain. 2023 Aug 15;24(1):108. doi: 10.1186/s10194-023-01640-y.","Wang K","J Headache Pain","2023","2023/08/15","PMC10426172","","10.1186/s10194-023-01640-y"
"37012858","Erenumab efficacy in migraine headache prophylaxis: A systematic review","Bagherzadeh-Fard M, Amin Yazdanifar M, Sadeghalvad M, Rezaei N.","Int Immunopharmacol. 2023 Apr;117:109366. doi: 10.1016/j.intimp.2022.109366. Epub 2023 Mar 9.","Bagherzadeh-Fard M","Int Immunopharmacol","2023","2023/04/04","","","10.1016/j.intimp.2022.109366"
"30625476","Prevalence of Migraine in the Elderly: A Narrated Review","Wijeratne T, Tang HM, Crewther D, Crewther S.","Neuroepidemiology. 2019;52(1-2):104-110. doi: 10.1159/000494758. Epub 2019 Jan 9.","Wijeratne T","Neuroepidemiology","2019","2019/01/10","","","10.1159/000494758"
"18413584","Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?","Goadsby PJ.","Neurology. 2008 Apr 15;70(16):1300-1. doi: 10.1212/01.wnl.0000309214.25038.fd.","Goadsby PJ","Neurology","2008","2008/04/17","","","10.1212/01.wnl.0000309214.25038.fd"
"37561313","Advances in the Acute and Preventive Treatment of Pediatric Migraine","Rastogi RG, Hastriter EV, Evans RL, Bassal F, Hickman C, Karnik KT, Little R, Lewis KS.","Curr Pain Headache Rep. 2023 Oct;27(10):521-529. doi: 10.1007/s11916-023-01157-8. Epub 2023 Aug 10.","Rastogi RG","Curr Pain Headache Rep","2023","2023/08/10","","","10.1007/s11916-023-01157-8"
"36668879","OnabotulinumtoxinA: Still the Present for Chronic Migraine","Baraldi C, Lo Castro F, Ornello R, Sacco S, Pani L, Guerzoni S.","Toxins (Basel). 2023 Jan 10;15(1):59. doi: 10.3390/toxins15010059.","Baraldi C","Toxins (Basel)","2023","2023/01/20","PMC9865956","","10.3390/toxins15010059"
"35353773","Transient receptor potential melastatin 8 is required for nitroglycerin- and calcitonin gene-related peptide-induced migraine-like pain behaviors in mice","Wei C, Kim B, McKemy DD.","Pain. 2022 Dec 1;163(12):2380-2389. doi: 10.1097/j.pain.0000000000002635. Epub 2022 Mar 29.","Wei C","Pain","2022","2022/03/30","PMC9519811","NIHMS1788186","10.1097/j.pain.0000000000002635"
"38307649","Treatment in the emergency department","Ling YH, Chowdhury D, Wang SJ.","Handb Clin Neurol. 2024;199:245-256. doi: 10.1016/B978-0-12-823357-3.00005-7.","Ling YH","Handb Clin Neurol","2024","2024/02/02","","","10.1016/B978-0-12-823357-3.00005-7"
"31684759","Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil","Younis S, Christensen CE, Toft NM, Søborg T, Amin FM, Hougaard A, Ashina M.","Cephalalgia. 2019 Dec;39(14):1776-1788. doi: 10.1177/0333102419882474. Epub 2019 Nov 4.","Younis S","Cephalalgia","2019","2019/11/06","","","10.1177/0333102419882474"
"35359298","Erster intravenöser Migräne-Antikörper zugelassen","Facharztmagazine R.","MMW Fortschr Med. 2022 Apr;164(Suppl 1):66. doi: 10.1007/s15006-022-1012-y.","Facharztmagazine R","MMW Fortschr Med","2022","2022/04/01","","","10.1007/s15006-022-1012-y"
"37561314","Serological Biomarkers of Chronic Migraine","Cho S, Chu MK.","Curr Pain Headache Rep. 2023 Oct;27(10):531-542. doi: 10.1007/s11916-023-01154-x. Epub 2023 Aug 10.","Cho S","Curr Pain Headache Rep","2023","2023/08/10","","","10.1007/s11916-023-01154-x"
"31393282","What's New in the Treatment of Migraine?","Digre KB.","J Neuroophthalmol. 2019 Sep;39(3):352-359. doi: 10.1097/WNO.0000000000000837.","Digre KB","J Neuroophthalmol","2019","2019/08/09","","","10.1097/WNO.0000000000000837"
"37543479","Calcitonin/PAC(1) receptor splice variants: a blind spot in migraine research","Rees TA, Labastida-Ramírez A, Rubio-Beltrán E.","Trends Pharmacol Sci. 2023 Oct;44(10):651-663. doi: 10.1016/j.tips.2023.07.003. Epub 2023 Aug 3.","Rees TA","Trends Pharmacol Sci","2023","2023/08/05","PMC10529278","NIHMS1922698","10.1016/j.tips.2023.07.003"
"28233915","CGRP and its receptors","Hay DL, Walker CS.","Headache. 2017 Apr;57(4):625-636. doi: 10.1111/head.13064. Epub 2017 Feb 24.","Hay DL","Headache","2017","2017/02/25","","","10.1111/head.13064"
"38215227","Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models","Rahman SM, Luebke AE.","Cephalalgia. 2024 Jan;44(1):3331024231223971. doi: 10.1177/03331024231223971.","Rahman SM","Cephalalgia","2024","2024/01/12","","","10.1177/03331024231223971"
"37345664","Migraine and cardiovascular disease: what cardiologists should know","Kalkman DN, Couturier EGM, El Bouziani A, Dahdal J, Neefs J, Woudstra J, Vogel B, Trabattoni D, MaassenVanDenBrink A, Mehran R, de Winter RJ, Appelman Y.","Eur Heart J. 2023 Aug 7;44(30):2815-2828. doi: 10.1093/eurheartj/ehad363.","Kalkman DN","Eur Heart J","2023","2023/06/22","","","10.1093/eurheartj/ehad363"
"31208068","Migraine: Experimental Models and Novel Therapeutic Approaches","Tardiolo G, Bramanti P, Mazzon E.","Int J Mol Sci. 2019 Jun 15;20(12):2932. doi: 10.3390/ijms20122932.","Tardiolo G","Int J Mol Sci","2019","2019/06/19","PMC6628212","","10.3390/ijms20122932"
"32988278","Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment","Blumenfeld AM.","J Prim Care Community Health. 2020 Jan-Dec;11:2150132720959935. doi: 10.1177/2150132720959935.","Blumenfeld AM","J Prim Care Community Health","2020","2020/09/29","PMC7536484","","10.1177/2150132720959935"
"27940880","CGRP in human models of primary headaches","Ashina H, Schytz HW, Ashina M.","Cephalalgia. 2018 Feb;38(2):353-360. doi: 10.1177/0333102416684344. Epub 2016 Dec 9.","Ashina H","Cephalalgia","2018","2016/12/13","","","10.1177/0333102416684344"
"32165029","Migraine and Sleep in Children: A Bidirectional Relationship","Pavkovic IM, Kothare SV.","Pediatr Neurol. 2020 Aug;109:20-27. doi: 10.1016/j.pediatrneurol.2019.12.013. Epub 2020 Feb 11.","Pavkovic IM","Pediatr Neurol","2020","2020/03/14","","","10.1016/j.pediatrneurol.2019.12.013"
"21457239","Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine","Hansen JM, Thomsen LL, Olesen J, Ashina M.","Headache. 2011 Apr;51(4):544-53. doi: 10.1111/j.1526-4610.2011.01861.x.","Hansen JM","Headache","2011","2011/04/05","","","10.1111/j.1526-4610.2011.01861.x"
"32241175","CGRP pathway monoclonal antibodies for cluster headache","Chan C, Goadsby PJ.","Expert Opin Biol Ther. 2020 Aug;20(8):947-953. doi: 10.1080/14712598.2020.1751114. Epub 2020 Apr 28.","Chan C","Expert Opin Biol Ther","2020","2020/04/04","","","10.1080/14712598.2020.1751114"
"28527063","The role of anti-CGRP antibodies in the pathophysiology of primary headaches","Barbanti P, Aurilia C, Fofi L, Egeo G, Ferroni P.","Neurol Sci. 2017 May;38(Suppl 1):31-35. doi: 10.1007/s10072-017-2907-8.","Barbanti P","Neurol Sci","2017","2017/05/21","","","10.1007/s10072-017-2907-8"
"35850597","Recently approved and emerging drug options for migraine prophylaxis","Bentivegna E, Luciani M, Ferrari V, Galastri S, Baldari F, Scarso F, Lamberti PA, Martelletti P.","Expert Opin Pharmacother. 2022 Aug;23(11):1325-1335. doi: 10.1080/14656566.2022.2102420. Epub 2022 Jul 25.","Bentivegna E","Expert Opin Pharmacother","2022","2022/07/19","","","10.1080/14656566.2022.2102420"
"37421480","Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine","Jinesh S.","Inflammopharmacology. 2023 Oct;31(5):2245-2251. doi: 10.1007/s10787-023-01276-z. Epub 2023 Jul 8.","Jinesh S","Inflammopharmacology","2023","2023/07/08","","","10.1007/s10787-023-01276-z"
"36018002","Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine","López-Bravo A, Oliveros-Cid A, Mínguez-Olaondo A, Cuadrado ML.","Headache. 2022 Sep;62(8):1063-1066. doi: 10.1111/head.14372. Epub 2022 Aug 26.","López-Bravo A","Headache","2022","2022/08/26","","","10.1111/head.14372"
"19236383","Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine","Fan PC, Kuo PH, Chang SH, Lee WT, Wu RM, Chiou LC.","Cephalalgia. 2009 Aug;29(8):883-90. doi: 10.1111/j.1468-2982.2008.01816.x. Epub 2009 Feb 19.","Fan PC","Cephalalgia","2009","2009/02/25","","","10.1111/j.1468-2982.2008.01816.x"
"37322195","CGRP aussichtsreichster Angriffspunkt für Migräneprophylaxe","Bublak R.","MMW Fortschr Med. 2023 Jun;165(12):18. doi: 10.1007/s15006-023-2792-4.","Bublak R","MMW Fortschr Med","2023","2023/06/15","","","10.1007/s15006-023-2792-4"
"33332483","Rimegepant for the treatment of migraine","Negro A, Martelletti P.","Drugs Today (Barc). 2020 Dec;56(12):769-780. doi: 10.1358/dot.2020.56.12.3211624.","Negro A","Drugs Today (Barc)","2020","2020/12/17","","","10.1358/dot.2020.56.12.3211624"
"23962310","Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies","Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A.","Expert Opin Drug Discov. 2013 Nov;8(11):1309-23. doi: 10.1517/17460441.2013.826644. Epub 2013 Aug 21.","Labruijere S","Expert Opin Drug Discov","2013","2013/08/22","","","10.1517/17460441.2013.826644"
"31291020","Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review","Yuan H, Spare NM, Silberstein SD.","Headache. 2019 Jul;59 Suppl 2:20-32. doi: 10.1111/head.13583.","Yuan H","Headache","2019","2019/07/11","","","10.1111/head.13583"
"34464833","Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis","Soni P, Chawla E.","Clin Neurol Neurosurg. 2021 Oct;209:106893. doi: 10.1016/j.clineuro.2021.106893. Epub 2021 Aug 13.","Soni P","Clin Neurol Neurosurg","2021","2021/08/31","","","10.1016/j.clineuro.2021.106893"
"23848170","Biomarkers associated with migraine and their potential role in migraine management","Durham P, Papapetropoulos S.","Headache. 2013 Sep;53(8):1262-77. doi: 10.1111/head.12174. Epub 2013 Jul 12.","Durham P","Headache","2013","2013/07/16","","","10.1111/head.12174"
"37104838","Prior authorization requirements for calcitonin gene-related peptide antagonists","Musial L, Kheloussi S.","Am J Manag Care. 2023 Apr 1;29(4):e117-e123. doi: 10.37765/ajmc.2023.89352.","Musial L","Am J Manag Care","2023","2023/04/27","","","10.37765/ajmc.2023.89352"
"36063264","Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review","Murray AM, Stern JI, Robertson CE, Chiang CC.","Curr Pain Headache Rep. 2022 Oct;26(10):783-794. doi: 10.1007/s11916-022-01077-z. Epub 2022 Sep 5.","Murray AM","Curr Pain Headache Rep","2022","2022/09/05","","","10.1007/s11916-022-01077-z"
"30866804","CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, Guglielmetti M, Koniari C, Mavridis T, Vaikjärv M, Verhagen I, Verzina A, Zick B, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2019 Mar 12;20(1):27. doi: 10.1186/s10194-019-0979-y.","Favoni V","J Headache Pain","2019","2019/03/15","PMC6734543","","10.1186/s10194-019-0979-y"
"35876297","Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States","Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R.","J Manag Care Spec Pharm. 2022 Aug;28(8):818-829. doi: 10.18553/jmcp.2022.28.8.818.","Varnado OJ","J Manag Care Spec Pharm","2022","2022/07/25","PMC10373045","","10.18553/jmcp.2022.28.8.818"
"32515018","Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis","Chan TLH, Cowan RP, Woldeamanuel YW.","Headache. 2020 Jul;60(7):1489-1499. doi: 10.1111/head.13858. Epub 2020 Jun 9.","Chan TLH","Headache","2020","2020/06/10","","","10.1111/head.13858"
"30906962","Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache","Rapoport AM, Edvinsson L.","Neurol Sci. 2019 May;40(Suppl 1):75-80. doi: 10.1007/s10072-019-03828-0.","Rapoport AM","Neurol Sci","2019","2019/03/26","","","10.1007/s10072-019-03828-0"
"29212383","Menstrual migraine: a review of current and developing pharmacotherapies for women","Allais G, Chiarle G, Sinigaglia S, Benedetto C.","Expert Opin Pharmacother. 2018 Feb;19(2):123-136. doi: 10.1080/14656566.2017.1414182. Epub 2017 Dec 12.","Allais G","Expert Opin Pharmacother","2018","2017/12/08","","","10.1080/14656566.2017.1414182"
"34580838","Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials","Yang CP, Zeng BY, Chang CM, Shih PH, Yang CC, Tseng PT, Wang SJ.","Neurotherapeutics. 2021 Oct;18(4):2639-2650. doi: 10.1007/s13311-021-01128-0. Epub 2021 Sep 27.","Yang CP","Neurotherapeutics","2021","2021/09/28","PMC8804075","","10.1007/s13311-021-01128-0"
"29116598","CGRP Monoclonal Antibodies for Migraine: Rationale and Progress","Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.","BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5.","Yuan H","BioDrugs","2017","2017/11/09","","","10.1007/s40259-017-0250-5"
"31181379","Are antimigraine drugs that influence CGRP levels justified?","Piechal A, Domitrz I, Kurkowska-Jastrzębska I, Mirowska-Guzel D.","Pharmacol Rep. 2019 Aug;71(4):624-635. doi: 10.1016/j.pharep.2019.03.002. Epub 2019 Mar 12.","Piechal A","Pharmacol Rep","2019","2019/06/11","","","10.1016/j.pharep.2019.03.002"
"33099721","Migraine neuroscience: from experimental models to target therapy","Greco R, Demartini C, De Icco R, Martinelli D, Putortì A, Tassorelli C.","Neurol Sci. 2020 Dec;41(Suppl 2):351-361. doi: 10.1007/s10072-020-04808-5.","Greco R","Neurol Sci","2020","2020/10/25","","","10.1007/s10072-020-04808-5"
"35725856","The ultimate guide to the anti-CGRP monoclonal antibodies galaxy","Mascarella D, Matteo E, Favoni V, Cevoli S.","Neurol Sci. 2022 Sep;43(9):5673-5685. doi: 10.1007/s10072-022-06199-1. Epub 2022 Jun 20.","Mascarella D","Neurol Sci","2022","2022/06/21","","","10.1007/s10072-022-06199-1"
"34761723","Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes","Foster SA, Hoyt M, Ye W, Mason O, Ford JH.","Curr Med Res Opin. 2022 May;38(5):653-660. doi: 10.1080/03007995.2021.2003127. Epub 2021 Dec 2.","Foster SA","Curr Med Res Opin","2022","2021/11/11","","","10.1080/03007995.2021.2003127"
"34714201","A rational approach to migraine diagnosis and management in primary care","Martin VT, Feoktistov A, Solomon GD.","Ann Med. 2021 Dec;53(1):1979-1990. doi: 10.1080/07853890.2021.1995626.","Martin VT","Ann Med","2021","2021/10/29","PMC8567924","","10.1080/07853890.2021.1995626"
"32103345","[Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache]","Meßlinger K.","Schmerz. 2020 Apr;34(2):181-187. doi: 10.1007/s00482-020-00448-y.","Meßlinger K","Schmerz","2020","2020/02/28","","","10.1007/s00482-020-00448-y"
"34076887","CGRP receptor antagonists for migraine. Are they also AMY(1) receptor antagonists?","Garelja ML, Walker CS, Hay DL.","Br J Pharmacol. 2022 Feb;179(3):454-459. doi: 10.1111/bph.15585. Epub 2021 Jun 24.","Garelja ML","Br J Pharmacol","2022","2021/06/02","","","10.1111/bph.15585"
"25790955","CGRP mechanism antagonists and migraine management","Karsan N, Goadsby PJ.","Curr Neurol Neurosci Rep. 2015 May;15(5):25. doi: 10.1007/s11910-015-0547-z.","Karsan N","Curr Neurol Neurosci Rep","2015","2015/03/21","","","10.1007/s11910-015-0547-z"
"37303034","The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics","Karlsson WK, Ashina H, Cullum CK, Christensen RH, Al-Khazali HM, Amin FM, Ashina M; REFORM Investigators.","J Headache Pain. 2023 Jun 12;24(1):70. doi: 10.1186/s10194-023-01604-2.","Karlsson WK","J Headache Pain","2023","2023/06/11","PMC10257973","","10.1186/s10194-023-01604-2"
"19434786","Calcitonin gene-related peptide: an update on the biology","Recober A, Russo AF.","Curr Opin Neurol. 2009 Jun;22(3):241-6. doi: 10.1097/wco.0b013e32832b2427.","Recober A","Curr Opin Neurol","2009","2009/05/13","PMC2844706","NIHMS186215","10.1097/wco.0b013e32832b2427"
"23839594","The pipeline in headache therapy","Vollbracht S, Rapoport AM.","CNS Drugs. 2013 Sep;27(9):717-29. doi: 10.1007/s40263-013-0090-x.","Vollbracht S","CNS Drugs","2013","2013/07/11","","","10.1007/s40263-013-0090-x"
"31328279","CGRP and Brain Functioning: Cautions for Migraine Treatment","Borkum JM.","Headache. 2019 Sep;59(8):1339-1357. doi: 10.1111/head.13591. Epub 2019 Jul 21.","Borkum JM","Headache","2019","2019/07/23","","","10.1111/head.13591"
"24725087","Disentangling the intricacies of migraine: a review","Girotra P, Singh SK, Saini D.","CNS Neurol Disord Drug Targets. 2014;13(5):776-91. doi: 10.2174/1871527313666140414120956.","Girotra P","CNS Neurol Disord Drug Targets","2014","2014/04/15","","","10.2174/1871527313666140414120956"
"25614243","Therapeutic antibodies against CGRP or its receptor","Bigal ME, Walter S, Rapoport AM.","Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591.","Bigal ME","Br J Clin Pharmacol","2015","2015/01/24","PMC4456121","","10.1111/bcp.12591"
"32116061","A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine","Parikh SK, Burkett JG, Silberstein SD.","Expert Opin Drug Saf. 2020 May;19(5):537-543. doi: 10.1080/14740338.2020.1737673. Epub 2020 Mar 9.","Parikh SK","Expert Opin Drug Saf","2020","2020/03/03","","","10.1080/14740338.2020.1737673"
"28321564","An update on migraine: current understanding and future directions","Puledda F, Messina R, Goadsby PJ.","J Neurol. 2017 Sep;264(9):2031-2039. doi: 10.1007/s00415-017-8434-y. Epub 2017 Mar 20.","Puledda F","J Neurol","2017","2017/03/22","PMC5587613","","10.1007/s00415-017-8434-y"
"33495027","Identifying New Antimigraine Targets: Lessons from Molecular Biology","Edvinsson L, Haanes KA.","Trends Pharmacol Sci. 2021 Apr;42(4):217-225. doi: 10.1016/j.tips.2021.01.002. Epub 2021 Jan 23.","Edvinsson L","Trends Pharmacol Sci","2021","2021/01/26","","","10.1016/j.tips.2021.01.002"
"35218478","Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments","Tsai CK, Tsai CL, Lin GY, Yang FC, Wang SJ.","Curr Pain Headache Rep. 2022 May;26(5):347-355. doi: 10.1007/s11916-022-01034-w. Epub 2022 Feb 26.","Tsai CK","Curr Pain Headache Rep","2022","2022/02/26","","","10.1007/s11916-022-01034-w"
"30681822","Burden of migraine and impact of emerging therapies on managed care","Rich SJ.","Am J Manag Care. 2019 Jan;25(2 Suppl):S35-S39.","Rich SJ","Am J Manag Care","2019","2019/01/26","","",""
"32578024","Recent Advances in the Management of Migraine in Older Patients","Soni PP, Lee M, Shadbehr N, Ahmed ZA.","Drugs Aging. 2020 Jul;37(7):463-468. doi: 10.1007/s40266-020-00776-9.","Soni PP","Drugs Aging","2020","2020/06/25","","","10.1007/s40266-020-00776-9"
"37438431","The 5-HT(1F) receptor as the target of ditans in migraine - from bench to bedside","Mitsikostas DD, Waeber C, Sanchez-Del-Rio M, Raffaelli B, Ashina H, Maassen van den Brink A, Andreou A, Pozo-Rosich P, Rapoport A, Ashina M, Moskowitz MA.","Nat Rev Neurol. 2023 Aug;19(8):489-505. doi: 10.1038/s41582-023-00842-x. Epub 2023 Jul 12.","Mitsikostas DD","Nat Rev Neurol","2023","2023/07/12","","","10.1038/s41582-023-00842-x"
"19402776","The triptans","Bigal ME, Krymchantowski AV, Hargreaves R.","Expert Rev Neurother. 2009 May;9(5):649-59. doi: 10.1586/ern.09.15.","Bigal ME","Expert Rev Neurother","2009","2009/05/01","","","10.1586/ern.09.15"
"28260603","The role of genetics on migraine induction triggered by CGRP and PACAP38","Guo S.","Dan Med J. 2017 Mar;64(3):B5351.","Guo S","Dan Med J","2017","2017/03/07","","",""
"22486257","Calcitonin gene-related peptide and size of the atrial septal defect in new-onset migraine after transcatheter closure: results of a preliminary study","Wei SH, Fan PC, Kuo PH, Chiou LC, Wang JK.","Headache. 2012 Jun;52(6):985-92. doi: 10.1111/j.1526-4610.2012.02152.x. Epub 2012 Apr 5.","Wei SH","Headache","2012","2012/04/11","","","10.1111/j.1526-4610.2012.02152.x"
"34586542","Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series","Iannone LF, Fattori D, Geppetti P, De Cesaris F.","Neurol Sci. 2022 Jan;43(1):697-703. doi: 10.1007/s10072-021-05624-1. Epub 2021 Sep 29.","Iannone LF","Neurol Sci","2022","2021/09/29","","","10.1007/s10072-021-05624-1"
"20173638","What have we learnt from triggering migraine?","Schytz HW, Schoonman GG, Ashina M.","Curr Opin Neurol. 2010 Jun;23(3):259-65. doi: 10.1097/WCO.0b013e328337b884.","Schytz HW","Curr Opin Neurol","2010","2010/02/23","","","10.1097/WCO.0b013e328337b884"
"35137404","Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations","Tepper SJ, Sheikh HU, Dougherty CO, Nahas SJ, Winner PK, Karanam AK, Blumenfeld AM, Abdrabboh A, Rasmussen S, Weiss JL, Ailani J.","Headache. 2022 Apr;62(4):420-435. doi: 10.1111/head.14266. Epub 2022 Feb 9.","Tepper SJ","Headache","2022","2022/02/09","","","10.1111/head.14266"
"32434430","Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives","De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S.","Expert Rev Neurother. 2020 Jun;20(6):627-641. doi: 10.1080/14737175.2020.1772758. Epub 2020 Jun 2.","De Matteis E","Expert Rev Neurother","2020","2020/05/22","","","10.1080/14737175.2020.1772758"
"21631474","Migraine genes and the relation to gender","Shyti R, de Vries B, van den Maagdenberg A.","Headache. 2011 Jun;51(6):880-90. doi: 10.1111/j.1526-4610.2011.01913.x.","Shyti R","Headache","2011","2011/06/03","","","10.1111/j.1526-4610.2011.01913.x"
"36843007","Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience","Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U.","J Headache Pain. 2023 Feb 27;24(1):16. doi: 10.1186/s10194-023-01552-x.","Raffaelli B","J Headache Pain","2023","2023/02/27","PMC9969617","","10.1186/s10194-023-01552-x"
"15237096","Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine","Brain SD.","Br J Pharmacol. 2004 Aug;142(7):1053-4. doi: 10.1038/sj.bjp.0705806. Epub 2004 Jul 5.","Brain SD","Br J Pharmacol","2004","2004/07/09","PMC1575173","","10.1038/sj.bjp.0705806"
"34521726","Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series","Briceño-Casado MDP, Gil-Sierra MD, De-La-Calle-Riaguas B.","Eur J Hosp Pharm. 2023 Jul;30(4):e19. doi: 10.1136/ejhpharm-2021-002946. Epub 2021 Sep 14.","Briceño-Casado MDP","Eur J Hosp Pharm","2023","2021/09/15","PMC10359803","","10.1136/ejhpharm-2021-002946"
"7828188","Neuropeptides in migraine and cluster headache","Edvinsson L, Goadsby PJ.","Cephalalgia. 1994 Oct;14(5):320-7. doi: 10.1046/j.1468-2982.1994.1405320.x.","Edvinsson L","Cephalalgia","1994","1994/10/01","","","10.1046/j.1468-2982.1994.1405320.x"
"35796521","Galcanezumab modulates Capsaicin-induced C-fiber reactivity","Basedau H, Oppermann T, Gundelwein Silva E, Peng KP, May A.","Cephalalgia. 2022 Nov;42(13):1331-1338. doi: 10.1177/03331024221112906. Epub 2022 Jul 7.","Basedau H","Cephalalgia","2022","2022/07/07","PMC9638712","","10.1177/03331024221112906"
"37962309","Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies","Dell Agnello G, Buzzoni C, Antenori A, Torelli F, Altamura C, Vernieri F.","Clin Neuropharmacol. 2023 Nov-Dec 01;46(6):220-228. doi: 10.1097/WNF.0000000000000571. Epub 2023 Sep 23.","Dell Agnello G","Clin Neuropharmacol","2023","2023/11/14","","","10.1097/WNF.0000000000000571"
"37335663","Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review","Rhyne C, Cohen JM, Seminerio MJ, Carr K, Krasenbaum LJ.","Medicine (Baltimore). 2023 Jun 9;102(23):e33874. doi: 10.1097/MD.0000000000033874.","Rhyne C","Medicine (Baltimore)","2023","2023/06/19","PMC10256346","","10.1097/MD.0000000000033874"
"16628534","Pathophysiology and management of transformed migraine and medication overuse headache","Boes CJ, Black DF, Dodick DW.","Semin Neurol. 2006 Apr;26(2):232-41. doi: 10.1055/s-2006-939924.","Boes CJ","Semin Neurol","2006","2006/04/22","","","10.1055/s-2006-939924"
"34210227","The role of a potential biomarker in patients with migraine: review and new insights","Ferreira KS, Dhillon H, Velly AM.","Expert Rev Neurother. 2021 Jul;21(7):817-831. doi: 10.1080/14737175.2021.1951236. Epub 2021 Jul 17.","Ferreira KS","Expert Rev Neurother","2021","2021/07/02","","","10.1080/14737175.2021.1951236"
"35587859","Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments","Chua AL, Mehla S, Orlova YY.","Curr Pain Headache Rep. 2022 Jul;26(7):493-504. doi: 10.1007/s11916-022-01051-9. Epub 2022 May 19.","Chua AL","Curr Pain Headache Rep","2022","2022/05/19","","","10.1007/s11916-022-01051-9"
"37313616","Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis","Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD.","Headache. 2023 Jun;63(6):730-742. doi: 10.1111/head.14536. Epub 2023 Jun 14.","Tepper SJ","Headache","2023","2023/06/14","","","10.1111/head.14536"
"11555322","Aspects on the pathophysiology of migraine and cluster headache","Edvinsson L.","Pharmacol Toxicol. 2001 Aug;89(2):65-73. doi: 10.1034/j.1600-0773.2001.d01-137.x.","Edvinsson L","Pharmacol Toxicol","2001","2001/09/14","","","10.1034/j.1600-0773.2001.d01-137.x"
"38307670","The evolving concept of multimorbidity and migraine","Altamura C, Coppola G, Vernieri F.","Handb Clin Neurol. 2024;199:535-566. doi: 10.1016/B978-0-12-823357-3.00014-8.","Altamura C","Handb Clin Neurol","2024","2024/02/02","","","10.1016/B978-0-12-823357-3.00014-8"
"25744685","Meningeal afferent signaling and the pathophysiology of migraine","Burgos-Vega C, Moy J, Dussor G.","Prog Mol Biol Transl Sci. 2015;131:537-64. doi: 10.1016/bs.pmbts.2015.01.001. Epub 2015 Feb 9.","Burgos-Vega C","Prog Mol Biol Transl Sci","2015","2015/03/07","","","10.1016/bs.pmbts.2015.01.001"
"37879637","Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society","Aleksovska K, Hershey AD, Deen M, Icco R, Lee MJ, Diener HC.","Cephalalgia. 2023 Oct;43(10):3331024231206162. doi: 10.1177/03331024231206162.","Aleksovska K","Cephalalgia","2023","2023/10/25","","","10.1177/03331024231206162"
"34263680","Emerging drugs for the prevention of migraine","Ogunlaja O, Karsan N, Goadsby P.","Expert Opin Emerg Drugs. 2021 Sep;26(3):271-280. doi: 10.1080/14728214.2021.1956463. Epub 2021 Jul 27.","Ogunlaja O","Expert Opin Emerg Drugs","2021","2021/07/15","","","10.1080/14728214.2021.1956463"
"24206166","The TRPA1 channel in migraine mechanism and treatment","Benemei S, Fusi C, Trevisan G, Geppetti P.","Br J Pharmacol. 2014 May;171(10):2552-67. doi: 10.1111/bph.12512.","Benemei S","Br J Pharmacol","2014","2013/11/12","PMC4008999","","10.1111/bph.12512"
"24210136","CGRP and migraine: could PACAP play a role too?","Kaiser EA, Russo AF.","Neuropeptides. 2013 Dec;47(6):451-61. doi: 10.1016/j.npep.2013.10.010. Epub 2013 Oct 23.","Kaiser EA","Neuropeptides","2013","2013/11/12","PMC3859433","NIHMS534425","10.1016/j.npep.2013.10.010"
"20633935","Regulation of signal transduction by calcitonin gene-related peptide receptors","Walker CS, Conner AC, Poyner DR, Hay DL.","Trends Pharmacol Sci. 2010 Oct;31(10):476-83. doi: 10.1016/j.tips.2010.06.006. Epub 2010 Jul 13.","Walker CS","Trends Pharmacol Sci","2010","2010/07/17","","","10.1016/j.tips.2010.06.006"
"34002347","The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update","Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A.","CNS Drugs. 2021 May;35(5):545-565. doi: 10.1007/s40263-021-00818-9. Epub 2021 May 17.","Sun-Edelstein C","CNS Drugs","2021","2021/05/18","","","10.1007/s40263-021-00818-9"
"38180396","Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside","Ashina M, Hoffmann J, Ashina H, Hay DL, Flores-Montanez Y, Do TP, De Icco R, Dodick DW.","Mayo Clin Proc. 2024 Feb;99(2):285-299. doi: 10.1016/j.mayocp.2023.07.003. Epub 2024 Jan 5.","Ashina M","Mayo Clin Proc","2024","2024/01/05","","","10.1016/j.mayocp.2023.07.003"
"37540009","Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans","Do TP, Deligianni C, Amirguliyev S, Snellman J, Lopez CL, Al-Karagholi MA, Guo S, Ashina M.","Brain. 2023 Dec 1;146(12):5224-5234. doi: 10.1093/brain/awad261.","Do TP","Brain","2023","2023/08/04","PMC10690017","","10.1093/brain/awad261"
"29350588","Arguments against the role of cortical spreading depression in migraine","Borgdorff P.","Neurol Res. 2018 Mar;40(3):173-181. doi: 10.1080/01616412.2018.1428406. Epub 2018 Jan 19.","Borgdorff P","Neurol Res","2018","2018/01/20","","","10.1080/01616412.2018.1428406"
"30827155","Discovery of CGRP in relation to migraine","Edvinsson L, Goadsby PJ.","Cephalalgia. 2019 Mar;39(3):331-332. doi: 10.1177/0333102418779544.","Edvinsson L","Cephalalgia","2019","2019/03/05","","","10.1177/0333102418779544"
"36718044","Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review","Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J.","Cephalalgia. 2023 Feb;43(2):3331024221137091. doi: 10.1177/03331024221137091.","Raffaelli B","Cephalalgia","2023","2023/01/31","","","10.1177/03331024221137091"
"28485848","The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine","Edvinsson L.","Headache. 2017 May;57 Suppl 2:47-55. doi: 10.1111/head.13081.","Edvinsson L","Headache","2017","2017/05/10","","","10.1111/head.13081"
"20430315","CGRP receptor antagonism and migraine","Edvinsson L, Ho TW.","Neurotherapeutics. 2010 Apr;7(2):164-75. doi: 10.1016/j.nurt.2010.02.004.","Edvinsson L","Neurotherapeutics","2010","2010/05/01","PMC5084097","","10.1016/j.nurt.2010.02.004"
"34731334","Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons","Wang X, He Q, Wen D, Ma L, You C.","Neurol Sci. 2022 Apr;43(4):2751-2758. doi: 10.1007/s10072-021-05701-5. Epub 2021 Nov 3.","Wang X","Neurol Sci","2022","2021/11/03","","","10.1007/s10072-021-05701-5"
"35674079","Therapies targeting CGRP signaling for medication overuse headache","Koumprentziotis IA, Mitsikostas DD.","Curr Opin Neurol. 2022 Jun 1;35(3):353-359. doi: 10.1097/WCO.0000000000001061.","Koumprentziotis IA","Curr Opin Neurol","2022","2022/06/08","","","10.1097/WCO.0000000000001061"
"36916250","[Anti-calcitonin generelated peptide (CGRP) therapies for migraine]","Moisset X, Demarquay G.","Rev Prat. 2023 Feb;73(2):123-126.","Moisset X","Rev Prat","2023","2023/03/14","","",""
"36867346","Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study","Guerzoni S, Baraldi C, Brovia D, Cainazzo MM, Castro FL, Pani L.","Acta Neurol Belg. 2023 Jun;123(3):1039-1047. doi: 10.1007/s13760-023-02190-5. Epub 2023 Mar 3.","Guerzoni S","Acta Neurol Belg","2023","2023/03/03","","","10.1007/s13760-023-02190-5"
"34845471","The state of migraine: An update on current and emerging treatments","Ray JC, Macindoe C, Ginevra M, Hutton EJ.","Aust J Gen Pract. 2021 Dec;50(12):915-921. doi: 10.31128/AJGP-01-21-5807.","Ray JC","Aust J Gen Pract","2021","2021/11/30","","","10.31128/AJGP-01-21-5807"
"30874961","CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review","Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, Viswanath O.","Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.","Urits I","Curr Pain Headache Rep","2019","2019/03/16","","","10.1007/s11916-019-0768-y"
"35575969","Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine","Ambat FDF, Bentivegna E, Martelletti P.","BioDrugs. 2022 May;36(3):337-339. doi: 10.1007/s40259-022-00532-y. Epub 2022 May 16.","Ambat FDF","BioDrugs","2022","2022/05/16","PMC9109201","","10.1007/s40259-022-00532-y"
"31177856","Fremanezumab for the preventive treatment of migraine","Silberstein SD, Cohen JM, Yeung PP.","Expert Opin Biol Ther. 2019 Aug;19(8):763-771. doi: 10.1080/14712598.2019.1627323. Epub 2019 Jul 1.","Silberstein SD","Expert Opin Biol Ther","2019","2019/06/11","","","10.1080/14712598.2019.1627323"
"36582062","Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era","Rollo E, Romozzi M, Vollono C, Calabresi P, Geppetti P, Iannone LF.","Curr Neuropharmacol. 2023;21(8):1767-1785. doi: 10.2174/1570159X21666221228095256.","Rollo E","Curr Neuropharmacol","2023","2022/12/30","PMC10514541","","10.2174/1570159X21666221228095256"
"23278169","The evolution of a migraine attack - a review of recent evidence","Charles A.","Headache. 2013 Feb;53(2):413-9. doi: 10.1111/head.12026. Epub 2012 Dec 20.","Charles A","Headache","2013","2013/01/03","","","10.1111/head.12026"
"21631491","Chemical mediators of migraine: preclinical and clinical observations","Gupta S, Nahas SJ, Peterlin BL.","Headache. 2011 Jun;51(6):1029-45. doi: 10.1111/j.1526-4610.2011.01929.x.","Gupta S","Headache","2011","2011/06/03","PMC3986727","NIHMS566039","10.1111/j.1526-4610.2011.01929.x"
"22868539","Migraine diagnosis and pathophysiology","Ward TN.","Continuum (Minneap Minn). 2012 Aug;18(4):753-63. doi: 10.1212/01.CON.0000418640.07405.31.","Ward TN","Continuum (Minneap Minn)","2012","2012/08/08","","","10.1212/01.CON.0000418640.07405.31"
"35240905","Real world considerations for newly approved CGRP receptor antagonists in migraine care","Scuteri D, Tonin P, Nicotera P, Bagetta G, Corasaniti MT.","Expert Rev Neurother. 2022 Mar;22(3):221-230. doi: 10.1080/14737175.2022.2049758. Epub 2022 Mar 14.","Scuteri D","Expert Rev Neurother","2022","2022/03/04","","","10.1080/14737175.2022.2049758"
"19328288","Calcitonin gene-related peptide receptor antagonists for the treatment of migraine","Williams TM, Burgey CS, Salvatore CA.","Prog Med Chem. 2009;47:1-35. doi: 10.1016/S0079-6468(08)00201-4.","Williams TM","Prog Med Chem","2009","2009/03/31","","","10.1016/S0079-6468(08)00201-4"
"31230338","[Migraine - therapy in transition]","Kamm K, Straube A, Neeb L.","MMW Fortschr Med. 2019 Jun;161(12):50-58. doi: 10.1007/s15006-019-0021-y.","Kamm K","MMW Fortschr Med","2019","2019/06/24","","","10.1007/s15006-019-0021-y"
"37460942","Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study","Pascual J, Panni T, Dell'Agnello G, Gonderten S, Novick D, Evers S.","J Headache Pain. 2023 Jul 17;24(1):88. doi: 10.1186/s10194-023-01623-z.","Pascual J","J Headache Pain","2023","2023/07/17","PMC10351193","","10.1186/s10194-023-01623-z"
"34137704","[Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide]","Goicochea MT, Bonamico L.","Medicina (B Aires). 2021;81(3):427-431.","Goicochea MT","Medicina (B Aires)","2021","2021/06/17","","",""
"25547922","Emerging drugs for migraine treatment","Giamberardino MA, Martelletti P.","Expert Opin Emerg Drugs. 2015 Mar;20(1):137-47. doi: 10.1517/14728214.2015.999040. Epub 2014 Dec 30.","Giamberardino MA","Expert Opin Emerg Drugs","2015","2014/12/31","","","10.1517/14728214.2015.999040"
"29396834","Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs","Ong JJY, Wei DY, Goadsby PJ.","Drugs. 2018 Mar;78(4):411-437. doi: 10.1007/s40265-018-0865-y.","Ong JJY","Drugs","2018","2018/02/04","","","10.1007/s40265-018-0865-y"
"33008510","Therapeutic implications of cortical spreading depression models in migraine","Takizawa T, Ayata C, Chen SP.","Prog Brain Res. 2020;255:29-67. doi: 10.1016/bs.pbr.2020.05.009. Epub 2020 Jun 27.","Takizawa T","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.05.009"
"26555040","New players in the preventive treatment of migraine","Mitsikostas DD, Rapoport AM.","BMC Med. 2015 Nov 10;13:279. doi: 10.1186/s12916-015-0522-1.","Mitsikostas DD","BMC Med","2015","2015/11/12","PMC4641418","","10.1186/s12916-015-0522-1"
"28409893","Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date","Pellesi L, Guerzoni S, Pini LA.","Clin Pharmacol Drug Dev. 2017 Nov;6(6):534-547. doi: 10.1002/cpdd.345. Epub 2017 Apr 14.","Pellesi L","Clin Pharmacol Drug Dev","2017","2017/04/15","PMC5697612","","10.1002/cpdd.345"
"27376323","Impact of Food Components on in vitro Calcitonin Gene-Related Peptide Secretion-A Potential Mechanism for Dietary Influence on Migraine","Slavin M, Bourguignon J, Jackson K, Orciga MA.","Nutrients. 2016 Jul 1;8(7):406. doi: 10.3390/nu8070406.","Slavin M","Nutrients","2016","2016/07/05","PMC4963882","","10.3390/nu8070406"
"17845144","Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists","Edvinsson L.","Expert Opin Ther Targets. 2007 Sep;11(9):1179-88. doi: 10.1517/14728222.11.9.1179.","Edvinsson L","Expert Opin Ther Targets","2007","2007/09/12","","","10.1517/14728222.11.9.1179"
"37185047","Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials","Silvestro M, Orologio I, Siciliano M, Trojsi F, Tessitore A, Tedeschi G, Russo A.","Expert Opin Emerg Drugs. 2023 Dec;28(2):79-96. doi: 10.1080/14728214.2023.2207819. Epub 2023 Apr 28.","Silvestro M","Expert Opin Emerg Drugs","2023","2023/05/15","","","10.1080/14728214.2023.2207819"
"32893246","[Novel migraine treatment with CGRP-related monoclonal antibodies]","Shibata M.","Rinsho Shinkeigaku. 2020 Oct 24;60(10):668-676. doi: 10.5692/clinicalneurol.cn-001469. Epub 2020 Sep 5.","Shibata M","Rinsho Shinkeigaku","2020","2020/09/07","","","10.5692/clinicalneurol.cn-001469"
"24234818","Does exercise make migraines worse and tension type headaches better?","Hindiyeh NA, Krusz JC, Cowan RP.","Curr Pain Headache Rep. 2013 Dec;17(12):380. doi: 10.1007/s11916-013-0380-5.","Hindiyeh NA","Curr Pain Headache Rep","2013","2013/11/16","","","10.1007/s11916-013-0380-5"
"36047857","A stated preference survey to explore patient preferences for novel preventive migraine treatments","Hubig LT, Smith T, Chua GN, Lloyd AJ, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lo SH.","Headache. 2022 Oct;62(9):1187-1197. doi: 10.1111/head.14386. Epub 2022 Sep 1.","Hubig LT","Headache","2022","2022/09/01","PMC9826196","","10.1111/head.14386"
"35240909","Positioning the new drugs for migraine","Benemei S, Bentivegna E, Martelletti P.","Expert Opin Drug Metab Toxicol. 2022 Jan;18(1):1-3. doi: 10.1080/17425255.2022.2049236. Epub 2022 Mar 9.","Benemei S","Expert Opin Drug Metab Toxicol","2022","2022/03/04","","","10.1080/17425255.2022.2049236"
"31323828","Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials","Huang IH, Wu PC, Lin EY, Chen CY, Kang YN.","Int J Mol Sci. 2019 Jul 18;20(14):3527. doi: 10.3390/ijms20143527.","Huang IH","Int J Mol Sci","2019","2019/07/21","PMC6678090","","10.3390/ijms20143527"
"25435318","The therapeutic armamentarium in migraine is quite elderly","Martelletti P.","Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):175-7. doi: 10.1517/17425255.2015.982089. Epub 2014 Dec 1.","Martelletti P","Expert Opin Drug Metab Toxicol","2015","2014/12/02","","","10.1517/17425255.2015.982089"
"26138383","Targeting CGRP: A New Era for Migraine Treatment","Wrobel Goldberg S, Silberstein SD.","CNS Drugs. 2015 Jun;29(6):443-52. doi: 10.1007/s40263-015-0253-z.","Wrobel Goldberg S","CNS Drugs","2015","2015/07/04","","","10.1007/s40263-015-0253-z"
"19917094","Migraine pathogenesis and state of pharmacological treatment options","Sprenger T, Goadsby PJ.","BMC Med. 2009 Nov 16;7:71. doi: 10.1186/1741-7015-7-71.","Sprenger T","BMC Med","2009","2009/11/18","PMC2784479","","10.1186/1741-7015-7-71"
"18437288","Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients","Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P.","J Headache Pain. 2008 Jun;9(3):151-7. doi: 10.1007/s10194-008-0036-8. Epub 2008 Apr 25.","Lassen LH","J Headache Pain","2008","2008/04/26","PMC2386847","","10.1007/s10194-008-0036-8"
"35151970","Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience","Mahović D, Bračić M, Jakuš L, Vukovic Cvetkovic V, Krpan M.","Clin Neurol Neurosurg. 2022 Mar;214:107169. doi: 10.1016/j.clineuro.2022.107169. Epub 2022 Feb 7.","Mahović D","Clin Neurol Neurosurg","2022","2022/02/13","","","10.1016/j.clineuro.2022.107169"
"10563228","Pathophysiology of migraine--new insights","Hargreaves RJ, Shepheard SL.","Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. doi: 10.1017/s0317167100000147.","Hargreaves RJ","Can J Neurol Sci","1999","1999/11/24","","","10.1017/s0317167100000147"
"35358493","Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review","Dos Santos JBR, da Silva MRR.","Eur J Pharmacol. 2022 May 5;922:174902. doi: 10.1016/j.ejphar.2022.174902. Epub 2022 Mar 28.","Dos Santos JBR","Eur J Pharmacol","2022","2022/03/31","","","10.1016/j.ejphar.2022.174902"
"37580864","Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors","Garelja ML, Alexander TI, Bennie A, Nimick M, Petersen J, Walker CS, Hay DL.","Br J Pharmacol. 2024 Jan;181(1):142-161. doi: 10.1111/bph.16218. Epub 2023 Sep 14.","Garelja ML","Br J Pharmacol","2024","2023/08/15","PMC10840612","NIHMS1925402","10.1111/bph.16218"
"37125484","Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study","Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P.","Cephalalgia. 2023 May;43(5):3331024231170807. doi: 10.1177/03331024231170807.","Ashina M","Cephalalgia","2023","2023/05/01","","","10.1177/03331024231170807"
"38307640","CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention","Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.","Handb Clin Neurol. 2024;199:107-124. doi: 10.1016/B978-0-12-823357-3.00024-0.","Caronna E","Handb Clin Neurol","2024","2024/02/02","","","10.1016/B978-0-12-823357-3.00024-0"
"32058712","Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success","Dubowchik GM, Conway CM, Xin AW.","J Med Chem. 2020 Jul 9;63(13):6600-6623. doi: 10.1021/acs.jmedchem.9b01810. Epub 2020 Feb 20.","Dubowchik GM","J Med Chem","2020","2020/02/15","","","10.1021/acs.jmedchem.9b01810"
"38365382","Potential treatment targets for migraine: emerging options and future prospects","Chiang CC, Porreca F, Robertson CE, Dodick DW.","Lancet Neurol. 2024 Mar;23(3):313-324. doi: 10.1016/S1474-4422(24)00003-6.","Chiang CC","Lancet Neurol","2024","2024/02/16","","","10.1016/S1474-4422(24)00003-6"
"24147647","An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine","Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P.","Headache. 2014 Feb;54(2):269-77. doi: 10.1111/head.12250. Epub 2013 Oct 22.","Cady R","Headache","2014","2013/10/24","","","10.1111/head.12250"
"36231054","Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine","Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C.","Cells. 2022 Sep 30;11(19):3092. doi: 10.3390/cells11193092.","Greco R","Cells","2022","2022/10/14","PMC9562879","","10.3390/cells11193092"
"30035299","Qualitative Change in Migraine Prevention?","Cady R, Lipton RB.","Headache. 2018 Jul;58(7):1092-1095. doi: 10.1111/head.13354. Epub 2018 Jul 23.","Cady R","Headache","2018","2018/07/24","","","10.1111/head.13354"
"20820195","CGRP and its receptors provide new insights into migraine pathophysiology","Ho TW, Edvinsson L, Goadsby PJ.","Nat Rev Neurol. 2010 Oct;6(10):573-82. doi: 10.1038/nrneurol.2010.127. Epub 2010 Sep 7.","Ho TW","Nat Rev Neurol","2010","2010/09/08","","","10.1038/nrneurol.2010.127"
"23212108","Emerging target-based paradigms to prevent and treat migraine","Silberstein SD.","Clin Pharmacol Ther. 2013 Jan;93(1):78-85. doi: 10.1038/clpt.2012.198. Epub 2012 Dec 5.","Silberstein SD","Clin Pharmacol Ther","2013","2012/12/06","","","10.1038/clpt.2012.198"
"11252141","Pathophysiology of primary headaches","Edvinsson L.","Curr Pain Headache Rep. 2001 Feb;5(1):71-8. doi: 10.1007/s11916-001-0013-2.","Edvinsson L","Curr Pain Headache Rep","2001","2001/03/17","","","10.1007/s11916-001-0013-2"
"23534301","Pathophysiology of migraine--from molecular to personalized medicine","Kojić Z, Stojanović D.","Med Pregl. 2013 Jan-Feb;66(1-2):53-7. doi: 10.2298/mpns1302053k.","Kojić Z","Med Pregl","2013","2013/03/29","","","10.2298/mpns1302053k"
"35781694","Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta-analysis","Siahaan YMT, Hartoyo V, Hariyanto TI.","Clin Exp Pharmacol Physiol. 2022 Nov;49(11):1156-1168. doi: 10.1111/1440-1681.13700. Epub 2022 Jul 20.","Siahaan YMT","Clin Exp Pharmacol Physiol","2022","2022/07/05","","","10.1111/1440-1681.13700"
"25892078","Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine","Dong X, Hu Y, Jing L, Chen J.","Mol Med Rep. 2015 Aug;12(2):1803-9. doi: 10.3892/mmr.2015.3616. Epub 2015 Apr 15.","Dong X","Mol Med Rep","2015","2015/04/21","PMC4463979","","10.3892/mmr.2015.3616"
"34268907","Predictors of response to erenumab after 12 months of treatment","Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S.","Brain Behav. 2021 Aug;11(8):e2260. doi: 10.1002/brb3.2260. Epub 2021 Jul 16.","Baraldi C","Brain Behav","2021","2021/07/16","PMC8413721","","10.1002/brb3.2260"
"35687795","Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies","Nsaka M, Scheffler A, Wurthmann S, Schenk H, Kleinschnitz C, Glas M, Holle D.","Brain Behav. 2022 Jul;12(7):e2662. doi: 10.1002/brb3.2662. Epub 2022 Jun 10.","Nsaka M","Brain Behav","2022","2022/06/10","PMC9304830","","10.1002/brb3.2662"
"19322554","[What is migraine?]","Schürks M.","Nervenarzt. 2009 Oct;80(10):1154, 1156-9. doi: 10.1007/s00115-009-2704-6.","Schürks M","Nervenarzt","2009","2009/03/27","","","10.1007/s00115-009-2704-6"
"37942638","Gepants in the acute management of migraine","Wells-Gatnik WD, Martelletti P.","Pain Manag. 2023 Nov;13(11):627-630. doi: 10.2217/pmt-2023-0106. Epub 2023 Nov 9.","Wells-Gatnik WD","Pain Manag","2023","2023/11/09","","","10.2217/pmt-2023-0106"
"35536501","Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments","Orlova YY, Mehla S, Chua AL.","Curr Pain Headache Rep. 2022 Jul;26(7):481-492. doi: 10.1007/s11916-022-01057-3. Epub 2022 May 10.","Orlova YY","Curr Pain Headache Rep","2022","2022/05/10","","","10.1007/s11916-022-01057-3"
"37062448","The association between migraines and periodontal disease: A systematic review of clinical studies","Dholakia SB, Rao P, Talluri S, Khan J.","J Oral Biosci. 2023 Jun;65(2):137-145. doi: 10.1016/j.job.2023.04.001. Epub 2023 Apr 14.","Dholakia SB","J Oral Biosci","2023","2023/04/16","","","10.1016/j.job.2023.04.001"
"31101004","Optimising migraine treatment: from drug-drug interactions to personalized medicine","Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P.","J Headache Pain. 2019 May 17;20(1):56. doi: 10.1186/s10194-019-1010-3.","Pomes LM","J Headache Pain","2019","2019/05/19","PMC6734220","","10.1186/s10194-019-1010-3"
"20607582","Verisimilitude (or ""truthlikeness"") as an alternative to pro and cons: migraine and cluster headache mechanisms","Tfelt-Hansen PC.","J Headache Pain. 2010 Oct;11(5):379-89. doi: 10.1007/s10194-010-0232-1. Epub 2010 Jul 7.","Tfelt-Hansen PC","J Headache Pain","2010","2010/07/08","PMC3452275","","10.1007/s10194-010-0232-1"
"32562057","The Use of Botulinum Toxin in the Management of Headache Disorders","Yuan H, Silberstein SD.","Handb Exp Pharmacol. 2021;263:227-249. doi: 10.1007/164_2020_365.","Yuan H","Handb Exp Pharmacol","2021","2020/06/21","","","10.1007/164_2020_365"
"33544305","Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials","Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL.","Adv Ther. 2021 Mar;38(3):1614-1626. doi: 10.1007/s12325-021-01632-x. Epub 2021 Feb 5.","Kuruppu DK","Adv Ther","2021","2021/02/05","PMC7932975","","10.1007/s12325-021-01632-x"
"34190614","Assessing migraine therapeutics","Xu C, Bussiere J.","Cephalalgia. 2021 Nov;41(13):1402-1403. doi: 10.1177/03331024211021569. Epub 2021 Jun 30.","Xu C","Cephalalgia","2021","2021/06/30","","","10.1177/03331024211021569"
"38397400","Understanding the Biological Relationship between Migraine and Depression","Viudez-Martínez A, Torregrosa AB, Navarrete F, García-Gutiérrez MS.","Biomolecules. 2024 Jan 30;14(2):163. doi: 10.3390/biom14020163.","Viudez-Martínez A","Biomolecules","2024","2024/02/24","PMC10886628","","10.3390/biom14020163"
"25138211","Targeting TRP channels for novel migraine therapeutics","Dussor G, Yan J, Xie JY, Ossipov MH, Dodick DW, Porreca F.","ACS Chem Neurosci. 2014 Nov 19;5(11):1085-96. doi: 10.1021/cn500083e. Epub 2014 Aug 29.","Dussor G","ACS Chem Neurosci","2014","2014/08/21","PMC4240253","","10.1021/cn500083e"
"35775208","Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine","Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A.","Cephalalgia. 2022 Nov;42(13):1323-1330. doi: 10.1177/03331024221111526. Epub 2022 Jul 1.","Iannone LF","Cephalalgia","2022","2022/07/01","","","10.1177/03331024221111526"
"36089587","Serum CGRP in migraine patients using erenumab as preventive treatment","de Vries Lentsch S, Garrelds IM, Danser AHJ, Terwindt GM, MaassenVanDenBrink A.","J Headache Pain. 2022 Sep 12;23(1):120. doi: 10.1186/s10194-022-01483-z.","de Vries Lentsch S","J Headache Pain","2022","2022/09/11","PMC9464612","","10.1186/s10194-022-01483-z"
"36517767","Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab","Schwedt TJ, Nikolova S, Dumkrieger G, Li J, Wu T, Chong CD.","J Headache Pain. 2022 Dec 14;23(1):159. doi: 10.1186/s10194-022-01526-5.","Schwedt TJ","J Headache Pain","2022","2022/12/14","PMC9748909","","10.1186/s10194-022-01526-5"
"36189628","Combining two CGRP inhibitors to treat migraine","Pellesi L.","Expert Opin Drug Saf. 2022 Sep;21(9):1135-1136. doi: 10.1080/14740338.2022.2130890. Epub 2022 Oct 3.","Pellesi L","Expert Opin Drug Saf","2022","2022/10/03","","","10.1080/14740338.2022.2130890"
"37208838","Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population","Guerzoni S, Baraldi C, Castro FL, Cainazzo MM, Pani L.","Brain Behav. 2023 Jun;13(6):e2799. doi: 10.1002/brb3.2799. Epub 2023 May 19.","Guerzoni S","Brain Behav","2023","2023/05/20","PMC10275517","","10.1002/brb3.2799"
"32701652","Intradural artery dilation during experimentally induced migraine attacks","Christensen CE, Younis S, Lindberg U, de Koning P, Tolnai D, Paulson OB, Larsson HBW, Amin FM, Ashina M.","Pain. 2021 Jan;162(1):176-183. doi: 10.1097/j.pain.0000000000002008.","Christensen CE","Pain","2021","2020/07/24","","","10.1097/j.pain.0000000000002008"
"17691979","CGRP-receptor antagonism in migraine treatment","Edvinsson L, Petersen KA.","CNS Neurol Disord Drug Targets. 2007 Aug;6(4):240-6. doi: 10.2174/187152707781387314.","Edvinsson L","CNS Neurol Disord Drug Targets","2007","2007/08/19","","","10.2174/187152707781387314"
"38238659","Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers","Shibata M, Fujita K, Hoshino E, Minami K, Koizumi K, Okada S, Sakai F.","BMC Neurol. 2024 Jan 18;24(1):32. doi: 10.1186/s12883-023-03521-y.","Shibata M","BMC Neurol","2024","2024/01/18","PMC10795407","","10.1186/s12883-023-03521-y"
"15689192","Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack","Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G.","Cephalalgia. 2005 Mar;25(3):179-83. doi: 10.1111/j.1468-2982.2005.00836.x.","Juhasz G","Cephalalgia","2005","2005/02/04","","","10.1111/j.1468-2982.2005.00836.x"
"16099727","Migraine: current concepts and emerging therapies","Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL.","Vascul Pharmacol. 2005 Sep;43(3):176-87. doi: 10.1016/j.vph.2005.07.001.","Arulmozhi DK","Vascul Pharmacol","2005","2005/08/16","","","10.1016/j.vph.2005.07.001"
"21404609","[Migraine: advances in the pathophysiology and treatment]","Shimizu T, Shibata M, Suzuki N.","Rinsho Shinkeigaku. 2011 Feb;51(2):103-9. doi: 10.5692/clinicalneurol.51.103.","Shimizu T","Rinsho Shinkeigaku","2011","2011/03/17","","","10.5692/clinicalneurol.51.103"
"34392708","Fremanezumab autoinjector pen for the prevention of migraine","Weatherall MW.","Ther Deliv. 2021 Sep;12(9):645-650. doi: 10.4155/tde-2021-0028. Epub 2021 Aug 16.","Weatherall MW","Ther Deliv","2021","2021/08/16","","","10.4155/tde-2021-0028"
"19157980","CGRP receptors in the control of pain and inflammation","Benemei S, Nicoletti P, Capone JG, Geppetti P.","Curr Opin Pharmacol. 2009 Feb;9(1):9-14. doi: 10.1016/j.coph.2008.12.007. Epub 2009 Jan 20.","Benemei S","Curr Opin Pharmacol","2009","2009/01/23","","","10.1016/j.coph.2008.12.007"
"35698795","Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine","Fitzek M, Raffaelli B, Reuter U.","Expert Opin Pharmacother. 2022 Jul;23(10):1143-1153. doi: 10.1080/14656566.2022.2088281. Epub 2022 Jun 13.","Fitzek M","Expert Opin Pharmacother","2022","2022/06/14","","","10.1080/14656566.2022.2088281"
"34294458","Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants","Do TP, Al-Saoudi A, Ashina M.","Rev Neurol (Paris). 2021 Sep;177(7):827-833. doi: 10.1016/j.neurol.2021.06.005. Epub 2021 Jul 20.","Do TP","Rev Neurol (Paris)","2021","2021/07/23","","","10.1016/j.neurol.2021.06.005"
"12453043","Adrenomedullin and migraine","Béla K, Csongor AS, Deli MA, Ueta Y.","Headache. 2002 Nov-Dec;42(10):1064-5. doi: 10.1046/j.1526-4610.2002.02241.x.","Béla K","Headache","2002","2002/11/28","","","10.1046/j.1526-4610.2002.02241.x"
"16696576","Role of melatonin in the pathophysiology of migraine: implications for treatment","Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME.","CNS Drugs. 2006;20(5):343-50. doi: 10.2165/00023210-200620050-00001.","Vogler B","CNS Drugs","2006","2006/05/16","","","10.2165/00023210-200620050-00001"
"30784544","Complicated decisions on new migraine-prevention therapies","The Lancet Neurology.","Lancet Neurol. 2019 Mar;18(3):221. doi: 10.1016/S1474-4422(19)30041-9. Epub 2019 Feb 12.","The Lancet Neurology","Lancet Neurol","2019","2019/02/21","","","10.1016/S1474-4422(19)30041-9"
"37321919","Consensus recommendations for the treatment of migraine prevention","Calleja-Hernández MÁ, Guerrero-Peral ÁL, Irimia-Sieira P, Martínez-López I, Santos-Lasaosa S, Sarobe-Carricas M, López-Matencio JMS, Láinez-Andrés JM.","Farm Hosp. 2023 Nov-Dec;47(6):246-253. doi: 10.1016/j.farma.2023.03.011. Epub 2023 Jun 14.","Calleja-Hernández MÁ","Farm Hosp","2023","2023/06/15","","","10.1016/j.farma.2023.03.011"
"21521208","One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010","Tfelt-Hansen PC, Koehler PJ.","Headache. 2011 May;51(5):752-78. doi: 10.1111/j.1526-4610.2011.01892.x.","Tfelt-Hansen PC","Headache","2011","2011/04/28","","","10.1111/j.1526-4610.2011.01892.x"
"33981769","The Influence of Calcitonin Gene-Related Peptide on Cerebral Hemodynamics in Nonmigraine Subjects with Calcitonin Gene-Related Peptide-Induced Headaches","Zupan M, Zaletel M, Visočnik D, Žvan B.","Biomed Res Int. 2021 Apr 24;2021:5540254. doi: 10.1155/2021/5540254. eCollection 2021.","Zupan M","Biomed Res Int","2021","2021/05/13","PMC8088344","","10.1155/2021/5540254"
"36321947","Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review","Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P.","Headache. 2022 Nov;62(10):1395-1405. doi: 10.1111/head.14404. Epub 2022 Nov 2.","Membrilla JA","Headache","2022","2022/11/02","","","10.1111/head.14404"
"29697155","Foreword: The CGRP Pathway and Migraine Prevention: Reducing the Burden of Disease","Holland PR.","Headache. 2018 May;58 Suppl 1:1-3. doi: 10.1111/head.13303.","Holland PR","Headache","2018","2018/04/27","","","10.1111/head.13303"
"35301884","Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients","Kwon S, Gil YE, Lee MJ.","Cephalalgia. 2022 Jul;42(8):705-714. doi: 10.1177/03331024221076481. Epub 2022 Mar 18.","Kwon S","Cephalalgia","2022","2022/03/18","","","10.1177/03331024221076481"
"15960987","The role of mast cells in migraine pathophysiology","Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A.","Brain Res Brain Res Rev. 2005 Jul;49(1):65-76. doi: 10.1016/j.brainresrev.2004.11.006.","Theoharides TC","Brain Res Brain Res Rev","2005","2005/06/18","","","10.1016/j.brainresrev.2004.11.006"
"35583486","Ratanasampil is more effective than flunarizine in relieving migraine","Zhu A, Zhong X, Zhu Y, Li P, Zhang J, Hou Y, Song L.","Int J Neurosci. 2023 Dec;133(12):1326-1337. doi: 10.1080/00207454.2022.2079503. Epub 2022 May 31.","Zhu A","Int J Neurosci","2023","2022/05/18","","","10.1080/00207454.2022.2079503"
"35795317","The Responses to CGRP in the Territory of the Posterior Cerebral Artery in Migraine","Visočnik D, Zaletel M, Zupan M, Žvan B.","Biomed Res Int. 2022 Jun 26;2022:2686689. doi: 10.1155/2022/2686689. eCollection 2022.","Visočnik D","Biomed Res Int","2022","2022/07/07","PMC9251091","","10.1155/2022/2686689"
"16249526","Neurogenic inflammation and migraine: implications for the therapeutics","Peroutka SJ.","Mol Interv. 2005 Oct;5(5):304-11. doi: 10.1124/mi.5.5.10.","Peroutka SJ","Mol Interv","2005","2005/10/27","","","10.1124/mi.5.5.10"
"37684346","Predictors of galcanezumab response in a real-world study of Korean patients with migraine","Kim SA, Jang H, Lee MJ.","Sci Rep. 2023 Sep 8;13(1):14825. doi: 10.1038/s41598-023-42110-4.","Kim SA","Sci Rep","2023","2023/09/08","PMC10491682","","10.1038/s41598-023-42110-4"
"35467013","The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review","Vig SJ, Garza J, Tao Y.","Headache. 2022 Nov;62(10):1256-1263. doi: 10.1111/head.14305. Epub 2022 Apr 25.","Vig SJ","Headache","2022","2022/04/25","","","10.1111/head.14305"
"34224026","Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache","Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S, Asioli GM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S.","Neurol Sci. 2022 Feb;43(2):1273-1280. doi: 10.1007/s10072-021-05426-5. Epub 2021 Jul 5.","Pensato U","Neurol Sci","2022","2021/07/05","","","10.1007/s10072-021-05426-5"
"37373250","Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine","Greco R, Francavilla M, Demartini C, Zanaboni AM, Facchetti S, Palmisani M, Franco V, Tassorelli C.","Int J Mol Sci. 2023 Jun 14;24(12):10102. doi: 10.3390/ijms241210102.","Greco R","Int J Mol Sci","2023","2023/06/28","PMC10299064","","10.3390/ijms241210102"
"7697699","The mode of action of sumatriptan is vascular? A debate","Humphrey PP, Goadsby PJ.","Cephalalgia. 1994 Dec;14(6):401-10; discussion 393. doi: 10.1046/j.1468-2982.1994.1406401.x.","Humphrey PP","Cephalalgia","1994","1994/12/01","","","10.1046/j.1468-2982.1994.1406401.x"
"35710354","Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE","Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A.","BMC Neurol. 2022 Jun 16;22(1):221. doi: 10.1186/s12883-022-02710-5.","Alsaadi T","BMC Neurol","2022","2022/06/16","PMC9202108","","10.1186/s12883-022-02710-5"
"19192933","Antidepressants in long-term migraine prevention","Koch HJ, Jürgens TP.","Drugs. 2009;69(1):1-19. doi: 10.2165/00003495-200969010-00001.","Koch HJ","Drugs","2009","2009/02/06","","","10.2165/00003495-200969010-00001"
"37216943","[Drug therapy of the acute migraine attack and prophylaxis of migraine]","Diener HC, Gaul C.","Dtsch Med Wochenschr. 2023 Jun;148(11):678-684. doi: 10.1055/a-1857-3887. Epub 2023 May 22.","Diener HC","Dtsch Med Wochenschr","2023","2023/05/22","","","10.1055/a-1857-3887"
"20331608","Headache-type adverse effects of NO donors: vasodilation and beyond","Bagdy G, Riba P, Kecskeméti V, Chase D, Juhász G.","Br J Pharmacol. 2010 May;160(1):20-35. doi: 10.1111/j.1476-5381.2010.00643.x. Epub 2010 Mar 19.","Bagdy G","Br J Pharmacol","2010","2010/03/25","PMC2860203","","10.1111/j.1476-5381.2010.00643.x"
"15853537","Future pharmacologic targets for acute and preventive treatments of migraine","Buchanan TM, Ramadan NM, Aurora S.","Expert Rev Neurother. 2004 May;4(3):391-430. doi: 10.1586/14737175.4.3.391.","Buchanan TM","Expert Rev Neurother","2004","2005/04/28","","","10.1586/14737175.4.3.391"
"37074825","Experts and national consultants' recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2","Stepień A, Słowik A, Domitrz I, Kozubski W, Rejdak K, Rożniecki J, Woroń J, Wachowska K, Gałecki P.","Psychiatr Pol. 2022 Aug 31;56(4):711-728. doi: 10.12740/PP/OnlineFirst/139596. Epub 2022 Aug 31.","Stepień A","Psychiatr Pol","2022","2023/04/19","","","10.12740/PP/OnlineFirst/139596"
"33989098","Current advances in the management of cluster headaches","Mavridis T, Breza M, Deligianni C, Mitsikostas DD.","Expert Opin Pharmacother. 2021 Oct;22(14):1931-1943. doi: 10.1080/14656566.2021.1924148. Epub 2021 May 14.","Mavridis T","Expert Opin Pharmacother","2021","2021/05/14","","","10.1080/14656566.2021.1924148"
"35199393","Synthesis of a dual carbon-14-labeled calcitonin gene-related peptide receptor antagonist for use in a human absorption-distribution-metabolism-elimination study","Turley WA, Easter JA, Burrell RC, Bonacorsi SJ Jr.","J Labelled Comp Radiopharm. 2022 May 15;65(5):126-139. doi: 10.1002/jlcr.3966. Epub 2022 Mar 10.","Turley WA","J Labelled Comp Radiopharm","2022","2022/02/24","","","10.1002/jlcr.3966"
"17141570","Recent advances in understanding migraine mechanisms, molecules and therapeutics","Goadsby PJ.","Trends Mol Med. 2007 Jan;13(1):39-44. doi: 10.1016/j.molmed.2006.11.005. Epub 2006 Dec 1.","Goadsby PJ","Trends Mol Med","2007","2006/12/05","","","10.1016/j.molmed.2006.11.005"
"21871019","Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine","Moore EL, Salvatore CA.","Br J Pharmacol. 2012 May;166(1):66-78. doi: 10.1111/j.1476-5381.2011.01633.x.","Moore EL","Br J Pharmacol","2012","2011/08/30","PMC3415638","","10.1111/j.1476-5381.2011.01633.x"
"34579559","Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study","Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U.","Cephalalgia. 2022 Apr;42(4-5):326-334. doi: 10.1177/03331024211046617. Epub 2021 Sep 27.","Raffaelli B","Cephalalgia","2022","2021/09/28","PMC8988461","","10.1177/03331024211046617"
"37723849","Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine","Chen PW, Karlsson MO, Ueckert S, Pritchard-Bell A, Hsu CP, Dutta S, Ahamadi M.","CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1988-2000. doi: 10.1002/psp4.13048. Epub 2023 Oct 11.","Chen PW","CPT Pharmacometrics Syst Pharmacol","2023","2023/09/19","PMC10725274","","10.1002/psp4.13048"
"28041540","[Basic mechanisms of migraine and new methods of treatment]","Hansen JM, Ashina M.","Ugeskr Laeger. 2016 Dec 19;178(51):V07160507.","Hansen JM","Ugeskr Laeger","2016","2017/01/03","","",""
"35170575","Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction","Peng KP, Basedau H, Oppermann T, May A.","Pain. 2022 Nov 1;163(11):2194-2199. doi: 10.1097/j.pain.0000000000002614. Epub 2022 Feb 14.","Peng KP","Pain","2022","2022/02/16","","","10.1097/j.pain.0000000000002614"
"37126606","Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis","Gaul C, Seidel K, Heuck A, Silaidos C, Mrosowsky T, Eberhardt A, Fritz B, Jacob C.","J Med Econ. 2023 Jan-Dec;26(1):667-678. doi: 10.1080/13696998.2023.2207413.","Gaul C","J Med Econ","2023","2023/05/01","","","10.1080/13696998.2023.2207413"
"22223502","[Perspective of pathophysiology and treatment of migraine]","Shimizu T, Suzuki N.","Brain Nerve. 2012 Jan;64(1):59-64.","Shimizu T","Brain Nerve","2012","2012/01/07","","",""
"34246226","Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study","Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC.","J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7.","Ashina M","J Headache Pain","2021","2021/07/11","PMC8272284","","10.1186/s10194-021-01279-7"
"34696711","CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J.","J Headache Pain. 2021 Oct 25;22(1):128. doi: 10.1186/s10194-021-01335-2.","Vandervorst F","J Headache Pain","2021","2021/10/26","PMC8547103","","10.1186/s10194-021-01335-2"
"37815254","An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study","Al-Khazali HM, Ashina H, Christensen RH, Wiggers A, Rose K, Iljazi A, Schytz HW, Amin FM, Ashina M.","Cephalalgia. 2023 Oct;43(10):3331024231206375. doi: 10.1177/03331024231206375.","Al-Khazali HM","Cephalalgia","2023","2023/10/10","","","10.1177/03331024231206375"
"18796271","Putative mechanisms of the relationship between obesity and migraine progression","Bigal ME, Lipton RB.","Curr Pain Headache Rep. 2008 Jun;12(3):207-12. doi: 10.1007/s11916-008-0036-z.","Bigal ME","Curr Pain Headache Rep","2008","2008/09/18","","","10.1007/s11916-008-0036-z"
"21466447","CGRP receptor antagonists: toward a novel migraine therapy","Salvatore CA, Kane SA.","Curr Pharm Biotechnol. 2011 Oct;12(10):1671-80. doi: 10.2174/138920111798357401.","Salvatore CA","Curr Pharm Biotechnol","2011","2011/04/07","","","10.2174/138920111798357401"
"15938667","Migraine treatment throughout the lifecycle","Landy SH, Lobo BL.","Expert Rev Neurother. 2005 May;5(3):343-53. doi: 10.1586/14737175.5.3.343.","Landy SH","Expert Rev Neurother","2005","2005/06/09","","","10.1586/14737175.5.3.343"
"29110503","CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data","Khan S, Olesen A, Ashina M.","Cephalalgia. 2019 Mar;39(3):374-389. doi: 10.1177/0333102417741297. Epub 2017 Nov 7.","Khan S","Cephalalgia","2019","2017/11/08","","","10.1177/0333102417741297"
"8395344","Cortical spreading depression does not result in the release of calcitonin gene-related peptide into the external jugular vein of the cat: relevance to human migraine","Piper RD, Edvinsson L, Ekman R, Lambert GA.","Cephalalgia. 1993 Jun;13(3):180-3; discussion 149. doi: 10.1046/j.1468-2982.1993.1303180.x.","Piper RD","Cephalalgia","1993","1993/06/01","","","10.1046/j.1468-2982.1993.1303180.x"
"37102254","[Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans]","Pérez-Rodríguez A, Bandrés-Hernández P, Anciones C, Terrón-Cuadrado C, Canuet-Delis L, Gilo-Arrojo F, Anciones B.","Rev Neurol. 2023 May 1;76(9):295-308. doi: 10.33588/rn.7609.2022238.","Pérez-Rodríguez A","Rev Neurol","2023","2023/04/27","PMC10478141","","10.33588/rn.7609.2022238"
"36350532","Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System","Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A.","Adv Ther. 2023 Feb;40(2):445-459. doi: 10.1007/s12325-022-02346-4. Epub 2022 Nov 9.","Silberstein SD","Adv Ther","2023","2022/11/09","PMC9898337","","10.1007/s12325-022-02346-4"
"34535065","The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events","González-Hernández A, Marichal-Cancino BA, Villalón CM.","Expert Opin Drug Metab Toxicol. 2021 Oct;17(10):1223-1235. doi: 10.1080/17425255.2021.1982892. Epub 2021 Oct 4.","González-Hernández A","Expert Opin Drug Metab Toxicol","2021","2021/09/18","","","10.1080/17425255.2021.1982892"
"35680766","The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine","Guerzoni S, Baraldi C, Pani L.","Neurol Sci. 2022 Sep;43(9):5687-5695. doi: 10.1007/s10072-022-06195-5. Epub 2022 Jun 10.","Guerzoni S","Neurol Sci","2022","2022/06/10","","","10.1007/s10072-022-06195-5"
"36602199","Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine","Blumenfeld AM, Boinpally R, De Abreu Ferreira R, Trugman JM, Dabruzzo B, Ailani J, Lipton RB.","Headache. 2023 Mar;63(3):322-332. doi: 10.1111/head.14433. Epub 2023 Jan 5.","Blumenfeld AM","Headache","2023","2023/01/05","","","10.1111/head.14433"
"36633118","Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review","Zorrilla N, Gelfand AA, Irwin SL.","Headache. 2023 Jan;63(1):177-182. doi: 10.1111/head.14452. Epub 2023 Jan 12.","Zorrilla N","Headache","2023","2023/01/12","","","10.1111/head.14452"
"16866713","Neuronal signal substances as biomarkers of migraine","Edvinsson L.","Headache. 2006 Jul-Aug;46(7):1088-94. doi: 10.1111/j.1526-4610.2006.00502.x.","Edvinsson L","Headache","2006","2006/07/27","","","10.1111/j.1526-4610.2006.00502.x"
"34936103","Two possible cases of erenumab-induced xerostomia","Selvi-Sabater P, Carvajal-Sanchez MA, Carrera-Hueso FJ.","J Clin Pharm Ther. 2022 Jun;47(6):824-825. doi: 10.1111/jcpt.13595. Epub 2021 Dec 22.","Selvi-Sabater P","J Clin Pharm Ther","2022","2021/12/22","","","10.1111/jcpt.13595"
"35305579","Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study","Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Egeo G, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Valle ED, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Nežádal T, Čtrnáctá D, Šípková J, Matoušová Z, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S.","J Headache Pain. 2022 Mar 19;23(1):38. doi: 10.1186/s10194-022-01408-w.","Ornello R","J Headache Pain","2022","2022/03/20","PMC8933935","","10.1186/s10194-022-01408-w"
"35403223","A real-world, observational study of erenumab for migraine prevention in Canadian patients","Becker WJ, Spacey S, Leroux E, Giammarco R, Gladstone J, Christie S, Akaberi A, Power GS, Minhas JK, Mancini J, Rochdi D, Filiz A, Bastien N.","Headache. 2022 Apr;62(4):522-529. doi: 10.1111/head.14291. Epub 2022 Apr 10.","Becker WJ","Headache","2022","2022/04/11","PMC9320807","","10.1111/head.14291"
"18545913","Peripheral mechanism of action of antimigraine prophylactic drugs","Frediani F, Villani V, Casucci G.","Neurol Sci. 2008 May;29 Suppl 1:S127-30. doi: 10.1007/s10072-008-0903-8.","Frediani F","Neurol Sci","2008","2008/07/17","","","10.1007/s10072-008-0903-8"
"36097203","Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review","Primiano G, Rollo E, Romozzi M, Calabresi P, Servidei S, Vollono C.","Neurol Sci. 2022 Dec;43(12):6955-6959. doi: 10.1007/s10072-022-06391-3. Epub 2022 Sep 13.","Primiano G","Neurol Sci","2022","2022/09/13","","","10.1007/s10072-022-06391-3"
"36826456","Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study","Lee HC, Cho S, Kim BK.","Neurol Sci. 2023 Jul;44(7):2455-2463. doi: 10.1007/s10072-023-06683-2. Epub 2023 Feb 24.","Lee HC","Neurol Sci","2023","2023/02/24","","","10.1007/s10072-023-06683-2"
"32654126","Moving the Needle, the Clinical Perspective","Schim J.","Headache. 2020 Oct;60(9):2042-2048. doi: 10.1111/head.13904. Epub 2020 Jul 11.","Schim J","Headache","2020","2020/07/13","","","10.1111/head.13904"
"17069890","Potential role of female sex hormones in the pathophysiology of migraine","Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A.","Pharmacol Ther. 2007 Feb;113(2):321-40. doi: 10.1016/j.pharmthera.2006.08.009. Epub 2006 Oct 25.","Gupta S","Pharmacol Ther","2007","2006/10/31","","","10.1016/j.pharmthera.2006.08.009"
"33765912","Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures","Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E.","J Headache Pain. 2021 Mar 25;22(1):15. doi: 10.1186/s10194-021-01230-w.","Schwedt TJ","J Headache Pain","2021","2021/03/26","PMC7992932","","10.1186/s10194-021-01230-w"
"35041064","[CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]","Hamann T, Rimmele F, Jürgens TP.","Schmerz. 2022 Feb;36(1):59-72. doi: 10.1007/s00482-021-00613-x. Epub 2022 Jan 18.","Hamann T","Schmerz","2022","2022/01/18","","","10.1007/s00482-021-00613-x"
"35469689","Atogepant (Qulipta®) for migraine prevention","Hay DL, Walker CS, Harris PWR.","Trends Pharmacol Sci. 2022 Aug;43(8):701-702. doi: 10.1016/j.tips.2022.03.013. Epub 2022 Apr 22.","Hay DL","Trends Pharmacol Sci","2022","2022/04/26","","","10.1016/j.tips.2022.03.013"
"37132481","Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine","Tepper SJ, Dong Y, Vincent M, Wietecha LA.","Headache. 2023 Nov-Dec;63(10):1380-1390. doi: 10.1111/head.14494. Epub 2023 May 3.","Tepper SJ","Headache","2023","2023/05/03","","","10.1111/head.14494"
"34537006","Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial","Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R, Numachi Y, Peng C, Mikol DD, Cheng S.","J Headache Pain. 2021 Sep 18;22(1):110. doi: 10.1186/s10194-021-01313-8.","Hirata K","J Headache Pain","2021","2021/09/19","PMC8449906","","10.1186/s10194-021-01313-8"
"16797716","New and future migraine therapy","Ramadan NM, Buchanan TM.","Pharmacol Ther. 2006 Oct;112(1):199-212. doi: 10.1016/j.pharmthera.2005.04.010. Epub 2006 Jun 23.","Ramadan NM","Pharmacol Ther","2006","2006/06/27","","","10.1016/j.pharmthera.2005.04.010"
"36620892","Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial","Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M, Trugman JM.","Cephalalgia. 2023 Jan;43(1):3331024221128250. doi: 10.1177/03331024221128250.","Klein BC","Cephalalgia","2023","2023/01/09","","","10.1177/03331024221128250"
"1709530","Migraine: a research field matured for the basic neurosciences","Olesen J, Edvinsson L.","Trends Neurosci. 1991 Jan;14(1):3-5. doi: 10.1016/0166-2236(91)90171-p.","Olesen J","Trends Neurosci","1991","1991/01/01","","","10.1016/0166-2236(91)90171-p"
"35135357","Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache","Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, Cainazzo MM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S.","Cephalalgia. 2022 Jun;42(7):645-653. doi: 10.1177/03331024211067791. Epub 2022 Feb 9.","Pensato U","Cephalalgia","2022","2022/02/09","PMC9109244","","10.1177/03331024211067791"
"25813389","Therapeutic prospects for migraine: can paradise be regained?","Goadsby PJ.","Ann Neurol. 2013 Sep;74(3):423-34. doi: 10.1002/ana.23996.","Goadsby PJ","Ann Neurol","2013","2015/03/28","","","10.1002/ana.23996"
"35538414","Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study","Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A.","J Headache Pain. 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8.","Schenk H","J Headache Pain","2022","2022/05/10","PMC9092816","","10.1186/s10194-022-01426-8"
"20416986","[Treatment of migraine: present and future]","Massiou H.","Rev Med Interne. 2010 Jun;31(6):399-402. doi: 10.1016/j.revmed.2009.12.009. Epub 2010 Apr 22.","Massiou H","Rev Med Interne","2010","2010/04/27","","","10.1016/j.revmed.2009.12.009"
"37118682","Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series","Kaltseis K, Filippi V, Frank F, Eckhardt C, Schiefecker A, Broessner G.","BMC Neurol. 2023 Apr 28;23(1):174. doi: 10.1186/s12883-023-03203-9.","Kaltseis K","BMC Neurol","2023","2023/04/28","PMC10142255","","10.1186/s12883-023-03203-9"
"32053714","Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine","Blumenfeld AM, Edvinsson L, Jakate A, Banerjee P.","J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S8-S12.","Blumenfeld AM","J Fam Pract","2020","2020/02/14","","",""
"35707907","A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine","Argyriou AA, Mantovani E, Mitsikostas DD, Vikelis M, Tamburin S.","Expert Rev Neurother. 2022 Jun;22(6):469-488. doi: 10.1080/14737175.2022.2091435. Epub 2022 Jun 27.","Argyriou AA","Expert Rev Neurother","2022","2022/06/16","","","10.1080/14737175.2022.2091435"
"37730507","[Translated article] Consensus recommendations on the preventive treatment of migraine","Calleja-Hernández MÁ, Guerrero-Peral ÁL, Irimia-Sieira P, Martínez-López I, Santos-Lasaosa S, Sarobe-Carricas M, López-Matencio JMS, Láinez-Andrés JM.","Farm Hosp. 2023 Nov-Dec;47(6):T246-T253. doi: 10.1016/j.farma.2023.07.002. Epub 2023 Sep 18.","Calleja-Hernández MÁ","Farm Hosp","2023","2023/09/20","","","10.1016/j.farma.2023.07.002"
"34429056","Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis","Yang Y, Chen M, Wu D, Sun Y, Jiang F, Chen Z, Wang Z.","Curr Neuropharmacol. 2022;20(2):460-470. doi: 10.2174/1570159X19666210823104916.","Yang Y","Curr Neuropharmacol","2022","2021/08/25","PMC9413785","","10.2174/1570159X19666210823104916"
"33023473","Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study","Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J.","J Headache Pain. 2020 Oct 6;21(1):120. doi: 10.1186/s10194-020-01186-3.","Silberstein S","J Headache Pain","2020","2020/10/07","PMC7539382","","10.1186/s10194-020-01186-3"
"22939884","Basic mechanisms of migraine and its acute treatment","Edvinsson L, Villalón CM, MaassenVanDenBrink A.","Pharmacol Ther. 2012 Dec;136(3):319-33. doi: 10.1016/j.pharmthera.2012.08.011. Epub 2012 Aug 24.","Edvinsson L","Pharmacol Ther","2012","2012/09/04","","","10.1016/j.pharmthera.2012.08.011"
"33338436","Oral rimegepant for migraine prevention","Edvinsson L.","Lancet. 2021 Jan 2;397(10268):4-5. doi: 10.1016/S0140-6736(20)32624-6. Epub 2020 Dec 15.","Edvinsson L","Lancet","2021","2020/12/18","","","10.1016/S0140-6736(20)32624-6"
"31508812","Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?","Barbanti P, Egeo G, Mitsikostas DD.","Headache. 2019 Oct;59(9):1659-1661. doi: 10.1111/head.13635. Epub 2019 Sep 11.","Barbanti P","Headache","2019","2019/09/12","","","10.1111/head.13635"
"34687446","Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study","Sakai F, Suzuki N, Ning X, Ishida M, Usuki C, Iba K, Isogai Y, Koga N.","Drug Saf. 2021 Dec;44(12):1355-1364. doi: 10.1007/s40264-021-01119-2. Epub 2021 Oct 23.","Sakai F","Drug Saf","2021","2021/10/23","PMC8626354","","10.1007/s40264-021-01119-2"
"38323326","Potential benefits and possible risks of CGRP-targeted multitherapy in migraine","Ihara K, Takizawa T, Watanabe N, Nakahara J, Martelletti P.","Expert Opin Drug Metab Toxicol. 2024 Jan-Feb;20(1-2):1-4. doi: 10.1080/17425255.2024.2316131. Epub 2024 Feb 12.","Ihara K","Expert Opin Drug Metab Toxicol","2024","2024/02/07","","","10.1080/17425255.2024.2316131"
"12045727","Chronic daily headache: nosology and pathophysiology","Welch KM, Goadsby PJ.","Curr Opin Neurol. 2002 Jun;15(3):287-95. doi: 10.1097/00019052-200206000-00011.","Welch KM","Curr Opin Neurol","2002","2002/06/05","","","10.1097/00019052-200206000-00011"
"37955395","Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis","Ashina M, Mitsikostas DD, Ramirez Campos V, Barash S, Ning X, Diener HC.","Headache. 2023 Nov-Dec;63(10):1351-1358. doi: 10.1111/head.14651. Epub 2023 Nov 13.","Ashina M","Headache","2023","2023/11/13","","","10.1111/head.14651"
"30935360","[Migraine prophylaxis 2019 - the role of CGRP antagonists]","Sandor PS, Gantenbein AR.","Ther Umsch. 2018;75(7):455-457. doi: 10.1024/0040-5930/a001024.","Sandor PS","Ther Umsch","2018","2019/04/03","","","10.1024/0040-5930/a001024"
"26264901","[Headache. Current status of research and treatment]","Straube A, Gaul C.","Schmerz. 2015 Oct;29(5):510-5. doi: 10.1007/s00482-015-0040-2.","Straube A","Schmerz","2015","2015/08/13","","","10.1007/s00482-015-0040-2"
"33059476","No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine","Ernstsen C, Christensen SL, Olesen J, Kristensen DM.","Cephalalgia. 2021 Mar;41(3):329-339. doi: 10.1177/0333102420963857. Epub 2020 Oct 15.","Ernstsen C","Cephalalgia","2021","2020/10/16","","","10.1177/0333102420963857"
"29800193","Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea","Loder EW, Robbins MS.","JAMA. 2018 May 15;319(19):1985-1987. doi: 10.1001/jama.2018.4852.","Loder EW","JAMA","2018","2018/05/26","","","10.1001/jama.2018.4852"
"21770930","Pathophysiology of chronic migraine and mode of action of preventive medications","Mathew NT.","Headache. 2011 Jul-Aug;51 Suppl 2:84-92. doi: 10.1111/j.1526-4610.2011.01955.x.","Mathew NT","Headache","2011","2011/07/21","","","10.1111/j.1526-4610.2011.01955.x"
"35655137","Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study","Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM.","J Headache Pain. 2022 Jun 2;23(1):61. doi: 10.1186/s10194-022-01433-9.","Cullum CK","J Headache Pain","2022","2022/06/02","PMC9164431","","10.1186/s10194-022-01433-9"
"37817084","Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study","Hong Y, Kang MK, Moon HS, Kim BK, Cho SJ.","J Headache Pain. 2023 Oct 10;24(1):136. doi: 10.1186/s10194-023-01661-7.","Hong Y","J Headache Pain","2023","2023/10/10","PMC10566025","","10.1186/s10194-023-01661-7"
"24866108","Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide","Walter S, Alibhoy A, Escandon R, Bigal ME.","MAbs. 2014 Jul-Aug;6(4):871-8. doi: 10.4161/mabs.29242. Epub 2014 May 21.","Walter S","MAbs","2014","2014/05/29","PMC4171022","","10.4161/mabs.29242"
"37987641","Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study","Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nežádal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Lyras L, Tassorelli C.","Cephalalgia. 2023 Nov;43(11):3331024231214987. doi: 10.1177/03331024231214987.","Ashina M","Cephalalgia","2023","2023/11/21","","","10.1177/03331024231214987"
"25230231","Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines","Iftikhar H, Ahmad I, Gan SH, Shaik MM, Iftikhar N, Nawaz MS, Greig NH, Kamal MA.","CNS Neurol Disord Drug Targets. 2014;13(7):1130-9. doi: 10.2174/1871527313666140917111341.","Iftikhar H","CNS Neurol Disord Drug Targets","2014","2014/09/18","PMC5201208","NIHMS837364","10.2174/1871527313666140917111341"
"37400756","Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine","Siersbæk N, Kilsdal L, Jervelund C, Antic S, Bendtsen L.","BMC Neurol. 2023 Jul 3;23(1):254. doi: 10.1186/s12883-023-03302-7.","Siersbæk N","BMC Neurol","2023","2023/07/03","PMC10316628","","10.1186/s12883-023-03302-7"
"35869443","Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation","Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K; NHS Greater Glasgow and Clyde Headache Service.","J Headache Pain. 2022 Jul 22;23(1):86. doi: 10.1186/s10194-022-01456-2.","Lowe M","J Headache Pain","2022","2022/07/22","PMC9306036","","10.1186/s10194-022-01456-2"
"35976315","Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?","Simioni CVMG.","Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):214-217. doi: 10.1590/0004-282X-ANP-2022-S125.","Simioni CVMG","Arq Neuropsiquiatr","2022","2022/08/17","PMC9491416","","10.1590/0004-282X-ANP-2022-S125"
"34592919","Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study","Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget MA, Matharu MS, Tassorelli C.","J Headache Pain. 2021 Sep 30;22(1):113. doi: 10.1186/s10194-021-01322-7.","Okonkwo R","J Headache Pain","2021","2021/10/01","PMC8482748","","10.1186/s10194-021-01322-7"
"23943638","BMS-927711 for the acute treatment of migraine","Bigal ME.","Cephalalgia. 2014 Feb;34(2):90-2. doi: 10.1177/0333102413500728. Epub 2013 Aug 13.","Bigal ME","Cephalalgia","2014","2013/08/15","","","10.1177/0333102413500728"
"28479104","Behavioral study of a rat model of migraine induced by CGRP","Yao G, Huang Q, Wang M, Yang CL, Liu CF, Yu TM.","Neurosci Lett. 2017 Jun 9;651:134-139. doi: 10.1016/j.neulet.2017.04.059. Epub 2017 May 4.","Yao G","Neurosci Lett","2017","2017/05/09","","","10.1016/j.neulet.2017.04.059"
"34521260","Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial","Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM.","Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14.","Schwedt TJ","Cephalalgia","2022","2021/09/15","PMC8739573","","10.1177/03331024211042385"
"30656853","CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis","Han L, Liu Y, Xiong H, Hong P.","Brain Behav. 2019 Feb;9(2):e01215. doi: 10.1002/brb3.1215. Epub 2019 Jan 18.","Han L","Brain Behav","2019","2019/01/19","PMC6379644","","10.1002/brb3.1215"
"35350990","Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience","Raffaelli B, Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, Reuter U.","J Headache Pain. 2022 Mar 30;23(1):40. doi: 10.1186/s10194-022-01417-9.","Raffaelli B","J Headache Pain","2022","2022/03/30","PMC8966337","","10.1186/s10194-022-01417-9"
"34405713","Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention","Rozen TD, Bhatt AA.","Cephalalgia. 2022 Mar;42(3):250-256. doi: 10.1177/03331024211037277. Epub 2021 Aug 18.","Rozen TD","Cephalalgia","2022","2021/08/18","","","10.1177/03331024211037277"
"11717813","Development of CGRP antagonists for the treatment of migraine","Doods H.","Curr Opin Investig Drugs. 2001 Sep;2(9):1261-8.","Doods H","Curr Opin Investig Drugs","2001","2001/11/23","","",""
"34874514","Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials","Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW.","Adv Ther. 2022 Jan;39(1):692-705. doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 7.","Blumenfeld AM","Adv Ther","2022","2021/12/07","PMC8799553","","10.1007/s12325-021-01923-3"
"20120204","CGRP antagonists: hope for a new era in acute migraine treatment","Schelstraete C, Paemeleire K.","Acta Neurol Belg. 2009 Dec;109(4):252-61.","Schelstraete C","Acta Neurol Belg","2009","2010/02/03","","",""
"36401172","Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results","Gantenbein AR, Agosti R, Kamm CP, Landmann G, Meier N, Merki-Feld GS, Petersen JA, Pohl H, Ryvlin P, Schankin CJ, Viceic D, Zecca C, Schäfer E, Meyer I, Arzt ME.","J Headache Pain. 2022 Nov 18;23(1):142. doi: 10.1186/s10194-022-01515-8.","Gantenbein AR","J Headache Pain","2022","2022/11/19","PMC9673191","","10.1186/s10194-022-01515-8"
"35166159","Successful treatment of primary headache associated with sexual activity using erenumab: Case report","Makarevičius G, Ryliškienė K.","Cephalalgia. 2022 Jun;42(7):680-683. doi: 10.1177/03331024221075074. Epub 2022 Feb 15.","Makarevičius G","Cephalalgia","2022","2022/02/15","PMC9109243","","10.1177/03331024221075074"
"36997843","Is the right way to go in between? : Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201)","Gantenbein AR, Kleinschmidt A.","J Headache Pain. 2023 Mar 30;24(1):33. doi: 10.1186/s10194-023-01565-6.","Gantenbein AR","J Headache Pain","2023","2023/03/30","PMC10061740","","10.1186/s10194-023-01565-6"
"36799326","[Integrating new migraine treatments into clinical practice. Part 2 : preventive treatment]","Fumal A, Timmermans G.","Rev Med Liege. 2023 Feb;78(2):89-98.","Fumal A","Rev Med Liege","2023","2023/02/17","","",""
"35201674","Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies","Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, Numachi Y, Yoshida R, Peng C, Mikol DD, Lima GPDS, Cheng S.","Brain Behav. 2022 Mar;12(3):e2526. doi: 10.1002/brb3.2526. Epub 2022 Feb 24.","Hirata K","Brain Behav","2022","2022/02/24","PMC8933787","","10.1002/brb3.2526"
"31060491","Ultra-high field MR angiography in human migraine models: a 3.0 T/7.0 T comparison study","Christensen CE, Younis S, Lindberg U, Boer VO, de Koning P, Petersen ET, Paulson OB, Larsson HBW, Amin FM, Ashina M.","J Headache Pain. 2019 May 6;20(1):48. doi: 10.1186/s10194-019-0996-x.","Christensen CE","J Headache Pain","2019","2019/05/08","PMC6734314","","10.1186/s10194-019-0996-x"
"15298069","CGRP receptor antagonists: a new choice for acute treatment of migraine?","Durham PL.","Curr Opin Investig Drugs. 2004 Jul;5(7):731-5.","Durham PL","Curr Opin Investig Drugs","2004","2004/08/10","","",""
"29034461","The Migraine Attack as a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory","Borkum JM.","Headache. 2018 Jan;58(1):118-135. doi: 10.1111/head.13214. Epub 2017 Oct 16.","Borkum JM","Headache","2018","2017/10/17","","","10.1111/head.13214"
"37940860","One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study","Lanteri-Minet M, Fabre R, Martin C, Pradat K, Alchaar A, Bozzolo E, Duchene ML, Van Obberghen EK, Donnet A, Fontaine D.","J Headache Pain. 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4.","Lanteri-Minet M","J Headache Pain","2023","2023/11/08","PMC10633983","","10.1186/s10194-023-01680-4"
"26368117","The Journey to Establish CGRP as a Migraine Target: A Retrospective View","Edvinsson L.","Headache. 2015 Oct;55(9):1249-55. doi: 10.1111/head.12656. Epub 2015 Sep 14.","Edvinsson L","Headache","2015","2015/09/15","","","10.1111/head.12656"
"36430285","Sustained Effects of CGRP Blockade on Cortical Spreading Depolarization-Induced Alterations in Facial Heat Pain Threshold, Light Aversiveness, and Locomotive Activity in the Light Environment","Kitagawa S, Tang C, Unekawa M, Kayama Y, Nakahara J, Shibata M.","Int J Mol Sci. 2022 Nov 9;23(22):13807. doi: 10.3390/ijms232213807.","Kitagawa S","Int J Mol Sci","2022","2022/11/26","PMC9698572","","10.3390/ijms232213807"
"26744391","A shot at migraine","Underwood E.","Science. 2016 Jan 8;351(6269):116-9. doi: 10.1126/science.351.6269.116.","Underwood E","Science","2016","2016/01/09","","","10.1126/science.351.6269.116"
"38099600","Targeting CGRP pathways and aura: A peripheral site with a central effect","Al-Karagholi MA.","Cephalalgia. 2023 Dec;43(12):3331024231212895. doi: 10.1177/03331024231212895.","Al-Karagholi MA","Cephalalgia","2023","2023/12/15","","","10.1177/03331024231212895"
"24291936","[Pathophysiology of migraine chronification]","Shibata M.","Rinsho Shinkeigaku. 2013;23(11):1220-2. doi: 10.5692/clinicalneurol.53.1220.","Shibata M","Rinsho Shinkeigaku","2013","2013/12/03","","","10.5692/clinicalneurol.53.1220"
"31595083","CGRP-targeted antibodies in difficult-to-treat migraine","de Vries T, MaassenVanDenBrink A.","Nat Rev Neurol. 2019 Dec;15(12):688-689. doi: 10.1038/s41582-019-0275-0.","de Vries T","Nat Rev Neurol","2019","2019/10/10","","","10.1038/s41582-019-0275-0"
"15174248","[Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks]","Stepień A, Jagustyn P, Trafny EA, Widerkiewicz K.","Neurol Neurochir Pol. 2003 Sep-Oct;37(5):1013-23.","Stepień A","Neurol Neurochir Pol","2003","2004/06/04","","",""
"16483070","Migraine development, treatments, research advances, and anesthesia implications","O'Sullivan J, McCabe JT.","AANA J. 2006 Feb;74(1):61-9.","O'Sullivan J","AANA J","2006","2006/02/18","","",""
"31816249","The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response","Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD.","Cephalalgia. 2020 Jan;40(1):28-38. doi: 10.1177/0333102419894559. Epub 2019 Dec 9.","Brandes JL","Cephalalgia","2020","2019/12/10","","","10.1177/0333102419894559"
"17157610","Migraine headaches: a historical prospective, a glimpse into the future, and migraine epidemiology","Unger J.","Dis Mon. 2006 Oct;52(10):367-84. doi: 10.1016/j.disamonth.2006.09.002.","Unger J","Dis Mon","2006","2006/12/13","","","10.1016/j.disamonth.2006.09.002"
"37516124","Atogepant, the first oral preventive treatment for chronic migraine","Haanes KA, Edvinsson L.","Lancet. 2023 Sep 2;402(10404):748-749. doi: 10.1016/S0140-6736(23)01462-9. Epub 2023 Jul 26.","Haanes KA","Lancet","2023","2023/07/29","","","10.1016/S0140-6736(23)01462-9"
"37594778","Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention","Regnier SA, Lee XY.","J Med Econ. 2023 Jan-Dec;26(1):1072-1080. doi: 10.1080/13696998.2023.2248842.","Regnier SA","J Med Econ","2023","2023/08/18","","","10.1080/13696998.2023.2248842"
"15620852","Headache: triumphs in translational research","Lipton RB, Bigal ME.","Lancet Neurol. 2005 Jan;4(1):11-2. doi: 10.1016/S1474-4422(04)00950-0.","Lipton RB","Lancet Neurol","2005","2004/12/29","","","10.1016/S1474-4422(04)00950-0"
"37882379","The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis","Moskatel LS, Graber-Naidich A, He Z, Zhang N.","Headache. 2024 Feb;64(2):188-194. doi: 10.1111/head.14642. Epub 2023 Oct 26.","Moskatel LS","Headache","2024","2023/10/26","","","10.1111/head.14642"
"34252914","Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis","Swerts DB, Benedetti F, Peres MFP.","Pain. 2022 Mar 1;163(3):415-424. doi: 10.1097/j.pain.0000000000002365.","Swerts DB","Pain","2022","2021/07/12","","","10.1097/j.pain.0000000000002365"
"37943442","Unmet Needs in the Acute Treatment of Migraine","Bentivegna E, Galastri S, Onan D, Martelletti P.","Adv Ther. 2024 Jan;41(1):1-13. doi: 10.1007/s12325-023-02650-7. Epub 2023 Nov 9.","Bentivegna E","Adv Ther","2024","2023/11/09","PMC10796525","","10.1007/s12325-023-02650-7"
"36054749","Level of therapeutic innovation from the registration studies of the new drugs for the prophylaxis of migraine","Motola D, Santi Laurini G, Bonaldo G, Montanaro N.","J Clin Pharm Ther. 2022 Dec;47(12):2130-2139. doi: 10.1111/jcpt.13760. Epub 2022 Aug 19.","Motola D","J Clin Pharm Ther","2022","2022/09/02","PMC10087688","","10.1111/jcpt.13760"
"30681655","Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention","","Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-180.","","Med Lett Drugs Ther","2018","2019/01/26","","",""
"33187570","Migraine Prophylaxis Using Novel Monoclonal Antibody Injections in a Commercial Pilot","Garber MA, Sirven JI, Roth RS, Hemphill JM.","Aerosp Med Hum Perform. 2020 Oct 1;91(10):824-825. doi: 10.3357/AMHP.5688.2020.","Garber MA","Aerosp Med Hum Perform","2020","2020/11/14","","","10.3357/AMHP.5688.2020"
"37043250","Study Provides New Insight Into Female Sex Hormones and Migraines","Marcus R.","JAMA. 2023 May 2;329(17):1439-1440. doi: 10.1001/jama.2023.5536.","Marcus R","JAMA","2023","2023/04/12","","","10.1001/jama.2023.5536"
"35976302","It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine","Kubota GT.","Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):218-226. doi: 10.1590/0004-282X-ANP-2022-S112.","Kubota GT","Arq Neuropsiquiatr","2022","2022/08/17","PMC9491437","","10.1590/0004-282X-ANP-2022-S112"
"35589634","[Unable to Work Due to Migraine for Which Tryptan is Taken 14 Times a Month or Less: Medication-Overuse Headache (MOH)]","Nagata E.","Brain Nerve. 2022 May;74(5):474-478. doi: 10.11477/mf.1416202067.","Nagata E","Brain Nerve","2022","2022/05/19","","","10.11477/mf.1416202067"
"21294334","[Calcitonin gene-related peptide and migraine. Increases understanding of physiopathology can lead to new drug therapy]","Edvinsson L.","Lakartidningen. 2010 Dec 15-21;107(50):3208-11.","Edvinsson L","Lakartidningen","2010","2011/02/08","","",""
"36623986","Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients","Castrillo A, Mendoza A, Caballero L, Cerdán D, Rodríguez MF, Guerrero P, Tabernero C, Ferrero M, Benito I, Marín L, Duarte J.","Med Clin (Barc). 2023 Apr 21;160(8):341-346. doi: 10.1016/j.medcli.2022.09.023. Epub 2023 Jan 7.","Castrillo A","Med Clin (Barc)","2023","2023/01/09","","","10.1016/j.medcli.2022.09.023"
"25881990","Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache","Cargnin S, Pautasso C, Viana M, Sances G, Mittino D, Cantello R, Tassorelli C, Nappi G, Terrazzino S.","Headache. 2015 May;55(5):658-68. doi: 10.1111/head.12559. Epub 2015 Apr 17.","Cargnin S","Headache","2015","2015/04/18","","","10.1111/head.12559"
"8869758","CGRP: blood flow and more?","Moskowitz MA, Cutrer FM.","Cephalalgia. 1996 Aug;16(5):287. doi: 10.1046/j.1468-2982.1996.1605287.x.","Moskowitz MA","Cephalalgia","1996","1996/08/01","","","10.1046/j.1468-2982.1996.1605287.x"
"36648736","Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies","Harris L, O'Connell T, Woolley JJ, L'Italien G, Martin T, Coric V, Moren JA.","Adv Ther. 2023 Mar;40(3):1141-1152. doi: 10.1007/s12325-022-02386-w. Epub 2023 Jan 17.","Harris L","Adv Ther","2023","2023/01/17","PMC9988741","","10.1007/s12325-022-02386-w"
"11993614","CGRP may play a causative role in migraine","Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J.","Cephalalgia. 2002 Feb;22(1):54-61. doi: 10.1046/j.1468-2982.2002.00310.x.","Lassen LH","Cephalalgia","2002","2002/05/08","","","10.1046/j.1468-2982.2002.00310.x"
"33176870","Effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine: a single-centre, randomised, double-blind, sham-controlled phase 2 trial (Magnet-EM)","Mohamad Safiai NI, Amir NA, Basri H, Inche Mat LN, Hoo FK, Yusof Khan AHK, Loh WC, Chia PK, Ramachandran V, Mat Din H, Samsudin IN, Fernandez A, Mohamed MH, Ching SM, Hashim HZ, Wan Sulaiman WA.","Trials. 2020 Nov 11;21(1):923. doi: 10.1186/s13063-020-04832-y.","Mohamad Safiai NI","Trials","2020","2020/11/12","PMC7657359","","10.1186/s13063-020-04832-y"
"37158755","Evaluation of the change in efficacy of erenumab when used long-term for migraine prevention after initial established benefit in a veteran population","Martin AW, Cubellis M.","Pharmacotherapy. 2023 Jun;43(6):494-501. doi: 10.1002/phar.2812. Epub 2023 May 22.","Martin AW","Pharmacotherapy","2023","2023/05/09","","","10.1002/phar.2812"
"26255883","Editorial for Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know","Markley HG.","Headache. 2015 Sep;55(8):1169-70. doi: 10.1111/head.12641. Epub 2015 Aug 10.","Markley HG","Headache","2015","2015/08/11","","","10.1111/head.12641"
"25869319","A novel formulation of veggies with potent anti-migraine activity","Jain MM, Kumari N, Rai G.","Int J Comput Biol Drug Des. 2015;8(1):54-61. doi: 10.1504/IJCBDD.2015.068787. Epub 2015 Apr 13.","Jain MM","Int J Comput Biol Drug Des","2015","2015/04/15","","","10.1504/IJCBDD.2015.068787"
"38332541","Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study","Cresta E, Bellotti A, Rinaldi G, Corbelli I, Sarchielli P.","CNS Neurosci Ther. 2024 Feb;30(2):e14595. doi: 10.1111/cns.14595.","Cresta E","CNS Neurosci Ther","2024","2024/02/09","PMC10853579","","10.1111/cns.14595"
"33730441","Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study","Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P.","Eur J Neurol. 2021 Jul;28(7):2378-2382. doi: 10.1111/ene.14828. Epub 2021 Apr 5.","Alpuente A","Eur J Neurol","2021","2021/03/17","","","10.1111/ene.14828"
"23975872","Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J.","Neurology. 2013 Oct 1;81(14):1191-6. doi: 10.1212/WNL.0b013e3182a6cb72. Epub 2013 Aug 23.","Cernuda-Morollón E","Neurology","2013","2013/08/27","","","10.1212/WNL.0b013e3182a6cb72"
"38491415","CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society","Takizawa T, Ihara K, Watanabe N, Takemura R, Takahashi N, Miyazaki N, Shibata M, Suzuki K, Imai N, Suzuki N, Hirata K, Takeshima T, Nakahara J.","J Headache Pain. 2024 Mar 15;25(1):39. doi: 10.1186/s10194-024-01737-y.","Takizawa T","J Headache Pain","2024","2024/03/16","PMC10941476","","10.1186/s10194-024-01737-y"
"1297398","[The pathogenetic bases of hemicrania]","Fanciullacci M, Alessandri M, Bandini EB.","Ann Ital Med Int. 1992 Jul-Sep;7(3 Suppl):41S-45S.","Fanciullacci M","Ann Ital Med Int","1992","1992/07/01","","",""
"38462625","Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials","Rizzoli P, Marmura MJ, Robblee J, McVige J, Sacco S, Nahas SJ, Ailani J, De Abreu Ferreira R, Ma J, Smith JH, Dabruzzo B, Ashina M.","J Headache Pain. 2024 Mar 11;25(1):35. doi: 10.1186/s10194-024-01736-z.","Rizzoli P","J Headache Pain","2024","2024/03/11","PMC10926658","","10.1186/s10194-024-01736-z"
"17157611","The pathophysiology of migraine","Schreiber CP.","Dis Mon. 2006 Oct;52(10):385-401. doi: 10.1016/j.disamonth.2006.09.003.","Schreiber CP","Dis Mon","2006","2006/12/13","","","10.1016/j.disamonth.2006.09.003"
"32359106","Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series","Silvestro M, Tessitore A, Scotto di Clemente F, Tedeschi G, Russo A.","Headache. 2020 Jun;60(6):1187-1195. doi: 10.1111/head.13832. Epub 2020 May 2.","Silvestro M","Headache","2020","2020/05/03","","","10.1111/head.13832"
"36815419","[Anti-CGRP monoclonal antibodies for the preventive treatment of migraine: a cost-effectiveness analysis in the Italian scenario.]","Zovi A, Vitiello A, Langella R, Lasala R, Ferrara F.","Recenti Prog Med. 2023 Mar;114(3):157-162. doi: 10.1701/3981.39640.","Zovi A","Recenti Prog Med","2023","2023/02/23","","","10.1701/3981.39640"
"18776915","CGRP blockers in migraine therapy: where do they act?","Edvinsson L.","Br J Pharmacol. 2008 Dec;155(7):967-9. doi: 10.1038/bjp.2008.346. Epub 2008 Sep 8.","Edvinsson L","Br J Pharmacol","2008","2008/09/09","PMC2597260","","10.1038/bjp.2008.346"
"32049005","Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)","Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C, Xu C, Wang Z.","Cell Rep. 2020 Feb 11;30(6):1714-1723.e6. doi: 10.1016/j.celrep.2020.01.029.","Garces F","Cell Rep","2020","2020/02/13","","","10.1016/j.celrep.2020.01.029"
"18344604","[Recent topics on migraine: issues of the current treatments and new drugs for the treatment of migraine]","Shimizu T, Suzuki N.","Nihon Yakurigaku Zasshi. 2008 Mar;131(3):210-4. doi: 10.1254/fpj.131.210.","Shimizu T","Nihon Yakurigaku Zasshi","2008","2008/03/18","","","10.1254/fpj.131.210"
"15157847","CGRP antagonists in the acute treatment of migraine","Lipton RB, Dodick DW.","Lancet Neurol. 2004 Jun;3(6):332. doi: 10.1016/S1474-4422(04)00764-1.","Lipton RB","Lancet Neurol","2004","2004/05/26","","","10.1016/S1474-4422(04)00764-1"
"19161565","Moving forward - essential questions for the next 10 years","Lipton RB, Sheftell FD.","Headache. 2009 Feb;49 Suppl 1:S43-6. doi: 10.1111/j.1526-4610.2008.01362.x.","Lipton RB","Headache","2009","2009/01/24","","","10.1111/j.1526-4610.2008.01362.x"
"38071464","Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study","Chase BA, Semenov I, Rubin S, Meyers S, Mark A, Makhlouf T, Chirayil TT, Maraganore D, Wei J, Zheng SL, Xu J, Epshteyn A, Pham A, Frigerio R, Markopoulou K.","Headache. 2024 Jan;64(1):68-92. doi: 10.1111/head.14655. Epub 2023 Dec 10.","Chase BA","Headache","2024","2023/12/10","","","10.1111/head.14655"
"32266593","Anti-CGRP in cluster headache therapy: a response","Wenzel R, Bardos J, Aurora S.","Neurol Sci. 2020 Sep;41(9):2641. doi: 10.1007/s10072-020-04335-3. Epub 2020 Apr 8.","Wenzel R","Neurol Sci","2020","2020/04/09","PMC7419360","","10.1007/s10072-020-04335-3"
"32860531","Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center","Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM, Merli E, Calabrò C, Cortelli P, Pierangeli G, Cevoli S.","Neurol Sci. 2020 Dec;41(Suppl 2):483-484. doi: 10.1007/s10072-020-04667-0.","Matteo E","Neurol Sci","2020","2020/08/30","","","10.1007/s10072-020-04667-0"
"20959429","CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine","Tvedskov JF, Tfelt-Hansen P, Petersen KA, Jensen LT, Olesen J.","Cephalalgia. 2010 Nov;30(11):1346-53. doi: 10.1177/0333102410363491. Epub 2010 Apr 7.","Tvedskov JF","Cephalalgia","2010","2010/10/21","","","10.1177/0333102410363491"
"37847661","Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study","Gonzalez-Martinez A, Sanz-García A, García-Azorín D, Rodríguez-Vico J, Jaimes A, Gómez García A, Casas-Limón J, Díaz de Terán J, Sastre-Real M, Membrilla J, Latorre G, Calle de Miguel C, Gil Luque S, Trevino-Peinado C, Quintas S, Heredia P, Echavarría-Íñiguez A, Guerrero-Peral Á, Sierra Á, González-García N, Porta-Etessam J, Gago-Veiga AB.","Pain Med. 2024 Mar 1;25(3):194-202. doi: 10.1093/pm/pnad141.","Gonzalez-Martinez A","Pain Med","2024","2023/10/17","","","10.1093/pm/pnad141"
"32053715","Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine","Dodick DW, Ailani J.","J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S13-S22.","Dodick DW","J Fam Pract","2020","2020/02/14","","",""
"16886948","Sumatriptan causes parallel decrease in plasma CGRP concentration and migraine headache during nitroglycerin-induced migraine attack","Vanmolkot F, Van der Schueren B, de Hoon J.","Cephalalgia. 2006 Aug;26(8):1037-8; author reply 1038-9. doi: 10.1111/j.1468-2982.2006.01133_1.x.","Vanmolkot F","Cephalalgia","2006","2006/08/05","","","10.1111/j.1468-2982.2006.01133_1.x"
"22558876","[Therapy and prophylaxis of migraine]","Diener HC, Rabe K.","MMW Fortschr Med. 2012 Apr 19;154(7):52-5.","Diener HC","MMW Fortschr Med","2012","2012/05/08","","",""
"33131305","Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine","Kopruszinski CM, Thornton P, Arnold J, Newton P, Lowne D, Navratilova E, Swiokla J, Dodick DW, Dobson C, Gurrell I, Chessell IP, Porreca F.","Cephalalgia. 2020 Dec;40(14):1535-1550. doi: 10.1177/0333102420966581. Epub 2020 Nov 1.","Kopruszinski CM","Cephalalgia","2020","2020/11/02","","","10.1177/0333102420966581"
"34877663","Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine","Ailani J, Blumenfeld AM.","Headache. 2022 Jan;62(1):106-108. doi: 10.1111/head.14244. Epub 2021 Dec 7.","Ailani J","Headache","2022","2021/12/08","PMC9300070","","10.1111/head.14244"
"19198084","[Migrainology learned from patients]","Sakai F.","Rinsho Shinkeigaku. 2008 Nov;48(11):785-91.","Sakai F","Rinsho Shinkeigaku","2008","2009/02/10","","",""
"31990360","[New migraine treatment requires better health care structure]","Sundholm A, Steinberg A.","Lakartidningen. 2020 Jan 21;117:FTS7.","Sundholm A","Lakartidningen","2020","2020/01/29","","",""
"25926620","Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine","Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WP, Koppenhaver J, Lines C, Ferrari MD, Michelson D.","Cephalalgia. 2016 Feb;36(2):148-61. doi: 10.1177/0333102415584308. Epub 2015 Apr 29.","Ho TW","Cephalalgia","2016","2015/05/01","","","10.1177/0333102415584308"
"27344850","[Progression of the mechanism study on experimental migraine treated with acupuncture in rat model]","Liu L, Pei P, Wang L.","Zhongguo Zhen Jiu. 2016 Mar;36(3):331-6.","Liu L","Zhongguo Zhen Jiu","2016","2016/06/28","","",""
"25297015","CGRP as a new target in prevention and treatment of migraine","Diener HC.","Lancet Neurol. 2014 Nov;13(11):1065-1067. doi: 10.1016/S1474-4422(14)70228-5. Epub 2014 Oct 5.","Diener HC","Lancet Neurol","2014","2014/10/10","","","10.1016/S1474-4422(14)70228-5"
"17914062","Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine","Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM; MK-0974 Protocol 004 study group.","Neurology. 2008 Apr 15;70(16):1304-12. doi: 10.1212/01.WNL.0000286940.29755.61. Epub 2007 Oct 3.","Ho TW","Neurology","2008","2007/10/05","","","10.1212/01.WNL.0000286940.29755.61"
"38284301","Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway","Waliszewska-Prosół M, Martelletti P.","Dent Med Probl. 2024 Jan-Feb;61(1):9-11. doi: 10.17219/dmp/174706.","Waliszewska-Prosół M","Dent Med Probl","2024","2024/01/29","","","10.17219/dmp/174706"
"20458901","[Effect of electroacupuncture on cortical spreading depression and plasma CGRP and substance P contents in migraine rats]","Shi H, Li JH, Ji CF, Shang HY, Qiu EC, Wang JJ, Jing XH.","Zhen Ci Yan Jiu. 2010 Feb;35(1):17-21.","Shi H","Zhen Ci Yan Jiu","2010","2010/05/13","","",""
"19469188","[CGRP antagonists: novel concept for treatment of migraine]","Nieber K.","Med Monatsschr Pharm. 2009 May;32(5):182-5.","Nieber K","Med Monatsschr Pharm","2009","2009/05/28","","",""
"29799961","Who Should Try New Antibody Treatments for Migraine?","Loder EW, Burch RC.","JAMA Neurol. 2018 Sep 1;75(9):1039-1040. doi: 10.1001/jamaneurol.2018.1268.","Loder EW","JAMA Neurol","2018","2018/05/26","","","10.1001/jamaneurol.2018.1268"
"22937543","[Molecular mechanism of migraine headache]","Suzuki N, Nakashima K.","Rinsho Shinkeigaku. 2010 Nov;50(11):988. doi: 10.5692/clinicalneurol.50.988.","Suzuki N","Rinsho Shinkeigaku","2010","2012/09/04","","","10.5692/clinicalneurol.50.988"
"8191378","[Headache--what is the current status?]","Diener HC, Limmroth V.","Ther Umsch. 1993 Nov;50(11):730-6.","Diener HC","Ther Umsch","1993","1993/11/01","","",""
"38381352","Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model","Thaliffdeen R, Yu A, Rascati K.","Clin Drug Investig. 2024 Mar;44(3):209-217. doi: 10.1007/s40261-024-01345-3. Epub 2024 Feb 21.","Thaliffdeen R","Clin Drug Investig","2024","2024/02/21","","","10.1007/s40261-024-01345-3"
"32971471","No pain, no gain: Will migraine therapies increase bone loss and impair fracture healing?","Kacena MA, White FA.","EBioMedicine. 2020 Oct;60:103025. doi: 10.1016/j.ebiom.2020.103025. Epub 2020 Sep 22.","Kacena MA","EBioMedicine","2020","2020/09/24","PMC7516061","","10.1016/j.ebiom.2020.103025"
"16162089","Migraine: new treatment options from molecular biology","Stam AH, Haan J, Frants RR, Ferrari MD, van den Maagdenberg AM.","Expert Rev Neurother. 2005 Sep;5(5):653-61. doi: 10.1586/14737175.5.5.653.","Stam AH","Expert Rev Neurother","2005","2005/09/16","","","10.1586/14737175.5.5.653"
"35420352","Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report","Cetta I, Messina R, Colombo B, Filippi M.","J Neurol. 2022 Sep;269(9):5170-5172. doi: 10.1007/s00415-022-11128-5. Epub 2022 Apr 14.","Cetta I","J Neurol","2022","2022/04/14","","","10.1007/s00415-022-11128-5"
"21321349","Current understanding and treatment of headache disorders: five new things","Marmura MJ, Silberstein SD.","Neurology. 2011 Feb 15;76(7 Suppl 2):S31-6. doi: 10.1212/WNL.0b013e31820c95cc.","Marmura MJ","Neurology","2011","2011/02/16","","","10.1212/WNL.0b013e31820c95cc"
"19146028","Pressure point","Mason MC.","Nurs Stand. 2008 Dec 17-2009 Jan 6;23(15-17):22.","Mason MC","Nurs Stand","2008","2009/01/17","","",""
"8902256","Neuropeptide changes in a case of chronic paroxysmal hemicrania--evidence for trigemino-parasympathetic activation","Goadsby PJ, Edvinsson L.","Cephalalgia. 1996 Oct;16(6):448-50. doi: 10.1046/j.1468-2982.1996.1606448.x.","Goadsby PJ","Cephalalgia","1996","1996/10/01","","","10.1046/j.1468-2982.1996.1606448.x"
"34841535","AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?","Charles JA, Turner IM.","Headache. 2022 Jan;62(1):109-110. doi: 10.1111/head.14232. Epub 2021 Nov 28.","Charles JA","Headache","2022","2021/11/29","","","10.1111/head.14232"
"15330838","Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release","Caputi CA.","Headache. 2004 Sep;44(8):837-8. doi: 10.1111/j.1526-4610.2004.04158_1.x.","Caputi CA","Headache","2004","2004/08/28","","","10.1111/j.1526-4610.2004.04158_1.x"
"21156441","Procalcitonin levels in migraine patients","Turan H, Horasanli B, Ugur M, Arslan H.","Can J Neurol Sci. 2011 Jan;38(1):124-8. doi: 10.1017/s0317167100011161.","Turan H","Can J Neurol Sci","2011","2010/12/16","","","10.1017/s0317167100011161"
"21809559","[Heat coagulation of middle meningeal artery affects plasma CGRP and substance P levels in migraine rat triggered by nitroglycerin]","Zhu X, Han Y, Xiong W, Wang H, Li J, Liu W, Fan Z.","Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 May;25(10):460-2, 468.","Zhu X","Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi","2011","2011/08/04","","",""
"23016921","Does the neurobiology of migraine make migraine patients ""difficult""?","Gupta S, Petersen KA.","Headache. 2012 Nov-Dec;52(10):1609-10. doi: 10.1111/j.1526-4610.2012.02256.x. Epub 2012 Sep 27.","Gupta S","Headache","2012","2012/09/29","","","10.1111/j.1526-4610.2012.02256.x"
"29904874","May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?","Lovati C, Giani L, Mariotti D Alessandro C, Tabaee Damavandi P, Mariani C, Pantoni L.","Neurol Sci. 2018 Jun;39(Suppl 1):153-154. doi: 10.1007/s10072-018-3388-0.","Lovati C","Neurol Sci","2018","2018/06/16","","","10.1007/s10072-018-3388-0"
"31033548","New Drugs for Preventing Migraines","Aschenbrenner DS.","Am J Nurs. 2019 May;119(5):22. doi: 10.1097/01.NAJ.0000557909.12528.af.","Aschenbrenner DS","Am J Nurs","2019","2019/04/30","","","10.1097/01.NAJ.0000557909.12528.af"
"19673899","Extracranial source of increased CGRP in migraine children?","Tfelt-Hansen P, Ashina M.","Cephalalgia. 2010 Mar;30(3):380-1. doi: 10.1111/j.1468-2982.2009.01953.x. Epub 2010 Feb 1.","Tfelt-Hansen P","Cephalalgia","2010","2009/08/14","","","10.1111/j.1468-2982.2009.01953.x"
"27154401","New migraine therapies promise prevention: A new generation of drugs could avert migraine attacks rather than merely relieve symptoms","Hunter P.","EMBO Rep. 2016 Jun;17(6):797-9. doi: 10.15252/embr.201642519. Epub 2016 May 6.","Hunter P","EMBO Rep","2016","2016/05/08","PMC5278615","","10.15252/embr.201642519"
"15014178","CGRP-receptor antagonists--a fresh approach to migraine therapy?","Durham PL.","N Engl J Med. 2004 Mar 11;350(11):1073-5. doi: 10.1056/NEJMp048016.","Durham PL","N Engl J Med","2004","2004/03/12","","","10.1056/NEJMp048016"
"15523577","[CGRP-receptor antagonists for the treatment of acute migraine: interesting option or therapeutic breakthrough?]","Kress HG.","Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Nov;39(11):655-6. doi: 10.1055/s-2004-826088.","Kress HG","Anasthesiol Intensivmed Notfallmed Schmerzther","2004","2004/11/04","","","10.1055/s-2004-826088"
"23535922","Antibody drugs set to revive flagging migraine target","Dolgin E.","Nat Rev Drug Discov. 2013 Apr;12(4):249-50. doi: 10.1038/nrd3991.","Dolgin E","Nat Rev Drug Discov","2013","2013/03/29","","","10.1038/nrd3991"
"1321319","[Migraine: new aspects on physiopathology and research]","Edvinsson L.","Lakartidningen. 1992 May 27;89(22):1993-5.","Edvinsson L","Lakartidningen","1992","1992/05/27","","",""
"15007953","[Recent progress in therapy for migraine headache]","Iizuka T, Sakai F.","Nihon Naika Gakkai Zasshi. 2004 Feb 10;93(2):404-11. doi: 10.2169/naika.93.404.","Iizuka T","Nihon Naika Gakkai Zasshi","2004","2004/03/11","","","10.2169/naika.93.404"
"25314737","New hope for people with migraine headaches","","Harv Health Lett. 2014 Jul;39(9):8.","","Harv Health Lett","2014","2014/10/16","","",""
"34742252","Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany","Straube A, Stude P, Gaul C, Schuh K, Koch M.","J Headache Pain. 2021 Nov 6;22(1):133. doi: 10.1186/s10194-021-01344-1.","Straube A","J Headache Pain","2021","2021/11/07","PMC8572451","","10.1186/s10194-021-01344-1"
"37830925","Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy","Hyeraci G, Paoletti O, Iannone LF, Gini R, De Cesaris F, Geppetti P, Roberto G.","Headache. 2023 Nov-Dec;63(10):1391-1402. doi: 10.1111/head.14639. Epub 2023 Oct 13.","Hyeraci G","Headache","2023","2023/10/13","","","10.1111/head.14639"
"31691955","A Popperian View on Anti-CGRP Biologics in Migraine","Chiarugi A.","Headache. 2019 Nov;59(10):1855-1860. doi: 10.1111/head.13695. Epub 2019 Nov 6.","Chiarugi A","Headache","2019","2019/11/07","","","10.1111/head.13695"
"37486684","Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine","Porreca F, Dodick DW.","JAMA Neurol. 2023 Sep 1;80(9):885-886. doi: 10.1001/jamaneurol.2023.2335.","Porreca F","JAMA Neurol","2023","2023/07/24","","","10.1001/jamaneurol.2023.2335"
"32093657","The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial","Ghorbani Z, Rafiee P, Fotouhi A, Haghighi S, Rasekh Magham R, Ahmadi ZS, Djalali M, Zareei M, Razeghi Jahromi S, Shahemi S, Mahmoudi M, Togha M.","J Headache Pain. 2020 Feb 24;21(1):22. doi: 10.1186/s10194-020-01090-w.","Ghorbani Z","J Headache Pain","2020","2020/02/26","PMC7041277","","10.1186/s10194-020-01090-w"
"17853752","[Observation on the therapeutic effect of ear point combined therapy on common migraine at the remission stage and effects on plasma CGRP and ET in the patient]","Yang DH, Han J, Shan QH.","Zhongguo Zhen Jiu. 2007 Aug;27(8):569-71.","Yang DH","Zhongguo Zhen Jiu","2007","2007/09/15","","",""
"36205100","Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment","Fofi L, Altamura C, Fiorentini G, Brunelli N, Marcosano M, Barbanti P, Vernieri F.","Headache. 2022 Oct;62(9):1143-1147. doi: 10.1111/head.14400. Epub 2022 Oct 7.","Fofi L","Headache","2022","2022/10/07","PMC9828231","","10.1111/head.14400"
"34256650","Targeting reactive nitroxidative species in preclinical models of migraine","Akerman S, Salvemini D, Romero-Reyes M.","Cephalalgia. 2021 Oct;41(11-12):1187-1200. doi: 10.1177/03331024211017884. Epub 2021 Jul 13.","Akerman S","Cephalalgia","2021","2021/07/14","","","10.1177/03331024211017884"
"11072637","[Physiopathology of the migraine attack and mechanisms of action of anti-migraine agents: recent findings in animals]","Mick G.","Pathol Biol (Paris). 2000 Sep;48(7):593-607.","Mick G","Pathol Biol (Paris)","2000","2000/11/10","","",""
"33027220","Different forms of traumatic brain injuries cause different tactile hypersensitivity profiles","Wattiez AS, Castonguay WC, Gaul OJ, Waite JS, Schmidt CM, Reis AS, Rea BJ, Sowers LP, Cintrón-Pérez CJ, Vázquez-Rosa E, Pieper AA, Russo AF.","Pain. 2021 Apr 1;162(4):1163-1175. doi: 10.1097/j.pain.0000000000002103.","Wattiez AS","Pain","2021","2020/10/07","PMC8008742","NIHMS1684656","10.1097/j.pain.0000000000002103"
"34545218","Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP","Krause DN, Warfvinge K, Haanes KA, Edvinsson L.","Nat Rev Neurol. 2021 Oct;17(10):621-633. doi: 10.1038/s41582-021-00544-2. Epub 2021 Sep 20.","Krause DN","Nat Rev Neurol","2021","2021/09/21","","","10.1038/s41582-021-00544-2"
"34406609","Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice","Storch P, Burow P, Möller B, Kraya T, Heintz S, Politz N, Naegel S.","Acta Neurol Belg. 2022 Aug;122(4):931-937. doi: 10.1007/s13760-021-01770-7. Epub 2021 Aug 18.","Storch P","Acta Neurol Belg","2022","2021/08/18","PMC9300569","","10.1007/s13760-021-01770-7"
"33648385","Evaluating rimegepant for the treatment of migraine","de Vries T, Al-Hassany L, MaassenVanDenBrink A.","Expert Opin Pharmacother. 2021 Jun;22(8):973-979. doi: 10.1080/14656566.2021.1895749. Epub 2021 Mar 10.","de Vries T","Expert Opin Pharmacother","2021","2021/03/02","","","10.1080/14656566.2021.1895749"
"30835001","CGRP and headache: a brief review","Tepper SJ.","Neurol Sci. 2019 May;40(Suppl 1):99-105. doi: 10.1007/s10072-019-03769-8.","Tepper SJ","Neurol Sci","2019","2019/03/06","","","10.1007/s10072-019-03769-8"
"35230651","Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety","Singh A, Balasundaram MK.","Clin Drug Investig. 2022 Apr;42(4):301-308. doi: 10.1007/s40261-022-01130-0. Epub 2022 Mar 1.","Singh A","Clin Drug Investig","2022","2022/03/01","","","10.1007/s40261-022-01130-0"
"37899428","Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany","Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, Reuter U, Raffaelli B.","J Headache Pain. 2023 Oct 30;24(1):144. doi: 10.1186/s10194-023-01682-2.","Hong JB","J Headache Pain","2023","2023/10/30","PMC10614330","","10.1186/s10194-023-01682-2"
"35468729","Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials","Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW.","J Headache Pain. 2022 Apr 25;23(1):50. doi: 10.1186/s10194-022-01419-7.","Lipton RB","J Headache Pain","2022","2022/04/26","PMC9036751","","10.1186/s10194-022-01419-7"
"30086681","Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab","Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.","Cephalalgia. 2018 Sep;38(10):1622-1631. doi: 10.1177/0333102418789072. Epub 2018 Aug 7.","Buse DC","Cephalalgia","2018","2018/08/09","","","10.1177/0333102418789072"
"36175833","Alterations in metabolic flux in migraine and the translational relevance","Grech O, Sassani M, Terwindt G, Lavery GG, Mollan SP, Sinclair AJ.","J Headache Pain. 2022 Sep 30;23(1):127. doi: 10.1186/s10194-022-01494-w.","Grech O","J Headache Pain","2022","2022/09/29","PMC9523955","","10.1186/s10194-022-01494-w"
"34752266","Immunotherapy for migraine: The use of erenumab in real life","Sánchez-Marín B, Heredia Ledesma D, Lizarralde Álvarez A, Grasa Ullrich JM.","Rev Clin Esp (Barc). 2021 Nov;221(9):557-559. doi: 10.1016/j.rceng.2020.07.007. Epub 2021 May 11.","Sánchez-Marín B","Rev Clin Esp (Barc)","2021","2021/11/09","","","10.1016/j.rceng.2020.07.007"
"28736918","Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine","de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, Bautista E, Hamilton L, Waksman J, Vu T, Vargas G.","Clin Pharmacol Ther. 2018 May;103(5):815-825. doi: 10.1002/cpt.799. Epub 2017 Oct 24.","de Hoon J","Clin Pharmacol Ther","2018","2017/07/25","","","10.1002/cpt.799"
"31220963","Fremanezumab for the preventive treatment of migraine in adults","Lionetto L, Curto M, Cisale GY, Capi M, Cipolla F, Guglielmetti M, Martelletti P.","Expert Rev Clin Pharmacol. 2019 Aug;12(8):741-748. doi: 10.1080/17512433.2019.1635452. Epub 2019 Jun 26.","Lionetto L","Expert Rev Clin Pharmacol","2019","2019/06/22","","","10.1080/17512433.2019.1635452"
"21819271","Migraine prophylactic drugs - something new under the sun?","Bekkelund SI, Alstadhaug KB.","Expert Opin Investig Drugs. 2011 Sep;20(9):1201-10. doi: 10.1517/13543784.2011.601741. Epub 2011 Aug 6.","Bekkelund SI","Expert Opin Investig Drugs","2011","2011/08/09","","","10.1517/13543784.2011.601741"
"18727638","The blood-brain barrier in migraine treatment","Edvinsson L, Tfelt-Hansen P.","Cephalalgia. 2008 Dec;28(12):1245-58. doi: 10.1111/j.1468-2982.2008.01675.x. Epub 2008 Aug 22.","Edvinsson L","Cephalalgia","2008","2008/08/30","","","10.1111/j.1468-2982.2008.01675.x"
"32270407","Rimegepant: First Approval","Scott LJ.","Drugs. 2020 May;80(7):741-746. doi: 10.1007/s40265-020-01301-3.","Scott LJ","Drugs","2020","2020/04/10","","","10.1007/s40265-020-01301-3"
"18789357","The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache","Olesen J.","Pharmacol Ther. 2008 Nov;120(2):157-71. doi: 10.1016/j.pharmthera.2008.08.003. Epub 2008 Aug 23.","Olesen J","Pharmacol Ther","2008","2008/09/16","","","10.1016/j.pharmthera.2008.08.003"
"37532991","Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study","Charleston L 4th, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ.","J Headache Pain. 2023 Aug 2;24(1):101. doi: 10.1186/s10194-023-01636-8.","Charleston L 4th","J Headache Pain","2023","2023/08/02","PMC10394944","","10.1186/s10194-023-01636-8"
"1379707","The trigemino-vascular system and migraine","Buzzi MG, Moskowitz MA.","Pathol Biol (Paris). 1992 Apr;40(4):313-7.","Buzzi MG","Pathol Biol (Paris)","1992","1992/04/01","","",""
"35762152","Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication","Varnado OJ, Hoyt M, Ye W, Nicholson R.","Curr Med Res Opin. 2022 Aug;38(8):1451-1457. doi: 10.1080/03007995.2022.2091333. Epub 2022 Jul 11.","Varnado OJ","Curr Med Res Opin","2022","2022/06/28","","","10.1080/03007995.2022.2091333"
"38454376","AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization","Lu G, Xiao S, Meng F, Zhang L, Chang Y, Zhao J, Gao N, Su W, Guo X, Liu Y, Li C, Tang W, Zou L, Yu S, Liu R.","J Headache Pain. 2024 Mar 8;25(1):29. doi: 10.1186/s10194-024-01739-w.","Lu G","J Headache Pain","2024","2024/03/08","PMC10921743","","10.1186/s10194-024-01739-w"
"30527443","New Insights into the Regulation of CGRP-Family Receptors","Gingell JJ, Hendrikse ER, Hay DL.","Trends Pharmacol Sci. 2019 Jan;40(1):71-83. doi: 10.1016/j.tips.2018.11.005. Epub 2018 Dec 4.","Gingell JJ","Trends Pharmacol Sci","2019","2018/12/12","","","10.1016/j.tips.2018.11.005"
"33338437","Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial","Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ.","Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15.","Croop R","Lancet","2021","2020/12/18","","","10.1016/S0140-6736(20)32544-7"
"30674285","Migraine day frequency in migraine prevention: longitudinal modelling approaches","Di Tanna GL, Porter JK, Lipton RB, Brennan A, Palmer S, Hatswell AJ, Sapra S, Villa G.","BMC Med Res Methodol. 2019 Jan 23;19(1):20. doi: 10.1186/s12874-019-0664-5.","Di Tanna GL","BMC Med Res Methodol","2019","2019/01/25","PMC6343253","","10.1186/s12874-019-0664-5"
"28948863","Neurovascular mechanisms of migraine and cluster headache","Hoffmann J, Baca SM, Akerman S.","J Cereb Blood Flow Metab. 2019 Apr;39(4):573-594. doi: 10.1177/0271678X17733655. Epub 2017 Sep 26.","Hoffmann J","J Cereb Blood Flow Metab","2019","2017/09/27","PMC6446418","","10.1177/0271678X17733655"
"18759547","Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class","Farinelli I, Missori S, Martelletti P.","Expert Rev Neurother. 2008 Sep;8(9):1347-54. doi: 10.1586/14737175.8.9.1347.","Farinelli I","Expert Rev Neurother","2008","2008/09/02","","","10.1586/14737175.8.9.1347"
"37138206","Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine","Greco R, Francavilla M, Demartini C, Zanaboni AM, Sodergren MH, Facchetti S, Pacchetti B, Palmisani M, Franco V, Tassorelli C.","J Headache Pain. 2023 May 3;24(1):48. doi: 10.1186/s10194-023-01589-y.","Greco R","J Headache Pain","2023","2023/05/03","PMC10155373","","10.1186/s10194-023-01589-y"
"33160424","[Chronic and Refractory Migraine: How to Diagnose and Treat]","Parreira E, Luzeiro I, Pereira Monteiro JM.","Acta Med Port. 2020 Nov 2;33(11):753-760. doi: 10.20344/amp.12004. Epub 2020 Nov 2.","Parreira E","Acta Med Port","2020","2020/11/08","","","10.20344/amp.12004"
"35098620","Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F.","Eur J Neurol. 2022 May;29(5):1505-1513. doi: 10.1111/ene.15260. Epub 2022 Feb 13.","Iannone LF","Eur J Neurol","2022","2022/01/31","","","10.1111/ene.15260"
"34861342","The role of TRP ion channels in migraine and headache","Iannone LF, De Logu F, Geppetti P, De Cesaris F.","Neurosci Lett. 2022 Jan 18;768:136380. doi: 10.1016/j.neulet.2021.136380. Epub 2021 Nov 30.","Iannone LF","Neurosci Lett","2022","2021/12/03","","","10.1016/j.neulet.2021.136380"
"28886662","Comment on: Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients","Min HJ, Kim KS.","Cephalalgia. 2018 Jun;38(7):1407-1408. doi: 10.1177/0333102417731352. Epub 2017 Sep 8.","Min HJ","Cephalalgia","2018","2017/09/10","","","10.1177/0333102417731352"
"28726232","[Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide]","Garcia-Estevez DA, Pardo-Parrado M, Silvarrey-Rodriguez S.","Rev Neurol. 2017 Aug 16;65(4):153-156.","Garcia-Estevez DA","Rev Neurol","2017","2017/07/21","","",""
"36647006","Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months","Troy E, Shrukalla AA, Buture A, Conaty K, Macken E, Lonergan R, Melling J, Long N, Shaikh E, Birrane K, Tomkins EM, Goadsby PJ, Ruttledge MH.","J Headache Pain. 2023 Jan 16;24(1):5. doi: 10.1186/s10194-022-01536-3.","Troy E","J Headache Pain","2023","2023/01/16","PMC9841480","","10.1186/s10194-022-01536-3"
"20170842","Current practice and future directions in the prevention and acute management of migraine","Goadsby PJ, Sprenger T.","Lancet Neurol. 2010 Mar;9(3):285-98. doi: 10.1016/S1474-4422(10)70005-3.","Goadsby PJ","Lancet Neurol","2010","2010/02/23","","","10.1016/S1474-4422(10)70005-3"
"25340934","Calcitonin gene-related peptide (CGRP): a new target for migraine","Russo AF.","Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.","Russo AF","Annu Rev Pharmacol Toxicol","2015","2014/10/24","PMC4392770","NIHMS677432","10.1146/annurev-pharmtox-010814-124701"
"27150105","Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB","Li Y, Zhang Q, Qi D, Zhang L, Yi L, Li Q, Zhang Z.","J Headache Pain. 2016;17:49. doi: 10.1186/s10194-016-0631-z. Epub 2016 May 6.","Li Y","J Headache Pain","2016","2016/05/07","PMC4859223","","10.1186/s10194-016-0631-z"
"33244740","Erenumab during pregnancy: a case report in a patient with chronic migraine","Fofi L, Egeo G, Aurilia C, Barbanti P.","Neurol Sci. 2021 May;42(5):2145-2146. doi: 10.1007/s10072-020-04931-3. Epub 2020 Nov 26.","Fofi L","Neurol Sci","2021","2020/11/27","","","10.1007/s10072-020-04931-3"
"35093013","The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials","Tao X, Yan Z, Meng J, Wang W, Dai Q, Zhou Q, Wang Z, Wang Z.","J Headache Pain. 2022 Jan 29;23(1):19. doi: 10.1186/s10194-022-01391-2.","Tao X","J Headache Pain","2022","2022/01/30","PMC8903713","","10.1186/s10194-022-01391-2"
"19939188","Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review","Paone DV, Staas DD.","Expert Opin Ther Pat. 2009 Dec;19(12):1675-713. doi: 10.1517/13543770903359822.","Paone DV","Expert Opin Ther Pat","2009","2009/11/27","","","10.1517/13543770903359822"
"33407608","Anti-migraine agents from an immunological point of view","Assas MB.","J Transl Med. 2021 Jan 6;19(1):23. doi: 10.1186/s12967-020-02681-6.","Assas MB","J Transl Med","2021","2021/01/07","PMC7789413","","10.1186/s12967-020-02681-6"
"34759933","Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine","Pederson S, Biondi DM, Allan B, Cady R, Schaeffler B, Baker B, Latham J.","Front Immunol. 2021 Oct 25;12:765822. doi: 10.3389/fimmu.2021.765822. eCollection 2021.","Pederson S","Front Immunol","2021","2021/11/11","PMC8573262","","10.3389/fimmu.2021.765822"
"35842569","Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention","Lovati C, Bernasconi G, Capogrosso C, Molteni L, Giorgetti F, Dell'Osso B, Pantoni L.","Neurol Sci. 2022 Sep;43(9):5765-5767. doi: 10.1007/s10072-022-06251-0. Epub 2022 Jul 16.","Lovati C","Neurol Sci","2022","2022/07/16","","","10.1007/s10072-022-06251-0"
"34325647","Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation","Jing F, Zou Q, Wang Y, Cai Z, Tang Y.","J Headache Pain. 2021 Jul 29;22(1):86. doi: 10.1186/s10194-021-01302-x.","Jing F","J Headache Pain","2021","2021/07/30","PMC8323319","","10.1186/s10194-021-01302-x"
"33713748","Insulin-like growth factor-1 inhibits nitroglycerin-induced trigeminal activation of oxidative stress, calcitonin gene-related peptide and c-Fos expression","Won L, Kraig RP.","Neurosci Lett. 2021 Apr 23;751:135809. doi: 10.1016/j.neulet.2021.135809. Epub 2021 Mar 10.","Won L","Neurosci Lett","2021","2021/03/13","PMC8058296","NIHMS1683308","10.1016/j.neulet.2021.135809"
"32517693","Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience","Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G.","J Headache Pain. 2020 Jun 9;21(1):69. doi: 10.1186/s10194-020-01143-0.","Russo A","J Headache Pain","2020","2020/06/11","PMC7282180","","10.1186/s10194-020-01143-0"
"38307667","CGRP receptor antagonists (gepants)","Younis S, Latysheva NV, Danilov AB, Ashina M.","Handb Clin Neurol. 2024;199:51-66. doi: 10.1016/B978-0-12-823357-3.00033-1.","Younis S","Handb Clin Neurol","2024","2024/02/02","","","10.1016/B978-0-12-823357-3.00033-1"
"38017629","Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2","MacGregor EA, Okonkwo R, Detke HC, Polavieja P, Fernandes MS, Pavlovic JM.","Headache. 2024 Feb;64(2):179-187. doi: 10.1111/head.14652. Epub 2023 Nov 28.","MacGregor EA","Headache","2024","2023/11/29","","","10.1111/head.14652"
"36054144","Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine","Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P.","Ann Neurol. 2022 Nov;92(5):846-859. doi: 10.1002/ana.26472. Epub 2022 Aug 24.","Alpuente A","Ann Neurol","2022","2022/09/02","","","10.1002/ana.26472"
"29869205","CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine","Maasumi K, Michael RL, Rapoport AM.","Drugs. 2018 Jun;78(9):913-928. doi: 10.1007/s40265-018-0923-5.","Maasumi K","Drugs","2018","2018/06/06","","","10.1007/s40265-018-0923-5"
"38043971","Migraine headache pathophysiology","Andreou AP, Pereira AD.","Handb Clin Neurol. 2023;198:61-69. doi: 10.1016/B978-0-12-823356-6.00018-4.","Andreou AP","Handb Clin Neurol","2023","2023/12/03","","","10.1016/B978-0-12-823356-6.00018-4"
"31274104","[New horizons for acute and prophylactic treatments of migraine]","Valade D.","Biol Aujourdhui. 2019;213(1-2):59-64. doi: 10.1051/jbio/2019021. Epub 2019 Jul 5.","Valade D","Biol Aujourdhui","2019","2019/07/06","","","10.1051/jbio/2019021"
"32293721","Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis","Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, Edvinsson L.","Headache. 2020 Jun;60(6):1132-1164. doi: 10.1111/head.13802. Epub 2020 Apr 15.","Frederiksen SD","Headache","2020","2020/04/16","","","10.1111/head.13802"
"25754596","TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine","Walter S, Bigal ME.","Curr Pain Headache Rep. 2015 Mar;19(3):6. doi: 10.1007/s11916-015-0476-1.","Walter S","Curr Pain Headache Rep","2015","2015/03/11","","","10.1007/s11916-015-0476-1"
"17425711","Pathophysiology of headache--past and present","Moskowitz MA.","Headache. 2007 Apr;47 Suppl 1:S58-63. doi: 10.1111/j.1526-4610.2007.00678.x.","Moskowitz MA","Headache","2007","2007/04/12","","","10.1111/j.1526-4610.2007.00678.x"
"19250288","Finding new drug targets for the treatment of migraine attacks","Olesen J, Tfelt-Hansen P, Ashina M.","Cephalalgia. 2009 Sep;29(9):909-20. doi: 10.1111/j.1468-2982.2008.01837.x. Epub 2009 Feb 25.","Olesen J","Cephalalgia","2009","2009/03/03","","","10.1111/j.1468-2982.2008.01837.x"
"21631476","Mechanisms of pain modulation by sex hormones in migraine","Gupta S, McCarson KE, Welch KM, Berman NE.","Headache. 2011 Jun;51(6):905-22. doi: 10.1111/j.1526-4610.2011.01908.x.","Gupta S","Headache","2011","2011/06/03","","","10.1111/j.1526-4610.2011.01908.x"
"36611947","Preclinical Studies of Posttraumatic Headache and the Potential Therapeutics","Tanaka M, Zhang Y.","Cells. 2022 Dec 30;12(1):155. doi: 10.3390/cells12010155.","Tanaka M","Cells","2022","2023/01/08","PMC9818317","","10.3390/cells12010155"
"29019093","Triptans and CGRP blockade - impact on the cranial vasculature","Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M; School of Advanced Studies of the European Headache Federation (EHF-SAS).","J Headache Pain. 2017 Oct 10;18(1):103. doi: 10.1186/s10194-017-0811-5.","Benemei S","J Headache Pain","2017","2017/10/12","PMC5635141","","10.1186/s10194-017-0811-5"
"10357601","Sumatriptan and sensory neuropeptide activity in subarachnoid haemorrhage: an hypothesis","White LR, Sjaastad O.","Cephalalgia. 1995 Dec;15(6):470-1. doi: 10.1046/j.1468-2982.1995.1506470.x.","White LR","Cephalalgia","1995","1995/12/01","","","10.1046/j.1468-2982.1995.1506470.x"
"33593077","Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients","de Tommaso M, Delussi M, Gentile E, Ricci K, Quitadamo SG, Libro G.","Cephalalgia. 2021 Aug;41(9):1004-1014. doi: 10.1177/0333102421996345. Epub 2021 Feb 16.","de Tommaso M","Cephalalgia","2021","2021/02/17","","","10.1177/0333102421996345"
"31539490","[Ion channels and mechanisms of inherited disease transmission causing migraine]","Royal P, Sandoz G.","Med Sci (Paris). 2019 Aug-Sep;35(8-9):608-610. doi: 10.1051/medsci/2019121. Epub 2019 Sep 18.","Royal P","Med Sci (Paris)","2019","2019/09/21","","","10.1051/medsci/2019121"
"26501962","DNA methylation of RAMP1 gene in migraine: an exploratory analysis","Wan D, Hou L, Zhang X, Han X, Chen M, Tang W, Liu R, Dong Z, Yu S.","J Headache Pain. 2015;16:90. doi: 10.1186/s10194-015-0576-7. Epub 2015 Oct 26.","Wan D","J Headache Pain","2015","2015/10/27","PMC4623078","","10.1186/s10194-015-0576-7"
"32487102","A prospective real-world analysis of erenumab in refractory chronic migraine","Lambru G, Hill B, Murphy M, Tylova I, Andreou AP.","J Headache Pain. 2020 Jun 1;21(1):61. doi: 10.1186/s10194-020-01127-0.","Lambru G","J Headache Pain","2020","2020/06/04","PMC7268737","","10.1186/s10194-020-01127-0"
"30825209","Calcitonin Gene-Related Protein (CGRP)-Targeted Treatments for Migraine Prevention","Tepper DE.","Headache. 2019 Mar;59(3):477-480. doi: 10.1111/head.13492.","Tepper DE","Headache","2019","2019/03/03","","","10.1111/head.13492"
"35302681","Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction","Lampl C, Rapoport AM, Cohen JM, Barash S, Ramirez Campos V, Seminerio MJ, Ning X, Silberstein SD.","Eur J Neurol. 2022 Jul;29(7):2129-2137. doi: 10.1111/ene.15328. Epub 2022 Mar 29.","Lampl C","Eur J Neurol","2022","2022/03/18","","","10.1111/ene.15328"
"32304480","Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists: An integrative review","Mallick-Searle T, Moriarty M.","J Am Assoc Nurse Pract. 2020 Apr 16;33(6):419-428. doi: 10.1097/JXX.0000000000000397.","Mallick-Searle T","J Am Assoc Nurse Pract","2020","2020/04/19","","","10.1097/JXX.0000000000000397"
"27842045","Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine","Guo S, Vollesen ALH, Olesen J, Ashina M.","Pain. 2016 Dec;157(12):2773-2781. doi: 10.1097/j.pain.0000000000000702.","Guo S","Pain","2016","2016/11/15","","","10.1097/j.pain.0000000000000702"
"23196486","[Triptans and calcitonin gene-related peptide (CGRP) receptor antagonists]","Negoro K.","Rinsho Shinkeigaku. 2012;52(11):971-2. doi: 10.5692/clinicalneurol.52.971.","Negoro K","Rinsho Shinkeigaku","2012","2012/12/01","","","10.5692/clinicalneurol.52.971"
"19779958","Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment","Tfelt-Hansen PC.","J Headache Pain. 2009 Dec;10(6):389-91. doi: 10.1007/s10194-009-0157-8. Epub 2009 Sep 25.","Tfelt-Hansen PC","J Headache Pain","2009","2009/09/26","PMC3476212","","10.1007/s10194-009-0157-8"
"28460891","Challenging chronic migraine: targeting the CGRP receptor","Giamberardino MA, Costantini R.","Lancet Neurol. 2017 Jun;16(6):410-411. doi: 10.1016/S1474-4422(17)30126-6. Epub 2017 Apr 28.","Giamberardino MA","Lancet Neurol","2017","2017/05/03","","","10.1016/S1474-4422(17)30126-6"
"32011737","Do Treatment Strategies of Fremanezumab Have Similar Effect on Migraine?","Lee YH, Huang IH, Kang YN.","Headache. 2020 Feb;60(2):473-475. doi: 10.1111/head.13740.","Lee YH","Headache","2020","2020/02/04","","","10.1111/head.13740"
"35332801","Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD","Strassman AM, Melo-Carrillo A, Houle TT, Adams A, Brin MF, Burstein R.","Cephalalgia. 2022 Aug;42(9):933-943. doi: 10.1177/03331024221083544. Epub 2022 Mar 25.","Strassman AM","Cephalalgia","2022","2022/03/25","PMC9329220","NIHMS1808569","10.1177/03331024221083544"
"35228705","PACAP - an alternative target to CGRP?","Fyfe I.","Nat Rev Neurol. 2022 Apr;18(4):187. doi: 10.1038/s41582-022-00639-4.","Fyfe I","Nat Rev Neurol","2022","2022/03/01","","","10.1038/s41582-022-00639-4"
"27687880","The influence of migraine and female hormones on capsaicin-induced dermal blood flow","Ibrahimi K, Vermeersch S, Frederiks P, Geldhof V, Draulans C, Buntinx L, Lesaffre E, MaassenVanDenBrink A, de Hoon J.","Cephalalgia. 2017 Oct;37(12):1164-1172. doi: 10.1177/0333102416668659. Epub 2016 Sep 28.","Ibrahimi K","Cephalalgia","2017","2016/10/01","","","10.1177/0333102416668659"
"31710104","Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies","Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, Aurora SK.","Headache. 2020 Feb;60(2):348-359. doi: 10.1111/head.13691. Epub 2019 Nov 11.","Detke HC","Headache","2020","2019/11/12","PMC7028148","","10.1111/head.13691"
"33840777","Targets for migraine treatment: beyond calcitonin gene-related peptide","Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ.","Curr Opin Neurol. 2021 Jun 1;34(3):363-372. doi: 10.1097/WCO.0000000000000935.","Moreno-Ajona D","Curr Opin Neurol","2021","2021/04/12","","","10.1097/WCO.0000000000000935"
"33824219","[Gepants and Ditans]","Kowa H.","Brain Nerve. 2021 Apr;73(4):315-325. doi: 10.11477/mf.1416201762.","Kowa H","Brain Nerve","2021","2021/04/07","","","10.11477/mf.1416201762"
"32647152","Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients","Eren OE, Gaul C, Peikert A, Gendolla A, Ruscheweyh R, Straube A.","Sci Rep. 2020 Jul 9;10(1):11382. doi: 10.1038/s41598-020-68149-1.","Eren OE","Sci Rep","2020","2020/07/11","PMC7347633","","10.1038/s41598-020-68149-1"
"37284790","Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization","Ryu S, Liu X, Guo T, Guo Z, Zhang J, Cao YQ.","Brain. 2023 Oct 3;146(10):4274-4291. doi: 10.1093/brain/awad191.","Ryu S","Brain","2023","2023/06/07","PMC10545624","","10.1093/brain/awad191"
"16279645","[Recent development of calcitonin gene-related peptide (CGRP) receptor antagonist]","Kojima S, Kamikawa Y.","Nihon Rinsho. 2005 Oct;63 Suppl 10:263-6.","Kojima S","Nihon Rinsho","2005","2005/11/11","","",""
"30977520","Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials","Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R.","Headache. 2019 Jun;59(6):880-890. doi: 10.1111/head.13534. Epub 2019 Apr 12.","Silberstein SD","Headache","2019","2019/04/13","","","10.1111/head.13534"
"36662724","Effectiveness of acupuncture in migraine rats: A systematic review","Su P, Xie X, Xu Y, Luo X, Niu J, Jin Z.","PLoS One. 2023 Jan 20;18(1):e0280556. doi: 10.1371/journal.pone.0280556. eCollection 2023.","Su P","PLoS One","2023","2023/01/20","PMC9858085","","10.1371/journal.pone.0280556"
"31077365","Vestibular Neuroscience for the Headache Specialist","Balaban CD, Black RD, Silberstein SD.","Headache. 2019 Jul;59(7):1109-1127. doi: 10.1111/head.13550. Epub 2019 May 11.","Balaban CD","Headache","2019","2019/05/12","","","10.1111/head.13550"
"24565009","Understanding the pharmacology of headache","Rolan PE.","Curr Opin Pharmacol. 2014 Feb;14:30-3. doi: 10.1016/j.coph.2013.10.005. Epub 2013 Nov 22.","Rolan PE","Curr Opin Pharmacol","2014","2014/02/26","","","10.1016/j.coph.2013.10.005"
"38266060","Ubrogepant: Mechanism of action, clinical and translational science","Boinpally R, Shebley M, Trugman J.","Clin Transl Sci. 2024 Jan;17(1):e13675. doi: 10.1111/cts.13675.","Boinpally R","Clin Transl Sci","2024","2024/01/24","PMC10777434","","10.1111/cts.13675"
"36942409","Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data","Kudrow D, Dafer R, Dodick DW, Starling A, Ailani J, Dougherty C, Kalidas K, Zhang F, Jeswani R, Patel N, Khodavirdi AC.","Headache. 2023 Mar;63(3):418-428. doi: 10.1111/head.14485.","Kudrow D","Headache","2023","2023/03/21","","","10.1111/head.14485"
"31710110","Further Questioning of the Significance of the Gepants: A Response","Loder EW, Tfelt-Hansen P.","Headache. 2019 Nov;59(10):1831. doi: 10.1111/head.13683.","Loder EW","Headache","2019","2019/11/12","","","10.1111/head.13683"
"32845488","Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience","Disco C, Billo G, De Boni A, De Luca C, Perini F.","Neurol Sci. 2020 Dec;41(Suppl 2):479-480. doi: 10.1007/s10072-020-04665-2.","Disco C","Neurol Sci","2020","2020/08/27","","","10.1007/s10072-020-04665-2"
"31710109","Further Questioning of the Significance of the Gepants","Nguyen J, Hu D.","Headache. 2019 Nov;59(10):1829-1830. doi: 10.1111/head.13672.","Nguyen J","Headache","2019","2019/11/12","","","10.1111/head.13672"
"35212025","Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study","Viudez-Martínez A, Pascual-Carrasco A, Beltrán-Blasco I, Hernandez-Lorido R, F Ruiz de Apodaca R.","J Clin Pharm Ther. 2022 Jun;47(6):814-823. doi: 10.1111/jcpt.13620. Epub 2022 Feb 25.","Viudez-Martínez A","J Clin Pharm Ther","2022","2022/02/25","","","10.1111/jcpt.13620"
"16362644","CGRP and migraine: neurogenic inflammation revisited","Geppetti P, Capone JG, Trevisani M, Nicoletti P, Zagli G, Tola MR.","J Headache Pain. 2005 Apr;6(2):61-70. doi: 10.1007/s10194-005-0153-6. Epub 2005 Apr 8.","Geppetti P","J Headache Pain","2005","2005/12/20","PMC3452316","","10.1007/s10194-005-0153-6"
"37668477","Treating acute migraine with ubrogepant","Schoenfuss ES.","JAAPA. 2023 Sep 1;36(9):25-28. doi: 10.1097/01.JAA.0000931424.73007.a5.","Schoenfuss ES","JAAPA","2023","2023/09/05","","","10.1097/01.JAA.0000931424.73007.a5"
"27637964","Migraine","Peck KR, Johnson YL, Smitherman TA.","Handb Clin Neurol. 2016;138:283-93. doi: 10.1016/B978-0-12-802973-2.00016-1.","Peck KR","Handb Clin Neurol","2016","2016/09/18","","","10.1016/B978-0-12-802973-2.00016-1"
"35836032","Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients","Curone M, Tullo V, Didier HA, Bussone G.","Neurol Sci. 2022 Sep;43(9):5759-5761. doi: 10.1007/s10072-022-06265-8. Epub 2022 Jul 14.","Curone M","Neurol Sci","2022","2022/07/14","","","10.1007/s10072-022-06265-8"
"15911785","Migraine as an inflammatory disorder","Waeber C, Moskowitz MA.","Neurology. 2005 May 24;64(10 Suppl 2):S9-15. doi: 10.1212/wnl.64.10_suppl_2.s9.","Waeber C","Neurology","2005","2005/05/25","","","10.1212/wnl.64.10_suppl_2.s9"
"32857326","Exploring new strategy in erenumab therapy for migraine patients","Frediani F, D'Arrigo G, Galli A, Altavilla R, Di Fiore P.","Neurol Sci. 2020 Dec;41(Suppl 2):507-508. doi: 10.1007/s10072-020-04678-x.","Frediani F","Neurol Sci","2020","2020/08/29","","","10.1007/s10072-020-04678-x"
"30106172","Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab","Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK.","Headache. 2018 Sep;58(8):1225-1235. doi: 10.1111/head.13383. Epub 2018 Aug 14.","Ayer DW","Headache","2018","2018/08/15","","","10.1111/head.13383"
"23745702","CGRP receptor antagonism and migraine therapy","Edvinsson L, Warfvinge K.","Curr Protein Pept Sci. 2013 Aug;14(5):386-92. doi: 10.2174/13892037113149990055.","Edvinsson L","Curr Protein Pept Sci","2013","2013/06/11","","","10.2174/13892037113149990055"
"36253732","CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury","Ashina H, Iljazi A, Al-Khazali HM, Do TP, Eigenbrodt AK, Larsen EL, Andersen AM, Hansen KJ, Bräuner KB, Chaudhry BA, Christensen CE, Amin FM, Schytz HW.","J Headache Pain. 2022 Oct 17;23(1):135. doi: 10.1186/s10194-022-01499-5.","Ashina H","J Headache Pain","2022","2022/10/17","PMC9578273","","10.1186/s10194-022-01499-5"
"26337644","[Positioning of headache units in the field of neurology: the importance of OnabotulinumtoxinA and other therapies in the treatment of headaches]","Torres-Ferrus M, Pozo-Rosich P.","Rev Neurol. 2015;61 Suppl 1:S3-7.","Torres-Ferrus M","Rev Neurol","2015","2015/09/05","","",""
"33269952","Interictal amylin levels in chronic migraine patients: A case-control study","Irimia P, Martínez-Valbuena I, Mínguez-Olaondo A, Domínguez-Vivero C, Sánchez-Arias JA, Martínez-Vila E, Luquin MR, Leira R.","Cephalalgia. 2021 Apr;41(5):604-612. doi: 10.1177/0333102420977106. Epub 2020 Dec 3.","Irimia P","Cephalalgia","2021","2020/12/03","","","10.1177/0333102420977106"
"17425706","Major therapeutic advances in the past 25 years","Solomon S.","Headache. 2007 Apr;47 Suppl 1:S20-2. doi: 10.1111/j.1526-4610.2007.00673.x.","Solomon S","Headache","2007","2007/04/12","","","10.1111/j.1526-4610.2007.00673.x"
"20336417","Migraine models","Benemei S, De Cesaris F, Nicoletti P, Materazzi S, Nassini R, Geppetti P.","Methods Mol Biol. 2010;617:105-14. doi: 10.1007/978-1-60327-323-7_9.","Benemei S","Methods Mol Biol","2010","2010/03/26","","","10.1007/978-1-60327-323-7_9"
"32852684","Erenumab efficacy in highly resistant chronic migraine: a real-life study","Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E, Calabrò C, Cortelli P, Pierangeli G, Cevoli S.","Neurol Sci. 2020 Dec;41(Suppl 2):457-459. doi: 10.1007/s10072-020-04658-1.","Pensato U","Neurol Sci","2020","2020/08/28","","","10.1007/s10072-020-04658-1"
"36808268","Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial","Li Y, Wang X, Ballesteros-Perez A, Bertz R, Lu Z.","Clin Pharmacol Drug Dev. 2023 Jun;12(6):594-601. doi: 10.1002/cpdd.1230. Epub 2023 Feb 20.","Li Y","Clin Pharmacol Drug Dev","2023","2023/02/22","","","10.1002/cpdd.1230"
"31649062","PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models","Anapindi KDB, Yang N, Romanova EV, Rubakhin SS, Tipton A, Dripps I, Sheets Z, Sweedler JV, Pradhan AA.","Mol Cell Proteomics. 2019 Dec;18(12):2447-2458. doi: 10.1074/mcp.RA119.001767. Epub 2019 Oct 24.","Anapindi KDB","Mol Cell Proteomics","2019","2019/10/26","PMC6885698","","10.1074/mcp.RA119.001767"
"27553188","Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment","Kuzawińska O, Lis K, Cessak G, Mirowska-Guzel D, Bałkowiec-Iskra E.","Neurol Neurochir Pol. 2016 Nov-Dec;50(6):463-467. doi: 10.1016/j.pjnns.2016.07.012. Epub 2016 Aug 10.","Kuzawińska O","Neurol Neurochir Pol","2016","2016/08/25","","","10.1016/j.pjnns.2016.07.012"
"32945948","[Migraine prophylaxis-all just antibodies? : Medical and nonmedical migraine preventive treatment in times of CGRP antibodies]","Hamann T, Kamm K, Kropp P, Rimmele F, Jürgens TP.","Schmerz. 2020 Dec;34(6):476-485. doi: 10.1007/s00482-020-00500-x. Epub 2020 Sep 18.","Hamann T","Schmerz","2020","2020/09/18","","","10.1007/s00482-020-00500-x"
"35086941","CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab","de Vries Lentsch S, Al-Hassany L, Ferrari MD, Terwindt GM, MaassenVanDenBrink A.","J Neurol Neurosurg Psychiatry. 2022 Aug;93(8):911-912. doi: 10.1136/jnnp-2021-327992. Epub 2022 Jan 27.","de Vries Lentsch S","J Neurol Neurosurg Psychiatry","2022","2022/01/28","","","10.1136/jnnp-2021-327992"
"34082147","Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials","Masoud AT, Hasan MT, Sayed A, Edward HN, Amer AM, Naga AE, Elfil M, Alghamdi BS, Perveen A, Ashraf GM, Bahbah EI.","J Neurol Sci. 2021 Aug 15;427:117505. doi: 10.1016/j.jns.2021.117505. Epub 2021 May 21.","Masoud AT","J Neurol Sci","2021","2021/06/03","","","10.1016/j.jns.2021.117505"
"33941080","Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group.","J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1.","Vernieri F","J Headache Pain","2021","2021/05/04","PMC8091153","","10.1186/s10194-021-01247-1"
"34906111","Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study","Dinh BBK, Aziz WH, Terruzzi A, Krieger DW.","BMC Neurol. 2021 Dec 14;21(1):486. doi: 10.1186/s12883-021-02507-y.","Dinh BBK","BMC Neurol","2021","2021/12/15","PMC8670192","","10.1186/s12883-021-02507-y"
"25107883","Eager for better migraine therapies: keep your (telcage)PANTs on","Lipton RB, Sandor PS.","Neurology. 2014 Sep 9;83(11):954-5. doi: 10.1212/WNL.0000000000000782. Epub 2014 Aug 8.","Lipton RB","Neurology","2014","2014/08/10","","","10.1212/WNL.0000000000000782"
"37563914","Evaluation of Safety and Efficacy of Add-on Alpha-Lipoic Acid on Migraine Prophylaxis in an Adolescent Population: A Randomized Controlled Trial","Puliappadamb HM, Satpathy AK, Mishra BR, Maiti R, Jena M.","J Clin Pharmacol. 2023 Dec;63(12):1398-1407. doi: 10.1002/jcph.2331. Epub 2023 Aug 24.","Puliappadamb HM","J Clin Pharmacol","2023","2023/08/11","","","10.1002/jcph.2331"
"34082583","Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases","González-Quintanilla V, Pérez-Pereda S, González-Suárez A, Madera J, Toriello M, Pascual J.","Cephalalgia. 2021 Oct;41(11-12):1272-1275. doi: 10.1177/03331024211017879. Epub 2021 Jun 4.","González-Quintanilla V","Cephalalgia","2021","2021/06/04","","","10.1177/03331024211017879"
"33291980","Galcanezumab for the prevention of migraine","Frerichs LM, Friedman DI.","Pain Manag. 2021 Mar;11(2):101-112. doi: 10.2217/pmt-2020-0030. Epub 2020 Dec 9.","Frerichs LM","Pain Manag","2021","2020/12/09","","","10.2217/pmt-2020-0030"
"32702245","Galcanezumab for the prevention of cluster headache","Giani L, Proietti Cecchini A, Leone M.","Expert Opin Biol Ther. 2020 Oct;20(10):1133-1142. doi: 10.1080/14712598.2020.1800635. Epub 2020 Aug 4.","Giani L","Expert Opin Biol Ther","2020","2020/07/24","","","10.1080/14712598.2020.1800635"
"31159727","Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U.","J Headache Pain. 2019 Jun 3;20(1):66. doi: 10.1186/s10194-019-1018-8.","Raffaelli B","J Headache Pain","2019","2019/06/05","PMC6734267","","10.1186/s10194-019-1018-8"
"33550872","Rimegepant: acute treatment for migraine headaches","Peters GL, Hennessey EK.","Pain Manag. 2021 May;11(3):259-266. doi: 10.2217/pmt-2020-0090. Epub 2021 Feb 8.","Peters GL","Pain Manag","2021","2021/02/08","","","10.2217/pmt-2020-0090"
"37655536","Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis","MacGregor EA, Hutchinson S, Lai H, Dabruzzo B, Yu SY, Trugman JM, Ailani J.","Headache. 2023 Sep;63(8):1135-1144. doi: 10.1111/head.14619. Epub 2023 Sep 1.","MacGregor EA","Headache","2023","2023/09/01","","","10.1111/head.14619"
"22123247","Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation","Raddant AC, Russo AF.","Expert Rev Mol Med. 2011 Nov 29;13:e36. doi: 10.1017/S1462399411002067.","Raddant AC","Expert Rev Mol Med","2011","2011/11/30","PMC3383830","NIHMS384585","10.1017/S1462399411002067"
"28343071","Analgesia effect of baicalein against NTG-induced migraine in rats","Zhang XF, Zhang WJ, Dong CL, Hu WL, Sun YY, Bao Y, Zhang CF, Guo CR, Wang CZ, Yuan CS.","Biomed Pharmacother. 2017 Jun;90:116-121. doi: 10.1016/j.biopha.2017.03.052. Epub 2017 Mar 24.","Zhang XF","Biomed Pharmacother","2017","2017/03/27","","","10.1016/j.biopha.2017.03.052"
"33439329","The use of calcitonin gene related peptide monoclonal antibodies in the difficult to treat migraine population","Cosslett T, Mitchell C.","J Neurol. 2021 Feb;268(2):734-736. doi: 10.1007/s00415-020-10392-7.","Cosslett T","J Neurol","2021","2021/01/13","","","10.1007/s00415-020-10392-7"
"19488079","Migraine: Telcagepant provides new hope for people with migraine","Edvinsson L.","Nat Rev Neurol. 2009 May;5(5):240-2. doi: 10.1038/nrneurol.2009.49.","Edvinsson L","Nat Rev Neurol","2009","2009/06/03","","","10.1038/nrneurol.2009.49"
"36437611","Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review","Kaltseis K, Hamann T, Gaul C, Broessner G.","Headache. 2022 Nov;62(10):1264-1271. doi: 10.1111/head.14415. Epub 2022 Nov 27.","Kaltseis K","Headache","2022","2022/11/28","PMC10100419","","10.1111/head.14415"
"34275653","CGRP and migraine: from bench to bedside","Edvinsson L.","Rev Neurol (Paris). 2021 Sep;177(7):785-790. doi: 10.1016/j.neurol.2021.06.003. Epub 2021 Jul 15.","Edvinsson L","Rev Neurol (Paris)","2021","2021/07/19","","","10.1016/j.neurol.2021.06.003"
"20855363","Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","Hansen JM, Hauge AW, Olesen J, Ashina M.","Cephalalgia. 2010 Oct;30(10):1179-86. doi: 10.1177/0333102410368444. Epub 2010 May 12.","Hansen JM","Cephalalgia","2010","2010/09/22","","","10.1177/0333102410368444"
"38307497","Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies","Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Giné-Ciprés E, Pozo-Rosich P.","Cephalalgia. 2024 Feb;44(2):3331024231222923. doi: 10.1177/03331024231222923.","Torres-Ferrús M","Cephalalgia","2024","2024/02/02","","","10.1177/03331024231222923"
"34021585","Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine","Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L'Italien G, Moren J.","Headache. 2021 Jun;61(6):906-915. doi: 10.1111/head.14128. Epub 2021 May 22.","Popoff E","Headache","2021","2021/05/22","PMC8361942","","10.1111/head.14128"
"29242523","Migraine: CGRP-targeting antibodies reduce migraine frequency","Wood H.","Nat Rev Neurol. 2018 Feb;14(2):63. doi: 10.1038/nrneurol.2017.177. Epub 2017 Dec 15.","Wood H","Nat Rev Neurol","2018","2017/12/16","","","10.1038/nrneurol.2017.177"
"31538885","Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin","Anderson G.","Curr Pharm Des. 2019;25(33):3550-3562. doi: 10.2174/1381612825666190920114611.","Anderson G","Curr Pharm Des","2019","2019/09/21","","","10.2174/1381612825666190920114611"
"21300636","CGRP in migraine","Olesen J.","Cephalalgia. 2011 Apr;31(5):638. doi: 10.1177/0333102410395790. Epub 2011 Feb 7.","Olesen J","Cephalalgia","2011","2011/02/09","","","10.1177/0333102410395790"
"37282507","A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants","Bertz R, Bhardwaj R, Morris BA, Ashbrenner E, Coric V, Croop R.","Cephalalgia. 2023 Jun;43(6):3331024231179131. doi: 10.1177/03331024231179131.","Bertz R","Cephalalgia","2023","2023/06/07","","","10.1177/03331024231179131"
"36919462","Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey","Pathak P, Yue L, Gupta S, Fang J, Cheadle MA, Tiwari S, Ferraris M, Joshi P, Thompson J, Shah R, Vo P.","Curr Med Res Opin. 2023 Dec;39(12):1585-1591. doi: 10.1080/03007995.2023.2191479. Epub 2023 Mar 28.","Pathak P","Curr Med Res Opin","2023","2023/03/15","","","10.1080/03007995.2023.2191479"
"36614146","TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine","Spekker E, Körtési T, Vécsei L.","Int J Mol Sci. 2022 Dec 31;24(1):700. doi: 10.3390/ijms24010700.","Spekker E","Int J Mol Sci","2022","2023/01/08","PMC9820749","","10.3390/ijms24010700"
"33407070","Association between response to triptans and response to erenumab: real-life data","Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, Affaitati G, Giamberardino MA, Viola S, Gabriele A, Pistoia F, Cerone D, Marini C, Sacco S, Ornello R.","J Headache Pain. 2021 Jan 6;22(1):1. doi: 10.1186/s10194-020-01213-3.","Frattale I","J Headache Pain","2021","2021/01/07","PMC7789681","","10.1186/s10194-020-01213-3"
"20308688","Randomized, controlled trial of telcagepant for the acute treatment of migraine","Nardin R.","Neurology. 2010 Mar 23;74(12):1007; author reply 1007-8. doi: 10.1212/WNL.0b013e3181d2b6de.","Nardin R","Neurology","2010","2010/03/24","","","10.1212/WNL.0b013e3181d2b6de"
"37569648","Migraine Treatment: Towards New Pharmacological Targets","Silvestro M, Iannone LF, Orologio I, Tessitore A, Tedeschi G, Geppetti P, Russo A.","Int J Mol Sci. 2023 Jul 31;24(15):12268. doi: 10.3390/ijms241512268.","Silvestro M","Int J Mol Sci","2023","2023/08/12","PMC10418850","","10.3390/ijms241512268"
"37596936","An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea","Sia T, Webb T, Li S, Moskatel LS, Chang ALS.","Br J Dermatol. 2023 Nov 16;189(6):776-778. doi: 10.1093/bjd/ljad277.","Sia T","Br J Dermatol","2023","2023/08/19","","","10.1093/bjd/ljad277"
"28114808","Comorbidity between idiopathic overactive bladder and chronic migraine","Ramos ML, García-Cabo C, Leira R, Domínguez C, Pozo-Rosich P, Vila C, Laínez MJ, Pascual J.","Cephalalgia. 2018 Mar;38(3):581-584. doi: 10.1177/0333102417690127. Epub 2017 Jan 23.","Ramos ML","Cephalalgia","2018","2017/01/25","","","10.1177/0333102417690127"
"31840684","Eptinezumab for the treatment of migraine","Scuteri D, Corasaniti MT, Tonin P, Bagetta G.","Drugs Today (Barc). 2019 Nov;55(11):695-703. doi: 10.1358/dot.2019.55.11.3069864.","Scuteri D","Drugs Today (Barc)","2019","2019/12/17","","","10.1358/dot.2019.55.11.3069864"
"30982963","CGRP and the Trigeminal System in Migraine","Iyengar S, Johnson KW, Ossipov MH, Aurora SK.","Headache. 2019 May;59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14.","Iyengar S","Headache","2019","2019/04/16","PMC6593989","","10.1111/head.13529"
"35593783","Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis","Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD.","Headache. 2022 May;62(5):624-633. doi: 10.1111/head.14313.","Ashina M","Headache","2022","2022/05/20","PMC9324861","","10.1111/head.14313"
"37315643","Shaoyao Gancao decoction alleviates the central hyperalgesia of recurrent NTG-induced migraine in rats by regulating the NGF/TRPV1/COX-2 signal pathway","Luo Y, Qiu Y, Zhou R, Zhang Y, Ji X, Liu Z, Li R, Zhang Y, Yang F, Hou J, Zhang S, Wang T, Song H, Tao X.","J Ethnopharmacol. 2023 Dec 5;317:116781. doi: 10.1016/j.jep.2023.116781. Epub 2023 Jun 12.","Luo Y","J Ethnopharmacol","2023","2023/06/14","","","10.1016/j.jep.2023.116781"
"28456113","The enhancement mechanism of wine-processed Radix Scutellaria on NTG-induced migraine rats","Cui CL, He X, Dong CL, Song ZJ, Ji J, Wang X, Wang L, Wang JY, Du WJ, Wang CZ, Yuan CS, Guo CR, Zhang CF.","Biomed Pharmacother. 2017 Jul;91:138-146. doi: 10.1016/j.biopha.2017.04.067. Epub 2017 Apr 27.","Cui CL","Biomed Pharmacother","2017","2017/04/30","","","10.1016/j.biopha.2017.04.067"
"23848260","Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development","Bigal ME, Walter S, Rapoport AM.","Headache. 2013 Sep;53(8):1230-44. doi: 10.1111/head.12179. Epub 2013 Jul 12.","Bigal ME","Headache","2013","2013/07/16","","","10.1111/head.12179"
"36112070","A non-oral gepant for acute treatment of migraine","Burch R.","Headache. 2022 Oct;62(9):1075-1076. doi: 10.1111/head.14397. Epub 2022 Sep 16.","Burch R","Headache","2022","2022/09/16","","","10.1111/head.14397"
"32563365","Testing rimegepant for migraine-time to revise the trial design? - Authors' reply","Croop R, Goadsby PJ, Stock DA, Lipton RB.","Lancet. 2020 Jun 20;395(10241):1901-1902. doi: 10.1016/S0140-6736(20)30231-2.","Croop R","Lancet","2020","2020/06/22","","","10.1016/S0140-6736(20)30231-2"
"31794788","Tibetan medicine Ru-yi-Zhen-bao Pills exhibits anti-migraine effect through mediating PAG anti-nociceptive channel","Luo YM, Ren XQ, Yang XQ, Song HR, Li R, Gao MH, Li YR, Zhou RR, Ma L, Zhang SJ, Dong RJ, Ge DY, Wang CG, Ren QJ, Tao XH.","J Ethnopharmacol. 2020 Mar 1;249:112437. doi: 10.1016/j.jep.2019.112437. Epub 2019 Nov 30.","Luo YM","J Ethnopharmacol","2020","2019/12/04","","","10.1016/j.jep.2019.112437"
"33824220","[Application of CGRP-Related Monoclonal Antibodies in Migraine Management]","Shibata M.","Brain Nerve. 2021 Apr;73(4):327-337. doi: 10.11477/mf.1416201763.","Shibata M","Brain Nerve","2021","2021/04/07","","","10.11477/mf.1416201763"
"31556018","Recent Advances in Pharmacotherapy for Episodic Migraine","Chan C, Goadsby PJ.","CNS Drugs. 2019 Nov;33(11):1053-1071. doi: 10.1007/s40263-019-00665-9.","Chan C","CNS Drugs","2019","2019/09/27","","","10.1007/s40263-019-00665-9"
"36709407","Narrative review of migraine management in patients with renal or hepatic disease","Stern JI, Datta S, Chiang CC, Garza I, Vieira DL, Robertson CE.","Headache. 2023 Jan;63(1):9-24. doi: 10.1111/head.14437.","Stern JI","Headache","2023","2023/01/29","","","10.1111/head.14437"
"37804861","Supporting the Young Adulthood Transitions in Women With Migraine","Morse BL, Karian V.","Nurs Womens Health. 2023 Dec;27(6):457-466. doi: 10.1016/j.nwh.2023.06.004. Epub 2023 Oct 5.","Morse BL","Nurs Womens Health","2023","2023/10/07","","","10.1016/j.nwh.2023.06.004"
"19788468","Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan","Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL.","Headache. 2009 Oct;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.x.","Cady RK","Headache","2009","2009/10/01","","","10.1111/j.1526-4610.2009.01523.x"
"32648856","Ubrogepant to treat migraine","Dhir A.","Drugs Today (Barc). 2020 Jul;56(7):459-467. doi: 10.1358/dot.2020.56.7.3157311.","Dhir A","Drugs Today (Barc)","2020","2020/07/11","","","10.1358/dot.2020.56.7.3157311"
"28948500","Blocking CGRP in migraine patients - a review of pros and cons","Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2017 Sep 25;18(1):96. doi: 10.1186/s10194-017-0807-1.","Deen M","J Headache Pain","2017","2017/09/27","PMC5612904","","10.1186/s10194-017-0807-1"
"16178016","No increase of calcitonin gene-related peptide in jugular blood during migraine","Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J.","Ann Neurol. 2005 Oct;58(4):561-8. doi: 10.1002/ana.20605.","Tvedskov JF","Ann Neurol","2005","2005/09/24","","","10.1002/ana.20605"
"19655105","Migraine","Benemei S, Nicoletti P, Capone JG, De Cesaris F, Geppetti P.","Handb Exp Pharmacol. 2009;(194):75-89. doi: 10.1007/978-3-540-79090-7_3.","Benemei S","Handb Exp Pharmacol","2009","2009/08/06","","","10.1007/978-3-540-79090-7_3"
"35085204","Atogepant (Qulipta) for migraine prevention","","Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-171.","","Med Lett Drugs Ther","2021","2022/01/27","","",""
"37569369","Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides","Karsan N, Gosalia H, Goadsby PJ.","Int J Mol Sci. 2023 Jul 26;24(15):11993. doi: 10.3390/ijms241511993.","Karsan N","Int J Mol Sci","2023","2023/08/12","PMC10418996","","10.3390/ijms241511993"
"17508187","Pain pharmacology in migraine: focus on CGRP and CGRP receptors","Benemei S, Nicoletti P, Capone JA, Geppetti P.","Neurol Sci. 2007 May;28 Suppl 2:S89-93. doi: 10.1007/s10072-007-0757-5.","Benemei S","Neurol Sci","2007","2007/05/18","","","10.1007/s10072-007-0757-5"
"32055802","Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache","Ossipov MH, Raffa RB, Pergolizzi JV.","Drugs Today (Barc). 2020 Jan;56(1):5-19. doi: 10.1358/dot.2020.56.1.3069863.","Ossipov MH","Drugs Today (Barc)","2020","2020/02/15","","","10.1358/dot.2020.56.1.3069863"
"35093197","CGRP-targeted drugs for migraine: still many uncertainties","Diener HC.","Lancet Neurol. 2022 Mar;21(3):209-210. doi: 10.1016/S1474-4422(21)00468-3. Epub 2022 Jan 31.","Diener HC","Lancet Neurol","2022","2022/01/30","","","10.1016/S1474-4422(21)00468-3"
"27250233","Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients","Riesco N, Cernuda-Morollón E, Martínez-Camblor P, Pérez-Alvarez AI, Verano L, García-Cabo C, Serrano-Pertierra E, Pascual J.","Cephalalgia. 2017 Aug;37(9):823-827. doi: 10.1177/0333102416653232. Epub 2016 Jun 1.","Riesco N","Cephalalgia","2017","2016/06/03","","","10.1177/0333102416653232"
"11198299","Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache?","Ebersberger A, Schaible HG, Averbeck B, Richter F.","Ann Neurol. 2001 Jan;49(1):7-13.","Ebersberger A","Ann Neurol","2001","2001/02/24","","",""
"24220568","Cortical spreading depression and calcitonin gene-related peptide: a brief review of current progress","Wang M.","Neuropeptides. 2013 Dec;47(6):463-6. doi: 10.1016/j.npep.2013.10.006. Epub 2013 Oct 23.","Wang M","Neuropeptides","2013","2013/11/14","","","10.1016/j.npep.2013.10.006"
"37972256","CGRP signalling in migraine: time to look downstream?","Levy D.","Brain. 2023 Dec 1;146(12):4796-4798. doi: 10.1093/brain/awad390.","Levy D","Brain","2023","2023/11/16","","","10.1093/brain/awad390"
"33874756","Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II","Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L.","Cephalalgia. 2021 Aug;41(9):979-990. doi: 10.1177/03331024211000311. Epub 2021 Apr 19.","Hutchinson S","Cephalalgia","2021","2021/04/20","","","10.1177/03331024211000311"
"35146696","Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score","Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F.","CNS Drugs. 2022 Feb;36(2):191-202. doi: 10.1007/s40263-021-00893-y. Epub 2022 Feb 11.","Iannone LF","CNS Drugs","2022","2022/02/11","PMC8863684","","10.1007/s40263-021-00893-y"
"33121411","The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System","Chong CM, Zhong Z, Vong CT, Wang S, Lu JJ, Zhong HJ, Su H, Wang Y.","Curr Neuropharmacol. 2021;19(7):1090-1100. doi: 10.2174/1570159X18666201029150937.","Chong CM","Curr Neuropharmacol","2021","2020/10/30","PMC8686315","","10.2174/1570159X18666201029150937"
"33413094","Immunogenicity of biologic therapies for migraine: a review of current evidence","Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J.","J Headache Pain. 2021 Jan 7;22(1):3. doi: 10.1186/s10194-020-01211-5.","Cohen JM","J Headache Pain","2021","2021/01/08","PMC7791637","","10.1186/s10194-020-01211-5"
"30006780","Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal","Lee MJ, Lee SY, Cho S, Kang ES, Chung CS.","J Headache Pain. 2018 Jul 13;19(1):53. doi: 10.1186/s10194-018-0883-x.","Lee MJ","J Headache Pain","2018","2018/07/15","PMC6045522","","10.1186/s10194-018-0883-x"
"19346171","A flexible and high throughput liquid chromatography-tandem mass spectrometric assay for the quantitation of telcagepant in human plasma","Du L, Miller-Stein CM, Valesky RJ, Martucci AN, Woolf EJ.","J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 15;877(14-15):1465-71. doi: 10.1016/j.jchromb.2009.03.019. Epub 2009 Mar 18.","Du L","J Chromatogr B Analyt Technol Biomed Life Sci","2009","2009/04/07","","","10.1016/j.jchromb.2009.03.019"
"35804294","Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab","Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R.","BMC Neurol. 2022 Jul 8;22(1):251. doi: 10.1186/s12883-022-02774-3.","Blumenfeld A","BMC Neurol","2022","2022/07/08","PMC9264513","","10.1186/s12883-022-02774-3"
"19690942","CGRP in migraine","Tfelt-Hansen P, Ashina M.","J Headache Pain. 2009 Oct;10(5):385; author reply 387-8. doi: 10.1007/s10194-009-0139-x. Epub 2009 Aug 19.","Tfelt-Hansen P","J Headache Pain","2009","2009/08/20","PMC3452099","","10.1007/s10194-009-0139-x"
"37847221","Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine","de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM.","Eur J Neurol. 2024 Feb;31(2):e16106. doi: 10.1111/ene.16106. Epub 2023 Oct 17.","de Vries Lentsch S","Eur J Neurol","2024","2023/10/17","","","10.1111/ene.16106"
"34644194","The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice","Kang L, Tang W, Zhang Y, Zhang M, Liu J, Li Y, Kong S, Zhao D, Yu S.","Cephalalgia. 2022 May;42(6):490-499. doi: 10.1177/03331024211050036. Epub 2021 Oct 13.","Kang L","Cephalalgia","2022","2021/10/13","","","10.1177/03331024211050036"
"33824218","[Migraine Mechanisms: In Relation to the Premonitory Phase and CGRP/CGRP Receptor Antagonists]","Awaki E, Takeshima T.","Brain Nerve. 2021 Apr;73(4):303-313. doi: 10.11477/mf.1416201761.","Awaki E","Brain Nerve","2021","2021/04/07","","","10.11477/mf.1416201761"
"33389227","Early outcomes of migraine after erenumab discontinuation: data from a real-life setting","De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R.","Neurol Sci. 2021 Aug;42(8):3297-3303. doi: 10.1007/s10072-020-05022-z. Epub 2021 Jan 2.","De Matteis E","Neurol Sci","2021","2021/01/03","","","10.1007/s10072-020-05022-z"
"30689086","CGRP in Animal Models of Migraine","Wattiez AS, Wang M, Russo AF.","Handb Exp Pharmacol. 2019;255:85-107. doi: 10.1007/164_2018_187.","Wattiez AS","Handb Exp Pharmacol","2019","2019/01/29","PMC7008000","NIHMS1551307","10.1007/164_2018_187"
"37742055","Novel peptide calcitonin gene-related peptide antagonists for migraine therapy","Killoran PM, Capel V, D'Aloisio V, Schofield A, Aczél T, Bölcskei K, Helyes Z, von Mentzer B, Kendall DA, Coxon CR, Hutcheon GA.","J Pharm Pharmacol. 2023 Dec 8;75(12):1581-1589. doi: 10.1093/jpp/rgad081.","Killoran PM","J Pharm Pharmacol","2023","2023/09/24","","","10.1093/jpp/rgad081"
"37542597","The Role of Step Therapy in the Treatment of Migraine","Moskatel LS, Zhang N.","Curr Pain Headache Rep. 2023 Oct;27(10):571-577. doi: 10.1007/s11916-023-01155-w. Epub 2023 Aug 5.","Moskatel LS","Curr Pain Headache Rep","2023","2023/08/05","","","10.1007/s11916-023-01155-w"
"30451300","The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?","Tfelt-Hansen P, Loder E.","Headache. 2019 Jan;59(1):113-117. doi: 10.1111/head.13444. Epub 2018 Nov 19.","Tfelt-Hansen P","Headache","2019","2018/11/20","","","10.1111/head.13444"
"34000847","Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study","Gantenbein AR, Agosti R, Gobbi C, Flügel D, Schankin CJ, Viceic D, Zecca C, Pohl H.","Cephalalgia. 2021 Oct;41(11-12):1181-1186. doi: 10.1177/03331024211014616. Epub 2021 May 17.","Gantenbein AR","Cephalalgia","2021","2021/05/18","PMC8504406","","10.1177/03331024211014616"
"32075406","Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J.","Cephalalgia. 2020 Mar;40(3):241-254. doi: 10.1177/0333102420905132. Epub 2020 Feb 19.","Ashina M","Cephalalgia","2020","2020/02/21","PMC7066477","","10.1177/0333102420905132"
"31629892","FAAH inhibition as a preventive treatment for migraine: A pre-clinical study","Greco R, Demartini C, Zanaboni AM, Tumelero E, Reggiani A, Misto A, Piomelli D, Tassorelli C.","Neurobiol Dis. 2020 Feb;134:104624. doi: 10.1016/j.nbd.2019.104624. Epub 2019 Oct 17.","Greco R","Neurobiol Dis","2020","2019/10/21","","","10.1016/j.nbd.2019.104624"
"11281817","Substance P receptor antagonists in the therapy of migraine","May A, Goadsby PJ.","Expert Opin Investig Drugs. 2001 Apr;10(4):673-8. doi: 10.1517/13543784.10.4.673.","May A","Expert Opin Investig Drugs","2001","2001/04/03","","","10.1517/13543784.10.4.673"
"36826751","New Migraine Drugs for Older Adults","Onan D, Wells-Gatnik WD, Bentivegna E, Lampl C, Martelletti P.","Drugs Aging. 2023 Apr;40(4):301-305. doi: 10.1007/s40266-023-01012-w. Epub 2023 Feb 24.","Onan D","Drugs Aging","2023","2023/02/24","","","10.1007/s40266-023-01012-w"
"29317063","Trigeminal long-term potentiation as a cellular substrate for migraine","Youn DH.","Med Hypotheses. 2018 Jan;110:27-30. doi: 10.1016/j.mehy.2017.10.026. Epub 2017 Oct 26.","Youn DH","Med Hypotheses","2018","2018/01/11","","","10.1016/j.mehy.2017.10.026"
"33119447","The effectiveness and value of novel acute treatments for migraine","Agboola F, Atlas SJ, Touchette DR, Borrelli EP, Rind DM, Pearson SD.","J Manag Care Spec Pharm. 2020 Nov;26(11):1456-1462. doi: 10.18553/jmcp.2020.26.11.1456.","Agboola F","J Manag Care Spec Pharm","2020","2020/10/29","PMC10391055","","10.18553/jmcp.2020.26.11.1456"
"34542830","Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial","Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, Stroud C, Tockhorn-Heidenreich A, Detke HC.","Adv Ther. 2021 Nov;38(11):5465-5483. doi: 10.1007/s12325-021-01911-7. Epub 2021 Sep 20.","Reuter U","Adv Ther","2021","2021/09/20","PMC8523004","","10.1007/s12325-021-01911-7"
"23237777","Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine","Sutherland HG, Buteri J, Menon S, Haupt LM, Macgregor EA, Lea RA, Griffiths LR.","Gene. 2013 Feb 15;515(1):187-92. doi: 10.1016/j.gene.2012.11.053. Epub 2012 Dec 10.","Sutherland HG","Gene","2013","2012/12/15","","","10.1016/j.gene.2012.11.053"
"37038933","The pharmacotherapeutic management of episodic and chronic migraine with gepants","Tajti J, Szok D, Csáti A, Vécsei L.","Expert Opin Pharmacother. 2023 Jun;24(8):947-958. doi: 10.1080/14656566.2023.2201375. Epub 2023 Apr 12.","Tajti J","Expert Opin Pharmacother","2023","2023/04/11","","","10.1080/14656566.2023.2201375"
"19820895","Is there an inherent limit to acute migraine treatment efficacy?","Bigal ME, Ho TW.","J Headache Pain. 2009 Dec;10(6):393-4. doi: 10.1007/s10194-009-0162-y. Epub 2009 Oct 10.","Bigal ME","J Headache Pain","2009","2009/10/13","PMC3476204","","10.1007/s10194-009-0162-y"
"38266063","Atogepant: Mechanism of action, clinical and translational science","Boinpally R, Shebley M, Trugman JM.","Clin Transl Sci. 2024 Jan;17(1):e13707. doi: 10.1111/cts.13707.","Boinpally R","Clin Transl Sci","2024","2024/01/24","PMC10777605","","10.1111/cts.13707"
"31547694","Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review","Tfelt-Hansen P, Diener HC, Steiner TJ.","Cephalalgia. 2020 Jan;40(1):122-126. doi: 10.1177/0333102419877663. Epub 2019 Sep 23.","Tfelt-Hansen P","Cephalalgia","2020","2019/09/25","","","10.1177/0333102419877663"
"26946372","Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura","Lindblad M, Hougaard A, Amin FM, Ashina M.","Cephalalgia. 2017 Jan;37(1):74-88. doi: 10.1177/0333102416636097. Epub 2016 Sep 29.","Lindblad M","Cephalalgia","2017","2016/03/07","","","10.1177/0333102416636097"
"37523183","Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder","Wang K, Fenton BT, Deng Y, Anthony SE, Dao VX, Schindler E, Lipton RB, Guirguis A, Skanderson M, Seng EK, Sico JJ.","JAMA Netw Open. 2023 Jul 3;6(7):e2326371. doi: 10.1001/jamanetworkopen.2023.26371.","Wang K","JAMA Netw Open","2023","2023/07/31","PMC10391301","","10.1001/jamanetworkopen.2023.26371"
"27334137","Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization","Durham PL.","Curr Pain Headache Rep. 2016 Aug;20(8):48. doi: 10.1007/s11916-016-0578-4.","Durham PL","Curr Pain Headache Rep","2016","2016/06/24","PMC5889915","NIHMS954884","10.1007/s11916-016-0578-4"
"33656015","Lasmiditan for acute treatment of migraine","Parikh S.","Drugs Today (Barc). 2021 Feb;57(2):89-100. doi: 10.1358/dot.2021.57.2.3238326.","Parikh S","Drugs Today (Barc)","2021","2021/03/03","","","10.1358/dot.2021.57.2.3238326"
"30927136","Erenumab: from scientific evidence to clinical practice-the first Italian real-life data","Barbanti P, Aurilia C, Egeo G, Fofi L.","Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.","Barbanti P","Neurol Sci","2019","2019/03/31","","","10.1007/s10072-019-03839-x"
"28644160","Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review","Schuster NM, Rapoport AM.","Clin Neuropharmacol. 2017 Jul/Aug;40(4):169-174. doi: 10.1097/WNF.0000000000000227.","Schuster NM","Clin Neuropharmacol","2017","2017/06/24","","","10.1097/WNF.0000000000000227"
"25496894","Site of effect of LY2951742 for migraine prophylaxis","Tfelt-Hansen P.","Lancet Neurol. 2015 Jan;14(1):31-2. doi: 10.1016/S1474-4422(14)70306-0.","Tfelt-Hansen P","Lancet Neurol","2015","2014/12/16","","","10.1016/S1474-4422(14)70306-0"
"32155317","Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","Baker B, Schaeffler B, Beliveau M, Rubets I, Pederson S, Trinh M, Smith J, Latham J.","Pharmacol Res Perspect. 2020 Apr;8(2):e00567. doi: 10.1002/prp2.567.","Baker B","Pharmacol Res Perspect","2020","2020/03/11","PMC7064329","","10.1002/prp2.567"
"31723033","Female-Specific Effects of CGRP Suggest Limited Efficacy of New Migraine Treatments in Males","Moehring F, Sadler KE.","J Neurosci. 2019 Nov 13;39(46):9062-9064. doi: 10.1523/JNEUROSCI.1254-19.2019.","Moehring F","J Neurosci","2019","2019/11/15","PMC6855686","","10.1523/JNEUROSCI.1254-19.2019"
"34922444","Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study","Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C.","J Headache Pain. 2021 Dec 18;22(1):154. doi: 10.1186/s10194-021-01363-y.","Vernieri F","J Headache Pain","2021","2021/12/19","PMC8903705","","10.1186/s10194-021-01363-y"
"34019304","Refractory migraine profile in CGRP-monoclonal antibodies scenario","Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A.","Acta Neurol Scand. 2021 Sep;144(3):325-333. doi: 10.1111/ane.13472. Epub 2021 May 21.","Silvestro M","Acta Neurol Scand","2021","2021/05/21","PMC8453754","","10.1111/ane.13472"
"38170954","Systemic allergic reaction to galcanezumab (emgality): a case report","Pico MJ, Badri M, Michalak N, Siefferman JW.","Cephalalgia. 2024 Jan;44(1):3331024231222914. doi: 10.1177/03331024231222914.","Pico MJ","Cephalalgia","2024","2024/01/03","","","10.1177/03331024231222914"
"25127171","Anti-CGRP antibodies: a new approach to migraine prevention","Reuter U.","Lancet Neurol. 2014 Sep;13(9):857-9. doi: 10.1016/S1474-4422(14)70126-7. Epub 2014 Aug 10.","Reuter U","Lancet Neurol","2014","2014/08/16","","","10.1016/S1474-4422(14)70126-7"
"35261165","Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: A meta-analysis","Huang T, Xu Y, Chen Y, Bian J, Chu Z, Zhao S, Ma L.","Brain Behav. 2022 Apr;12(4):e2542. doi: 10.1002/brb3.2542. Epub 2022 Mar 8.","Huang T","Brain Behav","2022","2022/03/09","PMC9015008","","10.1002/brb3.2542"
"1379708","The pathophysiology of migraine: a tentative synthesis","Lance JW.","Pathol Biol (Paris). 1992 Apr;40(4):355-60.","Lance JW","Pathol Biol (Paris)","1992","1992/04/01","","",""
"25253587","Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors","Tajti J, Csáti A, Vécsei L.","Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1509-20. doi: 10.1517/17425255.2014.963554. Epub 2014 Sep 25.","Tajti J","Expert Opin Drug Metab Toxicol","2014","2014/09/26","","","10.1517/17425255.2014.963554"
"37657674","Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response","Juhasz G, Gecse K, Baksa D.","Pharmacol Ther. 2023 Oct;250:108523. doi: 10.1016/j.pharmthera.2023.108523. Epub 2023 Aug 30.","Juhasz G","Pharmacol Ther","2023","2023/09/01","","","10.1016/j.pharmthera.2023.108523"
"37231663","Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan","Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, Hirata K.","Cephalalgia. 2023 May;43(5):3331024231177649. doi: 10.1177/03331024231177649.","Suzuki K","Cephalalgia","2023","2023/05/26","","","10.1177/03331024231177649"
"34148407","Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?","Benbow T, Cairns BE.","Cephalalgia. 2021 Oct;41(11-12):1249-1261. doi: 10.1177/03331024211017882. Epub 2021 Jun 20.","Benbow T","Cephalalgia","2021","2021/06/21","PMC8504403","","10.1177/03331024211017882"
"36804077","A nasal CGRP receptor antagonist for acute migraine therapy","Reuter U.","Lancet Neurol. 2023 Mar;22(3):190-191. doi: 10.1016/S1474-4422(23)00037-6.","Reuter U","Lancet Neurol","2023","2023/02/21","","","10.1016/S1474-4422(23)00037-6"
"34162288","Updated review on the link between cortical spreading depression and headache disorders","Vuralli D, Karatas H, Yemisci M, Bolay H.","Expert Rev Neurother. 2021 Oct;21(10):1069-1084. doi: 10.1080/14737175.2021.1947797. Epub 2021 Sep 17.","Vuralli D","Expert Rev Neurother","2021","2021/06/24","","","10.1080/14737175.2021.1947797"
"36982428","Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings","Demartini C, Francavilla M, Zanaboni AM, Facchetti S, De Icco R, Martinelli D, Allena M, Greco R, Tassorelli C.","Int J Mol Sci. 2023 Mar 10;24(6):5334. doi: 10.3390/ijms24065334.","Demartini C","Int J Mol Sci","2023","2023/03/29","PMC10049673","","10.3390/ijms24065334"
"35659622","Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial","Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R.","BMC Neurol. 2022 Jun 3;22(1):205. doi: 10.1186/s12883-022-02714-1.","Ailani J","BMC Neurol","2022","2022/06/06","PMC9164335","","10.1186/s12883-022-02714-1"
"25391253","The therapeutic potential of novel anti-migraine acute therapies","Sabato D, Lionetto L, Martelletti P.","Expert Opin Investig Drugs. 2015 Feb;24(2):141-4. doi: 10.1517/13543784.2015.983223. Epub 2014 Nov 13.","Sabato D","Expert Opin Investig Drugs","2015","2014/11/14","","","10.1517/13543784.2015.983223"
"33470852","An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies","González-Hernández A, Condés-Lara M, García-Boll E, Villalón CM.","Expert Opin Drug Metab Toxicol. 2021 Feb;17(2):179-199. doi: 10.1080/17425255.2021.1856366. Epub 2021 Jan 20.","González-Hernández A","Expert Opin Drug Metab Toxicol","2021","2021/01/20","","","10.1080/17425255.2021.1856366"
"36396451","Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial","Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D.","Neurology. 2023 Feb 21;100(8):e764-e777. doi: 10.1212/WNL.0000000000201568. Epub 2022 Nov 17.","Lipton RB","Neurology","2023","2022/11/17","PMC9984220","","10.1212/WNL.0000000000201568"
"32822621","Targeting CGRP in migraine: a matter of choice and dose","Al-Hassany L, Van Den Brink AM.","Lancet Neurol. 2020 Sep;19(9):712-713. doi: 10.1016/S1474-4422(20)30282-9.","Al-Hassany L","Lancet Neurol","2020","2020/08/22","","","10.1016/S1474-4422(20)30282-9"
"29691490","CGRP as the target of new migraine therapies - successful translation from bench to clinic","Edvinsson L, Haanes KA, Warfvinge K, Krause DN.","Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1.","Edvinsson L","Nat Rev Neurol","2018","2018/04/26","","","10.1038/s41582-018-0003-1"
"26728923","Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis","Hong P, Liu Y.","Int J Neurosci. 2017 Jan;127(1):20-27. doi: 10.3109/00207454.2015.1137915. Epub 2016 Jan 28.","Hong P","Int J Neurosci","2017","2016/01/06","","","10.3109/00207454.2015.1137915"
"36753861","Effectiveness and safety of CGRP monoclonal antibodies in migraine related to mitochondrial diseases in patients with NARP and PEO syndromes","Silvestro M, Orologio I, Trojsi F, Tessitore A, Tedeschi G, Russo A.","Clin Neurol Neurosurg. 2023 Mar;226:107611. doi: 10.1016/j.clineuro.2023.107611. Epub 2023 Jan 27.","Silvestro M","Clin Neurol Neurosurg","2023","2023/02/08","","","10.1016/j.clineuro.2023.107611"
"29611192","A Proposal for Acronyms for Anti-Calcitonin Gene-Related Peptide Antibodies","Evans RW, Loftus BD.","Headache. 2018 Apr;58(4):596. doi: 10.1111/head.13287.","Evans RW","Headache","2018","2018/04/04","","","10.1111/head.13287"
"19795182","New drugs for migraine","Stovner LJ, Tronvik E, Hagen K.","J Headache Pain. 2009 Dec;10(6):395-406. doi: 10.1007/s10194-009-0156-9. Epub 2009 Oct 1.","Stovner LJ","J Headache Pain","2009","2009/10/02","PMC3476209","","10.1007/s10194-009-0156-9"
"34601944","Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks","Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P.","Cephalalgia. 2022 Mar;42(3):186-196. doi: 10.1177/03331024211040467. Epub 2021 Oct 4.","Alpuente A","Cephalalgia","2022","2021/10/04","","","10.1177/03331024211040467"
"35881279","CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache","Chen ST, Wu JW.","Curr Pain Headache Rep. 2022 Sep;26(9):667-675. doi: 10.1007/s11916-022-01070-6. Epub 2022 Jul 26.","Chen ST","Curr Pain Headache Rep","2022","2022/07/26","","","10.1007/s11916-022-01070-6"
"33008504","A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system","Chen ST, Wu JW.","Prog Brain Res. 2020;255:123-142. doi: 10.1016/bs.pbr.2020.05.012. Epub 2020 Jun 16.","Chen ST","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.05.012"
"16939382","Migraine: emerging treatment options for preventive and acute attack therapy","Goadsby PJ.","Expert Opin Emerg Drugs. 2006 Sep;11(3):419-27. doi: 10.1517/14728214.11.3.419.","Goadsby PJ","Expert Opin Emerg Drugs","2006","2006/08/31","","","10.1517/14728214.11.3.419"
"30847888","[Headache - an Update 2018]","Diener HC, Gaul C, Holle-Lee D, Jürgens TP, Kraya T, Kurth T, Nägel S, Neeb L, Straube A.","Laryngorhinootologie. 2019 Mar;98(3):192-217. doi: 10.1055/a-0823-4814. Epub 2019 Mar 7.","Diener HC","Laryngorhinootologie","2019","2019/03/09","","","10.1055/a-0823-4814"
"20352590","Management of migraine headache in the emergency department","Robertson CE, Black DF, Swanson JW.","Semin Neurol. 2010 Apr;30(2):201-11. doi: 10.1055/s-0030-1249228. Epub 2010 Mar 29.","Robertson CE","Semin Neurol","2010","2010/03/31","","","10.1055/s-0030-1249228"
"30450545","The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment","Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.","Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.","Silberstein SD","Headache","2019","2018/11/20","","","10.1111/head.13446"
"24697226","The vasodilatory activity of CGRP: a response","Bigal ME, Walter S, Rapoport AM.","Headache. 2014 Apr;54(4):748-9. doi: 10.1111/head.12316.","Bigal ME","Headache","2014","2014/04/05","","","10.1111/head.12316"
"19084002","Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine","Moore EL, Burgey CS, Paone DV, Shaw AW, Tang YS, Kane SA, Salvatore CA.","Eur J Pharmacol. 2009 Jan 14;602(2-3):250-4. doi: 10.1016/j.ejphar.2008.11.050. Epub 2008 Dec 3.","Moore EL","Eur J Pharmacol","2009","2008/12/17","","","10.1016/j.ejphar.2008.11.050"
"34184869","To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations","Leung L, Liao S, Wu C.","ACS Chem Neurosci. 2021 Jul 21;12(14):2629-2642. doi: 10.1021/acschemneuro.1c00135. Epub 2021 Jun 29.","Leung L","ACS Chem Neurosci","2021","2021/06/29","","","10.1021/acschemneuro.1c00135"
"25496895","Site of effect of LY2951742 for migraine prophylaxis--authors' reply","Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS.","Lancet Neurol. 2015 Jan;14(1):32-3. doi: 10.1016/S1474-4422(14)70309-6.","Dodick DW","Lancet Neurol","2015","2014/12/16","","","10.1016/S1474-4422(14)70309-6"
"25022695","Reporting withdrawals due to adverse events in single-attack acute migraine clinical trials","Tfelt-Hansen P, Pascual J.","Cephalalgia. 2015 Apr;35(4):366-7. doi: 10.1177/0333102414540059. Epub 2014 Jul 14.","Tfelt-Hansen P","Cephalalgia","2015","2014/07/16","","","10.1177/0333102414540059"
"34419975","Quality of Life Related to Functional Disability in Migraine Patients: A Systematic Review and Network Meta-analysis","Soni P, Chawla E.","Clin J Pain. 2021 Nov 1;37(11):845-851. doi: 10.1097/AJP.0000000000000972.","Soni P","Clin J Pain","2021","2021/08/22","","","10.1097/AJP.0000000000000972"
"30995909","Therapeutic novelties in migraine: new drugs, new hope?","Do TP, Guo S, Ashina M.","J Headache Pain. 2019 Apr 17;20(1):37. doi: 10.1186/s10194-019-0974-3.","Do TP","J Headache Pain","2019","2019/04/19","PMC6734360","","10.1186/s10194-019-0974-3"
"34424593","Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study","de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM.","Eur J Neurol. 2021 Dec;28(12):4194-4203. doi: 10.1111/ene.15075. Epub 2021 Sep 7.","de Vries Lentsch S","Eur J Neurol","2021","2021/08/23","PMC9291504","","10.1111/ene.15075"
"22671857","Pathogenesis of migraine: role of neuromodulators","D'Andrea G, D'Arrigo A, Dalle Carbonare M, Leon A.","Headache. 2012 Jul-Aug;52(7):1155-63. doi: 10.1111/j.1526-4610.2012.02168.x. Epub 2012 Jun 1.","D'Andrea G","Headache","2012","2012/06/08","","","10.1111/j.1526-4610.2012.02168.x"
"29020807","Recognizing the role of CGRP and CGRP receptors in migraine and its treatment","Edvinsson L, Warfvinge K.","Cephalalgia. 2019 Mar;39(3):366-373. doi: 10.1177/0333102417736900. Epub 2017 Oct 11.","Edvinsson L","Cephalalgia","2019","2017/10/13","","","10.1177/0333102417736900"
"18459072","Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF","Giniatullin R, Nistri A, Fabbretti E.","Mol Neurobiol. 2008 Feb;37(1):83-90. doi: 10.1007/s12035-008-8020-5. Epub 2008 May 6.","Giniatullin R","Mol Neurobiol","2008","2008/05/07","","","10.1007/s12035-008-8020-5"
"23112192","Critical role of calcitonin gene-related peptide receptors in cortical spreading depression","Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, Picconi B, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P.","Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18985-90. doi: 10.1073/pnas.1215435109. Epub 2012 Oct 29.","Tozzi A","Proc Natl Acad Sci U S A","2012","2012/11/01","PMC3503217","","10.1073/pnas.1215435109"
"34330208","Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy","Scuteri D, Corasaniti MT, Tonin P, Nicotera P, Bagetta G.","J Headache Pain. 2021 Jul 30;22(1):87. doi: 10.1186/s10194-021-01295-7.","Scuteri D","J Headache Pain","2021","2021/07/31","PMC8325208","","10.1186/s10194-021-01295-7"
"35983926","Atogepant for migraine","Bedrin K, Ailani J.","Drugs Today (Barc). 2022 Aug;58(8):399-405. doi: 10.1358/dot.2022.58.8.3408815.","Bedrin K","Drugs Today (Barc)","2022","2022/08/19","","","10.1358/dot.2022.58.8.3408815"
"31856582","Contribution of intraganglionic CGRP to migraine-like responses in male and female rats","Araya EI, Turnes JM, Barroso AR, Chichorro JG.","Cephalalgia. 2020 Jun;40(7):689-700. doi: 10.1177/0333102419896539. Epub 2019 Dec 19.","Araya EI","Cephalalgia","2020","2019/12/21","","","10.1177/0333102419896539"
"29556965","Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy","Holland PR, Goadsby PJ.","Neurotherapeutics. 2018 Apr;15(2):304-312. doi: 10.1007/s13311-018-0617-4.","Holland PR","Neurotherapeutics","2018","2018/03/21","PMC5935646","","10.1007/s13311-018-0617-4"
"1690601","Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache","Nicolodi M, Del Bianco E.","Cephalalgia. 1990 Feb;10(1):39-50. doi: 10.1046/j.1468-2982.1990.1001039.x.","Nicolodi M","Cephalalgia","1990","1990/02/01","","","10.1046/j.1468-2982.1990.1001039.x"
"33441852","Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs","Leira Y, Domínguez C, Ameijeira P, López-Arias E, Ávila-Gómez P, Pérez-Mato M, Sobrino T, Campos F, Blanco J, Leira R.","Sci Rep. 2021 Jan 13;11(1):1092. doi: 10.1038/s41598-020-80283-4.","Leira Y","Sci Rep","2021","2021/01/14","PMC7806961","","10.1038/s41598-020-80283-4"
"24615704","Efficacy of BMS-927711 and other gepants vs triptans: there seem to be other players besides CGRP","Pascual J.","Cephalalgia. 2014 Oct;34(12):1028-9. doi: 10.1177/0333102414526052. Epub 2014 Mar 10.","Pascual J","Cephalalgia","2014","2014/03/12","","","10.1177/0333102414526052"
"32555113","Rimegepant (Nurtec ODT) for acute treatment of migraine","","Med Lett Drugs Ther. 2020 May 4;62(1597):70-72.","","Med Lett Drugs Ther","2020","2020/06/20","","",""
"35979920","Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice","Cantarelli L, Pestana Grafiña D, Gonzalez Perez A, García Gil S, Gutiérrez Nicolás F, Ramos Santana E, Navarro Dávila MA, Otazo Pérez SM, Calzado Gómez G, Perez Reyes S, Nazco Casariego GJ.","Ann Pharmacother. 2023 Apr;57(4):416-424. doi: 10.1177/10600280221118402. Epub 2022 Aug 18.","Cantarelli L","Ann Pharmacother","2023","2022/08/18","","","10.1177/10600280221118402"
"37386456","Inhibition of glutamatergic trigeminal nucleus caudalis- vestibular nucleus projection neurons attenuates vestibular dysfunction in the chronic-NTG model of migraine","Zhang Y, Zhang Y, Wang Y, Zhang X, Qin G, Zhang D, Chen L, Zhou J.","J Headache Pain. 2023 Jun 30;24(1):77. doi: 10.1186/s10194-023-01607-z.","Zhang Y","J Headache Pain","2023","2023/06/29","PMC10311850","","10.1186/s10194-023-01607-z"
"32993366","Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist","Joyner KR, Morgan KW.","Ann Pharmacother. 2021 Jun;55(6):745-759. doi: 10.1177/1060028020963574. Epub 2020 Sep 29.","Joyner KR","Ann Pharmacother","2021","2020/09/30","","","10.1177/1060028020963574"
"18039958","Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine","Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA.","J Pharmacol Exp Ther. 2008 Feb;324(2):416-21. doi: 10.1124/jpet.107.130344. Epub 2007 Nov 26.","Salvatore CA","J Pharmacol Exp Ther","2008","2007/11/28","","","10.1124/jpet.107.130344"
"32516986","A Pre-Existing Myogenic Temporomandibular Disorder Increases Trigeminal Calcitonin Gene-Related Peptide and Enhances Nitroglycerin-Induced Hypersensitivity in Mice","Shu H, Liu S, Tang Y, Schmidt BL, Dolan JC, Bellinger LL, Kramer PR, Bender SD, Tao F.","Int J Mol Sci. 2020 Jun 5;21(11):4049. doi: 10.3390/ijms21114049.","Shu H","Int J Mol Sci","2020","2020/06/11","PMC7313473","","10.3390/ijms21114049"
"37298078","The Epigenetics of Migraine","Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J.","Int J Mol Sci. 2023 May 23;24(11):9127. doi: 10.3390/ijms24119127.","Zobdeh F","Int J Mol Sci","2023","2023/06/10","PMC10252316","","10.3390/ijms24119127"
"8536290","Neuropeptides and migraine--a useful biological marker?","Goadsby P.","Cephalalgia. 1995 Oct;15(5):333-4.","Goadsby P","Cephalalgia","1995","1995/10/01","","",""
"22512641","CGRP receptor antagonists: an expanding drug class for acute migraine?","Negro A, Lionetto L, Simmaco M, Martelletti P.","Expert Opin Investig Drugs. 2012 Jun;21(6):807-18. doi: 10.1517/13543784.2012.681044. Epub 2012 Apr 19.","Negro A","Expert Opin Investig Drugs","2012","2012/04/20","","","10.1517/13543784.2012.681044"
"37073858","Pharmacological interventions for prophylaxis of vestibular migraine","Webster K, Dor A, Galbraith K, Kassem LH, Harrington-Benton N, Judd O, Kaski D, Maarsingh O, MacKeith S, Ray J, Van Vugt V, Burton M.","Cochrane Database Syst Rev. 2023 Apr 12;2023(4):CD015187. doi: 10.1002/14651858.CD015187.pub2.","Webster K","Cochrane Database Syst Rev","2023","2023/04/19","PMC10093999","","10.1002/14651858.CD015187.pub2"
"23053351","Lack of migraine in headaches of familial dysautonomia patients","Shihman B, Steiner I, Yovchev I, Maayan C.","J Neural Transm (Vienna). 2013 Mar;120(3):399-402. doi: 10.1007/s00702-012-0903-y. Epub 2012 Oct 9.","Shihman B","J Neural Transm (Vienna)","2013","2012/10/12","","","10.1007/s00702-012-0903-y"
"35648658","Calcitonin gene-related peptide antagonist therapy and migraines","Zolp A.","JAAPA. 2022 May 1;35(5):19-20. doi: 10.1097/01.JAA.0000835128.83757.c0.","Zolp A","JAAPA","2022","2022/06/01","","","10.1097/01.JAA.0000835128.83757.c0"
"31070784","Periodontal inflammation is related to increased serum calcitonin gene-related peptide levels in patients with chronic migraine","Leira Y, Ameijeira P, Domínguez C, López-Arias E, Ávila-Gómez P, Pérez-Mato M, Sobrino T, Campos F, D'Aiuto F, Leira R, Blanco J.","J Periodontol. 2019 Oct;90(10):1088-1095. doi: 10.1002/JPER.19-0051. Epub 2019 May 27.","Leira Y","J Periodontol","2019","2019/05/10","","","10.1002/JPER.19-0051"
"28584969","The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine","Ansari M, Karkhaneh A, Kheirollahi A, Emamgholipour S, Rafiee MH.","Acta Neurol Belg. 2017 Sep;117(3):677-685. doi: 10.1007/s13760-017-0803-x. Epub 2017 Jun 5.","Ansari M","Acta Neurol Belg","2017","2017/06/07","","","10.1007/s13760-017-0803-x"
"33772636","The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study","Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P.","J Neurol. 2021 Oct;268(10):3789-3798. doi: 10.1007/s00415-021-10523-8. Epub 2021 Mar 27.","Torres-Ferrús M","J Neurol","2021","2021/03/27","","","10.1007/s00415-021-10523-8"
"31164079","Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention","Mikol DD, Snellman J.","J Headache Pain. 2019 Jun 4;20(1):67. doi: 10.1186/s10194-019-0994-z.","Mikol DD","J Headache Pain","2019","2019/06/06","PMC6734219","","10.1186/s10194-019-0994-z"
"23975870","Is CGRP a marker for chronic migraine?","Silberstein SD, Edvinsson L.","Neurology. 2013 Oct 1;81(14):1184-5. doi: 10.1212/WNL.0b013e3182a6cc33. Epub 2013 Aug 23.","Silberstein SD","Neurology","2013","2013/08/27","","","10.1212/WNL.0b013e3182a6cc33"
"15132108","New drug curbs migraine pain","","Health News. 2004 May;10(5):7.","","Health News","2004","2004/05/11","","",""
"37227596","Zavegepant: First Approval","Dhillon S.","Drugs. 2023 Jun;83(9):825-831. doi: 10.1007/s40265-023-01885-6.","Dhillon S","Drugs","2023","2023/05/25","PMC10209931","","10.1007/s40265-023-01885-6"
"30142988","Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives","Sussman M, Benner J, Neumann P, Menzin J.","Cephalalgia. 2018 Sep;38(10):1644-1657. doi: 10.1177/0333102418796842. Epub 2018 Aug 24.","Sussman M","Cephalalgia","2018","2018/08/26","","","10.1177/0333102418796842"
"15523578","[Innovative treatment of acute migraine pain with CGRP receptor antagonists]","Herbert MK, Holzer P.","Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Nov;39(11):657-61. doi: 10.1055/s-2004-826037.","Herbert MK","Anasthesiol Intensivmed Notfallmed Schmerzther","2004","2004/11/04","","","10.1055/s-2004-826037"
"30189270","Orally inhaled migraine therapy: Where are we now?","Stapleton KW.","Adv Drug Deliv Rev. 2018 Aug;133:131-134. doi: 10.1016/j.addr.2018.08.014. Epub 2018 Sep 4.","Stapleton KW","Adv Drug Deliv Rev","2018","2018/09/07","","","10.1016/j.addr.2018.08.014"
"22815557","Endothelial progenitor cells: a new key for endothelial dysfunction in migraine","Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R.","Neurology. 2012 Jul 31;79(5):474-9. doi: 10.1212/WNL.0b013e31826170ce. Epub 2012 Jul 18.","Rodríguez-Osorio X","Neurology","2012","2012/07/21","","","10.1212/WNL.0b013e31826170ce"
"36729391","CGRP, Migraine, and Brain MRI in CADASIL: A Pilot Study","Goldstein ED, Gopal N, Badi MK, Hodge DO, de Havenon A, Glover P, Durham PL, Huang JF, Lin MP, Baradaran H, Majersik JJ, Meschia JF.","Neurologist. 2023 Jul 1;28(4):231-236. doi: 10.1097/NRL.0000000000000478.","Goldstein ED","Neurologist","2023","2023/02/02","PMC10277309","NIHMS1851502","10.1097/NRL.0000000000000478"
"30640381","Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine","Loder E, Renthal W.","JAMA Intern Med. 2019 Mar 1;179(3):421-422. doi: 10.1001/jamainternmed.2018.7536.","Loder E","JAMA Intern Med","2019","2019/01/15","","","10.1001/jamainternmed.2018.7536"
"35618933","CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients","Schiano di Cola F, Caratozzolo S, Bolchini M, Ceccardi G, Cortinovis M, Liberini P, Padovani A, Rao R.","Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26.","Schiano di Cola F","Neurol Sci","2022","2022/05/26","PMC9385831","","10.1007/s10072-022-06154-0"
"26153991","Migraine mAbs crowd into late-stage trials","Sinha G.","Nat Biotechnol. 2015 Jul;33(7):676-7. doi: 10.1038/nbt0715-676c.","Sinha G","Nat Biotechnol","2015","2015/07/09","","","10.1038/nbt0715-676c"
"16472331","Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders","Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C, Floridi A, Calabresi P.","Cephalalgia. 2006 Mar;26(3):257-65. doi: 10.1111/j.1468-2982.2005.01016.x.","Sarchielli P","Cephalalgia","2006","2006/02/14","","","10.1111/j.1468-2982.2005.01016.x"
"36756979","Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine","Nikolova S, Chong CD, Dumkrieger GM, Li J, Wu T, Schwedt TJ.","Cephalalgia. 2023 Feb;43(2):3331024221144783. doi: 10.1177/03331024221144783.","Nikolova S","Cephalalgia","2023","2023/02/09","PMC10316773","NIHMS1908746","10.1177/03331024221144783"
"26095133","Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists","Hougaard A, Tfelt-Hansen P.","Expert Opin Drug Metab Toxicol. 2015;11(9):1409-18. doi: 10.1517/17425255.2015.1055244. Epub 2015 Jun 26.","Hougaard A","Expert Opin Drug Metab Toxicol","2015","2015/06/23","","","10.1517/17425255.2015.1055244"
"34510038","Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series","Patier Ruiz I, Sánchez-Rubio Ferrández J, Cárcamo Fonfría A, Molina García T.","Eur Neurol. 2022;85(2):132-135. doi: 10.1159/000518899. Epub 2021 Sep 10.","Patier Ruiz I","Eur Neurol","2022","2021/09/12","","","10.1159/000518899"
"36404301","A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study","Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ.","J Headache Pain. 2022 Nov 21;23(1):146. doi: 10.1186/s10194-022-01514-9.","Yu S","J Headache Pain","2022","2022/11/20","PMC9676838","","10.1186/s10194-022-01514-9"
"35484504","Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients","de Tommaso M, La Rocca M, Quitadamo SG, Ricci K, Tancredi G, Clemente L, Gentile E, Ammendola E, Delussi M.","J Headache Pain. 2022 Apr 29;23(1):52. doi: 10.1186/s10194-022-01421-z.","de Tommaso M","J Headache Pain","2022","2022/04/28","PMC9052688","","10.1186/s10194-022-01421-z"
"21533724","New frontiers in headache therapy","Rapoport A.","Neurol Sci. 2011 May;32 Suppl 1:S105-9. doi: 10.1007/s10072-011-0542-3.","Rapoport A","Neurol Sci","2011","2011/05/03","","","10.1007/s10072-011-0542-3"
"20561068","DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons","Masterson CG, Durham PL.","Headache. 2010 Oct;50(9):1424-39. doi: 10.1111/j.1526-4610.2010.01714.x.","Masterson CG","Headache","2010","2010/06/22","PMC3138143","NIHMS304671","10.1111/j.1526-4610.2010.01714.x"
"18217201","Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system","Link AS, Kuris A, Edvinsson L.","J Headache Pain. 2008 Feb;9(1):5-12. doi: 10.1007/s10194-008-0011-4. Epub 2008 Jan 23.","Link AS","J Headache Pain","2008","2008/01/25","PMC2245994","","10.1007/s10194-008-0011-4"
"17982431","Emerging therapies for migraine","Goadsby PJ.","Nat Clin Pract Neurol. 2007 Nov;3(11):610-9. doi: 10.1038/ncpneuro0639.","Goadsby PJ","Nat Clin Pract Neurol","2007","2007/11/06","","","10.1038/ncpneuro0639"
"27312704","Neurovascular contributions to migraine: Moving beyond vasodilation","Jacobs B, Dussor G.","Neuroscience. 2016 Dec 3;338:130-144. doi: 10.1016/j.neuroscience.2016.06.012. Epub 2016 Jun 14.","Jacobs B","Neuroscience","2016","2016/06/18","PMC5083225","NIHMS798641","10.1016/j.neuroscience.2016.06.012"
"32810212","Differential medication overuse risk of novel anti-migraine therapeutics","Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR.","Brain. 2020 Sep 1;143(9):2681-2688. doi: 10.1093/brain/awaa211.","Saengjaroentham C","Brain","2020","2020/08/19","PMC7523700","","10.1093/brain/awaa211"
"34593167","Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach","Seddik AH, Schiener C, Ostwald DA, Schramm S, Huels J, Katsarava Z.","Value Health. 2021 Oct;24(10):1446-1453. doi: 10.1016/j.jval.2021.04.1281. Epub 2021 Jul 25.","Seddik AH","Value Health","2021","2021/10/01","","","10.1016/j.jval.2021.04.1281"
"33934575","Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle","Raffaelli B, Overeem LH, Mecklenburg J, Hofacker MD, Knoth H, Nowak CP, Neeb L, Ebert AD, Sehouli J, Mechsner S, Reuter U.","Ann Clin Transl Neurol. 2021 Jun;8(6):1251-1259. doi: 10.1002/acn3.51360. Epub 2021 May 2.","Raffaelli B","Ann Clin Transl Neurol","2021","2021/05/02","PMC8164854","","10.1002/acn3.51360"
"20855359","Calcitonin gene related peptide (CGRP)-provoked migraine-like attacks","Cutrer FM, Mathew P.","Cephalalgia. 2010 Oct;30(10):1155-6. doi: 10.1177/0333102410365014. Epub 2010 Mar 31.","Cutrer FM","Cephalalgia","2010","2010/09/22","","","10.1177/0333102410365014"
"32930994","Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)","Ford J, Tassorelli C, Leroux E, Wang S, Ayer D, Nichols R, Detke H.","Qual Life Res. 2021 Jan;30(1):105-115. doi: 10.1007/s11136-020-02623-1. Epub 2020 Sep 15.","Ford J","Qual Life Res","2021","2020/09/15","PMC7847867","","10.1007/s11136-020-02623-1"
"36471250","PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine","Guo S, Ernstsen C, Hay-Schmidt A, Kristensen DM, Ashina M, Olesen J, Christensen SL.","J Headache Pain. 2022 Dec 5;23(1):155. doi: 10.1186/s10194-022-01523-8.","Guo S","J Headache Pain","2022","2022/12/05","PMC9724374","","10.1186/s10194-022-01523-8"
"32909437","Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review","DeFalco AP, Lazim R, Cope NE.","Ann Pharmacother. 2021 May;55(5):650-657. doi: 10.1177/1060028020954800. Epub 2020 Sep 10.","DeFalco AP","Ann Pharmacother","2021","2020/09/10","","","10.1177/1060028020954800"
"29848264","The Therapeutic Impact of New Migraine Discoveries","Vécsei L, Lukács M, Tajti J, Fülöp F, Toldi J, Edvinsson L.","Curr Med Chem. 2019;26(34):6261-6281. doi: 10.2174/0929867325666180530114534.","Vécsei L","Curr Med Chem","2019","2018/06/01","","","10.2174/0929867325666180530114534"
"34108435","Protein kinase Cδ as a neuronal mechanism for headache in a chronic intermittent nitroglycerin model of migraine in mice","He Y, Shi Z, Kashyap Y, Messing RO, Wang ZJ.","Pain. 2021 Oct 1;162(10):2499-2511. doi: 10.1097/j.pain.0000000000002353.","He Y","Pain","2021","2021/06/10","PMC8448952","NIHMS1709405","10.1097/j.pain.0000000000002353"
"32832978","Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine","Friedman DI, Cohen JM.","Emerg Top Life Sci. 2020 Sep 8;4(2):179-190. doi: 10.1042/ETLS20200018.","Friedman DI","Emerg Top Life Sci","2020","2020/08/25","PMC7487173","","10.1042/ETLS20200018"
"26432183","CGRP antibodies: the Holy Grail for migraine prevention?","Pascual J.","Lancet Neurol. 2015 Nov;14(11):1066-7. doi: 10.1016/S1474-4422(15)00244-6. Epub 2015 Sep 30.","Pascual J","Lancet Neurol","2015","2015/10/04","","","10.1016/S1474-4422(15)00244-6"
"32052515","Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'","Goadsby PJ, Terwindt GM, Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK.","Eur J Neurol. 2020 May;27(5):e25. doi: 10.1111/ene.14168. Epub 2020 Mar 2.","Goadsby PJ","Eur J Neurol","2020","2020/02/14","","","10.1111/ene.14168"
"30725283","Role of CGRP in Migraine","Edvinsson L.","Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201.","Edvinsson L","Handb Exp Pharmacol","2019","2019/02/07","","","10.1007/164_2018_201"
"26879278","AMG 334 CGRP antibody for migraine: time to celebrate?","Ramos ML, Pascual J.","Lancet Neurol. 2016 Apr;15(4):347-9. doi: 10.1016/S1474-4422(16)00040-5. Epub 2016 Feb 12.","Ramos ML","Lancet Neurol","2016","2016/02/17","","","10.1016/S1474-4422(16)00040-5"
"16396667","Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects","de Hoon JN, Smits P, Troost J, Struijker-Boudier HA, Van Bortel LM.","Cephalalgia. 2006 Jan;26(1):56-63. doi: 10.1111/j.1468-2982.2005.00993.x.","de Hoon JN","Cephalalgia","2006","2006/01/07","","","10.1111/j.1468-2982.2005.00993.x"
"35785661","Calcitonin gene-related peptide and neurologic injury: An emerging target for headache management","Mehkri Y, Hanna C, Sriram S, Lucke-Wold B, Johnson RD, Busl K.","Clin Neurol Neurosurg. 2022 Sep;220:107355. doi: 10.1016/j.clineuro.2022.107355. Epub 2022 Jun 27.","Mehkri Y","Clin Neurol Neurosurg","2022","2022/07/05","","","10.1016/j.clineuro.2022.107355"
"35133312","Headache in Pregnancy and Lactation","Rayhill M.","Continuum (Minneap Minn). 2022 Feb 1;28(1):72-92. doi: 10.1212/CON.0000000000001070.","Rayhill M","Continuum (Minneap Minn)","2022","2022/02/08","","","10.1212/CON.0000000000001070"
"37373239","Molecular and Cellular Neurobiology of Circadian and Circannual Rhythms in Migraine: A Narrative Review","Imai N.","Int J Mol Sci. 2023 Jun 13;24(12):10092. doi: 10.3390/ijms241210092.","Imai N","Int J Mol Sci","2023","2023/06/28","PMC10298320","","10.3390/ijms241210092"
"30575850","Consideration of Costs and Open-label Studies of Erenumab","Charles JA.","JAMA Neurol. 2019 Feb 1;76(2):236. doi: 10.1001/jamaneurol.2018.4150.","Charles JA","JAMA Neurol","2019","2018/12/22","","","10.1001/jamaneurol.2018.4150"
"32746775","Efficacy and safety of erenumab in women with a history of menstrual migraine","Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, Zhang F, Picard H, Mikol DD.","J Headache Pain. 2020 Aug 3;21(1):95. doi: 10.1186/s10194-020-01167-6.","Pavlovic JM","J Headache Pain","2020","2020/08/05","PMC7398400","","10.1186/s10194-020-01167-6"
"35607281","Migraine Pathophysiology in Children and Adolescents: A Review of the Literature","Førland-Schill A, Berring-Uldum A, Debes NM.","J Child Neurol. 2022 Jun;37(7):642-651. doi: 10.1177/08830738221100888. Epub 2022 May 23.","Førland-Schill A","J Child Neurol","2022","2022/05/24","","","10.1177/08830738221100888"
"31668411","Targeting calcitonin gene-related peptide: a new era in migraine therapy","Charles A, Pozo-Rosich P.","Lancet. 2019 Nov 9;394(10210):1765-1774. doi: 10.1016/S0140-6736(19)32504-8. Epub 2019 Oct 23.","Charles A","Lancet","2019","2019/11/01","","","10.1016/S0140-6736(19)32504-8"
"30575855","Consideration of Costs and Open-Label Studies of Erenumab-Reply","Loder EW, Burch RC.","JAMA Neurol. 2019 Feb 1;76(2):236-237. doi: 10.1001/jamaneurol.2018.4141.","Loder EW","JAMA Neurol","2019","2018/12/22","","","10.1001/jamaneurol.2018.4141"
"30655610","Getting closer to a cure for migraine","Tassorelli C, De Icco R.","Nat Rev Neurol. 2019 Feb;15(2):64-65. doi: 10.1038/s41582-019-0134-z.","Tassorelli C","Nat Rev Neurol","2019","2019/01/19","","","10.1038/s41582-019-0134-z"
"29697156","A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine","Reuter U.","Headache. 2018 May;58 Suppl 1:48-59. doi: 10.1111/head.13302.","Reuter U","Headache","2018","2018/04/27","","","10.1111/head.13302"
"34003146","Acute Treatment of Migraine: What has Changed in Pharmacotherapies?","Yang CP, Huang KT, Chang CM, Yang CC, Wang SJ.","Neurol India. 2021 Mar-Apr;69(Supplement):S25-S42. doi: 10.4103/0028-3886.315995.","Yang CP","Neurol India","2021","2021/05/18","","","10.4103/0028-3886.315995"
"26376968","New therapeutic approaches for the prevention and treatment of migraine","Diener HC, Charles A, Goadsby PJ, Holle D.","Lancet Neurol. 2015 Oct;14(10):1010-22. doi: 10.1016/S1474-4422(15)00198-2.","Diener HC","Lancet Neurol","2015","2015/09/18","","","10.1016/S1474-4422(15)00198-2"
"20816469","Pharmacological migraine provocation: a human model of migraine","Ashina M, Hansen JM.","Handb Clin Neurol. 2010;97:773-9. doi: 10.1016/S0072-9752(10)97063-2.","Ashina M","Handb Clin Neurol","2010","2010/09/07","","","10.1016/S0072-9752(10)97063-2"
"26994298","Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients","Guo S, Vollesen AL, Hansen YB, Frandsen E, Andersen MR, Amin FM, Fahrenkrug J, Olesen J, Ashina M.","Cephalalgia. 2017 Feb;37(2):136-147. doi: 10.1177/0333102416639517. Epub 2016 Jul 11.","Guo S","Cephalalgia","2017","2016/03/20","","","10.1177/0333102416639517"
"29695168","Cortical spreading depression as a site of origin for migraine: Role of CGRP","Close LN, Eftekhari S, Wang M, Charles AC, Russo AF.","Cephalalgia. 2019 Mar;39(3):428-434. doi: 10.1177/0333102418774299. Epub 2018 Apr 25.","Close LN","Cephalalgia","2019","2018/04/27","PMC7007998","NIHMS1551297","10.1177/0333102418774299"
"35698032","CGRP and PACAP-38 play an important role in diagnosing pediatric migraine","Liu J, Wang G, Dan Y, Liu X.","J Headache Pain. 2022 Jun 13;23(1):68. doi: 10.1186/s10194-022-01435-7.","Liu J","J Headache Pain","2022","2022/06/13","PMC9195476","","10.1186/s10194-022-01435-7"
"33856547","Do anti-CGRP drugs have a role in migraine aura therapy?","Matteo E, Pensato U, Favoni V, Giannini G, Pierangeli G, Cevoli S.","J Neurol. 2021 Jun;268(6):2273-2274. doi: 10.1007/s00415-021-10546-1. Epub 2021 Apr 15.","Matteo E","J Neurol","2021","2021/04/15","","","10.1007/s00415-021-10546-1"
"29771142","The development of a mouse model of mTBI-induced post-traumatic migraine, and identification of the delta opioid receptor as a novel therapeutic target","Moye LS, Novack ML, Tipton AF, Krishnan H, Pandey SC, Pradhan AA.","Cephalalgia. 2019 Jan;39(1):77-90. doi: 10.1177/0333102418777507. Epub 2018 May 17.","Moye LS","Cephalalgia","2019","2018/05/18","PMC6472897","NIHMS1010533","10.1177/0333102418777507"
"19827419","[Migraine can signal a risk for heart and brain]","Vetter C.","MMW Fortschr Med. 2009 Sep 10;151(37):17. doi: 10.1007/BF03365809.","Vetter C","MMW Fortschr Med","2009","2009/10/16","","","10.1007/BF03365809"
"30661365","CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications","Dodick DW.","Cephalalgia. 2019 Mar;39(3):445-458. doi: 10.1177/0333102418821662. Epub 2019 Jan 19.","Dodick DW","Cephalalgia","2019","2019/01/22","","","10.1177/0333102418821662"
"36856015","Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis","Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K.","Cephalalgia. 2023 Apr;43(4):3331024231156922. doi: 10.1177/03331024231156922.","Giri S","Cephalalgia","2023","2023/03/01","","","10.1177/03331024231156922"
"32319039","Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review","Martin V, Samaan KH, Aurora S, Pearlman EM, Zhou C, Li X, Pallay R.","Adv Ther. 2020 May;37(5):2034-2049. doi: 10.1007/s12325-020-01319-9. Epub 2020 Apr 21.","Martin V","Adv Ther","2020","2020/04/23","PMC7467458","","10.1007/s12325-020-01319-9"
"22299771","Clinical pharmacology of current and future drugs for the acute treatment of migraine: a review and an update","Tfelt-Hansen P.","Curr Clin Pharmacol. 2012 Feb 1;7(1):66-72. doi: 10.2174/157488412799218770.","Tfelt-Hansen P","Curr Clin Pharmacol","2012","2012/02/04","","","10.2174/157488412799218770"
"32476127","De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm","Kearney E, Collins T, Sengupta S.","Headache. 2020 Jul;60(7):1435-1437. doi: 10.1111/head.13855. Epub 2020 Jun 1.","Kearney E","Headache","2020","2020/06/02","","","10.1111/head.13855"
"30799680","Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine","Zhang Q, Han X, Wu H, Zhang M, Hu G, Dong Z, Yu S.","Mol Pain. 2019 Jan-Dec;15:1744806918820452. doi: 10.1177/1744806918820452.","Zhang Q","Mol Pain","2019","2019/02/26","PMC6365643","","10.1177/1744806918820452"
"37267250","Gender bias in clinical trials of biological agents for migraine: A systematic review","Alonso-Moreno M, Rodríguez-de Francisco L, Ciudad-Gutiérrez P.","PLoS One. 2023 Jun 2;18(6):e0286453. doi: 10.1371/journal.pone.0286453. eCollection 2023.","Alonso-Moreno M","PLoS One","2023","2023/06/02","PMC10237417","","10.1371/journal.pone.0286453"
"31846550","Do different treatment strategies of galcanezumab have a similar effect on migraine?","Huang IH, Wu PC, Lee YH, Kang YN.","Eur J Neurol. 2020 Apr;27(4):e19-e20. doi: 10.1111/ene.14143. Epub 2020 Jan 3.","Huang IH","Eur J Neurol","2020","2019/12/18","","","10.1111/ene.14143"
"35567662","Interplay of Oral, Mandibular, and Facial Disorders and Migraine","Teruel A, Romero-Reyes M.","Curr Pain Headache Rep. 2022 Jul;26(7):517-523. doi: 10.1007/s11916-022-01054-6. Epub 2022 May 14.","Teruel A","Curr Pain Headache Rep","2022","2022/05/14","","","10.1007/s11916-022-01054-6"
"37430146","Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis","Lambru G, Caponnetto V, Hill B, Ratti S, Sacco S, Murphy M, Briscoe J, Andreou AP.","Neurotherapeutics. 2023 Sep;20(5):1284-1293. doi: 10.1007/s13311-023-01394-0. Epub 2023 Jul 10.","Lambru G","Neurotherapeutics","2023","2023/07/10","PMC10480365","","10.1007/s13311-023-01394-0"
"33874884","Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study","Tepper SJ, Fang J, Vo P, Shen Y, Zhou L, Abdrabboh A, Glassberg M, Ferraris M.","J Headache Pain. 2021 Apr 19;22(1):27. doi: 10.1186/s10194-021-01238-2.","Tepper SJ","J Headache Pain","2021","2021/04/20","PMC8054394","","10.1186/s10194-021-01238-2"
"26951335","A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan","Ibrahimi K, Danser A, Terwindt GM, van den Meiracker AH, MaassenVanDenBrink A.","Cephalalgia. 2017 Jan;37(1):94-98. doi: 10.1177/0333102416637833. Epub 2016 Sep 29.","Ibrahimi K","Cephalalgia","2017","2016/03/09","","","10.1177/0333102416637833"
"19796656","The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs","Villalón CM, Olesen J.","Pharmacol Ther. 2009 Dec;124(3):309-23. doi: 10.1016/j.pharmthera.2009.09.003. Epub 2009 Sep 29.","Villalón CM","Pharmacol Ther","2009","2009/10/03","","","10.1016/j.pharmthera.2009.09.003"
"29896653","CGRP in Human Models of Migraine","Ashina H, Schytz HW, Ashina M.","Handb Exp Pharmacol. 2019;255:109-120. doi: 10.1007/164_2018_128.","Ashina H","Handb Exp Pharmacol","2019","2018/06/14","","","10.1007/164_2018_128"
"30031595","Therapeutic role of monoclonal antibodies in Migraine: A new paradigm","Ashish K, Faisaluddin M, Bandyopadhyay D, Dhaduk K, Baral A.","Eur J Intern Med. 2018 Nov;57:e9-e10. doi: 10.1016/j.ejim.2018.07.015. Epub 2018 Jul 18.","Ashish K","Eur J Intern Med","2018","2018/07/23","","","10.1016/j.ejim.2018.07.015"
"35620946","Myocardial infarction associated with erenumab: A case report","Perino J, Corand V, Laurent E, Théophile H, Miremont-Salamé G, Pariente A, Colas JL, Couffinhal T, Salvo F.","Pharmacotherapy. 2022 Jul;42(7):585-589. doi: 10.1002/phar.2706. Epub 2022 Jun 8.","Perino J","Pharmacotherapy","2022","2022/05/27","PMC9541222","","10.1002/phar.2706"
"36429413","Reaching the Nadir of Medication Overuse in Chronic Migraine","Onan D, Wells-Gatnik WD, Martelletti P.","Int J Environ Res Public Health. 2022 Nov 9;19(22):14696. doi: 10.3390/ijerph192214696.","Onan D","Int J Environ Res Public Health","2022","2022/11/26","PMC9690126","","10.3390/ijerph192214696"
"37370051","Future targets for migraine treatment beyond CGRP","Al-Hassany L, Boucherie DM, Creeney H, van Drie RWA, Farham F, Favaretto S, Gollion C, Grangeon L, Lyons H, Marschollek K, Onan D, Pensato U, Stanyer E, Waliszewska-Prosół M, Wiels W, Chen HZ, Amin FM; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2023 Jun 28;24(1):76. doi: 10.1186/s10194-023-01567-4.","Al-Hassany L","J Headache Pain","2023","2023/06/27","PMC10304392","","10.1186/s10194-023-01567-4"
"28488307","Baicalin Alleviates Nitroglycerin-induced Migraine in Rats via the Trigeminovascular System","Sun YY, Zhang WJ, Dong CL, Zhang XF, Ji J, Wang X, Wang L, Hu WL, Du WJ, Cui CL, Zhang CF, Li F, Wang CZ, Yuan CS.","Phytother Res. 2017 Jun;31(6):899-905. doi: 10.1002/ptr.5811. Epub 2017 May 10.","Sun YY","Phytother Res","2017","2017/05/11","","","10.1002/ptr.5811"
"33369482","Novel synthetic treatment options for migraine","Negro A, Martelletti P.","Expert Opin Pharmacother. 2021 May;22(7):907-922. doi: 10.1080/14656566.2020.1862793. Epub 2020 Dec 28.","Negro A","Expert Opin Pharmacother","2021","2020/12/28","","","10.1080/14656566.2020.1862793"
"32804418","Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients","Riesco N, Cernuda-Morollón E, Martínez-Camblor P, Pérez-Pereda S, Pascual J.","Headache. 2020 Sep;60(8):1705-1711. doi: 10.1111/head.13919. Epub 2020 Aug 17.","Riesco N","Headache","2020","2020/08/18","","","10.1111/head.13919"
"30710130","CGRP antibodies for migraine prevention - new kids on the block","Diener HC.","Nat Rev Neurol. 2019 Mar;15(3):129-130. doi: 10.1038/s41582-019-0139-7.","Diener HC","Nat Rev Neurol","2019","2019/02/03","","","10.1038/s41582-019-0139-7"
"32731573","Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine","Domínguez Vivero C, Leira Y, Saavedra Piñeiro M, Rodríguez-Osorio X, Ramos-Cabrer P, Villalba Martín C, Sobrino T, Campos F, Castillo J, Leira R.","Toxins (Basel). 2020 Jul 28;12(8):479. doi: 10.3390/toxins12080479.","Domínguez Vivero C","Toxins (Basel)","2020","2020/08/01","PMC7472356","","10.3390/toxins12080479"
"36426766","Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report","Bedrin K, Ailani J, Dougherty C.","Headache. 2022 Nov;62(10):1419-1423. doi: 10.1111/head.14417. Epub 2022 Nov 25.","Bedrin K","Headache","2022","2022/11/25","","","10.1111/head.14417"
"33549036","Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine","Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E, Aurora SK.","J Headache Pain. 2021 Feb 6;22(1):6. doi: 10.1186/s10194-021-01215-9.","Ament M","J Headache Pain","2021","2021/02/07","PMC7868011","","10.1186/s10194-021-01215-9"
"31707574","Thymoquinone Inhibits Neurogenic Inflammation Underlying Migraine Through Modulation of Calcitonin Gene-Related Peptide Release and Stabilization of Meningeal Mast Cells in Glyceryltrinitrate-Induced Migraine Model in Rats","Kilinc E, Tore F, Dagistan Y, Bugdayci G.","Inflammation. 2020 Feb;43(1):264-273. doi: 10.1007/s10753-019-01115-w.","Kilinc E","Inflammation","2020","2019/11/11","","","10.1007/s10753-019-01115-w"
"31253091","Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)","Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC.","J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x.","Silberstein SD","J Headache Pain","2019","2019/06/30","PMC6734504","","10.1186/s10194-019-1024-x"
"29899031","New preventive treatments for migraine","Burch R, Rayhill M.","BMJ. 2018 Jun 13;361:k2507. doi: 10.1136/bmj.k2507.","Burch R","BMJ","2018","2018/06/15","","","10.1136/bmj.k2507"
"25194013","How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT)","Dufka FL, Dworkin RH, Rowbotham MC.","Neurology. 2014 Oct 7;83(15):1372-81. doi: 10.1212/WNL.0000000000000866. Epub 2014 Sep 5.","Dufka FL","Neurology","2014","2014/09/07","PMC4189098","","10.1212/WNL.0000000000000866"
"24322481","Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide","Nordgaard JC, Kruse LS, Møller M, Kruuse C.","Cephalalgia. 2014 Jun;34(7):503-13. doi: 10.1177/0333102413515345. Epub 2013 Dec 9.","Nordgaard JC","Cephalalgia","2014","2013/12/11","","","10.1177/0333102413515345"
"31603037","Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls","Kamm K, Straube A, Ruscheweyh R.","Cephalalgia. 2019 Oct;39(12):1535-1543. doi: 10.1177/0333102419856640. Epub 2019 Jun 10.","Kamm K","Cephalalgia","2019","2019/10/12","","","10.1177/0333102419856640"
"12811594","Neurogenic inflammation in primary headaches","Fusco M, D'Andrea G, Miccichè F, Stecca A, Bernardini D, Cananzi AL.","Neurol Sci. 2003 May;24 Suppl 2:S61-4. doi: 10.1007/s100720300043.","Fusco M","Neurol Sci","2003","2003/06/18","","","10.1007/s100720300043"
"38262999","Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years","Kernick D, Kondori N, Pain A, Mount J, Appel C, Ranopa M, Gulati T.","BMC Prim Care. 2024 Jan 24;25(1):34. doi: 10.1186/s12875-023-02242-y.","Kernick D","BMC Prim Care","2024","2024/01/23","PMC10807158","","10.1186/s12875-023-02242-y"
"32845740","Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine","Yang CP, Lee CF, Dell'Agnello G, Hundemer HP, Lipsius S, Wang SJ.","Curr Med Res Opin. 2020 Oct;36(10):1653-1666. doi: 10.1080/03007995.2020.1815181. Epub 2020 Sep 12.","Yang CP","Curr Med Res Opin","2020","2020/08/27","","","10.1080/03007995.2020.1815181"
"35604755","Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study","Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A.","Elife. 2022 May 23;11:e77146. doi: 10.7554/eLife.77146.","Basedau H","Elife","2022","2022/05/23","PMC9126581","","10.7554/eLife.77146"
"33541566","Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications","de Vries Lentsch S, Rubio-Beltrán E, MaassenVanDenBrink A.","Maturitas. 2021 Mar;145:73-77. doi: 10.1016/j.maturitas.2020.12.012. Epub 2021 Jan 6.","de Vries Lentsch S","Maturitas","2021","2021/02/05","","","10.1016/j.maturitas.2020.12.012"
"33856345","Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition","Bertels Z, Singh H, Dripps I, Siegersma K, Tipton AF, Witkowski WD, Sheets Z, Shah P, Conway C, Mangutov E, Ao M, Petukhova V, Karumudi B, Petukhov PA, Baca SM, Rasenick MM, Pradhan AA.","Elife. 2021 Apr 15;10:e63076. doi: 10.7554/eLife.63076.","Bertels Z","Elife","2021","2021/04/15","PMC8147088","","10.7554/eLife.63076"
"11955527","Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment","Moreno MJ, Abounader R, Hébert E, Doods H, Hamel E.","Neuropharmacology. 2002 Mar;42(4):568-76. doi: 10.1016/s0028-3908(02)00008-4.","Moreno MJ","Neuropharmacology","2002","2002/04/17","","","10.1016/s0028-3908(02)00008-4"
"32949542","Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC.","Lancet Neurol. 2020 Oct;19(10):814-825. doi: 10.1016/S1474-4422(20)30279-9. Epub 2020 Sep 16.","Mulleners WM","Lancet Neurol","2020","2020/09/19","","","10.1016/S1474-4422(20)30279-9"
"26669672","Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape","Fiala JL, Lowery D.","Nat Rev Drug Discov. 2016 Jan;15(1):8-9. doi: 10.1038/nrd.2015.11. Epub 2015 Dec 16.","Fiala JL","Nat Rev Drug Discov","2016","2015/12/17","","","10.1038/nrd.2015.11"
"30962278","Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models","Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G.","J Neurosci. 2019 May 29;39(22):4323-4331. doi: 10.1523/JNEUROSCI.0364-19.2019. Epub 2019 Apr 8.","Avona A","J Neurosci","2019","2019/04/10","PMC6538861","","10.1523/JNEUROSCI.0364-19.2019"
"32620151","Erenumab in highly therapy-refractory migraine patients: First German real-world evidence","Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D.","J Headache Pain. 2020 Jul 3;21(1):84. doi: 10.1186/s10194-020-01151-0.","Scheffler A","J Headache Pain","2020","2020/07/05","PMC7333436","","10.1186/s10194-020-01151-0"
"34130525","CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis","Frank F, Ulmer H, Sidoroff V, Broessner G.","Cephalalgia. 2021 Oct;41(11-12):1222-1239. doi: 10.1177/03331024211018137. Epub 2021 Jun 15.","Frank F","Cephalalgia","2021","2021/06/16","PMC8506070","","10.1177/03331024211018137"
"37194515","[Migraine Medication]","Kikui S, Takeshima T.","Brain Nerve. 2023 May;75(5):470-478. doi: 10.11477/mf.1416202361.","Kikui S","Brain Nerve","2023","2023/05/17","","","10.11477/mf.1416202361"
"33693863","Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine","Cohen F, Armand C, Lipton RB, Vollbracht S.","Pain Med. 2021 Aug 6;22(8):1857-1863. doi: 10.1093/pm/pnab093.","Cohen F","Pain Med","2021","2021/03/11","","","10.1093/pm/pnab093"
"17963849","CGRP antagonists: unravelling the role of CGRP in migraine","Doods H, Arndt K, Rudolf K, Just S.","Trends Pharmacol Sci. 2007 Nov;28(11):580-7. doi: 10.1016/j.tips.2007.10.005. Epub 2007 Oct 25.","Doods H","Trends Pharmacol Sci","2007","2007/10/30","","","10.1016/j.tips.2007.10.005"
"11072640","[Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses]","Hamon M, Bourgoin S.","Pathol Biol (Paris). 2000 Sep;48(7):619-29.","Hamon M","Pathol Biol (Paris)","2000","2000/11/10","","",""
"20659258","Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients","Jang MU, Park JW, Kho HS, Chung SC, Chung JW.","Oral Dis. 2011 Mar;17(2):187-93. doi: 10.1111/j.1601-0825.2010.01717.x.","Jang MU","Oral Dis","2011","2010/07/28","","","10.1111/j.1601-0825.2010.01717.x"
"35870898","Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences","Ashina H, Christensen RH, Ashina M.","J Headache Pain. 2022 Jul 23;23(1):87. doi: 10.1186/s10194-022-01464-2.","Ashina H","J Headache Pain","2022","2022/07/23","PMC9308906","","10.1186/s10194-022-01464-2"
"18779512","Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype","Hansen JM, Thomsen LL, Olesen J, Ashina M.","Neurology. 2008 Sep 9;71(11):841-7. doi: 10.1212/01.wnl.0000325482.64106.3f.","Hansen JM","Neurology","2008","2008/09/10","","","10.1212/01.wnl.0000325482.64106.3f"
"31050694","Fremanezumab for the prevention of chronic and episodic migraine","Lionetto L, Cipolla F, Guglielmetti M, Martelletti P.","Drugs Today (Barc). 2019 Apr;55(4):265-276. doi: 10.1358/dot.2019.55.4.2970909.","Lionetto L","Drugs Today (Barc)","2019","2019/05/04","","","10.1358/dot.2019.55.4.2970909"
"27362770","Involvement of CGRP receptors in retinal spreading depression","Wang Y, Li Y, Wang M.","Pharmacol Rep. 2016 Oct;68(5):935-8. doi: 10.1016/j.pharep.2016.05.001. Epub 2016 Jun 27.","Wang Y","Pharmacol Rep","2016","2016/07/01","","","10.1016/j.pharep.2016.05.001"
"31739342","Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine","McCarthy L.","Ann Intern Med. 2019 Nov 19;171(10):JC59. doi: 10.7326/ACPJ201911190-059.","McCarthy L","Ann Intern Med","2019","2019/11/19","","","10.7326/ACPJ201911190-059"
"33393835","A long-term open-label safety study of galcanezumab in Japanese patients with migraine","Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V.","Expert Opin Drug Saf. 2021 Jun;20(6):721-733. doi: 10.1080/14740338.2021.1866536. Epub 2021 Jan 4.","Hirata K","Expert Opin Drug Saf","2021","2021/01/04","","","10.1080/14740338.2021.1866536"
"29697153","The CGRP Pathway in Migraine as a Viable Target for Therapies","Edvinsson L.","Headache. 2018 May;58 Suppl 1:33-47. doi: 10.1111/head.13305.","Edvinsson L","Headache","2018","2018/04/27","","","10.1111/head.13305"
"33710044","Cost-effectiveness of Erenumab Versus Surgical Trigger Site Deactivation for the Treatment of Migraine Headaches: A Systematic Review","Shah N, Castro R, Attaripour Isfahani SN, Vyas RM.","J Craniofac Surg. 2021 Jun 1;32(4):e398-e401. doi: 10.1097/SCS.0000000000007617.","Shah N","J Craniofac Surg","2021","2021/03/12","","","10.1097/SCS.0000000000007617"
"31427047","Is targeting CGRP the right pathway to prevent migraine?","Tessitore A, Russo A.","Lancet. 2019 Sep 21;394(10203):984-986. doi: 10.1016/S0140-6736(19)31947-6. Epub 2019 Aug 16.","Tessitore A","Lancet","2019","2019/08/21","","","10.1016/S0140-6736(19)31947-6"
"20816023","Familial hemiplegic migraine","Hansen JM.","Dan Med Bull. 2010 Sep;57(9):B4183.","Hansen JM","Dan Med Bull","2010","2010/09/07","","",""
"33846231","PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP","Kuburas A, Mason BN, Hing B, Wattiez AS, Reis AS, Sowers LP, Moldovan Loomis C, Garcia-Martinez LF, Russo AF.","J Neurosci. 2021 May 26;41(21):4697-4715. doi: 10.1523/JNEUROSCI.2200-20.2021. Epub 2021 Apr 12.","Kuburas A","J Neurosci","2021","2021/04/13","PMC8260237","","10.1523/JNEUROSCI.2200-20.2021"
"34161831","Development and validation of a reporter gene assay for bioactivity determination of Anti-CGRP monoclonal antibodies","Guo X, Yu C, Wang L, Zhang F, Wang K, Huang J, Wang J.","Anal Biochem. 2021 Dec 1;634:114291. doi: 10.1016/j.ab.2021.114291. Epub 2021 Jun 20.","Guo X","Anal Biochem","2021","2021/06/23","","","10.1016/j.ab.2021.114291"
"36414952","Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure","Tepper SJ, Ailani J, Ray S, Hirman J, Shrewsbury SB, Aurora SK.","J Headache Pain. 2022 Nov 22;23(1):148. doi: 10.1186/s10194-022-01519-4.","Tepper SJ","J Headache Pain","2022","2022/11/22","PMC9682643","","10.1186/s10194-022-01519-4"
"32193827","Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials","Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z.","CNS Drugs. 2020 May;34(5):463-471. doi: 10.1007/s40263-020-00715-7.","Yang Y","CNS Drugs","2020","2020/03/21","","","10.1007/s40263-020-00715-7"
"36739513","Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review","Ruiz M, Cocores A, Tosti A, Goadsby PJ, Monteith TS.","Cephalalgia. 2023 Feb;43(2):3331024221143538. doi: 10.1177/03331024221143538.","Ruiz M","Cephalalgia","2023","2023/02/05","","","10.1177/03331024221143538"
"31288556","Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain","Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G.","Cephalalgia. 2019 Dec;39(14):1827-1837. doi: 10.1177/0333102419861726. Epub 2019 Jul 9.","Christensen SL","Cephalalgia","2019","2019/07/11","","","10.1177/0333102419861726"
"33348571","Botulinum Toxin in the Treatment of Headache","Becker WJ.","Toxins (Basel). 2020 Dec 17;12(12):803. doi: 10.3390/toxins12120803.","Becker WJ","Toxins (Basel)","2020","2020/12/22","PMC7766412","","10.3390/toxins12120803"
"24318669","Emerging targets in migraine","Hoffmann J, Goadsby PJ.","CNS Drugs. 2014 Jan;28(1):11-7. doi: 10.1007/s40263-013-0126-2.","Hoffmann J","CNS Drugs","2014","2013/12/10","","","10.1007/s40263-013-0126-2"
"34922436","Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study","MaassenVanDenBrink A, Terwindt GM, Cohen JM, Barash S, Campos VR, Galic M, Ning X, Kärppä M.","J Headache Pain. 2021 Dec 18;22(1):152. doi: 10.1186/s10194-021-01336-1.","MaassenVanDenBrink A","J Headache Pain","2021","2021/12/19","PMC8903667","","10.1186/s10194-021-01336-1"
"34409517","Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series","Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, Vajjala V, Viereck J, Liow KK.","Neurol Sci. 2021 Dec;42(12):5373-5376. doi: 10.1007/s10072-021-05547-x. Epub 2021 Aug 18.","Toni T","Neurol Sci","2021","2021/08/19","","","10.1007/s10072-021-05547-x"
"35015202","Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data","Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, Cevoli S, Pani L.","Neurol Sci. 2022 Jun;43(6):3823-3830. doi: 10.1007/s10072-022-05870-x. Epub 2022 Jan 11.","Guerzoni S","Neurol Sci","2022","2022/01/11","","","10.1007/s10072-022-05870-x"
"36924253","""Wearing-off"" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials","Asawavichienjinda T, Sathitratanacheewin S, Chokesuwattanaskul R.","Cephalalgia. 2023 Apr;43(4):3331024231161261. doi: 10.1177/03331024231161261.","Asawavichienjinda T","Cephalalgia","2023","2023/03/16","","","10.1177/03331024231161261"
"35675076","Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial","Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM.","JAMA Netw Open. 2022 Jun 1;5(6):e2215499. doi: 10.1001/jamanetworkopen.2022.15499.","Lipton RB","JAMA Netw Open","2022","2022/06/08","PMC9178435","","10.1001/jamanetworkopen.2022.15499"
"14535191","Treatment of migraine with acupuncture at points pertaining to the liver and gallbladder channels","Li W, Deng G, Liu Y, Liu W, Zhong G, Wang S, Wen L, Li X.","J Tradit Chin Med. 2003 Sep;23(3):205-6.","Li W","J Tradit Chin Med","2003","2003/10/11","","",""
"21631475","Sex-related differences in animal models of migraine headache","Bolay H, Berman NE, Akcali D.","Headache. 2011 Jun;51(6):891-904. doi: 10.1111/j.1526-4610.2011.01903.x.","Bolay H","Headache","2011","2011/06/03","","","10.1111/j.1526-4610.2011.01903.x"
"36918752","Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study","Iannone LF, Burgalassi A, Vigani G, Tabasso G, De Cesaris F, Chiarugi A, Geppetti P.","Cephalalgia. 2023 Apr;43(4):3331024231160519. doi: 10.1177/03331024231160519.","Iannone LF","Cephalalgia","2023","2023/03/15","","","10.1177/03331024231160519"
"33547541","Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study","Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S.","Neurol Sci. 2021 Oct;42(10):4193-4202. doi: 10.1007/s10072-021-05105-5. Epub 2021 Feb 5.","Cainazzo MM","Neurol Sci","2021","2021/02/06","","","10.1007/s10072-021-05105-5"
"34193048","CGRP induces migraine-like symptoms in mice during both the active and inactive phases","Wattiez AS, Gaul OJ, Kuburas A, Zorrilla E, Waite JS, Mason BN, Castonguay WC, Wang M, Robertson BR, Russo AF.","J Headache Pain. 2021 Jun 30;22(1):62. doi: 10.1186/s10194-021-01277-9.","Wattiez AS","J Headache Pain","2021","2021/07/01","PMC8243868","","10.1186/s10194-021-01277-9"
"34628738","[Effect of ZHU Lian's type Ⅱ inhibition acupuncture on chronic migraine and serum 5-HT, VEGF, CGRP]","Ke HK, Tu SH, Shen YJ, Qu QW.","Zhongguo Zhen Jiu. 2021 Oct 12;41(10):1079-83. doi: 10.13703/j.0255-2930.20200925-0001.","Ke HK","Zhongguo Zhen Jiu","2021","2021/10/10","","","10.13703/j.0255-2930.20200925-0001"
"28862758","Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines","Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME.","Headache. 2017 Oct;57(9):1375-1384. doi: 10.1111/head.13156. Epub 2017 Sep 1.","Cohen JM","Headache","2017","2017/09/02","","","10.1111/head.13156"
"32588458","A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine","von Mentzer B, Russo AF, Zhang Z, Kuburas A, Killoran PM, D'Aloisio V, Nizic L, Capel V, Kendall DA, Coxon CR, Hutcheon GA.","J Pharm Pharmacol. 2020 Oct;72(10):1352-1360. doi: 10.1111/jphp.13317. Epub 2020 Jun 25.","von Mentzer B","J Pharm Pharmacol","2020","2020/06/27","PMC7486274","NIHMS1615210","10.1111/jphp.13317"
"30550780","CGRP Antibodies as Prophylaxis in Migraine","Edvinsson L.","Cell. 2018 Dec 13;175(7):1719. doi: 10.1016/j.cell.2018.11.049.","Edvinsson L","Cell","2018","2018/12/15","","","10.1016/j.cell.2018.11.049"
"31470791","Current and emerging evidence-based treatment options in chronic migraine: a narrative review","Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A; Italian chronic migraine group.","J Headache Pain. 2019 Aug 30;20(1):92. doi: 10.1186/s10194-019-1038-4.","Agostoni EC","J Headache Pain","2019","2019/09/01","PMC6734211","","10.1186/s10194-019-1038-4"
"31020659","Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class","Hargreaves R, Olesen J.","Headache. 2019 Jun;59(6):951-970. doi: 10.1111/head.13510. Epub 2019 Apr 25.","Hargreaves R","Headache","2019","2019/04/26","","","10.1111/head.13510"
"34600468","Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study","Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G.","J Headache Pain. 2021 Oct 2;22(1):114. doi: 10.1186/s10194-021-01333-4.","Bottiroli S","J Headache Pain","2021","2021/10/03","PMC8487575","","10.1186/s10194-021-01333-4"
"36507609","Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study","Jaimes A, Gómez A, Pajares O, Rodríguez-Vico J.","Pain Pract. 2023 Apr;23(4):349-358. doi: 10.1111/papr.13196. Epub 2022 Dec 24.","Jaimes A","Pain Pract","2023","2022/12/12","","","10.1111/papr.13196"
"29411638","The role of the brainstem in migraine: Potential brainstem effects of CGRP and CGRP receptor activation in animal models","Holland PR, Saengjaroentham C, Vila-Pueyo M.","Cephalalgia. 2019 Mar;39(3):390-402. doi: 10.1177/0333102418756863. Epub 2018 Feb 7.","Holland PR","Cephalalgia","2019","2018/02/08","","","10.1177/0333102418756863"
"19319812","[Gepants: the beginning of a new age in the symptomatic treatment of migraine?]","Pascual-Gómez J.","Rev Neurol. 2009 Apr 1-15;48(7):337-8.","Pascual-Gómez J","Rev Neurol","2009","2009/03/26","","",""
"31291018","Emerging Treatment Targets for Migraine and Other Headaches","Bertels Z, Pradhan AAA.","Headache. 2019 Jul;59 Suppl 2(Suppl 2):50-65. doi: 10.1111/head.13585.","Bertels Z","Headache","2019","2019/07/11","PMC6986366","NIHMS1059362","10.1111/head.13585"
"37604658","Beyond the Guidelines: A Narrative Review of Treatments on the Horizon for Migraine in Children and Adolescents","VanderPluym JH, Victorio MCC, Oakley CB, Rastogi RG, Orr SL.","Neurology. 2023 Oct 31;101(18):788-797. doi: 10.1212/WNL.0000000000207677. Epub 2023 Aug 21.","VanderPluym JH","Neurology","2023","2023/08/21","PMC10634646","","10.1212/WNL.0000000000207677"
"22321965","Trigeminal satellite cells modulate neuronal responses to triptans: relevance for migraine therapy","de Corato A, Capuano A, Currò D, Tringali G, Navarra P, Dello Russo C.","Neuron Glia Biol. 2011 May;7(2-4):109-16. doi: 10.1017/S1740925X11000172. Epub 2012 Feb 10.","de Corato A","Neuron Glia Biol","2011","2012/02/11","","","10.1017/S1740925X11000172"
"38311745","Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview","Mazzacane F, Vaghi G, Cotta Ramusino M, Perini G, Costa A.","J Headache Pain. 2024 Feb 5;25(1):13. doi: 10.1186/s10194-024-01720-7.","Mazzacane F","J Headache Pain","2024","2024/02/04","PMC10840219","","10.1186/s10194-024-01720-7"
"23879550","Cortical spreading depression as a target for anti-migraine agents","Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, Sarchielli P.","J Headache Pain. 2013 Jul 23;14(1):62. doi: 10.1186/1129-2377-14-62.","Costa C","J Headache Pain","2013","2013/07/25","PMC3728002","","10.1186/1129-2377-14-62"
"37537578","Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study","Manack Adams A, Hutchinson S, Engstrom E, Ayasse ND, Serrano D, Davis L, Sommer K, Contreras-De Lama J, Lipton RB.","J Headache Pain. 2023 Aug 3;24(1):102. doi: 10.1186/s10194-023-01622-0.","Manack Adams A","J Headache Pain","2023","2023/08/03","PMC10399003","","10.1186/s10194-023-01622-0"
"37904724","The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study","Bhardwaj R, Morris B, Bertz R, Croop R, Liu J.","Clin Pharmacol Drug Dev. 2024 Jan;13(1):37-44. doi: 10.1002/cpdd.1337. Epub 2023 Oct 30.","Bhardwaj R","Clin Pharmacol Drug Dev","2024","2023/10/31","","","10.1002/cpdd.1337"
"32563366","Testing rimegepant for migraine-time to revise the trial design?","Gasparini S, Torino C, Branca D, Ferlazzo E, Aguglia U.","Lancet. 2020 Jun 20;395(10241):1901. doi: 10.1016/S0140-6736(20)30241-5.","Gasparini S","Lancet","2020","2020/06/22","","","10.1016/S0140-6736(20)30241-5"
"29616830","CGRP - a target for acute therapy in migraine: Clinical data","Messina R, Goadsby PJ.","Cephalalgia. 2019 Mar;39(3):420-427. doi: 10.1177/0333102418768095. Epub 2018 Apr 4.","Messina R","Cephalalgia","2019","2018/04/05","","","10.1177/0333102418768095"
"34364313","The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon","Breen ID, Mangold AR, VanderPluym JH.","Headache. 2021 Sep;61(8):1274-1276. doi: 10.1111/head.14198. Epub 2021 Aug 7.","Breen ID","Headache","2021","2021/08/07","","","10.1111/head.14198"
"31707815","Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions","Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD.","Cephalalgia. 2019 Dec;39(14):1798-1808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.","Ashina M","Cephalalgia","2019","2019/11/12","","","10.1177/0333102419888222"
"30074549","Preventive Therapy of Migraine","Schwedt TJ.","Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1052-1065. doi: 10.1212/CON.0000000000000635.","Schwedt TJ","Continuum (Minneap Minn)","2018","2018/08/04","","","10.1212/CON.0000000000000635"
"24068339","Calcitonin gene-related peptide receptor antagonists: beyond migraine pain--a possible analgesic strategy for osteoarthritis?","Bullock CM, Kelly S.","Curr Pain Headache Rep. 2013 Nov;17(11):375. doi: 10.1007/s11916-013-0375-2.","Bullock CM","Curr Pain Headache Rep","2013","2013/09/27","PMC3824306","","10.1007/s11916-013-0375-2"
"34350590","Everything old is new again","Freitag FG.","Headache. 2021 Sep;61(8):1286. doi: 10.1111/head.14181. Epub 2021 Aug 5.","Freitag FG","Headache","2021","2021/08/05","","","10.1111/head.14181"
"29124576","[Monoclonal antibodies for targeted migraine prevention]","Reuter U, Israel-Willner H.","MMW Fortschr Med. 2017 Nov;159(19):70-73. doi: 10.1007/s15006-017-0284-0.","Reuter U","MMW Fortschr Med","2017","2017/11/11","","","10.1007/s15006-017-0284-0"
"27269043","A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D.","Cephalalgia. 2016 Aug;36(9):887-98. doi: 10.1177/0333102416653233. Epub 2016 Jun 6.","Voss T","Cephalalgia","2016","2016/06/09","","","10.1177/0333102416653233"
"28389966","The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis","Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J.","J Headache Pain. 2017 Dec;18(1):42. doi: 10.1186/s10194-017-0750-1. Epub 2017 Apr 7.","Hou M","J Headache Pain","2017","2017/04/09","PMC5383797","","10.1186/s10194-017-0750-1"
"35997735","Monoclonal Antibody Overcomes Migraine Treatment Failure","Slomski A.","JAMA. 2022 Aug 23;328(8):700. doi: 10.1001/jama.2022.13588.","Slomski A","JAMA","2022","2022/08/23","","","10.1001/jama.2022.13588"
"37219606","Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study","Suzuki K, Suzuki S, Shiina T, Haruyama Y, Fujita H, Funakoshi K, Hirata K.","J Neurol. 2023 Sep;270(9):4377-4384. doi: 10.1007/s00415-023-11788-x. Epub 2023 May 23.","Suzuki K","J Neurol","2023","2023/05/23","","","10.1007/s00415-023-11788-x"
"24820828","Migraine & paediatric obesity: a plausible link?","Ravid S.","Indian J Med Res. 2014 Mar;139(3):343-8.","Ravid S","Indian J Med Res","2014","2014/05/14","PMC4069728","",""
"34544359","CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience","Scheffler A, Schenk H, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Holle D.","J Headache Pain. 2021 Sep 20;22(1):111. doi: 10.1186/s10194-021-01323-6.","Scheffler A","J Headache Pain","2021","2021/09/21","PMC8454157","","10.1186/s10194-021-01323-6"
"30823868","Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","Nichols R, Skljarevski V, Dell'Agnello G, Hundemer HP, Aurora SK.","J Headache Pain. 2019 Mar 1;20(1):22. doi: 10.1186/s10194-019-0975-2.","Nichols R","J Headache Pain","2019","2019/03/03","PMC6734426","","10.1186/s10194-019-0975-2"
"37296378","Revisiting dose-finding of monoclonal antibodies in migraine","Al-Hassany L, Karsan N, Lampl C, Goadsby PJ, MaassenVanDenBrink A.","J Headache Pain. 2023 Jun 9;24(1):69. doi: 10.1186/s10194-023-01602-4.","Al-Hassany L","J Headache Pain","2023","2023/06/09","PMC10251584","","10.1186/s10194-023-01602-4"
"29654418","Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients","Fekrazad R, Sardarian A, Azma K, Karami M, Borhani-Haghighi A, Gharesi-Fard B, Movahedi B.","Neurol Sci. 2018 Jul;39(7):1217-1223. doi: 10.1007/s10072-018-3340-3. Epub 2018 Apr 13.","Fekrazad R","Neurol Sci","2018","2018/04/15","","","10.1007/s10072-018-3340-3"
"19415426","Antimigraine drugs: new frontiers","Rapoport A.","Neurol Sci. 2009 May;30 Suppl 1:S49-54. doi: 10.1007/s10072-009-0069-z.","Rapoport A","Neurol Sci","2009","2009/05/06","","","10.1007/s10072-009-0069-z"
"29719223","The Transient Receptor Potential Ankyrin Type 1 Plays a Critical Role in Cortical Spreading Depression","Jiang L, Wang Y, Xu Y, Ma D, Wang M.","Neuroscience. 2018 Jul 1;382:23-34. doi: 10.1016/j.neuroscience.2018.04.025. Epub 2018 Apr 30.","Jiang L","Neuroscience","2018","2018/05/03","","","10.1016/j.neuroscience.2018.04.025"
"29989427","Current understanding of trigeminal ganglion structure and function in headache","Messlinger K, Russo AF.","Cephalalgia. 2019 Nov;39(13):1661-1674. doi: 10.1177/0333102418786261. Epub 2018 Jul 10.","Messlinger K","Cephalalgia","2019","2018/07/11","PMC7007999","NIHMS1551308","10.1177/0333102418786261"
"35271240","[The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology]","Dobrynina LA, Gubanova MV, Belopasova AV, Baydina EV, Afanasev MA.","Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(2):74-80. doi: 10.17116/jnevro202212202174.","Dobrynina LA","Zh Nevrol Psikhiatr Im S S Korsakova","2022","2022/03/10","","","10.17116/jnevro202212202174"
"19277835","Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period","Gupta R, Ahmed T, Banerjee B, Bhatia M.","J Headache Pain. 2009 Jun;10(3):161-6. doi: 10.1007/s10194-009-0110-x. Epub 2009 Mar 11.","Gupta R","J Headache Pain","2009","2009/03/12","PMC3451985","","10.1007/s10194-009-0110-x"
"35144528","Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model","Pan Q, Wang Y, Tian R, Wen Q, Qin G, Zhang D, Chen L, Zhang Y, Zhou J.","J Headache Pain. 2022 Feb 10;23(1):25. doi: 10.1186/s10194-022-01397-w.","Pan Q","J Headache Pain","2022","2022/02/11","PMC8903593","","10.1186/s10194-022-01397-w"
"24563332","PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells","Bhatt DK, Gupta S, Olesen J, Jansen-Olesen I.","Cephalalgia. 2014 Oct;34(11):877-86. doi: 10.1177/0333102414523846. Epub 2014 Feb 21.","Bhatt DK","Cephalalgia","2014","2014/02/25","","","10.1177/0333102414523846"
"37691118","Mode and site of action of therapies targeting CGRP signaling","Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitunidze N, Gudadze T, Pozo-Rosich P, Burstein R, Hoffmann J.","J Headache Pain. 2023 Sep 11;24(1):125. doi: 10.1186/s10194-023-01644-8.","Labastida-Ramírez A","J Headache Pain","2023","2023/09/10","PMC10494408","","10.1186/s10194-023-01644-8"
"32060729","Targeting BK(Ca) Channels in Migraine: Rationale and Perspectives","Al-Karagholi MA, Gram C, Nielsen CAW, Ashina M.","CNS Drugs. 2020 Apr;34(4):325-335. doi: 10.1007/s40263-020-00706-8.","Al-Karagholi MA","CNS Drugs","2020","2020/02/16","","","10.1007/s40263-020-00706-8"
"31420791","Rhynchophylline attenuates migraine in trigeminal nucleus caudalis in nitroglycerin-induced rat model by inhibiting MAPK/NF-кB signaling","Lai T, Chen L, Chen X, He J, Lv P, Ge H.","Mol Cell Biochem. 2019 Nov;461(1-2):205-212. doi: 10.1007/s11010-019-03603-x. Epub 2019 Aug 16.","Lai T","Mol Cell Biochem","2019","2019/08/18","","","10.1007/s11010-019-03603-x"
"33066724","Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?","Greco R, De Icco R, Demartini C, Zanaboni AM, Tumelero E, Sances G, Allena M, Tassorelli C.","J Headache Pain. 2020 Oct 16;21(1):122. doi: 10.1186/s10194-020-01189-0.","Greco R","J Headache Pain","2020","2020/10/17","PMC7565351","","10.1186/s10194-020-01189-0"
"25288609","TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp","Silberstein SD.","J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):361. doi: 10.1136/jnnp-2014-309295. Epub 2014 Oct 6.","Silberstein SD","J Neurol Neurosurg Psychiatry","2015","2014/10/08","","","10.1136/jnnp-2014-309295"
"32686605","Physical exercise enhances vulnerability to migraine headache associated with CGRP up-expression in trigeminal nucleus caudalis of stressed rats","Kooshki R, Abbasnejad M, Shamsizadeh A, Raoof M, Askari-Zahabi K, Esmaeili-Mahani S.","Neurol Res. 2020 Nov;42(11):952-958. doi: 10.1080/01616412.2020.1794243. Epub 2020 Jul 18.","Kooshki R","Neurol Res","2020","2020/07/21","","","10.1080/01616412.2020.1794243"
"27852962","Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine","Rice FL, Xie JY, Albrecht PJ, Acker E, Bourgeois J, Navratilova E, Dodick DW, Porreca F.","Cephalalgia. 2017 Dec;37(14):1350-1372. doi: 10.1177/0333102416677051. Epub 2016 Nov 16.","Rice FL","Cephalalgia","2017","2016/11/18","","","10.1177/0333102416677051"
"26888294","Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis","van Dongen RM, Zielman R, Noga M, Dekkers OM, Hankemeier T, van den Maagdenberg AM, Terwindt GM, Ferrari MD.","Cephalalgia. 2017 Jan;37(1):49-63. doi: 10.1177/0333102415625614. Epub 2016 Sep 30.","van Dongen RM","Cephalalgia","2017","2016/02/19","","","10.1177/0333102415625614"
"32555116","Eptinezumab (Vyepti) for migraine prevention","","Med Lett Drugs Ther. 2020 Jun 1;62(1599):85-87.","","Med Lett Drugs Ther","2020","2020/06/20","","",""
"19770473","Randomized, controlled trial of telcagepant for the acute treatment of migraine","Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW.","Neurology. 2009 Sep 22;73(12):970-7. doi: 10.1212/WNL.0b013e3181b87942.","Connor KM","Neurology","2009","2009/09/23","PMC2754336","","10.1212/WNL.0b013e3181b87942"
"29124668","The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities","Martelletti P.","BioDrugs. 2017 Dec;31(6):483-485. doi: 10.1007/s40259-017-0251-4.","Martelletti P","BioDrugs","2017","2017/11/11","","","10.1007/s40259-017-0251-4"
"11680150","[Both neurogenic and vascular causes of primary headache]","Edvinsson L.","Lakartidningen. 2001 Sep 26;98(39):4176-83.","Edvinsson L","Lakartidningen","2001","2001/10/30","","",""
"34105377","PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine","Ashina M, Amin FM, Kokturk P, Cohen JM, Konings M, Tassorelli C, Lyras L, Mitsikostas DD.","Pain Manag. 2021 Nov;11(6):647-654. doi: 10.2217/pmt-2021-0015. Epub 2021 Jun 9.","Ashina M","Pain Manag","2021","2021/06/09","","","10.2217/pmt-2021-0015"
"34972502","Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies","Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, Raffaelli B, Reuter U.","J Headache Pain. 2021 Dec 31;22(1):158. doi: 10.1186/s10194-021-01368-7.","Terhart M","J Headache Pain","2021","2022/01/01","PMC8903665","","10.1186/s10194-021-01368-7"
"22221076","Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease","Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW.","Headache. 2012 Feb;52(2):224-35. doi: 10.1111/j.1526-4610.2011.02052.x. Epub 2012 Jan 6.","Ho TW","Headache","2012","2012/01/07","","","10.1111/j.1526-4610.2011.02052.x"
"34109839","Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment","Nedd M, Garland S, Falk N, Wilk A.","Ann Pharmacother. 2022 Mar;56(3):346-351. doi: 10.1177/10600280211023810. Epub 2021 Jun 10.","Nedd M","Ann Pharmacother","2022","2021/06/10","","","10.1177/10600280211023810"
"23721243","Not all CGRP antagonists are created equal","Peroutka SJ.","Headache. 2013 Jun;53(6):1004-6. doi: 10.1111/head.12107.","Peroutka SJ","Headache","2013","2013/06/01","","","10.1111/head.12107"
"28497257","[Therapy of migranes]","Holle-Lee D, Nägel S, Gaul C.","Nervenarzt. 2017 Aug;88(8):929-941. doi: 10.1007/s00115-017-0338-7.","Holle-Lee D","Nervenarzt","2017","2017/05/13","","","10.1007/s00115-017-0338-7"
"33891348","Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study","Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC.","Headache. 2021 Apr;61(4):662-672. doi: 10.1111/head.14097.","Lipton RB","Headache","2021","2021/04/23","PMC8251795","","10.1111/head.14097"
"32944843","Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study","Ford JH, Stauffer VL, McAllister P, Akkala S, Sexson M, Ayer DW, Wang S.","Qual Life Res. 2021 Feb;30(2):455-464. doi: 10.1007/s11136-020-02632-0. Epub 2020 Sep 17.","Ford JH","Qual Life Res","2021","2020/09/18","PMC7886775","","10.1007/s11136-020-02632-0"
"27834685","Antagonism of cannabinoid receptor 1 attenuates the anti-inflammatory effects of electroacupuncture in a rodent model of migraine","Zhang H, He S, Hu Y, Zheng H.","Acupunct Med. 2016 Dec;34(6):463-470. doi: 10.1136/acupmed-2016-011113. Epub 2016 Nov 10.","Zhang H","Acupunct Med","2016","2016/11/12","","","10.1136/acupmed-2016-011113"
"35676636","Real-World experience of interictal burden and treatment in migraine: a qualitative interview study","Lo SH, Gallop K, Smith T, Powell L, Johnston K, Hubig LT, Williams E, Coric V, Harris L, L'Italien G, Lloyd AJ.","J Headache Pain. 2022 Jun 8;23(1):65. doi: 10.1186/s10194-022-01429-5.","Lo SH","J Headache Pain","2022","2022/06/08","PMC9174626","","10.1186/s10194-022-01429-5"
"37395575","Detection and Quantification of Calcitonin Gene-Related Peptide (CGRP) in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay","Krishnan PS, Zamuner FT, Jenks CM, Xie JY, Zhang L, Lehar M, Fedarko NS, Brait M, Carey JP.","J Vis Exp. 2023 Jun 16;(196). doi: 10.3791/64775.","Krishnan PS","J Vis Exp","2023","2023/07/03","","","10.3791/64775"
"30187471","Antigens and Antibodies in Disease With Specifics About CGRP Immunology","Taylor FR.","Headache. 2018 Nov;58 Suppl 3:230-237. doi: 10.1111/head.13409. Epub 2018 Sep 5.","Taylor FR","Headache","2018","2018/09/07","","","10.1111/head.13409"
"37268904","Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients","Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, Olivier M, Campdelacreu J, Prat J, Camiña Muñiz J, Molina Martínez FJ, Mínguez-Olaondo A, Ruibal Salgado M, Santos Lasaosa S, Navarro Pérez MP, Morollón N, López Bravo A, Cano Sánchez LM, García-Sánchez SM, García-Ull J, Rubio-Flores L, Gonzalez-Martinez A, Quintas S, Echavarría Íñiguez A, Gil Luque S, Castro-Sánchez MV, Adell Ortega V, García Alhama J, Berrocal-Izquierdo N, Belvís R, Díaz-Insa S, Pozo-Rosich P, Huerta-Villanueva M.","J Headache Pain. 2023 Jun 2;24(1):63. doi: 10.1186/s10194-023-01585-2.","Muñoz-Vendrell A","J Headache Pain","2023","2023/06/02","PMC10236648","","10.1186/s10194-023-01585-2"
"36678160","Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine","Fila M, Chojnacki J, Sobczuk P, Chojnacki C, Blasiak J.","Nutrients. 2023 Jan 6;15(2):289. doi: 10.3390/nu15020289.","Fila M","Nutrients","2023","2023/01/21","PMC9864721","","10.3390/nu15020289"
"36031682","New Oral Drugs for Migraine","Karsan N, Goadsby PJ.","CNS Drugs. 2022 Sep;36(9):933-949. doi: 10.1007/s40263-022-00948-8. Epub 2022 Aug 29.","Karsan N","CNS Drugs","2022","2022/08/28","PMC9477894","","10.1007/s40263-022-00948-8"
"34819017","Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies","Nahas SJ, Naegel S, Cohen JM, Ning X, Janka L, Campos VR, Krasenbaum LJ, Holle-Lee D, Kudrow D, Lampl C.","J Headache Pain. 2021 Nov 24;22(1):141. doi: 10.1186/s10194-021-01351-2.","Nahas SJ","J Headache Pain","2021","2021/11/25","PMC8903616","","10.1186/s10194-021-01351-2"
"30231626","Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed","Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J.","Cephalalgia. 2019 Apr;39(5):608-616. doi: 10.1177/0333102418801579. Epub 2018 Sep 19.","Vo P","Cephalalgia","2019","2018/09/21","","","10.1177/0333102418801579"
"32043537","[Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine]","Doctorovich ED, Martín-Bertuzzi F, Goicochea MT, Miranda S, Figuerola ML, Schubaroff PA, Buonanotte F, Rocchi V, Rua I, Bruera OC, Giglio J, De Paz JJ, Pelli-Noble R, Arago L, Burgos M, Ayala LS, Davidow L, Bonamico L.","Rev Neurol. 2020 Feb 16;70(4):149-158. doi: 10.33588/rn.7004.2019399.","Doctorovich ED","Rev Neurol","2020","2020/02/12","","","10.33588/rn.7004.2019399"
"32046655","Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials","Yang Y, Wang Z, Gao B, Xuan H, Zhu Y, Chen Z, Wang Z.","J Headache Pain. 2020 Feb 11;21(1):14. doi: 10.1186/s10194-020-1085-x.","Yang Y","J Headache Pain","2020","2020/02/13","PMC7014619","","10.1186/s10194-020-1085-x"
"24673487","CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J.","Headache. 2014 Jun;54(6):987-95. doi: 10.1111/head.12372. Epub 2014 May 6.","Cernuda-Morollón E","Headache","2014","2014/03/29","","","10.1111/head.12372"
"32525262","Gepants for abortive treatment of migraine: A network meta-analysis","Hong P, Tan T, Liu Y, Xiao J.","Brain Behav. 2020 Aug;10(8):e01701. doi: 10.1002/brb3.1701. Epub 2020 Jun 11.","Hong P","Brain Behav","2020","2020/06/12","PMC7428487","","10.1002/brb3.1701"
"32251023","Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?","Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ.","Curr Opin Neurol. 2020 Jun;33(3):309-315. doi: 10.1097/WCO.0000000000000806.","Moreno-Ajona D","Curr Opin Neurol","2020","2020/04/07","","","10.1097/WCO.0000000000000806"
"35445471","Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence","Khalil M, Moreno-Ajona D, Villar-Martínez MD, Greenwood F, Hoffmann J, Goadsby PJ.","Eur J Neurol. 2022 Aug;29(8):2473-2480. doi: 10.1111/ene.15364. Epub 2022 May 9.","Khalil M","Eur J Neurol","2022","2022/04/21","PMC9545124","","10.1111/ene.15364"
"24986857","Receiver operating characteristic curve generalization for non-monotone relationships","Martínez-Camblor P, Corral N, Rey C, Pascual J, Cernuda-Morollón E.","Stat Methods Med Res. 2017 Feb;26(1):113-123. doi: 10.1177/0962280214541095. Epub 2016 Jul 11.","Martínez-Camblor P","Stat Methods Med Res","2017","2014/07/03","","","10.1177/0962280214541095"
"35476143","[Galcanezumab for episodic and chronic cluster headache]","Pohl H, Holle-Lee D, Broicher SD, Schwerdtner I, Gantenbein AR, Gaul C.","Schmerz. 2023 Jun;37(3):168-174. doi: 10.1007/s00482-022-00648-8. Epub 2022 Apr 27.","Pohl H","Schmerz","2023","2022/04/27","","","10.1007/s00482-022-00648-8"
"23941062","TRPA1 and other TRP channels in migraine","Benemei S, De Cesaris F, Fusi C, Rossi E, Lupi C, Geppetti P.","J Headache Pain. 2013 Aug 13;14(1):71. doi: 10.1186/1129-2377-14-71.","Benemei S","J Headache Pain","2013","2013/08/15","PMC3844362","","10.1186/1129-2377-14-71"
"35614870","Visual snow syndrome is probably not mediated by CGRP: A case series","Evers S, Holle-Lee D, Schankin CJ, Kull P, Raffaelli B.","Cephalalgia. 2022 Oct;42(11-12):1294-1298. doi: 10.1177/03331024221099220. Epub 2022 May 25.","Evers S","Cephalalgia","2022","2022/05/26","","","10.1177/03331024221099220"
"31127003","CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura","Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, Burstein R.","J Neurosci. 2019 Jul 24;39(30):6001-6011. doi: 10.1523/JNEUROSCI.0232-19.2019. Epub 2019 May 24.","Schain AJ","J Neurosci","2019","2019/05/26","PMC6650995","","10.1523/JNEUROSCI.0232-19.2019"
"31532138","[Effect of otopoint pellet-pressing combined with medication on clinical symptoms of migraine patients and changes of plasma 5-HT and CGRP contents]","Xing AQ, Chen CH, Ji XT.","Zhen Ci Yan Jiu. 2019 Sept 25;44(9):672-6. doi: 10.13702/j.1000-0607.180737.","Xing AQ","Zhen Ci Yan Jiu","2019","2019/09/19","","","10.13702/j.1000-0607.180737"
"34287786","Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada","Eghtesadi M, Leroux E, Pagé G.","Clin Drug Investig. 2021 Aug;41(8):733-739. doi: 10.1007/s40261-021-01059-w. Epub 2021 Jul 21.","Eghtesadi M","Clin Drug Investig","2021","2021/07/21","","","10.1007/s40261-021-01059-w"
"34374086","Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study","Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC.","Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10.","Spierings ELH","Headache","2021","2021/08/10","PMC8597120","","10.1111/head.14196"
"22540203","Opioids should not be used in migraine","Tepper SJ.","Headache. 2012 May;52 Suppl 1:30-4. doi: 10.1111/j.1526-4610.2012.02140.x.","Tepper SJ","Headache","2012","2012/05/01","","","10.1111/j.1526-4610.2012.02140.x"
"32924075","Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine","Cetinkaya A, Kilinc E, Camsari C, Ogun MN.","Exp Brain Res. 2020 Nov;238(11):2625-2639. doi: 10.1007/s00221-020-05923-7. Epub 2020 Sep 13.","Cetinkaya A","Exp Brain Res","2020","2020/09/14","","","10.1007/s00221-020-05923-7"
"33181579","Therapeutic targeting of nitroglycerin-mediated trigeminovascular neuronal hypersensitivity predicts clinical outcomes of migraine abortives","Akerman S, Romero-Reyes M, Karsan N, Bose P, Hoffmann JR, Holland PR, Goadsby PJ.","Pain. 2021 May 1;162(5):1567-1577. doi: 10.1097/j.pain.0000000000002142.","Akerman S","Pain","2021","2020/11/12","","","10.1097/j.pain.0000000000002142"
"30426478","Basic Considerations for the Use of Monoclonal Antibodies in Migraine","Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.","Headache. 2018 Nov;58(10):1689-1696. doi: 10.1111/head.13439. Epub 2018 Nov 13.","Levin M","Headache","2018","2018/11/15","PMC6283065","","10.1111/head.13439"
"21631478","Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study","Behm MO, Blanchard RL, Murphy MG, Palcza JS, Harris DE, Butterfield KL, Smith WB, Preston RA, Chodakewitz JA, Krucoff MW.","Headache. 2011 Jun;51(6):954-60. doi: 10.1111/j.1526-4610.2011.01901.x.","Behm MO","Headache","2011","2011/06/03","","","10.1111/j.1526-4610.2011.01901.x"
"18344603","[Strategies for antimigraine agents]","Ishii T, Taniguchi H, Saito A.","Nihon Yakurigaku Zasshi. 2008 Mar;131(3):205-9. doi: 10.1254/fpj.131.205.","Ishii T","Nihon Yakurigaku Zasshi","2008","2008/03/18","","","10.1254/fpj.131.205"
"32758365","Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention","Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G.","Rev Neurol (Paris). 2020 Dec;176(10):788-803. doi: 10.1016/j.neurol.2020.04.027. Epub 2020 Aug 2.","Schoenen J","Rev Neurol (Paris)","2020","2020/08/08","","","10.1016/j.neurol.2020.04.027"
"18808506","Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine","Tepper SJ, Stillman MJ.","Headache. 2008 Sep;48(8):1259-68. doi: 10.1111/j.1526-4610.2008.01214.x.","Tepper SJ","Headache","2008","2008/09/24","","","10.1111/j.1526-4610.2008.01214.x"
"19499287","Migraine pain: reflections against vasodilatation","Panconesi A, Bartolozzi ML, Guidi L.","J Headache Pain. 2009 Oct;10(5):317-25. doi: 10.1007/s10194-009-0130-6. Epub 2009 Jun 5.","Panconesi A","J Headache Pain","2009","2009/06/06","PMC3452097","","10.1007/s10194-009-0130-6"
"33495299","Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects","Ray JC, Kapoor M, Stark RJ, Wang SJ, Bendtsen L, Matharu M, Hutton EJ.","J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1325-1334. doi: 10.1136/jnnp-2020-324674. Epub 2021 Jan 25.","Ray JC","J Neurol Neurosurg Psychiatry","2021","2021/01/26","","","10.1136/jnnp-2020-324674"
"33939497","Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study","Diener HC, Ashina M, Ritter S, Paiva Da Silva Lima G, Rasmussen S, Zielman R, Tfelt-Hansen P.","Cephalalgia. 2021 Oct;41(11-12):1262-1267. doi: 10.1177/03331024211010308. Epub 2021 May 3.","Diener HC","Cephalalgia","2021","2021/05/03","PMC8504413","","10.1177/03331024211010308"
"34620085","Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months","Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.","J Headache Pain. 2021 Oct 7;22(1):120. doi: 10.1186/s10194-021-01328-1.","Caronna E","J Headache Pain","2021","2021/10/08","PMC8499507","","10.1186/s10194-021-01328-1"
"36705344","Characterization of trigeminal C-fiber reactivity through capsaicin-induced release of calcitonin gene-related peptide","Basedau H, Oppermann T, Gundelwein Silva E, Peng KP, May A.","Headache. 2023 Mar;63(3):353-359. doi: 10.1111/head.14471. Epub 2023 Jan 27.","Basedau H","Headache","2023","2023/01/27","","","10.1111/head.14471"
"29989892","Aimovig for Migraine Prevention: The New Kid May Have Trouble Fitting in","Reinke T.","Manag Care. 2018 Jul;27(7):10-11.","Reinke T","Manag Care","2018","2018/07/11","","",""
"38181724","Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial","Raffaelli B, Do TP, Chaudhry BA, Amin FM, Ashina H, Snellman J, Maio-Twofoot T, Ashina M.","Cephalalgia. 2024 Jan;44(1):3331024231222916. doi: 10.1177/03331024231222916.","Raffaelli B","Cephalalgia","2024","2024/01/05","","","10.1177/03331024231222916"
"22843221","Different trigemino-vascular responsiveness between adolescent and adult rats in a migraine model","Fan PC, Kuo PH, Hu JW, Chang SH, Hsieh ST, Chiou LC.","Cephalalgia. 2012 Oct;32(13):979-90. doi: 10.1177/0333102412455710. Epub 2012 Jul 26.","Fan PC","Cephalalgia","2012","2012/07/31","","","10.1177/0333102412455710"
"32853126","Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison","Briceño-Casado MDP, Gil-Sierra MD, Fénix-Caballero S.","Farm Hosp. 2020 Aug 21;44(5):212-217. doi: 10.7399/fh.11419.","Briceño-Casado MDP","Farm Hosp","2020","2020/08/28","","","10.7399/fh.11419"
"35650458","Gepants - a long way to cure: a narrative review","Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F.","Neurol Sci. 2022 Sep;43(9):5697-5708. doi: 10.1007/s10072-022-06184-8. Epub 2022 Jun 2.","Altamura C","Neurol Sci","2022","2022/06/01","PMC9159895","","10.1007/s10072-022-06184-8"
"35672126","Calcitonin gene-related peptide in migraine: from pathophysiology to treatment","Santos-Lasaosa S, Belvís R, Cuadrado ML, Díaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, Láinez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sánchez Del Río M, Viguera J, Pozo-Rosich P.","Neurologia (Engl Ed). 2022 Jun;37(5):390-402. doi: 10.1016/j.nrleng.2019.03.025. Epub 2021 May 26.","Santos-Lasaosa S","Neurologia (Engl Ed)","2022","2022/06/07","","","10.1016/j.nrleng.2019.03.025"
"37551544","Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients","La Rocca M, Laporta A, Clemente L, Ammendola E, Delussi MD, Ricci K, Tancredi G, Stramaglia S, de Tommaso M.","Cephalalgia. 2023 Aug;43(8):3331024231189751. doi: 10.1177/03331024231189751.","La Rocca M","Cephalalgia","2023","2023/08/08","","","10.1177/03331024231189751"
"31301747","Approvals and indications of CGRP antibodies","Nichols R, Detke HC, Hundemer HP, Aurora SK.","Lancet Neurol. 2019 Aug;18(8):718. doi: 10.1016/S1474-4422(19)30229-7.","Nichols R","Lancet Neurol","2019","2019/07/15","","","10.1016/S1474-4422(19)30229-7"
"29761294","Monoclonal antibodies for migraine: an update","Castle D, Robertson NP.","J Neurol. 2018 Jun;265(6):1491-1492. doi: 10.1007/s00415-018-8886-8.","Castle D","J Neurol","2018","2018/05/16","PMC5990571","","10.1007/s00415-018-8886-8"
"20433208","Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine","Durham PL, Vause CV.","CNS Drugs. 2010 Jul;24(7):539-48. doi: 10.2165/11534920-000000000-00000.","Durham PL","CNS Drugs","2010","2010/05/04","PMC3138175","NIHMS304672","10.2165/11534920-000000000-00000"
"36456902","Expression of vasopressin and its receptors in migraine-related regions in CNS and the trigeminal system: influence of sex","Maddahi A, Edvinsson L, Warfvinge K.","J Headache Pain. 2022 Dec 1;23(1):152. doi: 10.1186/s10194-022-01524-7.","Maddahi A","J Headache Pain","2022","2022/12/01","PMC9713967","","10.1186/s10194-022-01524-7"
"11772240","Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators","Doggrell SA.","Expert Opin Investig Drugs. 2001 Jun;10(6):1131-8. doi: 10.1517/13543784.10.6.1131.","Doggrell SA","Expert Opin Investig Drugs","2001","2002/01/05","","","10.1517/13543784.10.6.1131"
"35502612","Treatment of migraine with monoclonal antibodies","Serra López-Matencio JM, Gago-Veiga AB, Gómez M, Alañón Plaza E, Mejía GP, González-Gay MÁ, Castañeda S.","Expert Opin Biol Ther. 2022 Jun;22(6):707-716. doi: 10.1080/14712598.2022.2072207. Epub 2022 May 13.","Serra López-Matencio JM","Expert Opin Biol Ther","2022","2022/05/03","","","10.1080/14712598.2022.2072207"
"36216323","Does Calcified Neurocysticercosis Affect Migraine Characteristics and Treatment Responsiveness? A Case-Control Study","Sharma K, Uniyal R, Garg RK, Verma R, Paliwal VK, Malhotra HS, Sharma PK, Kumar N, Pandey S, Rizvi I.","Am J Trop Med Hyg. 2022 Oct 10;107(6):1190-1195. doi: 10.4269/ajtmh.22-0335. Print 2022 Dec 14.","Sharma K","Am J Trop Med Hyg","2022","2022/10/10","PMC9768286","","10.4269/ajtmh.22-0335"
"36813730","Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study","Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS, Reuter U.","Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.","Raffaelli B","Neurology","2023","2023/02/22","PMC10136010","","10.1212/WNL.0000000000207114"
"29432219","Calcitonin-gene-related peptide pathway mAbs and migraine prevention","Paemeleire K, MaassenVanDenBrink A.","Curr Opin Neurol. 2018 Jun;31(3):274-280. doi: 10.1097/WCO.0000000000000548.","Paemeleire K","Curr Opin Neurol","2018","2018/02/13","","","10.1097/WCO.0000000000000548"
"31194488","Erenumab (Aimovig) for Migraine Prophylaxis in Adults","Shreiber AM.","Am Fam Physician. 2019 Jun 15;99(12):781-782.","Shreiber AM","Am Fam Physician","2019","2019/06/14","","",""
"37672405","Emerging experimental drugs in clinical trials for migraine: observations and key talking points","Wells-Gatnik WD, Wences Chirino TY, Onan FN, Onan D, Martelletti P.","Expert Opin Investig Drugs. 2023 Jul-Dec;32(8):761-771. doi: 10.1080/13543784.2023.2254691. Epub 2023 Sep 8.","Wells-Gatnik WD","Expert Opin Investig Drugs","2023","2023/09/06","","","10.1080/13543784.2023.2254691"
"35174666","Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial","Boinpally R, Lu K.","Clin Pharmacol Drug Dev. 2022 Jul;11(7):857-864. doi: 10.1002/cpdd.1066. Epub 2022 Feb 16.","Boinpally R","Clin Pharmacol Drug Dev","2022","2022/02/17","PMC9306593","","10.1002/cpdd.1066"
"31160203","Migraine and the trigeminovascular system-40 years and counting","Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA.","Lancet Neurol. 2019 Aug;18(8):795-804. doi: 10.1016/S1474-4422(19)30185-1. Epub 2019 May 31.","Ashina M","Lancet Neurol","2019","2019/06/05","PMC7164539","NIHMS1579515","10.1016/S1474-4422(19)30185-1"
"37072224","Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study","Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S; Italian Migraine Registry study group.","Neurology. 2023 Sep 12;101(11):482-488. doi: 10.1212/WNL.0000000000207292. Epub 2023 Apr 18.","Barbanti P","Neurology","2023","2023/04/18","PMC10513886","","10.1212/WNL.0000000000207292"
"37555331","Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study","Alpuente A, Torre-Sune A, Caronna E, Gine-Cipres E, Torres-Ferrús M, Pozo-Rosich P.","Cephalalgia. 2023 Aug;43(8):3331024231177636. doi: 10.1177/03331024231177636.","Alpuente A","Cephalalgia","2023","2023/08/09","","","10.1177/03331024231177636"
"19041880","Effect of some acute and prophylactic antimigraine drugs on the vasodepressor sensory CGRPergic outflow in pithed rats","Lozano-Cuenca J, González-Hernández A, Muñoz-Islas E, Sánchez-López A, Centurión D, Cobos-Puc LE, Villalón CM.","Life Sci. 2009 Jan 30;84(5-6):125-31. doi: 10.1016/j.lfs.2008.11.008. Epub 2008 Nov 19.","Lozano-Cuenca J","Life Sci","2009","2008/12/02","","","10.1016/j.lfs.2008.11.008"
"34459825","Investigating Migraine-Like Behavior Using Light Aversion in Mice","Wang M, Mason BN, Sowers LP, Kuburas A, Rea BJ, Russo AF.","J Vis Exp. 2021 Aug 11;(174):10.3791/62839. doi: 10.3791/62839.","Wang M","J Vis Exp","2021","2021/08/30","PMC8428768","NIHMS1735845","10.3791/62839"
"35139816","Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients","Takeshima T, Nakai M, Shibasaki Y, Ishida M, Kim BK, Ning X, Koga N.","J Headache Pain. 2022 Feb 9;23(1):24. doi: 10.1186/s10194-022-01393-0.","Takeshima T","J Headache Pain","2022","2022/02/10","PMC8903536","","10.1186/s10194-022-01393-0"
"31109209","Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies","Negro A, Martelletti P.","Expert Rev Neurother. 2019 Aug;19(8):769-776. doi: 10.1080/14737175.2019.1621749. Epub 2019 May 29.","Negro A","Expert Rev Neurother","2019","2019/05/22","","","10.1080/14737175.2019.1621749"
"17123735","Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods","Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K.","Pain. 2007 Apr;128(3):209-214. doi: 10.1016/j.pain.2006.09.017. Epub 2006 Nov 22.","Fusayasu E","Pain","2007","2006/11/25","","","10.1016/j.pain.2006.09.017"
"34021438","Impact of COVID-19 on chronic migraine treated with erenumab: a case report","Grassini A, Marcinnò A, Roveta F, Gallo E, Cermelli A, Boschi S, Rubino E, Rainero I.","Neurol Sci. 2021 Aug;42(8):3079-3081. doi: 10.1007/s10072-021-05329-5. Epub 2021 May 21.","Grassini A","Neurol Sci","2021","2021/05/22","PMC8139216","","10.1007/s10072-021-05329-5"
"32745488","Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus caudalis of rats","Kooshki R, Abbasnejad M, Esmaeili-Mahani S, Raoof M, Sheibani V.","Neuropharmacology. 2020 Nov 1;178:107981. doi: 10.1016/j.neuropharm.2020.107981. Epub 2020 Jul 31.","Kooshki R","Neuropharmacology","2020","2020/08/04","","","10.1016/j.neuropharm.2020.107981"
"24000375","Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation","Ramachandran R, Bhatt DK, Ploug KB, Hay-Schmidt A, Jansen-Olesen I, Gupta S, Olesen J.","Cephalalgia. 2014 Feb;34(2):136-47. doi: 10.1177/0333102413502735. Epub 2013 Sep 2.","Ramachandran R","Cephalalgia","2014","2013/09/04","","","10.1177/0333102413502735"
"31302899","Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece","Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P.","Clin Drug Investig. 2019 Oct;39(10):979-990. doi: 10.1007/s40261-019-00827-z.","Giannouchos TV","Clin Drug Investig","2019","2019/07/15","","","10.1007/s40261-019-00827-z"
"31291516","Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine","Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ.","N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.","Lipton RB","N Engl J Med","2019","2019/07/11","","","10.1056/NEJMoa1811090"
"35954288","Could Experimental Inflammation Provide Better Understanding of Migraines?","Reducha PV, Edvinsson L, Haanes KA.","Cells. 2022 Aug 6;11(15):2444. doi: 10.3390/cells11152444.","Reducha PV","Cells","2022","2022/08/12","PMC9368653","","10.3390/cells11152444"
"32951099","Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice","Pérez-Pereda S, Toriello-Suárez M, Ocejo-Vinyals G, Guiral-Foz S, Castillo-Obeso J, Montes-Gómez S, Martínez-Nieto RM, Iglesias F, González-Quintanilla V, Oterino A.","Mol Biol Rep. 2020 Sep;47(9):7125-7138. doi: 10.1007/s11033-020-05781-0. Epub 2020 Sep 20.","Pérez-Pereda S","Mol Biol Rep","2020","2020/09/20","","","10.1007/s11033-020-05781-0"
"19438925","Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine","Gupta S, Bhatt DK, Boni LJ, Olesen J.","Cephalalgia. 2010 Jan;30(1):27-36. doi: 10.1111/j.1468-2982.2009.01888.x.","Gupta S","Cephalalgia","2010","2009/05/15","","","10.1111/j.1468-2982.2009.01888.x"
"28593473","Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects","Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, Wu LS, Hamilton L, Vargas G.","Pharm Res. 2017 Sep;34(9):1784-1795. doi: 10.1007/s11095-017-2183-6. Epub 2017 Jun 7.","Vu T","Pharm Res","2017","2017/06/09","PMC5533838","","10.1007/s11095-017-2183-6"
"32238376","CGRP antagonists for decreasing migraine frequency: New options, long overdue","Bucklan J, Ahmed Z.","Cleve Clin J Med. 2020 Apr;87(4):211-218. doi: 10.3949/ccjm.87a.19048.","Bucklan J","Cleve Clin J Med","2020","2020/04/03","","","10.3949/ccjm.87a.19048"
"35392739","Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study","Pozo-Rosich P, Detke HC, Wang S, Doležil D, Li LQ, Aurora SK, Reuter U.","Curr Med Res Opin. 2022 May;38(5):731-742. doi: 10.1080/03007995.2022.2059975. Epub 2022 Apr 15.","Pozo-Rosich P","Curr Med Res Opin","2022","2022/04/08","","","10.1080/03007995.2022.2059975"
"38308939","Calcitonin gene-related peptide (CGRP) levels in peripheral blood in patients with idiopathic intracranial hypertension and migraine","Ak AK, Gemici YI, Batum M, Karakaş B, Özmen EY, Gökçay F, Çelebisoy N.","Clin Neurol Neurosurg. 2024 Feb;237:108136. doi: 10.1016/j.clineuro.2024.108136. Epub 2024 Jan 26.","Ak AK","Clin Neurol Neurosurg","2024","2024/02/03","","","10.1016/j.clineuro.2024.108136"
"36932352","Serum alpha-CGRP levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system","Gárate G, Toriello M, González-Quintanilla V, Pérez-Pereda S, Madera J, Pascual M, Olmos JM, Pascual J.","BMC Neurol. 2023 Mar 17;23(1):109. doi: 10.1186/s12883-023-03156-z.","Gárate G","BMC Neurol","2023","2023/03/18","PMC10021037","","10.1186/s12883-023-03156-z"
"36432556","Quercetin Attenuates Nitroglycerin-Induced Migraine Headaches by Inhibiting Oxidative Stress and Inflammatory Mediators","Foudah AI, Devi S, Alqarni MH, Alam A, Salkini MA, Kumar M, Almalki HS.","Nutrients. 2022 Nov 17;14(22):4871. doi: 10.3390/nu14224871.","Foudah AI","Nutrients","2022","2022/11/26","PMC9695045","","10.3390/nu14224871"
"33269829","[Effects of electroacupuncture on miR-34a-5p/SIRT1 signaling in the trigeminal ganglion of rats with migraine]","Zhang H, He SD, Zong DD, Zhang XM, Luo J, Zheng JK.","Zhen Ci Yan Jiu. 2020 Nov 25;45(11):868-74. doi: 10.13702/j.1000-0607.200378.","Zhang H","Zhen Ci Yan Jiu","2020","2020/12/03","","","10.13702/j.1000-0607.200378"
"20816423","Botulinum neurotoxin in the treatment of headache disorders","Mauskop A.","Handb Clin Neurol. 2010;97:217-32. doi: 10.1016/S0072-9752(10)97017-6.","Mauskop A","Handb Clin Neurol","2010","2010/09/07","","","10.1016/S0072-9752(10)97017-6"
"32687594","Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies","Domitrz I, Lipa A, Rożniecki J, Stępień A, Kozubski W.","Neurol Neurochir Pol. 2020;54(4):337-343. doi: 10.5603/PJNNS.a2020.0054. Epub 2020 Jul 20.","Domitrz I","Neurol Neurochir Pol","2020","2020/07/21","","","10.5603/PJNNS.a2020.0054"
"28301400","The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","Iyengar S, Ossipov MH, Johnson KW.","Pain. 2017 Apr;158(4):543-559. doi: 10.1097/j.pain.0000000000000831.","Iyengar S","Pain","2017","2017/03/17","PMC5359791","","10.1097/j.pain.0000000000000831"
"35971655","Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)","Tobin JA, Joshi S, Ford JH, Nichols RM, Foster SA, Ruff D, Detke HC, Aurora SK.","J Med Econ. 2022 Jan-Dec;25(1):1030-1038. doi: 10.1080/13696998.2022.2109335.","Tobin JA","J Med Econ","2022","2022/08/16","","","10.1080/13696998.2022.2109335"
"38256423","CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine","Finelli F, Catalano A, De Lisa M, Ferraro GA, Genovese S, Giuzio F, Salvia R, Scieuzo C, Sinicropi MS, Svolacchia F, Vassallo A, Santarsiere A, Saturnino C.","Medicina (Kaunas). 2024 Jan 15;60(1):163. doi: 10.3390/medicina60010163.","Finelli F","Medicina (Kaunas)","2024","2024/01/23","PMC10820088","","10.3390/medicina60010163"
"31377466","Effect of Paeonia lactiflora, a traditional Chinese herb, on migraines based on clinical application and animal behavior analyses","Liao CC, Li JM, Chen CH, Lin CL, Hsieh CL.","Biomed Pharmacother. 2019 Oct;118:109276. doi: 10.1016/j.biopha.2019.109276. Epub 2019 Aug 1.","Liao CC","Biomed Pharmacother","2019","2019/08/05","","","10.1016/j.biopha.2019.109276"
"24004534","Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment","Seiler K, Nusser JI, Lennerz JK, Neuhuber WL, Messlinger K.","J Headache Pain. 2013 Sep 3;14(1):74. doi: 10.1186/1129-2377-14-74.","Seiler K","J Headache Pain","2013","2013/09/06","PMC3847895","","10.1186/1129-2377-14-74"
"34407654","Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies","Lipton RB, Dodick DW, Kudrow D, Reuter U, Tenenbaum N, Zhang F, Lima GPDS, Chou DE, Mikol DD.","Cephalalgia. 2021 Dec;41(14):1458-1466. doi: 10.1177/03331024211028966. Epub 2021 Aug 18.","Lipton RB","Cephalalgia","2021","2021/08/19","","","10.1177/03331024211028966"
"33252452","Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache","Guo Z, Czerpaniak K, Zhang J, Cao YQ.","Pain. 2021 May 1;162(5):1483-1499. doi: 10.1097/j.pain.0000000000002147.","Guo Z","Pain","2021","2020/11/30","PMC8049961","NIHMS1646121","10.1097/j.pain.0000000000002147"
"31060490","How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice","Tiseo C, Ornello R, Pistoia F, Sacco S.","J Headache Pain. 2019 May 6;20(1):49. doi: 10.1186/s10194-019-1000-5.","Tiseo C","J Headache Pain","2019","2019/05/08","PMC6734464","","10.1186/s10194-019-1000-5"
"37806714","Migraine and treatment-resistant depression","Chen SP.","Prog Brain Res. 2023;281:149-173. doi: 10.1016/bs.pbr.2023.05.001. Epub 2023 Jun 23.","Chen SP","Prog Brain Res","2023","2023/10/08","","","10.1016/bs.pbr.2023.05.001"
"27339365","Anti-CGRP monoclonal antibodies in migraine: current perspectives","Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P.","Intern Emerg Med. 2016 Dec;11(8):1045-1057. doi: 10.1007/s11739-016-1489-4. Epub 2016 Jun 23.","Giamberardino MA","Intern Emerg Med","2016","2016/06/25","","","10.1007/s11739-016-1489-4"
"32917805","Central effects of erenumab in migraine patients: An event-related functional imaging study","Ziegeler C, Mehnert J, Asmussen K, May A.","Neurology. 2020 Nov 17;95(20):e2794-e2802. doi: 10.1212/WNL.0000000000010740. Epub 2020 Sep 11.","Ziegeler C","Neurology","2020","2020/09/12","","","10.1212/WNL.0000000000010740"
"34227105","Calcitonin gene-related peptide-induced hemodynamic changes in migraine with and without aura","Zupan M, Zaletel M, Visočnik D, Žvan B.","Acta Neurol Scand. 2021 Dec;144(6):616-622. doi: 10.1111/ane.13495. Epub 2021 Jul 6.","Zupan M","Acta Neurol Scand","2021","2021/07/06","","","10.1111/ane.13495"
"37866119","Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study","Szabo E, Ashina S, Melo-Carrillo A, Bolo NR, Borsook D, Burstein R.","Neuroimage Clin. 2023;40:103531. doi: 10.1016/j.nicl.2023.103531. Epub 2023 Oct 14.","Szabo E","Neuroimage Clin","2023","2023/10/22","PMC10623369","","10.1016/j.nicl.2023.103531"
"11371757","Pharmacological opportunities and pitfalls in the therapy of migraine","May A, Goadsby PJ.","Curr Opin Neurol. 2001 Jun;14(3):341-5. doi: 10.1097/00019052-200106000-00012.","May A","Curr Opin Neurol","2001","2001/05/24","","","10.1097/00019052-200106000-00012"
"28731365","Chemical Composition and Antimigraine Activity of Essential Oil of Angelicae dahuricae Radix","Sun J, Li H, Sun J, Liu H, Chen J, Wang C.","J Med Food. 2017 Aug;20(8):797-803. doi: 10.1089/jmf.2016.3898. Epub 2017 Jul 21.","Sun J","J Med Food","2017","2017/07/22","","","10.1089/jmf.2016.3898"
"21350792","Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment","Tfelt-Hansen P.","J Headache Pain. 2011 Jun;12(3):275-80. doi: 10.1007/s10194-011-0309-5. Epub 2011 Feb 25.","Tfelt-Hansen P","J Headache Pain","2011","2011/02/26","PMC3094671","","10.1007/s10194-011-0309-5"
"20097071","Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine","Nichols PL, Brand J, Briggs M, D'Angeli M, Farge J, Garland SL, Goldsmith P, Hutchings R, Kilford I, Li HY, MacPherson D, Nimmo F, Sanderson FD, Sehmi S, Shuker N, Skidmore J, Stott M, Sweeting J, Tajuddin H, Takle AK, Trani G, Wall ID, Ward R, Wilson DM, Witty D.","Bioorg Med Chem Lett. 2010 Feb 15;20(4):1368-72. doi: 10.1016/j.bmcl.2010.01.012. Epub 2010 Jan 11.","Nichols PL","Bioorg Med Chem Lett","2010","2010/01/26","","","10.1016/j.bmcl.2010.01.012"
"9949863","Serotonin in migraine: theories, animal models and emerging therapies","Johnson KW, Phebus LA, Cohen ML.","Prog Drug Res. 1998;51:219-44. doi: 10.1007/978-3-0348-8845-5_6.","Johnson KW","Prog Drug Res","1998","1999/02/09","","","10.1007/978-3-0348-8845-5_6"
"9399012","Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine","Martin GR.","Cephalalgia. 1997 Oct;17 Suppl 18:4-14. doi: 10.1177/0333102497017S1802.","Martin GR","Cephalalgia","1997","1997/12/17","","","10.1177/0333102497017S1802"
"34625019","Inflammatory complications of CGRP monoclonal antibodies: a case series","Ray JC, Allen P, Bacsi A, Bosco JJ, Chen L, Eller M, Kua H, Lim LL, Matharu MS, Monif M, Ruttledge M, Stark RJ, Hutton EJ.","J Headache Pain. 2021 Oct 9;22(1):121. doi: 10.1186/s10194-021-01330-7.","Ray JC","J Headache Pain","2021","2021/10/09","PMC8501661","","10.1186/s10194-021-01330-7"
"16458930","Characterisation of CGRP receptors in the human isolated middle meningeal artery","Gupta S, Mehrotra S, Avezaat CJ, Villalón CM, Saxena PR, Maassenvandenbrink A.","Life Sci. 2006 Jun 13;79(3):265-71. doi: 10.1016/j.lfs.2006.01.003. Epub 2006 Feb 3.","Gupta S","Life Sci","2006","2006/02/07","","","10.1016/j.lfs.2006.01.003"
"33269951","Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension","Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD.","Cephalalgia. 2021 Jan;41(1):6-16. doi: 10.1177/0333102420973994. Epub 2020 Dec 3.","Lipton RB","Cephalalgia","2021","2020/12/03","PMC7786390","","10.1177/0333102420973994"
"35906640","Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial","Babapour M, Khorvash F, Rouhani MH, Ghavami A, Ghasemi-Tehrani H, Heidari Z, Karbasi M, Moradi F, Askari G.","Nutr J. 2022 Jul 30;21(1):50. doi: 10.1186/s12937-022-00802-z.","Babapour M","Nutr J","2022","2022/07/29","PMC9338649","","10.1186/s12937-022-00802-z"
"29350125","Current management: migraine headache","Silberstein SD.","CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.","Silberstein SD","CNS Spectr","2017","2018/01/20","","","10.1017/S1092852917000864"
"35100579","Effectiveness of Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Treatment: A Meta-Analysis","Pak K, Kim J, Lee GH, Cho JW, Kim HW.","Eur Neurol. 2022;85(3):195-201. doi: 10.1159/000521697. Epub 2022 Jan 31.","Pak K","Eur Neurol","2022","2022/01/31","","","10.1159/000521697"
"29968151","Erenumab: First Global Approval","Markham A.","Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.","Markham A","Drugs","2018","2018/07/04","","","10.1007/s40265-018-0944-0"
"37232078","Roles of mast cells and their interactions with the trigeminal nerve in migraine headache","Guan LC, Dong X, Green DP.","Mol Pain. 2023 Jan-Dec;19:17448069231181358. doi: 10.1177/17448069231181358.","Guan LC","Mol Pain","2023","2023/05/26","PMC10262643","","10.1177/17448069231181358"
"35476215","Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale","Cohen F, Yuan H, Silberstein SD.","BioDrugs. 2022 May;36(3):341-358. doi: 10.1007/s40259-022-00530-0. Epub 2022 Apr 27.","Cohen F","BioDrugs","2022","2022/04/27","PMC9043885","","10.1007/s40259-022-00530-0"
"34635045","CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021","Tajti J, Szok D, Nyári A, Vécsei L.","CNS Neurol Disord Drug Targets. 2022;21(6):460-478. doi: 10.2174/1871527320666211011110307.","Tajti J","CNS Neurol Disord Drug Targets","2022","2021/10/12","","","10.2174/1871527320666211011110307"
"30209688","Expression of ASIC3 in the Trigeminal Nucleus Caudalis Plays a Role in a Rat Model of Recurrent Migraine","Wang S, Wu BX, Liu CY, Qin GC, Yan WH, Zhou JY, Chen LX.","J Mol Neurosci. 2018 Sep;66(1):44-52. doi: 10.1007/s12031-018-1113-3. Epub 2018 Sep 12.","Wang S","J Mol Neurosci","2018","2018/09/14","","","10.1007/s12031-018-1113-3"
"35038983","Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201)","Johnston K, Harris L, Powell L, Popoff E, Coric V, L'Italien G, Schreiber CP.","J Headache Pain. 2022 Jan 17;23(1):10. doi: 10.1186/s10194-021-01378-5.","Johnston K","J Headache Pain","2022","2022/01/18","PMC8903552","","10.1186/s10194-021-01378-5"
"33633424","Lasmiditan for the Treatment of Migraines With or Without Aura in Adults","Berger AA, Winnick A, Popovsky D, Kaneb A, Berardino K, Kaye AM, Cornett EM, Kaye AD, Viswanath O, Urits I.","Psychopharmacol Bull. 2020 Oct 15;50(4 Suppl 1):163-188.","Berger AA","Psychopharmacol Bull","2020","2021/02/26","PMC7901123","",""
"37628733","The Role of Glial Cells in Different Phases of Migraine: Lessons from Preclinical Studies","Vila-Pueyo M, Gliga O, Gallardo VJ, Pozo-Rosich P.","Int J Mol Sci. 2023 Aug 8;24(16):12553. doi: 10.3390/ijms241612553.","Vila-Pueyo M","Int J Mol Sci","2023","2023/08/26","PMC10454125","","10.3390/ijms241612553"
"29687858","MiR-30a relieves migraine by degrading CALCA","Zhai Y, Zhu YY.","Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2022-2028. doi: 10.26355/eurrev_201804_14731.","Zhai Y","Eur Rev Med Pharmacol Sci","2018","2018/04/25","","","10.26355/eurrev_201804_14731"
"33676408","Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials","Yan Z, Xue T, Chen S, Wu X, Yang X, Liu G, Gao S, Chen Z, Wang Z.","J Headache Pain. 2021 Mar 6;22(1):10. doi: 10.1186/s10194-021-01220-y.","Yan Z","J Headache Pain","2021","2021/03/07","PMC7937260","","10.1186/s10194-021-01220-y"
"35861239","The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system","Citak A, Kilinc E, Torun IE, Ankarali S, Dagistan Y, Yoldas H.","Cephalalgia. 2022 Nov;42(13):1375-1386. doi: 10.1177/03331024221114773. Epub 2022 Jul 21.","Citak A","Cephalalgia","2022","2022/07/21","","","10.1177/03331024221114773"
"35062860","Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model","Liu TT, Morais A, Takizawa T, Mulder I, Simon BJ, Chen SP, Wang SJ, Ayata C, Yen JC.","J Headache Pain. 2022 Jan 21;23(1):12. doi: 10.1186/s10194-022-01384-1.","Liu TT","J Headache Pain","2022","2022/01/22","PMC8903561","","10.1186/s10194-022-01384-1"
"33855218","Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients","Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J.","Endocrinol Diabetes Metab. 2021 Feb 2;4(2):e00217. doi: 10.1002/edm2.217. eCollection 2021 Apr.","Baker B","Endocrinol Diabetes Metab","2021","2021/04/15","PMC8029561","","10.1002/edm2.217"
"37210098","Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial","Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z, Liu J, Moon HS, Tan G, Yang Q, McGrath D, Hanna M, Stock DA, Gao Y, Croop R, Lu Z.","Lancet Neurol. 2023 Jun;22(6):476-484. doi: 10.1016/S1474-4422(23)00126-6.","Yu S","Lancet Neurol","2023","2023/05/20","","","10.1016/S1474-4422(23)00126-6"
"28707585","Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects","Lukacs M, Tajti J, Fulop F, Toldi J, Edvinsson L, Vecsei L.","Curr Med Chem. 2017;24(33):3649-3665. doi: 10.2174/0929867324666170712163437.","Lukacs M","Curr Med Chem","2017","2017/07/15","","","10.2174/0929867324666170712163437"
"31675102","Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine","Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y.","Headache. 2019 Nov;59(10):1743-1752. doi: 10.1111/head.13654. Epub 2019 Nov 1.","Winner PK","Headache","2019","2019/11/02","","","10.1111/head.13654"
"32903061","Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods","Hanci F, Kilinc YB, Kilinc E, Turay S, Dilek M, Kabakus N.","Cephalalgia. 2021 Feb;41(2):166-175. doi: 10.1177/0333102420957588. Epub 2020 Sep 9.","Hanci F","Cephalalgia","2021","2020/09/09","","","10.1177/0333102420957588"
"36071388","Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis","Wang X, Wen D, He Q, You C, Ma L.","J Headache Pain. 2022 Sep 8;23(1):105. doi: 10.1186/s10194-022-01472-2.","Wang X","J Headache Pain","2022","2022/09/07","PMC9454201","","10.1186/s10194-022-01472-2"
"31096904","The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse","van Hoogstraten WS, MaassenVanDenBrink A.","J Headache Pain. 2019 May 16;20(1):54. doi: 10.1186/s10194-019-1007-y.","van Hoogstraten WS","J Headache Pain","2019","2019/05/18","PMC6734450","","10.1186/s10194-019-1007-y"
"23425327","CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?","Walker CS, Hay DL.","Br J Pharmacol. 2013 Dec;170(7):1293-307. doi: 10.1111/bph.12129.","Walker CS","Br J Pharmacol","2013","2013/02/22","PMC3838677","","10.1111/bph.12129"
"32639078","Receptor mechanisms mediating the anti-neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine","Kilinc E, Ankarali S, Torun IE, Dagistan Y.","Eur J Neurosci. 2022 Feb;55(4):1015-1031. doi: 10.1111/ejn.14897. Epub 2020 Jul 25.","Kilinc E","Eur J Neurosci","2022","2020/07/09","","","10.1111/ejn.14897"
"33626922","Migraine therapeutics differentially modulate the CGRP pathway","Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD.","Cephalalgia. 2021 Apr;41(5):499-514. doi: 10.1177/0333102420983282. Epub 2021 Feb 24.","Bhakta M","Cephalalgia","2021","2021/02/25","PMC8054164","","10.1177/0333102420983282"
"30614741","Erenumab for episodic migraine prophylaxis","Overeem LH, Neeb L, Reuter U.","Expert Rev Neurother. 2019 Aug;19(8):751-757. doi: 10.1080/14737175.2019.1565996. Epub 2019 Jan 29.","Overeem LH","Expert Rev Neurother","2019","2019/01/08","","","10.1080/14737175.2019.1565996"
"35726393","Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study","Gonzalez-Martinez A, Pagán J, Sanz-García A, García-Azorín D, Rodríguez-Vico JS, Jaimes A, García AG, de Terán JD, González-García N, Quintas S, Belascoaín R, Casas Limón J, Latorre G, Calle de Miguel C, Sierra Á, Guerrero-Peral ÁL, Trevino-Peinado C, Gago-Veiga AB.","Eur J Neurol. 2022 Oct;29(10):3102-3111. doi: 10.1111/ene.15458. Epub 2022 Jul 12.","Gonzalez-Martinez A","Eur J Neurol","2022","2022/06/21","","","10.1111/ene.15458"
"17425708","New migraine and pain research","Hargreaves R.","Headache. 2007 Apr;47 Suppl 1:S26-43. doi: 10.1111/j.1526-4610.2006.00675.x.","Hargreaves R","Headache","2007","2007/04/12","","","10.1111/j.1526-4610.2006.00675.x"
"36198645","[Novel Migraine Treatment: From Bench to Bedside]","Kato Y.","Brain Nerve. 2022 Oct;74(10):1197-1204. doi: 10.11477/mf.1416202209.","Kato Y","Brain Nerve","2022","2022/10/05","","","10.11477/mf.1416202209"
"11304026","Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks","Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V.","Cephalalgia. 2000 Dec;20(10):907-18. doi: 10.1046/j.1468-2982.2000.00146.x.","Sarchielli P","Cephalalgia","2000","2001/04/17","","","10.1046/j.1468-2982.2000.00146.x"
"34148405","CGRP release in an experimental human trigeminal pain model","Frese A, Summ O, Evers S.","Cephalalgia. 2021 Oct;41(11-12):1268-1271. doi: 10.1177/03331024211017250. Epub 2021 Jun 20.","Frese A","Cephalalgia","2021","2021/06/21","PMC8504405","","10.1177/03331024211017250"
"37754544","Comparative retention and effectiveness of migraine preventive treatments: A nationwide registry-based cohort study","Bjørk MH, Borkenhagen S, Oteiza F, Dueland AN, Sørgaard FE, Saether EM, Bugge C.","Eur J Neurol. 2024 Jan;31(1):e16062. doi: 10.1111/ene.16062. Epub 2023 Sep 27.","Bjørk MH","Eur J Neurol","2024","2023/09/27","","","10.1111/ene.16062"
"32460120","Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis","Alasad YW, Asha MZ.","Clin Neurol Neurosurg. 2020 Aug;195:105900. doi: 10.1016/j.clineuro.2020.105900. Epub 2020 May 11.","Alasad YW","Clin Neurol Neurosurg","2020","2020/05/28","","","10.1016/j.clineuro.2020.105900"
"33001407","Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study","Altamura C, Cevoli S, Aurilia C, Egeo G, Fofi L, Torelli P, Brunelli N, Pierangeli G, Favoni V, Fallacara A, Pensato U, Barbanti P, Vernieri F.","Neurol Sci. 2020 Dec;41(12):3385-3389. doi: 10.1007/s10072-020-04767-x. Epub 2020 Oct 1.","Altamura C","Neurol Sci","2020","2020/10/01","PMC7527669","","10.1007/s10072-020-04767-x"
"32799790","Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region","Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S.","J Headache Pain. 2020 Aug 15;21(1):102. doi: 10.1186/s10194-020-01171-w.","Ornello R","J Headache Pain","2020","2020/08/18","PMC7429460","","10.1186/s10194-020-01171-w"
"29800211","Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial","Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.","JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.","Dodick DW","JAMA","2018","2018/05/26","PMC6583237","","10.1001/jama.2018.4853"
"32173558","Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","de Vries T, Villalón CM, MaassenVanDenBrink A.","Pharmacol Ther. 2020 Jul;211:107528. doi: 10.1016/j.pharmthera.2020.107528. Epub 2020 Mar 12.","de Vries T","Pharmacol Ther","2020","2020/03/17","","","10.1016/j.pharmthera.2020.107528"
"30553789","Inhibition of Nerve Growth Factor Signaling Alleviates Repeated Dural Stimulation-induced Hyperalgesia in Rats","Zhou H, Wang X, Wang S, Liu C, Fu Q, Qin G, Zhou J, Chen L.","Neuroscience. 2019 Feb 1;398:252-262. doi: 10.1016/j.neuroscience.2018.12.006. Epub 2018 Dec 14.","Zhou H","Neuroscience","2019","2018/12/17","","","10.1016/j.neuroscience.2018.12.006"
"25101728","Anti-CGRP antibodies for migraine turn industry heads","Elvidge S.","Nat Biotechnol. 2014 Aug;32(8):707. doi: 10.1038/nbt0814-707a.","Elvidge S","Nat Biotechnol","2014","2014/08/08","","","10.1038/nbt0814-707a"
"22429470","Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group","Luo G, Chen L, Civiello R, Pin SS, Xu C, Kostich W, Kelley M, Conway CM, Macor JE, Dubowchik GM.","Bioorg Med Chem Lett. 2012 Apr 15;22(8):2917-21. doi: 10.1016/j.bmcl.2012.02.065. Epub 2012 Mar 3.","Luo G","Bioorg Med Chem Lett","2012","2012/03/21","","","10.1016/j.bmcl.2012.02.065"
"20954694","Asymmetric synthesis of telcagepant, a CGRP receptor antagonist for the treatment of migraine","Xu F, Zacuto M, Yoshikawa N, Desmond R, Hoerrner S, Itoh T, Journet M, Humphrey GR, Cowden C, Strotman N, Devine P.","J Org Chem. 2010 Nov 19;75(22):7829-41. doi: 10.1021/jo101704b. Epub 2010 Oct 18.","Xu F","J Org Chem","2010","2010/10/20","","","10.1021/jo101704b"
"35751798","Cardiovascular Disease and Migraine: Are the New Treatments Safe?","Robblee J, Harvey LK.","Curr Pain Headache Rep. 2022 Aug;26(8):647-655. doi: 10.1007/s11916-022-01064-4. Epub 2022 Jun 25.","Robblee J","Curr Pain Headache Rep","2022","2022/06/25","","","10.1007/s11916-022-01064-4"
"35243611","Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine","López-Bravo A, Oliveros-Cid A, Sevillano-Orte L.","Acta Neurol Scand. 2022 Jun;145(6):669-675. doi: 10.1111/ane.13599. Epub 2022 Mar 3.","López-Bravo A","Acta Neurol Scand","2022","2022/03/04","","","10.1111/ane.13599"
"19660121","Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology","Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C.","Mol Pain. 2009 Aug 6;5:43. doi: 10.1186/1744-8069-5-43.","Capuano A","Mol Pain","2009","2009/08/08","PMC2731738","","10.1186/1744-8069-5-43"
"35313740","Erenumab for episodic migraine","Datta A, Gupta S, Maryala S, Aggarwal V, Chopra P, Jain S.","Pain Manag. 2022 Jul;12(5):587-594. doi: 10.2217/pmt-2021-0077. Epub 2022 Mar 22.","Datta A","Pain Manag","2022","2022/03/22","","","10.2217/pmt-2021-0077"
"29568973","Neurogenic inflammation and its role in migraine","Ramachandran R.","Semin Immunopathol. 2018 May;40(3):301-314. doi: 10.1007/s00281-018-0676-y. Epub 2018 Mar 22.","Ramachandran R","Semin Immunopathol","2018","2018/03/24","","","10.1007/s00281-018-0676-y"
"34898306","Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain","Edvinsson JC, Reducha PV, Sheykhzade M, Warfvinge K, Haanes KA, Edvinsson L.","Mol Pain. 2021 Jan-Dec;17:17448069211059400. doi: 10.1177/17448069211059400.","Edvinsson JC","Mol Pain","2021","2021/12/13","PMC8679402","","10.1177/17448069211059400"
"31418911","Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine","Fiedler-Kelly JB, Cohen-Barak O, Morris DN, Ludwig E, Rasamoelisolo M, Shen H, Levi M.","Br J Clin Pharmacol. 2019 Dec;85(12):2721-2733. doi: 10.1111/bcp.14096. Epub 2019 Dec 9.","Fiedler-Kelly JB","Br J Clin Pharmacol","2019","2019/08/17","PMC6955415","","10.1111/bcp.14096"
"30810596","Migraine treatment: the doors for the future are open, but with caution and prudence","Krymchantowski AV, Krymchantowski AGF, Jevoux CDC.","Arq Neuropsiquiatr. 2019 Feb;77(2):115-121. doi: 10.1590/0004-282X20190004.","Krymchantowski AV","Arq Neuropsiquiatr","2019","2019/02/28","","","10.1590/0004-282X20190004"
"37210713","Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study","Boinpally R, McGeeney D, Borbridge L, Trugman J.","Clin Pharmacol Drug Dev. 2023 Oct;12(10):1013-1021. doi: 10.1002/cpdd.1267. Epub 2023 May 21.","Boinpally R","Clin Pharmacol Drug Dev","2023","2023/05/21","","","10.1002/cpdd.1267"
"33008509","Managing migraine in pregnancy and breastfeeding","Parikh SK, Delbono MV, Silberstein SD.","Prog Brain Res. 2020;255:275-309. doi: 10.1016/bs.pbr.2020.07.011. Epub 2020 Aug 18.","Parikh SK","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.07.011"
"33352285","Downregulation of metabotropic glutamate receptor 5 alleviates central sensitization by activating autophagy via inhibiting mTOR pathway in a rat model of chronic migraine","Niu Y, Zeng X, Qin G, Zhang D, Zhou J, Chen L.","Neurosci Lett. 2021 Jan 19;743:135552. doi: 10.1016/j.neulet.2020.135552. Epub 2020 Dec 19.","Niu Y","Neurosci Lett","2021","2020/12/22","","","10.1016/j.neulet.2020.135552"
"31081399","Gepants for the treatment of migraine","Negro A, Martelletti P.","Expert Opin Investig Drugs. 2019 Jun;28(6):555-567. doi: 10.1080/13543784.2019.1618830. Epub 2019 May 17.","Negro A","Expert Opin Investig Drugs","2019","2019/05/14","","","10.1080/13543784.2019.1618830"
"31623501","Plasma levels of inflammatory mediators in vestibular migraine","Karaaslan Z, Özçelik P, Ulukan Ç, Ulusoy C, Orhan KS, Orhan EK, Küçükali Cİ, Tüzün E, Baykan B, Akdal G.","Int J Neurosci. 2020 Apr;130(4):330-335. doi: 10.1080/00207454.2019.1681994. Epub 2019 Oct 24.","Karaaslan Z","Int J Neurosci","2020","2019/10/19","","","10.1080/00207454.2019.1681994"
"34576297","Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders","Fila M, Chojnacki J, Pawlowska E, Szczepanska J, Chojnacki C, Blasiak J.","Int J Mol Sci. 2021 Sep 20;22(18):10134. doi: 10.3390/ijms221810134.","Fila M","Int J Mol Sci","2021","2021/09/28","PMC8469852","","10.3390/ijms221810134"
"30643015","Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide","Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF.","J Pharmacol Exp Ther. 2019 Apr;369(1):26-36. doi: 10.1124/jpet.118.253443. Epub 2019 Jan 14.","Moldovan Loomis C","J Pharmacol Exp Ther","2019","2019/01/16","","","10.1124/jpet.118.253443"
"37326902","Epigenetic Connections of the TRPA1 Ion Channel in Pain Transmission and Neurogenic Inflammation - a Therapeutic Perspective in Migraine?","Fila M, Pawlowska E, Szczepanska J, Blasiak J.","Mol Neurobiol. 2023 Oct;60(10):5578-5591. doi: 10.1007/s12035-023-03428-2. Epub 2023 Jun 16.","Fila M","Mol Neurobiol","2023","2023/06/16","PMC10471718","","10.1007/s12035-023-03428-2"
"35760098","From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex","Gimeno-Ferrer F, Eitner A, Bauer R, Lehmenkühler A, Edenhofer ML, Kress M, Schaible HG, Richter F.","Exp Neurol. 2022 Oct;356:114152. doi: 10.1016/j.expneurol.2022.114152. Epub 2022 Jun 26.","Gimeno-Ferrer F","Exp Neurol","2022","2022/06/27","","","10.1016/j.expneurol.2022.114152"
"30484333","Emerging drugs for migraine treatment: an update","Lambru G, Andreou AP, Guglielmetti M, Martelletti P.","Expert Opin Emerg Drugs. 2018 Dec;23(4):301-318. doi: 10.1080/14728214.2018.1552939. Epub 2018 Nov 30.","Lambru G","Expert Opin Emerg Drugs","2018","2018/11/29","","","10.1080/14728214.2018.1552939"
"32929719","Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP","Akerman S, Romero-Reyes M.","Br J Pharmacol. 2020 Dec;177(24):5555-5568. doi: 10.1111/bph.15263. Epub 2020 Oct 21.","Akerman S","Br J Pharmacol","2020","2020/09/15","PMC7707098","","10.1111/bph.15263"
"37038806","Serum Alpha and Beta-CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor","Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J, Pascual J.","Ann Neurol. 2023 Aug;94(2):285-294. doi: 10.1002/ana.26658. Epub 2023 Apr 21.","Gárate G","Ann Neurol","2023","2023/04/11","","","10.1002/ana.26658"
"34895133","Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study","Thiele A, Klehr L, Strauß S, Angermaier A, Schminke U, Kronenbuerger M, Naegel S, Fleischmann R.","J Headache Pain. 2021 Dec 11;22(1):149. doi: 10.1186/s10194-021-01364-x.","Thiele A","J Headache Pain","2021","2021/12/13","PMC8903683","","10.1186/s10194-021-01364-x"
"33772845","Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients","Ghanizada H, Al-Karagholi MA, Walker CS, Arngrim N, Rees T, Petersen J, Siow A, Mørch-Rasmussen M, Tan S, O'Carroll SJ, Harris P, Skovgaard LT, Jørgensen NR, Brimble M, Waite JS, Rea BJ, Sowers LP, Russo AF, Hay DL, Ashina M.","Ann Neurol. 2021 Jun;89(6):1157-1171. doi: 10.1002/ana.26072. Epub 2021 Apr 8.","Ghanizada H","Ann Neurol","2021","2021/03/27","PMC8486152","NIHMS1742121","10.1002/ana.26072"
"37241168","Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?","Torrisi M, Corallo F, Lo Buono V, Di Cara M, Grugno R, Lo Presti R, Quartarone A, De Cola MC.","Medicina (Kaunas). 2023 May 12;59(5):936. doi: 10.3390/medicina59050936.","Torrisi M","Medicina (Kaunas)","2023","2023/05/27","PMC10222452","","10.3390/medicina59050936"
"34301173","Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials","Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.","J Headache Pain. 2021 Jul 23;22(1):81. doi: 10.1186/s10194-021-01292-w.","Tepper SJ","J Headache Pain","2021","2021/07/24","PMC8299690","","10.1186/s10194-021-01292-w"
"25107879","Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D.","Neurology. 2014 Sep 9;83(11):958-66. doi: 10.1212/WNL.0000000000000771. Epub 2014 Aug 8.","Ho TW","Neurology","2014","2014/08/10","","","10.1212/WNL.0000000000000771"
"19036425","Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial","Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK.","Lancet. 2008 Dec 20;372(9656):2115-23. doi: 10.1016/S0140-6736(08)61626-8. Epub 2008 Nov 25.","Ho TW","Lancet","2008","2008/11/28","","","10.1016/S0140-6736(08)61626-8"
"35941572","Measuring interictal burden among people affected by migraine: a descriptive survey study","Hubig LT, Smith T, Williams E, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lloyd AJ, Lo SH.","J Headache Pain. 2022 Aug 8;23(1):97. doi: 10.1186/s10194-022-01467-z.","Hubig LT","J Headache Pain","2022","2022/08/08","PMC9358846","","10.1186/s10194-022-01467-z"
"35799128","Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine","Greco R, Demartini C, Zanaboni AM, Francavilla M, Reggiani A, Realini N, Scarpelli R, Piomelli D, Tassorelli C.","J Headache Pain. 2022 Jul 7;23(1):79. doi: 10.1186/s10194-022-01449-1.","Greco R","J Headache Pain","2022","2022/07/07","PMC9264488","","10.1186/s10194-022-01449-1"
"35272533","Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions","Zhou Y, Zhang F, Starcevic Manning M, Hu Z, Hsu CP, Chen PW, Peng C, Loop B, Mytych DT, Paiva da Silva Lima G.","Cephalalgia. 2022 Jul;42(8):749-760. doi: 10.1177/03331024221075621. Epub 2022 Mar 10.","Zhou Y","Cephalalgia","2022","2022/03/11","","","10.1177/03331024221075621"
"31053059","Effects of two isometheptene enantiomers in isolated human blood vessels and rat middle meningeal artery - potential antimigraine efficacy","Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, de Vries R, Dammers R, Bogers AJJC, van den Bogaerdt A, Daugherty BL, Danser AHJ, Villalón CM, MaassenVanDenBrink A.","J Headache Pain. 2019 May 3;20(1):47. doi: 10.1186/s10194-019-1003-2.","Labastida-Ramírez A","J Headache Pain","2019","2019/05/05","PMC6734216","","10.1186/s10194-019-1003-2"
"29131327","CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study","Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, Campos F, Martínez F, Castillo J, Leira R.","Headache. 2018 Jan;58(1):78-87. doi: 10.1111/head.13211. Epub 2017 Nov 13.","Domínguez C","Headache","2018","2017/11/14","","","10.1111/head.13211"
"8388188","The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","Goadsby PJ, Edvinsson L.","Ann Neurol. 1993 Jan;33(1):48-56. doi: 10.1002/ana.410330109.","Goadsby PJ","Ann Neurol","1993","1993/01/01","","","10.1002/ana.410330109"
"36189708","Focus on zavegepant: the first intranasal third-generation gepant","Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT.","Pain Manag. 2022 Nov;12(8):879-885. doi: 10.2217/pmt-2022-0054. Epub 2022 Oct 3.","Scuteri D","Pain Manag","2022","2022/10/03","","","10.2217/pmt-2022-0054"
"32000407","Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review","She T, Chen Y, Tang T, Chen M, Zheng H.","Medicine (Baltimore). 2020 Jan;99(5):e18929. doi: 10.1097/MD.0000000000018929.","She T","Medicine (Baltimore)","2020","2020/02/01","PMC7004656","","10.1097/MD.0000000000018929"
"12191595","New insights into the molecular actions of serotonergic antimigraine drugs","Durham PL, Russo AF.","Pharmacol Ther. 2002 Apr-May;94(1-2):77-92. doi: 10.1016/s0163-7258(02)00173-0.","Durham PL","Pharmacol Ther","2002","2002/08/23","","","10.1016/s0163-7258(02)00173-0"
"33008503","Update in migraine preventive treatment","Lai TH, Huang TC.","Prog Brain Res. 2020;255:1-27. doi: 10.1016/bs.pbr.2020.05.017. Epub 2020 Jun 12.","Lai TH","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.05.017"
"35093196","Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions","Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A.","Lancet Neurol. 2022 Mar;21(3):284-294. doi: 10.1016/S1474-4422(21)00409-9. Epub 2022 Jan 31.","Al-Hassany L","Lancet Neurol","2022","2022/01/30","","","10.1016/S1474-4422(21)00409-9"
"32730879","Anti-migraine effect of wine-processed Radix scutellariae: Pharmacodynamic verification in nitroglycerin-induced rats and correlation study between compounds dissolution and the fractal dimension","Lu F, Zhang WJ, Zhai S, Sun YW, Chen QJ, Yang XL, Zhang CF, Wang CZ, Yuan CS.","J Ethnopharmacol. 2020 Dec 5;263:113131. doi: 10.1016/j.jep.2020.113131. Epub 2020 Jul 28.","Lu F","J Ethnopharmacol","2020","2020/07/31","","","10.1016/j.jep.2020.113131"
"18240900","Ramping it up: RAMP1 and the implications for migraine","Russo AF.","Pharmacogenomics. 2007 Jul;8(7):687-90. doi: 10.2217/14622416.8.7.687.","Russo AF","Pharmacogenomics","2007","2008/02/05","","","10.2217/14622416.8.7.687"
"36115947","Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial","De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.","J Headache Pain. 2022 Sep 17;23(1):123. doi: 10.1186/s10194-022-01480-2.","De Icco R","J Headache Pain","2022","2022/09/17","PMC9482180","","10.1186/s10194-022-01480-2"
"37889468","Vestibular Migraine Pathophysiology and Treatment: a Narrative Review","Ceriani CEJ.","Curr Pain Headache Rep. 2024 Feb;28(2):47-54. doi: 10.1007/s11916-023-01182-7. Epub 2023 Oct 27.","Ceriani CEJ","Curr Pain Headache Rep","2024","2023/10/27","","","10.1007/s11916-023-01182-7"
"32990477","What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group","Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, Tedeschi G, Martelletti P.","Expert Rev Neurother. 2020 Dec;20(12):1275-1286. doi: 10.1080/14737175.2020.1825077. Epub 2020 Sep 30.","Sacco S","Expert Rev Neurother","2020","2020/09/29","","","10.1080/14737175.2020.1825077"
"19882941","[Metabolic syndrome and prevention of migraine headache]","Takeshima T.","Brain Nerve. 2009 Oct;61(10):1143-53.","Takeshima T","Brain Nerve","2009","2009/11/04","","",""
"25288608","TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine","Del Fiacco M, Quartu M, Boi M, Serra MP, Melis T, Boccaletti R, Shevel E, Cianchetti C.","J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):393-7. doi: 10.1136/jnnp-2014-308813. Epub 2014 Oct 6.","Del Fiacco M","J Neurol Neurosurg Psychiatry","2015","2014/10/08","","","10.1136/jnnp-2014-308813"
"32096558","Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!","Grazzi L, Rizzoli P.","Headache. 2020 Apr;60(4):804-806. doi: 10.1111/head.13776. Epub 2020 Feb 25.","Grazzi L","Headache","2020","2020/02/26","","","10.1111/head.13776"
"38243174","Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat","Friedrich N, Németh K, Tanner M, Rosta J, Dobos I, Oszlács O, Jancsó G, Messlinger K, Dux M.","J Headache Pain. 2024 Jan 19;25(1):9. doi: 10.1186/s10194-024-01717-2.","Friedrich N","J Headache Pain","2024","2024/01/19","PMC10799508","","10.1186/s10194-024-01717-2"
"37221478","Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study","Straube A, Broessner G, Gaul C, Hamann X, Hipp J, Kraya T, Neeb L.","J Headache Pain. 2023 May 23;24(1):59. doi: 10.1186/s10194-023-01593-2.","Straube A","J Headache Pain","2023","2023/05/23","PMC10207758","","10.1186/s10194-023-01593-2"
"21459461","Emerging migraine treatments and drug targets","Olesen J, Ashina M.","Trends Pharmacol Sci. 2011 Jun;32(6):352-9. doi: 10.1016/j.tips.2011.02.016. Epub 2011 Apr 2.","Olesen J","Trends Pharmacol Sci","2011","2011/04/05","","","10.1016/j.tips.2011.02.016"
"36555690","Characterization of Antibodies against Receptor Activity-Modifying Protein 1 (RAMP1): A Cautionary Tale","Hendrikse ER, Rees TA, Tasma Z, Garelja ML, Siow A, Harris PWR, Pawlak JB, Caron KM, Blakeney ES, Russo AF, Sowers LP, Lutz TA, Le Foll C, Walker CS, Hay DL.","Int J Mol Sci. 2022 Dec 16;23(24):16035. doi: 10.3390/ijms232416035.","Hendrikse ER","Int J Mol Sci","2022","2022/12/23","PMC9787598","","10.3390/ijms232416035"
"32216456","Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study","Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD.","Cephalalgia. 2020 May;40(6):543-553. doi: 10.1177/0333102420912726. Epub 2020 Mar 26.","Tepper SJ","Cephalalgia","2020","2020/03/29","","","10.1177/0333102420912726"
"31872442","Up-regulation of astrocyte excitatory amino acid transporter 2 alleviates central sensitization in a rat model of chronic migraine","Zhou X, Liang J, Wang J, Fei Z, Qin G, Zhang D, Zhou J, Chen L.","J Neurochem. 2020 Nov;155(4):370-389. doi: 10.1111/jnc.14944. Epub 2020 Jan 7.","Zhou X","J Neurochem","2020","2019/12/25","","","10.1111/jnc.14944"
"36656298","Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine","Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P, De Cesaris F.","CNS Drugs. 2023 Feb;37(2):189-202. doi: 10.1007/s40263-022-00983-5. Epub 2023 Jan 19.","Iannone LF","CNS Drugs","2023","2023/01/19","","","10.1007/s40263-022-00983-5"
"31321541","CGRP and Painful Pathologies Other than Headache","Walsh DA, McWilliams DF.","Handb Exp Pharmacol. 2019;255:141-167. doi: 10.1007/164_2019_242.","Walsh DA","Handb Exp Pharmacol","2019","2019/07/20","","","10.1007/164_2019_242"
"34979683","Newer Horizon for Treatment of Acute Attack of Migraine: Lasmiditan and Ubrogepant","Maitra A, Mukhopadhyay S, Das A, Choudhury S.","Neurol India. 2021 Nov-Dec;69(6):1759-1762. doi: 10.4103/0028-3886.333495.","Maitra A","Neurol India","2021","2022/01/04","","","10.4103/0028-3886.333495"
"36195452","Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study","de Vries Lentsch S, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM.","Neurology. 2022 Oct 25;99(17):e1897-e1904. doi: 10.1212/WNL.0000000000201008. Epub 2022 Oct 4.","de Vries Lentsch S","Neurology","2022","2022/10/04","PMC9620812","","10.1212/WNL.0000000000201008"
"34128998","Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis","VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z.","JAMA. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939.","VanderPluym JH","JAMA","2021","2021/06/15","PMC8207243","","10.1001/jama.2021.7939"
"25297013","Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J; ALD403 study investigators.","Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5.","Dodick DW","Lancet Neurol","2014","2014/10/10","","","10.1016/S1474-4422(14)70209-1"
"31810401","Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions","Warfvinge K, Edvinsson L.","Cephalalgia. 2020 May;40(6):527-542. doi: 10.1177/0333102419893962. Epub 2019 Dec 6.","Warfvinge K","Cephalalgia","2020","2019/12/08","","","10.1177/0333102419893962"
"10657470","Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288","Knight YE, Edvinsson L, Goadsby PJ.","Neuropeptides. 1999 Feb;33(1):41-6. doi: 10.1054/npep.1999.0009.","Knight YE","Neuropeptides","1999","2000/02/05","","","10.1054/npep.1999.0009"
"24960305","Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine","Bell IM.","J Med Chem. 2014 Oct 9;57(19):7838-58. doi: 10.1021/jm500364u. Epub 2014 Jun 24.","Bell IM","J Med Chem","2014","2014/06/25","","","10.1021/jm500364u"
"36252594","Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I","Melhado EM, Santos PSF, Kaup AO, Costa ATNMD, Roesler CAP, Piovesan ÉJ, Sarmento EM, Theotonio GOM, Campos HC, Fortini I, Souza JA, Maciel Júnior JA, Segundo JBA, Carvalho JJF, Speziali JG, Calia LC, Barea LM, Queiroz LP, Souza MNP, Figueiredo MRCF, Costa MENM, Peres MFP, Jurno ME, Peixoto PM, Kowacs PA, Rocha-Filho PAS, Moreira Filho PF, Silva-Neto RP, Fragoso YD.","Arq Neuropsiquiatr. 2022 Aug;80(8):845-861. doi: 10.1055/s-0042-1756441. Epub 2022 Oct 17.","Melhado EM","Arq Neuropsiquiatr","2022","2022/10/17","PMC9703891","","10.1055/s-0042-1756441"
"32536268","Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report","Wurthmann S, Nägel S, Hadaschik E, Schlott S, Scheffler A, Kleinschnitz C, Holle D.","Cephalalgia. 2020 Oct;40(11):1255-1260. doi: 10.1177/0333102420933571. Epub 2020 Jun 14.","Wurthmann S","Cephalalgia","2020","2020/06/16","","","10.1177/0333102420933571"
"31944310","Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers","Falkenberg K, Rønde Bjerg H, Yamani N, Olesen J.","Headache. 2020 Apr;60(4):665-676. doi: 10.1111/head.13747. Epub 2020 Jan 16.","Falkenberg K","Headache","2020","2020/01/17","","","10.1111/head.13747"
"30989485","Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets","Haanes KA, Edvinsson L.","CNS Drugs. 2019 Jun;33(6):525-537. doi: 10.1007/s40263-019-00630-6.","Haanes KA","CNS Drugs","2019","2019/04/17","","","10.1007/s40263-019-00630-6"
"23155193","NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models","Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J.","Cephalalgia. 2013 Jan;33(2):87-100. doi: 10.1177/0333102412466967. Epub 2012 Nov 15.","Bhatt DK","Cephalalgia","2013","2012/11/17","","","10.1177/0333102412466967"
"19288089","Migraine: where and how does the pain originate?","Messlinger K.","Exp Brain Res. 2009 Jun;196(1):179-93. doi: 10.1007/s00221-009-1756-y. Epub 2009 Mar 14.","Messlinger K","Exp Brain Res","2009","2009/03/17","","","10.1007/s00221-009-1756-y"
"35614095","The role of the meningeal lymphatic system in local meningeal inflammation and trigeminal nociception","Mikhailov N, Virenque A, Koroleva K, Eme-Scolan E, Teleman M, Abdollahzadeh A, Giniatullina R, Gafurov O, Krivoshein G, Malm T, Hämäläinen RH, Sierra A, Tohka J, Rua R, Noe FM, Giniatullin R.","Sci Rep. 2022 May 25;12(1):8804. doi: 10.1038/s41598-022-12540-7.","Mikhailov N","Sci Rep","2022","2022/05/25","PMC9133044","","10.1038/s41598-022-12540-7"
"28393079","Tyrosine Phosphorylation of NR2B Contributes to Chronic Migraines via Increased Expression of CGRP in Rats","Liang X, Wang S, Qin G, Xie J, Tan G, Zhou J, McBride DW, Chen L.","Biomed Res Int. 2017;2017:7203458. doi: 10.1155/2017/7203458. Epub 2017 Mar 14.","Liang X","Biomed Res Int","2017","2017/04/11","PMC5368391","","10.1155/2017/7203458"
"36835524","Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain","Tajti J, Szok D, Csáti A, Szabó Á, Tanaka M, Vécsei L.","Int J Mol Sci. 2023 Feb 18;24(4):4114. doi: 10.3390/ijms24044114.","Tajti J","Int J Mol Sci","2023","2023/02/25","PMC9959352","","10.3390/ijms24044114"
"2266336","Extracerebral manifestations in migraine. A peptidergic involvement?","Edvinsson L, Goadsby PJ.","J Intern Med. 1990 Oct;228(4):299-304. doi: 10.1111/j.1365-2796.1990.tb00236.x.","Edvinsson L","J Intern Med","1990","1990/10/01","","","10.1111/j.1365-2796.1990.tb00236.x"
"34171973","Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study","Wang SJ, Roxas AA Jr, Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P.","Cephalalgia. 2021 Nov;41(13):1285-1297. doi: 10.1177/03331024211024160. Epub 2021 Jun 25.","Wang SJ","Cephalalgia","2021","2021/06/26","PMC8592099","","10.1177/03331024211024160"
"34411289","Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene-related peptide family of peptides","Edvinsson L, Edvinsson JCA, Haanes KA.","Br J Pharmacol. 2022 Feb;179(3):371-380. doi: 10.1111/bph.15669. Epub 2021 Oct 7.","Edvinsson L","Br J Pharmacol","2022","2021/08/19","","","10.1111/bph.15669"
"36797223","Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study","Lipton RB, Buse DC, Sandoe CH, Ford JH, Hand AL, Jedynak JP, Port MD, Detke HC.","Headache. 2023 May;63(5):683-691. doi: 10.1111/head.14460. Epub 2023 Feb 16.","Lipton RB","Headache","2023","2023/02/16","","","10.1111/head.14460"
"33232919","Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents","Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL.","Pediatr Neurol. 2021 Jan;114:62-67. doi: 10.1016/j.pediatrneurol.2020.09.014. Epub 2020 Oct 5.","Greene KA","Pediatr Neurol","2021","2020/11/24","PMC7770043","NIHMS1634966","10.1016/j.pediatrneurol.2020.09.014"
"35311748","A Markov Analysis of Surgical versus Medical Management of Chronic Migraines","Yesantharao PS, Lee E, Klifto KM, Colakoglu S, Dellon AL, Reddy SK.","Plast Reconstr Surg. 2022 May 1;149(5):1187-1196. doi: 10.1097/PRS.0000000000009048. Epub 2022 Mar 18.","Yesantharao PS","Plast Reconstr Surg","2022","2022/03/21","","","10.1097/PRS.0000000000009048"
"32811190","CGRP inhibitors for migraine prophylaxis: a safety review","Rivera-Mancilla E, Villalón CM, MaassenVanDenBrink A.","Expert Opin Drug Saf. 2020 Oct;19(10):1237-1250. doi: 10.1080/14740338.2020.1811229. Epub 2020 Sep 21.","Rivera-Mancilla E","Expert Opin Drug Saf","2020","2020/08/20","","","10.1080/14740338.2020.1811229"
"37563570","Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review","Karsan N, Goadsby PJ.","J Headache Pain. 2023 Aug 11;24(1):106. doi: 10.1186/s10194-023-01617-x.","Karsan N","J Headache Pain","2023","2023/08/10","PMC10416375","","10.1186/s10194-023-01617-x"
"30475090","Advances in orally administered pharmacotherapy for the treatment of migraine","Martelletti P, Giamberardino MA.","Expert Opin Pharmacother. 2019 Feb;20(2):209-218. doi: 10.1080/14656566.2018.1549223. Epub 2018 Nov 26.","Martelletti P","Expert Opin Pharmacother","2019","2018/11/27","","","10.1080/14656566.2018.1549223"
"33003955","Pharmacological strategies to treat attacks of episodic migraine in adults","Tfelt-Hansen P.","Expert Opin Pharmacother. 2021 Feb;22(3):305-316. doi: 10.1080/14656566.2020.1828347. Epub 2020 Oct 9.","Tfelt-Hansen P","Expert Opin Pharmacother","2021","2020/10/02","","","10.1080/14656566.2020.1828347"
"37946113","Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway","Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, Lu J, Wade RL, Frerichs L, Bensink ME.","J Headache Pain. 2023 Nov 9;24(1):153. doi: 10.1186/s10194-023-01678-y.","Zhou Z","J Headache Pain","2023","2023/11/09","PMC10634163","","10.1186/s10194-023-01678-y"
"18557979","Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues","Harriott AM, Gold MS.","Cephalalgia. 2008 Sep;28(9):933-44. doi: 10.1111/j.1468-2982.2008.01635.x. Epub 2008 Jun 28.","Harriott AM","Cephalalgia","2008","2008/06/19","PMC2682350","NIHMS103607","10.1111/j.1468-2982.2008.01635.x"
"23136725","[Botulinum neurotoxin--a therapy in migraine]","Tajti J, Szok D, Tuka B, Csáti A, Kuris A, Majláth Z, Lukács M, Vécsei L.","Ideggyogy Sz. 2012 Mar 30;65(3-4):77-82.","Tajti J","Ideggyogy Sz","2012","2012/11/10","","",""
"37344811","Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review","Vandenbussche N, Pisarek K, Paemeleire K.","J Headache Pain. 2023 Jun 22;24(1):75. doi: 10.1186/s10194-023-01611-3.","Vandenbussche N","J Headache Pain","2023","2023/06/21","PMC10286407","","10.1186/s10194-023-01611-3"
"37996401","New drugs targeting calcitonin gene-related peptide for the management of migraines","Tana C, Cipollone F, Giamberardino MA, Martelletti P.","Expert Opin Emerg Drugs. 2023 Dec;28(4):233-240. doi: 10.1080/14728214.2023.2288334. Epub 2023 Dec 26.","Tana C","Expert Opin Emerg Drugs","2023","2023/11/23","","","10.1080/14728214.2023.2288334"
"23968948","Calcitonin gene related peptide gene polymorphism in migraine patients","Guldiken B, Sipahi T, Tekinarslan R, Kabayel L, Ozkan H, Unlu A, Yamasan BE, Okman-Kilic T, Turgut N.","Can J Neurol Sci. 2013 Sep;40(5):722-5. doi: 10.1017/s0317167100014980.","Guldiken B","Can J Neurol Sci","2013","2013/08/24","","","10.1017/s0317167100014980"
"30651064","European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P.","J Headache Pain. 2019 Jan 16;20(1):6. doi: 10.1186/s10194-018-0955-y.","Sacco S","J Headache Pain","2019","2019/01/18","PMC6734227","","10.1186/s10194-018-0955-y"
"23153230","Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine","Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE.","J Med Chem. 2012 Dec 13;55(23):10644-51. doi: 10.1021/jm3013147. Epub 2012 Nov 15.","Luo G","J Med Chem","2012","2012/11/17","","","10.1021/jm3013147"
"37511336","Calcitonin Gene-Related Peptide mRNA Synthesis in Trigeminal Ganglion Neurons after Cortical Spreading Depolarization","Shibata M, Kitagawa S, Unekawa M, Takizawa T, Nakahara J.","Int J Mol Sci. 2023 Jul 18;24(14):11578. doi: 10.3390/ijms241411578.","Shibata M","Int J Mol Sci","2023","2023/07/29","PMC10380864","","10.3390/ijms241411578"
"32541386","Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger","Avona A, Mason BN, Lackovic J, Wajahat N, Motina M, Quigley L, Burgos-Vega C, Moldovan Loomis C, Garcia-Martinez LF, Akopian AN, Price TJ, Dussor G.","Pain. 2020 Nov;161(11):2539-2550. doi: 10.1097/j.pain.0000000000001953.","Avona A","Pain","2020","2020/06/17","PMC7572536","NIHMS1601697","10.1097/j.pain.0000000000001953"
"37776119","Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies","Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.","J Manag Care Spec Pharm. 2023 Oct;29(10):1119-1128. doi: 10.18553/jmcp.2023.29.10.1119.","Schwedt TJ","J Manag Care Spec Pharm","2023","2023/09/30","PMC10541629","","10.18553/jmcp.2023.29.10.1119"
"32019317","Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class","Arca K, Reynolds J, Sands KA, Shiue HJ.","Ann Pharmacother. 2020 Aug;54(8):795-803. doi: 10.1177/1060028020903417. Epub 2020 Feb 5.","Arca K","Ann Pharmacother","2020","2020/02/06","","","10.1177/1060028020903417"
"25735000","OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J.","Pain. 2015 May;156(5):820-824. doi: 10.1097/j.pain.0000000000000119.","Cernuda-Morollón E","Pain","2015","2015/03/04","","","10.1097/j.pain.0000000000000119"
"26094101","Migraine and neuropeptides","Tajti J, Szok D, Majláth Z, Tuka B, Csáti A, Vécsei L.","Neuropeptides. 2015 Aug;52:19-30. doi: 10.1016/j.npep.2015.03.006. Epub 2015 Mar 30.","Tajti J","Neuropeptides","2015","2015/06/22","","","10.1016/j.npep.2015.03.006"
"30242830","History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment","Tepper SJ.","Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22.","Tepper SJ","Headache","2018","2018/09/23","","","10.1111/head.13379"
"19551474","Future drugs for migraine","Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P.","Intern Emerg Med. 2009 Oct;4(5):367-73. doi: 10.1007/s11739-009-0273-0. Epub 2009 Jun 24.","Farinelli I","Intern Emerg Med","2009","2009/06/25","","","10.1007/s11739-009-0273-0"
"32862469","Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine","Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB.","Headache. 2020 Oct;60(9):2003-2013. doi: 10.1111/head.13946. Epub 2020 Aug 30.","Houts CR","Headache","2020","2020/08/31","PMC7693226","","10.1111/head.13946"
"31014225","CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA","Moreno-Mayordomo R, Ruiz M, Pascual J, Gallego de la Sacristana M, Vidriales I, Sobrado M, Cernuda-Morollon E, Gago-Veiga AB, Garcia-Azorin D, Telleria JJ, Guerrero AL.","J Headache Pain. 2019 Apr 23;20(1):39. doi: 10.1186/s10194-019-0989-9.","Moreno-Mayordomo R","J Headache Pain","2019","2019/04/25","PMC6734474","","10.1186/s10194-019-0989-9"
"15689190","Correlation between CGRP and migraine attacks","Edvinsson L.","Cephalalgia. 2005 Mar;25(3):163-4. doi: 10.1111/j.1468-2982.2005.00908.x.","Edvinsson L","Cephalalgia","2005","2005/02/04","","","10.1111/j.1468-2982.2005.00908.x"
"35076090","Does ""wearing off"" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials","Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM.","Headache. 2022 Feb;62(2):198-207. doi: 10.1111/head.14257. Epub 2022 Jan 25.","Ailani J","Headache","2022","2022/01/25","PMC9306502","","10.1111/head.14257"
"33852525","Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine","Al-Hassany L, MaassenVanDenBrink A.","Curr Opin Neurol. 2021 Jun 1;34(3):330-338. doi: 10.1097/WCO.0000000000000932.","Al-Hassany L","Curr Opin Neurol","2021","2021/04/14","","","10.1097/WCO.0000000000000932"
"38270379","RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine","Romero Del Rincón C, Gonzalez-Martinez A, Quintas S, García-Azorín D, Fernández Lázaro I, Guerrero-Peral AL, Gonzalez Osorio Y, Santos-Lasaosa S, González Oria C, Sánchez Rodríguez N, Iglesias Díez F, Echavarría Íñiguez A, Gil Luque S, Huerta-Villanueva M, Campoy Díaz S, Muñoz-Vendrell A, Lozano Ros A, Sánchez-Soblechero A, Velasco Juanes F, Kortazar-Zubizarreta I, Echeverría A, Rodríguez-Vico J, Jaimes Sánchez A, Gómez García A, Morollón Sánchez-Mateos N, Belvis R, Navarro Pérez MP, García-Moncó JC, Álvarez Escudero MR, Montes N, Gago-Veiga AB.","Eur J Neurol. 2024 Apr;31(4):e16203. doi: 10.1111/ene.16203. Epub 2024 Jan 25.","Romero Del Rincón C","Eur J Neurol","2024","2024/01/25","","","10.1111/ene.16203"
"19036426","CGRP-receptor antagonism in migraine treatment","Edvinsson L.","Lancet. 2008 Dec 20;372(9656):2089-90. doi: 10.1016/S0140-6736(08)61710-9. Epub 2008 Nov 25.","Edvinsson L","Lancet","2008","2008/11/28","","","10.1016/S0140-6736(08)61710-9"
"35584542","Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies","Krymchantowski A, Silva-Néto RP, Jevoux C, Krymchantowski AG.","Postgrad Med. 2022 Aug;134(6):598-602. doi: 10.1080/00325481.2022.2080381. Epub 2022 May 27.","Krymchantowski A","Postgrad Med","2022","2022/05/18","","","10.1080/00325481.2022.2080381"
"16802852","Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist","Trocóniz IF, Wolters JM, Tillmann C, Schaefer HG, Roth W.","Clin Pharmacokinet. 2006;45(7):715-28. doi: 10.2165/00003088-200645070-00006.","Trocóniz IF","Clin Pharmacokinet","2006","2006/06/29","","","10.2165/00003088-200645070-00006"
"21979827","Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine","Messlinger K, Fischer MJ, Lennerz JK.","Keio J Med. 2011;60(3):82-9. doi: 10.2302/kjm.60.82.","Messlinger K","Keio J Med","2011","2011/10/08","","","10.2302/kjm.60.82"
"37488760","Major Targets Involved in Clinical Management of Migraine","Rushendran R, Chitra V, Ilango K.","Curr Neurovasc Res. 2023;20(3):296-313. doi: 10.2174/1567202620666230721111144.","Rushendran R","Curr Neurovasc Res","2023","2023/07/25","","","10.2174/1567202620666230721111144"
"32486909","Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system","Edvinsson JCA, Grell AS, Warfvinge K, Sheykhzade M, Edvinsson L, Haanes KA.","Cephalalgia. 2020 Oct;40(12):1296-1309. doi: 10.1177/0333102420929026. Epub 2020 Jun 2.","Edvinsson JCA","Cephalalgia","2020","2020/06/04","","","10.1177/0333102420929026"
"35567661","CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies","Wang YF, Wang SJ.","Curr Pain Headache Rep. 2022 Jul;26(7):543-554. doi: 10.1007/s11916-022-01056-4. Epub 2022 May 14.","Wang YF","Curr Pain Headache Rep","2022","2022/05/14","","","10.1007/s11916-022-01056-4"
"35922609","Bariatric Surgery in Migraine patients: CGRP Level and Weight Loss","Etefagh HH, Shahmiri SS, Melali H, Sayadi M, Ansari H, Shahzamani A, Deyhimi MS.","Obes Surg. 2022 Nov;32(11):3635-3640. doi: 10.1007/s11695-022-06218-2. Epub 2022 Aug 3.","Etefagh HH","Obes Surg","2022","2022/08/03","","","10.1007/s11695-022-06218-2"
"30982348","Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.","Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.","Goadsby PJ","Cephalalgia","2019","2019/04/16","","","10.1177/0333102419835459"
"36856538","An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor","Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.","Eur J Neurol. 2023 Jun;30(6):1764-1773. doi: 10.1111/ene.15761. Epub 2023 Mar 15.","Schiano di Cola F","Eur J Neurol","2023","2023/03/01","","","10.1111/ene.15761"
"32611244","Localization of TRPA1 channels and characterization of TRPA1 mediated responses in dural and pial arteries in vivo after intracarotid infusion of Na(2)S","Hansted AK, Jensen LJ, Olesen J, Jansen-Olesen I.","Cephalalgia. 2020 Oct;40(12):1310-1320. doi: 10.1177/0333102420937724. Epub 2020 Jul 1.","Hansted AK","Cephalalgia","2020","2020/07/03","","","10.1177/0333102420937724"
"30094981","[Manual Acupuncture Stimulation Regulates Expression of Receptor Activity-modifying Protein 1 and 5-HT 1 D Receptor Proteins and Genes in Migraine Rats]","Wang MM, Yu XH, Geng W, Cui HF, Wang CC, Han J, Yang DH.","Zhen Ci Yan Jiu. 2018 Jul 25;43(7):440-4. doi: 10.13702/j.1000-0607.170346.","Wang MM","Zhen Ci Yan Jiu","2018","2018/08/11","","","10.13702/j.1000-0607.170346"
"36226464","Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle","Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.","Headache. 2023 Feb;63(2):233-242. doi: 10.1111/head.14403. Epub 2022 Oct 13.","Dodick DW","Headache","2023","2022/10/13","","","10.1111/head.14403"
"36170136","[New developments in headache management in 2022]","Della Vedova L, Hashemi P, Meynard-Colomb A, Kleinschmidt A, Arsever S.","Rev Med Suisse. 2022 Sep 28;18(797):1812-1815. doi: 10.53738/REVMED.2022.18.797.1812.","Della Vedova L","Rev Med Suisse","2022","2022/09/28","","","10.53738/REVMED.2022.18.797.1812"
"29471874","Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment","MaassenVanDenBrink A, Terwindt GM, van den Maagdenberg AMJM.","Genome Med. 2018 Feb 22;10(1):10. doi: 10.1186/s13073-018-0524-7.","MaassenVanDenBrink A","Genome Med","2018","2018/02/24","PMC5824555","","10.1186/s13073-018-0524-7"
"23721242","Clinical trials update--2012: year in review--a comment","Bigal ME.","Headache. 2013 Jun;53(6):1003-4. doi: 10.1111/head.12099.","Bigal ME","Headache","2013","2013/06/01","","","10.1111/head.12099"
"31800988","Ubrogepant for the Treatment of Migraine","Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A.","N Engl J Med. 2019 Dec 5;381(23):2230-2241. doi: 10.1056/NEJMoa1813049.","Dodick DW","N Engl J Med","2019","2019/12/05","","","10.1056/NEJMoa1813049"
"35162776","The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis","Fernández-Bravo-Rodrigo J, Pascual-Morena C, Flor-García A, Saz-Lara A, Sequí-Dominguez I, Álvarez-Bueno C, Barreda-Hernández D, Cavero-Redondo I.","Int J Environ Res Public Health. 2022 Feb 3;19(3):1753. doi: 10.3390/ijerph19031753.","Fernández-Bravo-Rodrigo J","Int J Environ Res Public Health","2022","2022/02/15","PMC8835448","","10.3390/ijerph19031753"
"21521205","Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine","Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE, Berman NE.","Headache. 2011 May;51(5):674-92. doi: 10.1111/j.1526-4610.2011.01882.x.","Stucky NL","Headache","2011","2011/04/28","PMC4079043","NIHMS591591","10.1111/j.1526-4610.2011.01882.x"
"32668023","Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis","Forbes RB, McCarron M, Cardwell CR.","Headache. 2020 Sep;60(8):1542-1557. doi: 10.1111/head.13907. Epub 2020 Jul 15.","Forbes RB","Headache","2020","2020/07/16","","","10.1111/head.13907"
"27884929","Pro-nociceptive migraine mediator CGRP provides neuroprotection of sensory, cortical and cerebellar neurons via multi-kinase signaling","Abushik PA, Bart G, Korhonen P, Leinonen H, Giniatullina R, Sibarov DA, Levonen AL, Malm T, Antonov SM, Giniatullin R.","Cephalalgia. 2017 Dec;37(14):1373-1383. doi: 10.1177/0333102416681588. Epub 2016 Nov 25.","Abushik PA","Cephalalgia","2017","2016/11/26","","","10.1177/0333102416681588"
"16688611","Inflammation and excitotoxicity: role in migraine pathogenesis","Longoni M, Ferrarese C.","Neurol Sci. 2006 May;27 Suppl 2:S107-10. doi: 10.1007/s10072-006-0582-2.","Longoni M","Neurol Sci","2006","2006/05/12","","","10.1007/s10072-006-0582-2"
"20655327","The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors","Gupta S, Villalón CM.","Pharmacol Ther. 2010 Oct;128(1):170-90. doi: 10.1016/j.pharmthera.2010.06.005. Epub 2010 Jul 22.","Gupta S","Pharmacol Ther","2010","2010/07/27","","","10.1016/j.pharmthera.2010.06.005"
"15867953","Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks","Edvinsson L.","CNS Drug Rev. 2005 Spring;11(1):69-76. doi: 10.1111/j.1527-3458.2005.tb00036.x.","Edvinsson L","CNS Drug Rev","2005","2005/05/04","PMC6741734","","10.1111/j.1527-3458.2005.tb00036.x"
"34281473","Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine","Shi M, Guo J, Li Z, Sun H, Yang X, Yang D, Zhao H.","Neurol Res. 2021 Nov;43(11):932-949. doi: 10.1080/01616412.2021.1940672. Epub 2021 Jul 19.","Shi M","Neurol Res","2021","2021/07/20","","","10.1080/01616412.2021.1940672"
"31763951","Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines","Henson B, Hollingsworth H, Nevois E, Herndon C.","J Pain Palliat Care Pharmacother. 2020 Mar;34(1):22-31. doi: 10.1080/15360288.2019.1690616. Epub 2019 Nov 25.","Henson B","J Pain Palliat Care Pharmacother","2020","2019/11/26","","","10.1080/15360288.2019.1690616"
"35815440","Efficacy and safety of galcanezumab for migraine: evidences from direct and indirect comparisons","Wang X, Song J, You C.","Int J Neurosci. 2023 Dec;133(8):925-933. doi: 10.1080/00207454.2022.2098732. Epub 2022 Jul 19.","Wang X","Int J Neurosci","2023","2022/07/11","","","10.1080/00207454.2022.2098732"
"36924863","Network pharmacology and experimental verification to explore the anti-migraine mechanism of Yufeng Ningxin Tablet","Yu S, Fan C, Li Y, Pei H, Tian Y, Zuo Z, Wang Z, Liu C, Zhao X, Wang Z.","J Ethnopharmacol. 2023 Jun 28;310:116384. doi: 10.1016/j.jep.2023.116384. Epub 2023 Mar 15.","Yu S","J Ethnopharmacol","2023","2023/03/16","","","10.1016/j.jep.2023.116384"
"33982623","Efficacy of erenumab in chronic migraine patients with and without ictal allodynia","Lipton RB, Burstein R, Buse DC, Dodick DW, Koukakis R, Klatt J, Cheng S, Chou DE.","Cephalalgia. 2021 Oct;41(11-12):1152-1160. doi: 10.1177/03331024211010305. Epub 2021 May 13.","Lipton RB","Cephalalgia","2021","2021/05/13","","","10.1177/03331024211010305"
"32791922","Real-world effectiveness and tolerability of erenumab: A retrospective cohort study","Kanaan S, Hettie G, Loder E, Burch R.","Cephalalgia. 2020 Nov;40(13):1511-1522. doi: 10.1177/0333102420946725. Epub 2020 Aug 13.","Kanaan S","Cephalalgia","2020","2020/08/15","","","10.1177/0333102420946725"
"19268029","An oral calcitonin gene-related peptide receptor antagonist for acute migraine management: sign of a possible new chapter in headache medicine","Garza I.","Curr Neurol Neurosci Rep. 2009 Mar;9(2):91-3. doi: 10.1007/s11910-009-0014-9.","Garza I","Curr Neurol Neurosci Rep","2009","2009/03/10","","","10.1007/s11910-009-0014-9"
"32870468","Implications of Transient Receptor Potential Cation Channels in Migraine Pathophysiology","Shibata M, Tang C.","Neurosci Bull. 2021 Jan;37(1):103-116. doi: 10.1007/s12264-020-00569-5. Epub 2020 Sep 1.","Shibata M","Neurosci Bull","2021","2020/09/02","PMC7811976","","10.1007/s12264-020-00569-5"
"35260079","Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model","Tian R, Zhang Y, Pan Q, Wang Y, Wen Q, Fan X, Qin G, Zhang D, Chen L, Zhang Y, Zhou J.","J Headache Pain. 2022 Mar 8;23(1):35. doi: 10.1186/s10194-022-01403-1.","Tian R","J Headache Pain","2022","2022/03/09","PMC8903578","","10.1186/s10194-022-01403-1"
"31640402","PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model","Shi S, Han Y, Wang D, Guo P, Wang J, Ren T, Wang W.","Cephalalgia. 2020 Mar;40(3):288-298. doi: 10.1177/0333102419883374. Epub 2019 Oct 22.","Shi S","Cephalalgia","2020","2019/10/24","","","10.1177/0333102419883374"
"16141957","The treatment of acute migraine","Olesen J.","Rev Neurol (Paris). 2005 Jul;161(6-7):679-80. doi: 10.1016/s0035-3787(05)85115-x.","Olesen J","Rev Neurol (Paris)","2005","2005/09/06","","","10.1016/s0035-3787(05)85115-x"
"32340471","Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine","Martinez JM, Hindiyeh N, Anglin G, Kalidas K, Hodsdon ME, Kielbasa W, Moser BA, Pearlman EM, Garces S.","Cephalalgia. 2020 Aug;40(9):978-989. doi: 10.1177/0333102420920642. Epub 2020 Apr 27.","Martinez JM","Cephalalgia","2020","2020/04/29","PMC7469706","","10.1177/0333102420920642"
"38369488","Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation","Vuralli D, Ceren Akgor M, Gok Dagidir H, Gulbahar O, Yalinay M, Bolay H.","J Headache Pain. 2024 Feb 19;25(1):23. doi: 10.1186/s10194-024-01730-5.","Vuralli D","J Headache Pain","2024","2024/02/18","PMC10875763","","10.1186/s10194-024-01730-5"
"18776916","CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat","Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, Garcia CA, Pons J, Rosenthal A, Shelton DL.","Br J Pharmacol. 2008 Dec;155(7):1093-103. doi: 10.1038/bjp.2008.334. Epub 2008 Sep 8.","Zeller J","Br J Pharmacol","2008","2008/09/09","PMC2597266","","10.1038/bjp.2008.334"
"20974601","Randomized, controlled trial of telcagepant over four migraine attacks","Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW.","Cephalalgia. 2010 Dec;30(12):1443-57. doi: 10.1177/0333102410370878. Epub 2010 Jun 8.","Ho AP","Cephalalgia","2010","2010/10/27","","","10.1177/0333102410370878"
"24382126","Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis","Cui XP, Ye JX, Lin H, Mu JS, Lin M.","Pain Pract. 2015 Feb;15(2):124-31. doi: 10.1111/papr.12158. Epub 2013 Dec 30.","Cui XP","Pain Pract","2015","2014/01/03","","","10.1111/papr.12158"
"12354573","The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels","Akerman S, Williamson DJ, Kaube H, Goadsby PJ.","Eur J Pharmacol. 2002 Oct 4;452(2):223-8. doi: 10.1016/s0014-2999(02)02307-5.","Akerman S","Eur J Pharmacol","2002","2002/10/02","","","10.1016/s0014-2999(02)02307-5"
"32799325","Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine","Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.","Headache. 2020 Sep;60(8):1734-1742. doi: 10.1111/head.13930. Epub 2020 Aug 16.","Berman G","Headache","2020","2020/08/18","PMC7496574","","10.1111/head.13930"
"30341990","100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies","Rosen N, Pearlman E, Ruff D, Day K, Jim Nagy A.","Headache. 2018 Oct;58(9):1347-1357. doi: 10.1111/head.13427. Epub 2018 Oct 20.","Rosen N","Headache","2018","2018/10/21","PMC6221112","","10.1111/head.13427"
"30182284","The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis","Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X.","Neurol Sci. 2018 Dec;39(12):2097-2106. doi: 10.1007/s10072-018-3547-3. Epub 2018 Sep 4.","Zhu Y","Neurol Sci","2018","2018/09/06","","","10.1007/s10072-018-3547-3"
"33413075","Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials","Silberstein SD, Cohen JM, Yang R, Gandhi SK, Du E, Jann AE, Marmura MJ.","J Headache Pain. 2021 Jan 7;22(1):2. doi: 10.1186/s10194-020-01212-4.","Silberstein SD","J Headache Pain","2021","2021/01/08","PMC7792179","","10.1186/s10194-020-01212-4"
"10779670","Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks","Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J.","Pain. 2000 May;86(1-2):133-8. doi: 10.1016/s0304-3959(00)00232-3.","Ashina M","Pain","2000","2000/04/26","","","10.1016/s0304-3959(00)00232-3"
"37358548","Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies","de Vries Lentsch S, Perenboom MJL, Carpay JA, MaassenVanDenBrink A, Terwindt GM.","Headache. 2023 Jul-Aug;63(7):926-933. doi: 10.1111/head.14531. Epub 2023 Jun 26.","de Vries Lentsch S","Headache","2023","2023/06/26","","","10.1111/head.14531"
"30543270","Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies","Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS.","Am J Manag Care. 2018 Dec;24(24 Suppl):S527-S533.","Mwamburi M","Am J Manag Care","2018","2018/12/14","","",""
"27191890","Molecular factors in migraine","Kowalska M, Prendecki M, Kozubski W, Lianeri M, Dorszewska J.","Oncotarget. 2016 Aug 2;7(31):50708-50718. doi: 10.18632/oncotarget.9367.","Kowalska M","Oncotarget","2016","2016/05/19","PMC5226615","","10.18632/oncotarget.9367"
"31488896","Calcitonin gene-related peptide - beyond migraine prophylaxis","Olesen J, Ashina M.","Nat Rev Neurol. 2019 Oct;15(10):562-564. doi: 10.1038/s41582-019-0258-1.","Olesen J","Nat Rev Neurol","2019","2019/09/07","","","10.1038/s41582-019-0258-1"
"24452707","Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache","Peroutka SJ.","BioDrugs. 2014 Jun;28(3):237-44. doi: 10.1007/s40259-014-0083-4.","Peroutka SJ","BioDrugs","2014","2014/01/24","","","10.1007/s40259-014-0083-4"
"33402188","P2X7R-mediated autophagic impairment contributes to central sensitization in a chronic migraine model with recurrent nitroglycerin stimulation in mice","Jiang L, Zhang Y, Jing F, Long T, Qin G, Zhang D, Chen L, Zhou J.","J Neuroinflammation. 2021 Jan 5;18(1):5. doi: 10.1186/s12974-020-02056-0.","Jiang L","J Neuroinflammation","2021","2021/01/06","PMC7786980","","10.1186/s12974-020-02056-0"
"33426614","Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis","Ha DK, Kim MJ, Han N, Kwak JH, Baek IH.","Clin Drug Investig. 2021 Feb;41(2):119-132. doi: 10.1007/s40261-020-00997-1. Epub 2021 Jan 11.","Ha DK","Clin Drug Investig","2021","2021/01/11","","","10.1007/s40261-020-00997-1"
"29984601","Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD.","Cephalalgia. 2018 Sep;38(10):1611-1621. doi: 10.1177/0333102418788347. Epub 2018 Jul 8.","Ashina M","Cephalalgia","2018","2018/07/10","","","10.1177/0333102418788347"
"36482037","Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis","Bomtempo FF, Rocha RB, Cenci GI, Nager GB, Telles JPM.","Clin Drug Investig. 2023 Jan;43(1):45-59. doi: 10.1007/s40261-022-01230-x. Epub 2022 Dec 8.","Bomtempo FF","Clin Drug Investig","2023","2022/12/09","","","10.1007/s40261-022-01230-x"
"35026523","Wuzhuyu Decoction relieves hyperalgesia by regulating central and peripheral 5-HT in chronic migraine model rats","Nan N, Gong MX, Wang Q, Li MJ, Xu R, Ma Z, Wang SH, Zhao H, Xu YS.","Phytomedicine. 2022 Feb;96:153905. doi: 10.1016/j.phymed.2021.153905. Epub 2021 Dec 25.","Nan N","Phytomedicine","2022","2022/01/13","","","10.1016/j.phymed.2021.153905"
"30430259","CGRP Discovery and Timeline","Arkless K, Argunhan F, Brain SD.","Handb Exp Pharmacol. 2019;255:1-12. doi: 10.1007/164_2018_129.","Arkless K","Handb Exp Pharmacol","2019","2018/11/16","","","10.1007/164_2018_129"
"35112219","Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial","Matin H, Taghian F, Chitsaz A.","Neurol Sci. 2022 Jul;43(7):4413-4424. doi: 10.1007/s10072-021-05843-6. Epub 2022 Feb 3.","Matin H","Neurol Sci","2022","2022/02/03","","","10.1007/s10072-021-05843-6"
"38477313","Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex","Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW.","Cephalalgia. 2024 Mar;44(3):3331024241238153. doi: 10.1177/03331024241238153.","Porreca F","Cephalalgia","2024","2024/03/13","","","10.1177/03331024241238153"
"32870296","Rimegepant (Nurtec ODT) for Acute Treatment of Migraine","","JAMA. 2020 Sep 1;324(9):890-891. doi: 10.1001/jama.2020.8493.","","JAMA","2020","2020/09/02","","","10.1001/jama.2020.8493"
"37638395","Autophagy may protect the brain against prolonged consequences of headache attacks: A narrative/hypothesis review","Fila M, Pawlowska E, Szczepanska J, Blasiak J.","Headache. 2023 Sep;63(8):1154-1166. doi: 10.1111/head.14625. Epub 2023 Aug 28.","Fila M","Headache","2023","2023/08/28","","","10.1111/head.14625"
"23577145","The mechanism of functional up-regulation of P2X3 receptors of trigeminal sensory neurons in a genetic mouse model of familial hemiplegic migraine type 1 (FHM-1)","Hullugundi SK, Ferrari MD, van den Maagdenberg AM, Nistri A.","PLoS One. 2013;8(4):e60677. doi: 10.1371/journal.pone.0060677. Epub 2013 Apr 5.","Hullugundi SK","PLoS One","2013","2013/04/12","PMC3618040","","10.1371/journal.pone.0060677"
"35319319","Atogepant: an emerging treatment for migraine","Rustichelli C, Avallone R, Ferrari A.","Expert Opin Pharmacother. 2022 Apr;23(6):653-662. doi: 10.1080/14656566.2022.2057221. Epub 2022 Mar 28.","Rustichelli C","Expert Opin Pharmacother","2022","2022/03/23","","","10.1080/14656566.2022.2057221"
"31018157","Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis","Tringali G, Navarra P.","Peptides. 2019 Jun;116:16-21. doi: 10.1016/j.peptides.2019.04.012. Epub 2019 Apr 21.","Tringali G","Peptides","2019","2019/04/25","","","10.1016/j.peptides.2019.04.012"
"36430567","Modulation of Glia Activation by TRPA1 Antagonism in Preclinical Models of Migraine","Demartini C, Greco R, Magni G, Zanaboni AM, Riboldi B, Francavilla M, Nativi C, Ceruti S, Tassorelli C.","Int J Mol Sci. 2022 Nov 15;23(22):14085. doi: 10.3390/ijms232214085.","Demartini C","Int J Mol Sci","2022","2022/11/26","PMC9697613","","10.3390/ijms232214085"
"31932515","Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB.","Neurology. 2020 May 19;94(20):e2121-e2125. doi: 10.1212/WNL.0000000000008944. Epub 2020 Jan 13.","Mullin K","Neurology","2020","2020/01/15","PMC7526667","","10.1212/WNL.0000000000008944"
"32072189","[Modern migraine therapy-interdisciplinary long-term care]","Göbel H, Heinze A, Heinze-Kuhn K, Göbel CHH.","Internist (Berl). 2020 Mar;61(3):326-332. doi: 10.1007/s00108-020-00757-5.","Göbel H","Internist (Berl)","2020","2020/02/20","","","10.1007/s00108-020-00757-5"
"32437038","Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?","Pellesi L, Do TP, Ashina H, Ashina M, Burstein R.","Headache. 2020 Jun;60(6):1056-1065. doi: 10.1111/head.13843. Epub 2020 May 21.","Pellesi L","Headache","2020","2020/05/22","","","10.1111/head.13843"
"34214182","A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management","Joshi S, Tepper SJ, Lucas S, Rasmussen S, Nelson R.","Headache. 2021 Jun;61(6):838-853. doi: 10.1111/head.14135.","Joshi S","Headache","2021","2021/07/02","PMC8361687","","10.1111/head.14135"
"34187083","Beyond CGRP: The calcitonin peptide family as targets for migraine and pain","Rees TA, Hendrikse ER, Hay DL, Walker CS.","Br J Pharmacol. 2022 Feb;179(3):381-399. doi: 10.1111/bph.15605. Epub 2021 Jul 27.","Rees TA","Br J Pharmacol","2022","2021/06/29","PMC9441195","NIHMS1832504","10.1111/bph.15605"
"28842814","Protein Kinase C γ Contributes to Central Sensitization in a Rat Model of Chronic Migraine","Wu B, Wang S, Qin G, Xie J, Tan G, Zhou J, Chen L.","J Mol Neurosci. 2017 Oct;63(2):131-141. doi: 10.1007/s12031-017-0960-7. Epub 2017 Aug 25.","Wu B","J Mol Neurosci","2017","2017/08/27","","","10.1007/s12031-017-0960-7"
"37917246","Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial","Li XN, Xu HR, Cui E, Petersen KB, Ryding J, Ettrup A, Østergaard JB, Larsen F.","Clin Drug Investig. 2023 Nov;43(11):873-881. doi: 10.1007/s40261-023-01315-1. Epub 2023 Nov 2.","Li XN","Clin Drug Investig","2023","2023/11/02","PMC10632206","","10.1007/s40261-023-01315-1"
"29980913","Pathways of CGRP Release from Primary Sensory Neurons","De Logu F, Nassini R, Landini L, Geppetti P.","Handb Exp Pharmacol. 2019;255:65-84. doi: 10.1007/164_2018_145.","De Logu F","Handb Exp Pharmacol","2019","2018/07/08","","","10.1007/164_2018_145"
"11323131","An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system","Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, Michel MC.","Pain. 2001 May;92(1-2):101-6. doi: 10.1016/s0304-3959(00)00475-9.","Limmroth V","Pain","2001","2001/04/27","","","10.1016/s0304-3959(00)00475-9"
"35331009","Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies","Diener HC, McAllister P, Jürgens TP, Kessler Y, Ning X, Cohen JM, Campos VR, Barash S, Silberstein SD.","Cephalalgia. 2022 Jul;42(8):769-780. doi: 10.1177/03331024221076485. Epub 2022 Mar 25.","Diener HC","Cephalalgia","2022","2022/03/25","PMC9218411","","10.1177/03331024221076485"
"31498522","Quantification of Trigeminovascular Hypersensitivity Using Laser Speckle Contrast Analysis in a Patient With Chronic Migraine","Unal-Cevik I, Yilmaz E.","Pain Pract. 2020 Feb;20(2):204-210. doi: 10.1111/papr.12834. Epub 2019 Nov 7.","Unal-Cevik I","Pain Pract","2020","2019/09/10","","","10.1111/papr.12834"
"29310444","Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study","Oakes TMM, Skljarevski V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, Camporeale A, Saper JR.","Cephalalgia. 2018 May;38(6):1015-1025. doi: 10.1177/0333102417747230. Epub 2018 Jan 8.","Oakes TMM","Cephalalgia","2018","2018/01/10","","","10.1177/0333102417747230"
"33402419","Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study","Lanteri-Minet M, Goadsby PJ, Reuter U, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.","J Neurol Neurosurg Psychiatry. 2021 May;92(5):466-472. doi: 10.1136/jnnp-2020-324396. Epub 2021 Jan 5.","Lanteri-Minet M","J Neurol Neurosurg Psychiatry","2021","2021/01/06","PMC8053327","","10.1136/jnnp-2020-324396"
"30689083","Calcitonin Gene-Related Peptide Antagonists and Therapeutic Antibodies","Rujan RM, Reynolds CA.","Handb Exp Pharmacol. 2019;255:169-192. doi: 10.1007/164_2018_173.","Rujan RM","Handb Exp Pharmacol","2019","2019/01/29","","","10.1007/164_2018_173"
"23190076","Pathophysiology of migraine","Pietrobon D, Moskowitz MA.","Annu Rev Physiol. 2013;75:365-91. doi: 10.1146/annurev-physiol-030212-183717. Epub 2012 Nov 26.","Pietrobon D","Annu Rev Physiol","2013","2012/11/30","","","10.1146/annurev-physiol-030212-183717"
"29357368","Serum apolipoprotein E may be a novel biomarker of migraine","Yuasa N, Nagata E, Fujii N, Ito M, Tsukamoto H, Takizawa S.","PLoS One. 2018 Jan 22;13(1):e0190620. doi: 10.1371/journal.pone.0190620. eCollection 2018.","Yuasa N","PLoS One","2018","2018/01/23","PMC5777658","","10.1371/journal.pone.0190620"
"26231160","Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine","Crowley BM, Stump CA, Nguyen DN, Potteiger CM, McWherter MA, Paone DV, Quigley AG, Bruno JG, Cui D, Culberson JC, Danziger A, Fandozzi C, Gauvreau D, Kemmerer AL, Menzel K, Moore EL, Mosser SD, Reddy V, White RB, Salvatore CA, Kane SA, Bell IM, Selnick HG, Fraley ME, Burgey CS.","Bioorg Med Chem Lett. 2015 Nov 1;25(21):4777-4781. doi: 10.1016/j.bmcl.2015.07.021. Epub 2015 Jul 14.","Crowley BM","Bioorg Med Chem Lett","2015","2015/08/02","","","10.1016/j.bmcl.2015.07.021"
"29623520","CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine","Israel H, Neeb L, Reuter U.","Curr Pain Headache Rep. 2018 Apr 6;22(5):38. doi: 10.1007/s11916-018-0686-4.","Israel H","Curr Pain Headache Rep","2018","2018/04/07","","","10.1007/s11916-018-0686-4"
"30714429","Pharmacokinetics and pharmacodynamics of new acute treatments for migraine","Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A.","Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):189-198. doi: 10.1080/17425255.2019.1578749. Epub 2019 Feb 12.","Lupi C","Expert Opin Drug Metab Toxicol","2019","2019/02/05","","","10.1080/17425255.2019.1578749"
"31085251","Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine","Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM, Chellman GJ, Balasubramanian G, Rubio-Beltran E, MaassenVanDenBrink A, Monticello TM.","Regul Toxicol Pharmacol. 2019 Aug;106:224-238. doi: 10.1016/j.yrtph.2019.05.013. Epub 2019 May 11.","Bussiere JL","Regul Toxicol Pharmacol","2019","2019/05/16","","","10.1016/j.yrtph.2019.05.013"
"32814432","Adverse effects of erenumab on cerebral proliferative angiopathy: A case report","Lehman LL, Bruccoleri R, Danehy A, Swanson J, Mrakotsky C, Smith E, Orbach DB, Burstein R.","Cephalalgia. 2021 Jan;41(1):122-126. doi: 10.1177/0333102420950484. Epub 2020 Aug 19.","Lehman LL","Cephalalgia","2021","2020/08/21","","","10.1177/0333102420950484"
"26931452","Methylprednisolone blocks interleukin 1 beta induced calcitonin gene related peptide release in trigeminal ganglia cells","Neeb L, Hellen P, Hoffmann J, Dirnagl U, Reuter U.","J Headache Pain. 2016;17:19. doi: 10.1186/s10194-016-0609-x. Epub 2016 Mar 1.","Neeb L","J Headache Pain","2016","2016/03/03","PMC4773314","","10.1186/s10194-016-0609-x"
"32994317","Three new drugs for the prevention of migraine","","Drug Ther Bull. 2020 Oct;58(10):151-156. doi: 10.1136/dtb.2020.000037.","","Drug Ther Bull","2020","2020/09/30","","","10.1136/dtb.2020.000037"
"29226741","Side effects associated with current and prospective antimigraine pharmacotherapies","González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM.","Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):25-41. doi: 10.1080/17425255.2018.1416097. Epub 2017 Dec 15.","González-Hernández A","Expert Opin Drug Metab Toxicol","2018","2017/12/12","","","10.1080/17425255.2018.1416097"
"37539825","Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis","Yang L, Zhou Y, Zhang L, Wang Y, Zhang Y, Xiao Z.","Headache. 2023 Sep;63(8):1045-1060. doi: 10.1111/head.14599. Epub 2023 Aug 4.","Yang L","Headache","2023","2023/08/04","","","10.1111/head.14599"
"31726975","Association of diet and headache","Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M; School of Advanced Studies of the European Headache Federation (EHF-SAS).","J Headache Pain. 2019 Nov 14;20(1):106. doi: 10.1186/s10194-019-1057-1.","Razeghi Jahromi S","J Headache Pain","2019","2019/11/16","PMC6854770","","10.1186/s10194-019-1057-1"
"33608115","Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review","Ferrari A, Rustichelli C.","Clin Ther. 2021 Apr;43(4):654-670. doi: 10.1016/j.clinthera.2021.01.020. Epub 2021 Feb 16.","Ferrari A","Clin Ther","2021","2021/02/20","","","10.1016/j.clinthera.2021.01.020"
"31291016","Targeting CGRP and 5-HT(1F) Receptors for the Acute Therapy of Migraine: A Literature Review","Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ.","Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582.","Moreno-Ajona D","Headache","2019","2019/07/11","","","10.1111/head.13582"
"34930112","Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States","McAllister P, Lamerato L, Krasenbaum LJ, Cohen JM, Tangirala K, Thompson S, Driessen M, Casciano J, Dotiwala Z, Mauskop A.","J Headache Pain. 2021 Dec 20;22(1):156. doi: 10.1186/s10194-021-01358-9.","McAllister P","J Headache Pain","2021","2021/12/21","PMC8903530","","10.1186/s10194-021-01358-9"
"30406901","Fremanezumab: First Global Approval","Hoy SM.","Drugs. 2018 Nov;78(17):1829-1834. doi: 10.1007/s40265-018-1004-5.","Hoy SM","Drugs","2018","2018/11/09","PMC6422958","","10.1007/s40265-018-1004-5"
"36890436","Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study","Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, Hori S, Takemura R, Nakahara J, Takizawa T.","J Headache Pain. 2023 Mar 9;24(1):23. doi: 10.1186/s10194-023-01556-7.","Ihara K","J Headache Pain","2023","2023/03/08","PMC9996919","","10.1186/s10194-023-01556-7"
"29797087","CGRP Receptor Biology: Is There More Than One Receptor?","Hay DL.","Handb Exp Pharmacol. 2019;255:13-22. doi: 10.1007/164_2018_131.","Hay DL","Handb Exp Pharmacol","2019","2018/05/26","","","10.1007/164_2018_131"
"1699472","Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","Goadsby PJ, Edvinsson L, Ekman R.","Ann Neurol. 1990 Aug;28(2):183-7. doi: 10.1002/ana.410280213.","Goadsby PJ","Ann Neurol","1990","1990/08/01","","","10.1002/ana.410280213"
"12534582","Decreased sTNF-RI in migraine patients?","Empl M, Sostak P, Riedel M, Schwarz M, Müller N, Förderreuther S, Straube A.","Cephalalgia. 2003 Feb;23(1):55-8. doi: 10.1046/j.1468-2982.2003.00453.x.","Empl M","Cephalalgia","2003","2003/01/22","","","10.1046/j.1468-2982.2003.00453.x"
"35635478","Ex vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents","Rasmussen RH, Jansen-Olesen I, Kristensen DM, Christensen SL.","J Vis Exp. 2022 May 16;(183). doi: 10.3791/63723.","Rasmussen RH","J Vis Exp","2022","2022/05/31","","","10.3791/63723"
"21161301","Migraine is a neuronal disease","Tajti J, Párdutz A, Vámos E, Tuka B, Kuris A, Bohár Z, Fejes A, Toldi J, Vécsei L.","J Neural Transm (Vienna). 2011 Apr;118(4):511-24. doi: 10.1007/s00702-010-0515-3. Epub 2010 Dec 15.","Tajti J","J Neural Transm (Vienna)","2011","2010/12/17","","","10.1007/s00702-010-0515-3"
"28129635","Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis","Hong P, Wu X, Liu Y.","Clin Neurol Neurosurg. 2017 Mar;154:74-78. doi: 10.1016/j.clineuro.2017.01.009. Epub 2017 Jan 22.","Hong P","Clin Neurol Neurosurg","2017","2017/01/28","","","10.1016/j.clineuro.2017.01.009"
"17515549","Obesity, migraine, and chronic migraine: possible mechanisms of interaction","Bigal ME, Lipton RB, Holland PR, Goadsby PJ.","Neurology. 2007 May 22;68(21):1851-61. doi: 10.1212/01.wnl.0000262045.11646.b1.","Bigal ME","Neurology","2007","2007/05/23","","","10.1212/01.wnl.0000262045.11646.b1"
"37542222","Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study","Zhou J, Zhong L, Chowdhury D, Skorobogatykh K, Luo G, Yang X, Zhang M, Sun L, Liu H, Qian C, Yu S.","J Headache Pain. 2023 Aug 4;24(1):103. doi: 10.1186/s10194-023-01613-1.","Zhou J","J Headache Pain","2023","2023/08/04","PMC10401806","","10.1186/s10194-023-01613-1"
"32790216","Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom","Toptan T, Aktan Ç, Başarı A, Bolay H.","Headache. 2020 Sep;60(8):1788-1792. doi: 10.1111/head.13940. Epub 2020 Aug 17.","Toptan T","Headache","2020","2020/08/14","PMC7436308","","10.1111/head.13940"
"35729340","Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis","Lee S, Staatz CE, Han N, Baek IH.","Eur J Clin Pharmacol. 2022 Sep;78(9):1365-1376. doi: 10.1007/s00228-022-03347-6. Epub 2022 Jun 22.","Lee S","Eur J Clin Pharmacol","2022","2022/06/21","","","10.1007/s00228-022-03347-6"
"34551130","Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache","Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R.","Headache. 2021 Oct;61(9):1421-1431. doi: 10.1111/head.14206. Epub 2021 Sep 22.","Marmura MJ","Headache","2021","2021/09/22","PMC9291601","","10.1111/head.14206"
"24754925","Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds","Grände G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L.","J Headache Pain. 2014 Apr 23;15(1):22. doi: 10.1186/1129-2377-15-22.","Grände G","J Headache Pain","2014","2014/04/24","PMC4011837","","10.1186/1129-2377-15-22"
"24867844","New treatments for headache","Vollbracht S, Rapoport AM.","Neurol Sci. 2014 May;35 Suppl 1:89-97. doi: 10.1007/s10072-014-1747-z.","Vollbracht S","Neurol Sci","2014","2014/05/29","","","10.1007/s10072-014-1747-z"
"34841526","Timing and durability of response to erenumab in patients with episodic migraine","McAllister PJ, Turner I, Reuter U, Wang A, Scanlon J, Klatt J, Chou DE, Paiva da Silva Lima G.","Headache. 2021 Nov;61(10):1553-1561. doi: 10.1111/head.14233. Epub 2021 Nov 28.","McAllister PJ","Headache","2021","2021/11/29","","","10.1111/head.14233"
"29318857","[Effect of Electroacupuncture on Expression of 5-HT(7) Receptor in Periaqueductal Gray and Plasma Calcitonin Gene-related Peptide in Migraine Rats]","Pei P, Chen HZ, Wang YX, Yang WM, Liu L, Wang LP.","Zhen Ci Yan Jiu. 2017 Dec 25;42(6):510-3. doi: 10.13702/j.1000-0607.2017.06.008.","Pei P","Zhen Ci Yan Jiu","2017","2018/01/11","","","10.13702/j.1000-0607.2017.06.008"
"36239038","Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial","Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB.","Headache. 2022 Oct;62(9):1153-1163. doi: 10.1111/head.14389. Epub 2022 Oct 14.","Croop R","Headache","2022","2022/10/14","PMC9827820","","10.1111/head.14389"
"32660269","The potential danger of blocking CGRP for treating migraine in CADASIL patients","de Boer I, MaassenVanDenBrink A, Terwindt GM.","Cephalalgia. 2020 Dec;40(14):1676-1678. doi: 10.1177/0333102420941814. Epub 2020 Jul 13.","de Boer I","Cephalalgia","2020","2020/07/15","PMC7691636","","10.1177/0333102420941814"
"23815106","Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs","Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A.","Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2.","Ramírez Rosas MB","Expert Opin Pharmacother","2013","2013/07/03","","","10.1517/14656566.2013.806487"
"20959432","BDNF and CGRP interaction: implications in migraine susceptibility","Lemos C, Mendonça D, Pereira-Monteiro J, Barros J, Sequeiros J, Alonso I, Sousa A.","Cephalalgia. 2010 Nov;30(11):1375-82. doi: 10.1177/0333102410368443. Epub 2010 May 10.","Lemos C","Cephalalgia","2010","2010/10/21","","","10.1177/0333102410368443"
"34309862","Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study","Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F; EARLY Study Group.","Headache. 2021 Oct;61(9):1351-1363. doi: 10.1111/head.14194. Epub 2021 Jul 26.","Barbanti P","Headache","2021","2021/07/26","","","10.1111/head.14194"
"35136961","The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?","Ernstsen C, Christensen SL, Rasmussen RH, Nielsen BS, Jansen-Olesen I, Olesen J, Kristensen DM.","Brain. 2022 Jul 29;145(7):2450-2460. doi: 10.1093/brain/awac040.","Ernstsen C","Brain","2022","2022/02/09","","","10.1093/brain/awac040"
"22005682","Trigeminal ganglion neuron subtype-specific alterations of Ca(V)2.1 calcium current and excitability in a Cacna1a mouse model of migraine","Fioretti B, Catacuzzeno L, Sforna L, Gerke-Duncan MB, van den Maagdenberg AM, Franciolini F, Connor M, Pietrobon D.","J Physiol. 2011 Dec 1;589(Pt 23):5879-95. doi: 10.1113/jphysiol.2011.220533. Epub 2011 Oct 17.","Fioretti B","J Physiol","2011","2011/10/19","PMC3249056","","10.1113/jphysiol.2011.220533"
"15014183","Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM; BIBN 4096 BS Clinical Proof of Concept Study Group.","N Engl J Med. 2004 Mar 11;350(11):1104-10. doi: 10.1056/NEJMoa030505.","Olesen J","N Engl J Med","2004","2004/03/12","","","10.1056/NEJMoa030505"
"34003147","Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety","Singh A, Gupta D, Singh A.","Neurol India. 2021 Mar-Apr;69(Supplement):S43-S50. doi: 10.4103/0028-3886.315991.","Singh A","Neurol India","2021","2021/05/18","","","10.4103/0028-3886.315991"
"10499171","Acute management of migraine: triptans and beyond","Diener HC, Limmroth V.","Curr Opin Neurol. 1999 Jun;12(3):261-7. doi: 10.1097/00019052-199906000-00004.","Diener HC","Curr Opin Neurol","1999","1999/09/28","","","10.1097/00019052-199906000-00004"
"33141461","Rates of Vascular Events in Patients With Migraine: A MarketScan(®) Database Retrospective Cohort Study","Gill K, Chia VM, Hernandez RK, Navetta M.","Headache. 2020 Nov;60(10):2265-2280. doi: 10.1111/head.14001. Epub 2020 Nov 3.","Gill K","Headache","2020","2020/11/03","PMC7756746","","10.1111/head.14001"
"34477213","Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine","Domitrz I, Sławek J, Słowik A, Boczarska-Jedynak M, Stępień A, Rejdak K, Gierczyński J, Rożniecki J.","Neurol Neurochir Pol. 2022;56(1):39-47. doi: 10.5603/PJNNS.a2021.0061. Epub 2021 Sep 3.","Domitrz I","Neurol Neurochir Pol","2022","2021/09/03","","","10.5603/PJNNS.a2021.0061"
"29471679","ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.","Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.","Dodick DW","Cephalalgia","2018","2018/02/24","","","10.1177/0333102418759786"
"33421995","Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes","Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S.","J Headache Pain. 2021 Jan 9;22(1):5. doi: 10.1186/s10194-020-01214-2.","Talbot J","J Headache Pain","2021","2021/01/10","PMC7797151","","10.1186/s10194-020-01214-2"
"35763113","Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience","Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group.","J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28.","Altamura C","J Neurol","2022","2022/06/28","PMC9243974","","10.1007/s00415-022-11226-4"
"23598374","Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients","Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsányi J, Szabó N, Tóth E, Kincses ZT, Vécsei L, Tajti J.","Cephalalgia. 2013 Oct;33(13):1085-95. doi: 10.1177/0333102413483931. Epub 2013 Apr 18.","Tuka B","Cephalalgia","2013","2013/04/20","","","10.1177/0333102413483931"
"29136283","Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling","Li CC, Dockendorf M, Kowalski K, Yang B, Xu Y, Xie I, Kleijn HJ, Bosch R, Jones C, Thornton B, Marcantonio EE, Voss T, Bateman KP, Kothare PA.","J Clin Pharmacol. 2018 Mar;58(3):294-303. doi: 10.1002/jcph.1021. Epub 2017 Nov 14.","Li CC","J Clin Pharmacol","2018","2017/11/15","","","10.1002/jcph.1021"
"16889959","Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine","Burgey CS, Stump CA, Nguyen DN, Deng JZ, Quigley AG, Norton BR, Bell IM, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Vacca JP, Graham SL, Williams TM.","Bioorg Med Chem Lett. 2006 Oct 1;16(19):5052-6. doi: 10.1016/j.bmcl.2006.07.044. Epub 2006 Aug 2.","Burgey CS","Bioorg Med Chem Lett","2006","2006/08/08","","","10.1016/j.bmcl.2006.07.044"
"34315403","Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model","Wang Y, Pan Q, Tian R, Wen Q, Qin G, Zhang D, Chen L, Zhang Y, Zhou J.","J Headache Pain. 2021 Jul 27;22(1):84. doi: 10.1186/s10194-021-01299-3.","Wang Y","J Headache Pain","2021","2021/07/28","PMC8314458","","10.1186/s10194-021-01299-3"
"33004160","Utilization of B12 for the treatment of chronic migraine","Urits I, Yilmaz M, Bahrun E, Merley C, Scoon L, Lassiter G, An D, Orhurhu V, Kaye AD, Viswanath O.","Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):479-491. doi: 10.1016/j.bpa.2020.07.009. Epub 2020 Jul 20.","Urits I","Best Pract Res Clin Anaesthesiol","2020","2020/10/02","","","10.1016/j.bpa.2020.07.009"
"33155431","miR-34a-5p up-regulates the IL-1β/COX2/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons","Zhang H, Zhang XM, Zong DD, Ji XY, Jiang H, Zhang FZ, He SD.","FEBS Open Bio. 2021 Jan;11(1):300-311. doi: 10.1002/2211-5463.13027. Epub 2020 Dec 16.","Zhang H","FEBS Open Bio","2021","2020/11/06","PMC7780114","","10.1002/2211-5463.13027"
"34217775","Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine","Srinivasan K, Kozminski K, Zhang Y, Wisniewski K, Kohout T, Wisniewska H, Harris G, Lindstrom B, Hargrove D.","J Pharm Sci. 2022 Jan;111(1):247-261. doi: 10.1016/j.xphs.2021.06.034. Epub 2021 Jul 2.","Srinivasan K","J Pharm Sci","2022","2021/07/04","","","10.1016/j.xphs.2021.06.034"
"32811179","Vascular actions of peripheral CGRP in migraine-like photophobia in mice","Mason BN, Wattiez AS, Balcziak LK, Kuburas A, Kutschke WJ, Russo AF.","Cephalalgia. 2020 Dec;40(14):1585-1604. doi: 10.1177/0333102420949173. Epub 2020 Aug 18.","Mason BN","Cephalalgia","2020","2020/08/20","PMC7785273","NIHMS1656530","10.1177/0333102420949173"
"32020557","Ubrogepant: First Approval","Scott LJ.","Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5.","Scott LJ","Drugs","2020","2020/02/06","PMC7062659","","10.1007/s40265-020-01264-5"
"34272688","Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis","Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.","CNS Drugs. 2021 Aug;35(8):805-820. doi: 10.1007/s40263-021-00834-9. Epub 2021 Jul 16.","Overeem LH","CNS Drugs","2021","2021/07/17","PMC8354912","","10.1007/s40263-021-00834-9"
"36006191","Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine","Scuteri D, Tonin P, Nicotera P, Vulnera M, Altieri GC, Tarsitano A, Bagetta G, Corasaniti MT.","Toxins (Basel). 2022 Aug 1;14(8):529. doi: 10.3390/toxins14080529.","Scuteri D","Toxins (Basel)","2022","2022/08/25","PMC9413678","","10.3390/toxins14080529"
"36701806","Recent Developments in Vestibular Migraine: A Narrative Review","Benjamin T, Gardi A, Sharon JD.","Am J Audiol. 2023 Nov;32(3S):739-745. doi: 10.1044/2022_AJA-22-00120. Epub 2023 Jan 26.","Benjamin T","Am J Audiol","2023","2023/01/26","","","10.1044/2022_AJA-22-00120"
"19845789","Distribution of artemin and GFRalpha3 labeled nerve fibers in the dura mater of rat: artemin and GFRalpha3 in the dura","McIlvried LA, Albers K, Gold MS.","Headache. 2010 Mar;50(3):442-50. doi: 10.1111/j.1526-4610.2009.01548.x. Epub 2009 Oct 21.","McIlvried LA","Headache","2010","2009/10/23","PMC3074600","NIHMS261675","10.1111/j.1526-4610.2009.01548.x"
"34428465","Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits","Martins-Oliveira M, Tavares I, Goadsby PJ.","Brain Res. 2021 Nov 1;1770:147629. doi: 10.1016/j.brainres.2021.147629. Epub 2021 Aug 21.","Martins-Oliveira M","Brain Res","2021","2021/08/24","","","10.1016/j.brainres.2021.147629"
"9176880","Molecular aspects of headaches and migraines. 7th International Headache Research Seminar. Copenhagen, Denmark, 22-24 November 1996","Edvinsson L, Olesen J.","Mol Med Today. 1997 May;3(5):191-3. doi: 10.1016/S1357-4310(97)01037-X.","Edvinsson L","Mol Med Today","1997","1997/05/01","","","10.1016/S1357-4310(97)01037-X"
"25731075","CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","Edvinsson L.","Br J Clin Pharmacol. 2015 Aug;80(2):193-9. doi: 10.1111/bcp.12618. Epub 2015 May 19.","Edvinsson L","Br J Clin Pharmacol","2015","2015/03/04","PMC4541967","","10.1111/bcp.12618"
"31612482","A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults","Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD.","Headache. 2019 Nov;59(10):1731-1742. doi: 10.1111/head.13652. Epub 2019 Oct 14.","Sakai F","Headache","2019","2019/10/16","PMC6900095","","10.1111/head.13652"
"31559638","Novel Medications for the Treatment of Migraine","Ceriani CEJ, Wilhour DA, Silberstein SD.","Headache. 2019 Oct;59(9):1597-1608. doi: 10.1111/head.13661. Epub 2019 Sep 26.","Ceriani CEJ","Headache","2019","2019/09/28","","","10.1111/head.13661"
"30360965","Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.","Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.","Reuter U","Lancet","2018","2018/10/27","","","10.1016/S0140-6736(18)32534-0"
"31758661","Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment","Li CC, Voss T, Kowalski K, Yang B, Kleijn HJ, Jones CJ, Bosch R, Michelson D, DeAngelis M, Xu Y, Xie I, Kothare PA.","Clin Transl Sci. 2020 May;13(3):482-490. doi: 10.1111/cts.12730. Epub 2020 Jan 16.","Li CC","Clin Transl Sci","2020","2019/11/24","PMC7214662","","10.1111/cts.12730"
"34128999","Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial","Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R.","JAMA. 2021 Jun 15;325(23):2348-2356. doi: 10.1001/jama.2021.7665.","Winner PK","JAMA","2021","2021/06/15","PMC8207242","","10.1001/jama.2021.7665"
"2001478","Innervation and effects of dilatory neuropeptides on cerebral vessels. New aspects","Edvinsson L.","Blood Vessels. 1991;28(1-3):35-45. doi: 10.1159/000158841.","Edvinsson L","Blood Vessels","1991","1991/01/01","","","10.1159/000158841"
"38307647","Evidence-based symptomatic treatment of migraine","Mitsikostas DD, Ward TN.","Handb Clin Neurol. 2024;199:203-218. doi: 10.1016/B978-0-12-823357-3.00004-5.","Mitsikostas DD","Handb Clin Neurol","2024","2024/02/02","","","10.1016/B978-0-12-823357-3.00004-5"
"21464715","Treatment of migraine: update on new therapies","Magis D, Schoenen J.","Curr Opin Neurol. 2011 Jun;24(3):203-10. doi: 10.1097/WCO.0b013e3283462c3f.","Magis D","Curr Opin Neurol","2011","2011/04/06","","","10.1097/WCO.0b013e3283462c3f"
"21467933","Advances in understanding the mechanisms of migraine-type photophobia","Noseda R, Burstein R.","Curr Opin Neurol. 2011 Jun;24(3):197-202. doi: 10.1097/WCO.0b013e3283466c8e.","Noseda R","Curr Opin Neurol","2011","2011/04/07","PMC4502959","NIHMS697196","10.1097/WCO.0b013e3283466c8e"
"12463284","Acute treatments: future developments","Ramadan NM.","Curr Med Res Opin. 2001;17 Suppl 1:s81-6. doi: 10.1185/0300799039117018.","Ramadan NM","Curr Med Res Opin","2001","2002/12/05","","","10.1185/0300799039117018"
"25147936","Possible association between dysfunction of vitamin D binding protein (GC Globulin) and migraine attacks","Nagata E, Fujii N, Hosomichi K, Mitsunaga S, Suzuki Y, Mashimo Y, Tsukamoto H, Satoh T, Osawa M, Inoue I, Hata A, Takizawa S.","PLoS One. 2014 Aug 22;9(8):e105319. doi: 10.1371/journal.pone.0105319. eCollection 2014.","Nagata E","PLoS One","2014","2014/08/23","PMC4141767","","10.1371/journal.pone.0105319"
"26650258","Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine","Luo G, Chen L, Conway CM, Kostich W, Macor JE, Dubowchik GM.","Org Lett. 2015 Dec 18;17(24):5982-5. doi: 10.1021/acs.orglett.5b02921. Epub 2015 Dec 9.","Luo G","Org Lett","2015","2015/12/10","","","10.1021/acs.orglett.5b02921"
"36804093","Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ.","Lancet Neurol. 2023 Mar;22(3):209-217. doi: 10.1016/S1474-4422(22)00517-8.","Lipton RB","Lancet Neurol","2023","2023/02/21","","","10.1016/S1474-4422(22)00517-8"
"37998384","From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment","Tanaka M, Szabó Á, Körtési T, Szok D, Tajti J, Vécsei L.","Cells. 2023 Nov 17;12(22):2649. doi: 10.3390/cells12222649.","Tanaka M","Cells","2023","2023/11/24","PMC10670698","","10.3390/cells12222649"
"33347632","Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache","Kang SA, Govindarajan R.","Muscle Nerve. 2021 Apr;63(4):563-567. doi: 10.1002/mus.27153. Epub 2021 Jan 8.","Kang SA","Muscle Nerve","2021","2020/12/21","","","10.1002/mus.27153"
"35260463","Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial","Ray JC, Chen Z, Ramsay G, Germaine J, Hutton EJ.","BMJ Open. 2022 Mar 8;12(3):e059647. doi: 10.1136/bmjopen-2021-059647.","Ray JC","BMJ Open","2022","2022/03/09","PMC8905943","","10.1136/bmjopen-2021-059647"
"36333710","Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis","Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, Lambru G.","J Headache Pain. 2022 Nov 4;23(1):139. doi: 10.1186/s10194-022-01507-8.","Andreou AP","J Headache Pain","2022","2022/11/05","PMC9635079","","10.1186/s10194-022-01507-8"
"32958075","The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study","Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z.","J Headache Pain. 2020 Sep 21;21(1):114. doi: 10.1186/s10194-020-01173-8.","Silberstein SD","J Headache Pain","2020","2020/09/22","PMC7507645","","10.1186/s10194-020-01173-8"
"35426060","The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine","Cohen F, Yuan H, DePoy EMG, Silberstein SD.","Neurotherapeutics. 2022 Apr;19(3):922-930. doi: 10.1007/s13311-022-01230-x. Epub 2022 Apr 14.","Cohen F","Neurotherapeutics","2022","2022/04/15","PMC9294119","","10.1007/s13311-022-01230-x"
"32423331","Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling","Younis S, Christensen CE, Vestergaard MB, Lindberg U, Tolnai D, Paulson OB, Larsson HB, Hougaard A, Ashina M.","J Cereb Blood Flow Metab. 2021 Mar;41(3):604-616. doi: 10.1177/0271678X20906902. Epub 2020 May 19.","Younis S","J Cereb Blood Flow Metab","2021","2020/05/20","PMC7922760","","10.1177/0271678X20906902"
"11069595","Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model","Knyihár-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihály A, Vécsei L.","Eur J Neurosci. 2000 Nov;12(11):3991-4002. doi: 10.1046/j.1460-9568.2000.00299.x.","Knyihár-Csillik E","Eur J Neurosci","2000","2000/11/09","","","10.1046/j.1460-9568.2000.00299.x"
"35115687","Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles","Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA, Thomas LF, Noordam R, Benner C, Gormley P, Artto V, Banasik K, Bjornsdottir A, Boomsma DI, Brumpton BM, Burgdorf KS, Buring JE, Chalmer MA, de Boer I, Dichgans M, Erikstrup C, Färkkilä M, Garbrielsen ME, Ghanbari M, Hagen K, Häppölä P, Hottenga JJ, Hrafnsdottir MG, Hveem K, Johnsen MB, Kähönen M, Kristoffersen ES, Kurth T, Lehtimäki T, Lighart L, Magnusson SH, Malik R, Pedersen OB, Pelzer N, Penninx BWJH, Ran C, Ridker PM, Rosendaal FR, Sigurdardottir GR, Skogholt AH, Sveinsson OA, Thorgeirsson TE, Ullum H, Vijfhuizen LS, Widén E, van Dijk KW; International Headache Genetics Consortium; HUNT All-in Headache; Danish Blood Donor Study Genomic Cohort; Aromaa A, Belin AC, Freilinger T, Ikram MA, Järvelin MR, Raitakari OT, Terwindt GM, Kallela M, Wessman M, Olesen J, Chasman DI, Nyholt DR, Stefánsson H, Stefansson K, van den Maagdenberg AMJM, Hansen TF, Ripatti S, Zwart JA, Palotie A, Pirinen M.","Nat Genet. 2022 Feb;54(2):152-160. doi: 10.1038/s41588-021-00990-0. Epub 2022 Feb 3.","Hautakangas H","Nat Genet","2022","2022/02/04","PMC8837554","","10.1038/s41588-021-00990-0"
"20236348","Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine","Wang X, Fang Y, Liang J, Yin Z, Miao J, Luo N.","Headache. 2010 Apr;50(4):579-87. doi: 10.1111/j.1526-4610.2010.01632.x. Epub 2010 Mar 5.","Wang X","Headache","2010","2010/03/19","","","10.1111/j.1526-4610.2010.01632.x"
"31937253","Microglia P2X4R-BDNF signalling contributes to central sensitization in a recurrent nitroglycerin-induced chronic migraine model","Long T, He W, Pan Q, Zhang S, Zhang D, Qin G, Chen L, Zhou J.","J Headache Pain. 2020 Jan 14;21(1):4. doi: 10.1186/s10194-019-1070-4.","Long T","J Headache Pain","2020","2020/01/16","PMC6961410","","10.1186/s10194-019-1070-4"
"37996793","Real-life experiences with galcanezumab and predictors for treatment response in Turkey","Yalinay Dikmen P, Baykan B, Uludüz D, Özge A, Ilgaz Aydınlar E, Polat B, Karlı N, Tepe N, Çelebisoy N, Ergin Toktaş H, Niflioğlu B, Karacı R, Mayda Domaç F, Uludüz E, Erdogan Soyukibar T, Öksüz N, Ertaş M.","BMC Neurol. 2023 Nov 23;23(1):418. doi: 10.1186/s12883-023-03467-1.","Yalinay Dikmen P","BMC Neurol","2023","2023/11/23","PMC10666377","","10.1186/s12883-023-03467-1"
"38402495","Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System","Sorbara EE, Barbieri MA, Russo G, Cicala G, Spina E.","BioDrugs. 2024 Mar;38(2):275-285. doi: 10.1007/s40259-024-00651-8. Epub 2024 Feb 25.","Sorbara EE","BioDrugs","2024","2024/02/25","","","10.1007/s40259-024-00651-8"
"20369076","Calcitonin gene-related peptide: A molecular link between obesity and migraine?","Recober A, Goadsby PJ.","Drug News Perspect. 2010 Mar;23(2):112-7. doi: 10.1358/dnp.2010.23.2.1475909.","Recober A","Drug News Perspect","2010","2010/04/07","PMC2947336","NIHMS225156","10.1358/dnp.2010.23.2.1475909"
"28425871","The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'","Xavier AS, Lakshmanan M, Gunaseelan V.","Curr Clin Pharmacol. 2017;12(1):36-40. doi: 10.2174/1574884712666170419155048.","Xavier AS","Curr Clin Pharmacol","2017","2017/04/21","","","10.2174/1574884712666170419155048"
"36548744","OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine","Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M.","Toxins (Basel). 2022 Dec 2;14(12):847. doi: 10.3390/toxins14120847.","Argyriou AA","Toxins (Basel)","2022","2022/12/22","PMC9785576","","10.3390/toxins14120847"
"27866934","Pharmacodynamic action and mechanism of Du Liang soft capsule, a traditional Chinese medicine capsule, on treating nitroglycerin-induced migraine","Hou M, Tang Q, Xue Q, Zhang X, Liu Y, Yang S, Chen L, Xu X.","J Ethnopharmacol. 2017 Jan 4;195:231-237. doi: 10.1016/j.jep.2016.11.025. Epub 2016 Nov 17.","Hou M","J Ethnopharmacol","2017","2016/11/22","","","10.1016/j.jep.2016.11.025"
"35978286","Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials","Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z, Ritter S, Klatt J, Snellman J.","J Headache Pain. 2022 Aug 18;23(1):104. doi: 10.1186/s10194-022-01470-4.","Lampl C","J Headache Pain","2022","2022/08/17","PMC9386939","","10.1186/s10194-022-01470-4"
"30813769","Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention","Garland SG, Smith SM, Gums JG.","Ann Pharmacother. 2019 Sep;53(9):933-939. doi: 10.1177/1060028019835166. Epub 2019 Feb 27.","Garland SG","Ann Pharmacother","2019","2019/03/01","","","10.1177/1060028019835166"
"30793254","Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety","Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M.","Drugs. 2019 Mar;79(4):417-431. doi: 10.1007/s40265-019-01069-1.","Lattanzi S","Drugs","2019","2019/02/23","","","10.1007/s40265-019-01069-1"
"33892641","Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments","Kuruppu DK, Tobin J, Dong Y, Aurora SK, Yunes-Medina L, Green AL.","BMC Neurol. 2021 Apr 23;21(1):175. doi: 10.1186/s12883-021-02196-7.","Kuruppu DK","BMC Neurol","2021","2021/04/24","PMC8063415","","10.1186/s12883-021-02196-7"
"32715736","Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study","De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni AM, Allena M, Guaschino E, Martinelli D, Putortì A, Grillo V, Sances G, Tassorelli C.","Cephalalgia. 2020 Oct;40(12):1336-1345. doi: 10.1177/0333102420942230. Epub 2020 Jul 26.","De Icco R","Cephalalgia","2020","2020/07/28","","","10.1177/0333102420942230"
"36373822","Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials","Gui T, Li H, Zhu F, Wang Q, Zhou X, Xue Q.","Headache. 2022 Nov;62(10):1281-1292. doi: 10.1111/head.14423. Epub 2022 Nov 14.","Gui T","Headache","2022","2022/11/14","","","10.1111/head.14423"
"34654536","Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications","Caronna E, José Gallardo V, Alpuente A, Torres-Ferrus M, Sánchez-Mateo NM, Viguera-Romero J, López-Veloso AC, López-Bravo A, Gago-Veiga AB, Irimia Sieira P, Porta-Etessam J, Santos-Lasaosa S, Pozo-Rosich P; Spanish CGRP-COVID Study Group.","Neurologia (Engl Ed). 2021 Oct;36(8):611-617. doi: 10.1016/j.nrleng.2021.03.005.","Caronna E","Neurologia (Engl Ed)","2021","2021/10/16","PMC8506139","","10.1016/j.nrleng.2021.03.005"
"11245884","Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine","Mitsikostas DD, Sanchez del Rio M.","Brain Res Brain Res Rev. 2001 Mar;35(1):20-35. doi: 10.1016/s0165-0173(00)00048-5.","Mitsikostas DD","Brain Res Brain Res Rev","2001","2001/03/14","","","10.1016/s0165-0173(00)00048-5"
"22862686","Emerging treatment for chronic migraine and refractory chronic migraine","Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P.","Expert Opin Emerg Drugs. 2012 Sep;17(3):393-406. doi: 10.1517/14728214.2012.709846. Epub 2012 Aug 3.","Lionetto L","Expert Opin Emerg Drugs","2012","2012/08/07","","","10.1517/14728214.2012.709846"
"32636324","One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study","Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD.","Neurology. 2020 Aug 4;95(5):e469-e479. doi: 10.1212/WNL.0000000000010019. Epub 2020 Jul 7.","Goadsby PJ","Neurology","2020","2020/07/09","PMC7455346","","10.1212/WNL.0000000000010019"
"30996056","Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD.","Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.","Tepper SJ","Neurology","2019","2019/04/19","PMC6598821","","10.1212/WNL.0000000000007497"
"35179780","The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain","Greco R, Demartini C, Zanaboni AM, Francavilla M, De Icco R, Ahmad L, Tassorelli C.","Headache. 2022 Mar;62(3):227-240. doi: 10.1111/head.14267. Epub 2022 Feb 18.","Greco R","Headache","2022","2022/02/18","","","10.1111/head.14267"
"32445498","Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses","Fiedler-Kelly J, Passarell J, Ludwig E, Levi M, Cohen-Barak O.","Headache. 2020 Jul;60(7):1376-1391. doi: 10.1111/head.13845. Epub 2020 May 23.","Fiedler-Kelly J","Headache","2020","2020/05/24","PMC7496732","","10.1111/head.13845"
"35662382","Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study","Cetta I, Messina R, Zanandrea L, Colombo B, Filippi M.","Neurol Sci. 2022 Sep;43(9):5769-5771. doi: 10.1007/s10072-022-06190-w. Epub 2022 Jun 4.","Cetta I","Neurol Sci","2022","2022/06/06","","","10.1007/s10072-022-06190-w"
"33136176","Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials","Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z.","Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. doi: 10.1007/s00210-020-02009-7. Epub 2020 Nov 2.","Gao B","Naunyn Schmiedebergs Arch Pharmacol","2021","2020/11/02","","","10.1007/s00210-020-02009-7"
"32459561","The current state of acute treatment for migraine in adults in the United States","Cooper W, Doty EG, Hochstetler H, Hake A, Martin V.","Postgrad Med. 2020 Sep;132(7):581-589. doi: 10.1080/00325481.2020.1767402. Epub 2020 May 27.","Cooper W","Postgrad Med","2020","2020/05/28","","","10.1080/00325481.2020.1767402"
"35904295","[Efficiency of erenumab in neurologist's real practice]","Belskaya GN, Kiryanova EA, Krasnikov AV, Prokopovich ME, Sakharova EV.","Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7):74-80. doi: 10.17116/jnevro202212207174.","Belskaya GN","Zh Nevrol Psikhiatr Im S S Korsakova","2022","2022/07/29","","","10.17116/jnevro202212207174"
"31952501","Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies","Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, Yunes-Medina L, Stauffer VL.","BMC Neurol. 2020 Jan 17;20(1):25. doi: 10.1186/s12883-020-1609-7.","Bangs ME","BMC Neurol","2020","2020/01/19","PMC6966798","","10.1186/s12883-020-1609-7"
"37909725","Xenobiotic Exposure and Migraine-Associated Signaling: A Multimethod Experimental Study Exploring Cellular Assays in Combination with Ex Vivo and In Vivo Mouse Models","Rasmussen RH, Christensen SL, Calloe K, Nielsen BS, Rehfeld A, Taylor-Clark TE, Haanes KA, Taboureau O, Audouze K, Klaerke DA, Olesen J, Kristensen DM.","Environ Health Perspect. 2023 Nov;131(11):117003. doi: 10.1289/EHP12413. Epub 2023 Nov 1.","Rasmussen RH","Environ Health Perspect","2023","2023/11/01","PMC10619430","","10.1289/EHP12413"
"30996060","Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study","Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.","Neurology. 2019 May 7;92(19):e2250-e2260. doi: 10.1212/WNL.0000000000007452. Epub 2019 Apr 17.","Lipton RB","Neurology","2019","2019/04/19","PMC6537129","","10.1212/WNL.0000000000007452"
"29082826","Gender aspects of CGRP in migraine","Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, MaassenVanDenBrink A.","Cephalalgia. 2019 Mar;39(3):435-444. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.","Labastida-Ramírez A","Cephalalgia","2019","2017/10/31","PMC6402050","","10.1177/0333102417739584"
"19587287","Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine","Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF.","J Neurosci. 2009 Jul 8;29(27):8798-804. doi: 10.1523/JNEUROSCI.1727-09.2009.","Recober A","J Neurosci","2009","2009/07/10","PMC2944225","NIHMS232292","10.1523/JNEUROSCI.1727-09.2009"
"12783573","New therapeutic target in primary headaches - blocking theCGRP receptor","Edvinsson L.","Expert Opin Ther Targets. 2003 Jun;7(3):377-83. doi: 10.1517/14728222.7.3.377.","Edvinsson L","Expert Opin Ther Targets","2003","2003/06/05","","","10.1517/14728222.7.3.377"
"17616394","Caprolactams as potent CGRP receptor antagonists for the treatment of migraine","Shaw AW, Paone DV, Nguyen DN, Stump CA, Burgey CS, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Graham SL, Vacca JP, Williams TM.","Bioorg Med Chem Lett. 2007 Sep 1;17(17):4795-8. doi: 10.1016/j.bmcl.2007.06.062. Epub 2007 Jun 26.","Shaw AW","Bioorg Med Chem Lett","2007","2007/07/10","","","10.1016/j.bmcl.2007.06.062"
"21172952","BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study","Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J.","Cephalalgia. 2011 Apr;31(5):573-84. doi: 10.1177/0333102410388435. Epub 2010 Dec 20.","Diener HC","Cephalalgia","2011","2010/12/22","","","10.1177/0333102410388435"
"34407650","CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine","Christensen SL, Rasmussen RH, Ernstsen C, La Cour S, David A, Chaker J, Haanes KA, Christensen ST, Olesen J, Kristensen DM.","Cephalalgia. 2021 Dec;41(14):1413-1426. doi: 10.1177/03331024211038884. Epub 2021 Aug 18.","Christensen SL","Cephalalgia","2021","2021/08/19","","","10.1177/03331024211038884"
"31146544","Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine","Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.","Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.","Ashina M","Cephalalgia","2019","2019/06/01","PMC6779015","","10.1177/0333102419854082"
"32638445","Effect of cinnamon on migraine attacks and inflammatory markers: A randomized double-blind placebo-controlled trial","Zareie A, Sahebkar A, Khorvash F, Bagherniya M, Hasanzadeh A, Askari G.","Phytother Res. 2020 Nov;34(11):2945-2952. doi: 10.1002/ptr.6721. Epub 2020 Jul 7.","Zareie A","Phytother Res","2020","2020/07/09","","","10.1002/ptr.6721"
"31872439","Non-Responders to Treatment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class","Ziegeler C, May A.","Headache. 2020 Feb;60(2):469-470. doi: 10.1111/head.13729. Epub 2019 Dec 24.","Ziegeler C","Headache","2020","2019/12/25","","","10.1111/head.13729"
"33040782","Tuling Wendan Decoction combined with flunarizine in the treatment of migraine patients and the effect of intervention on serum cyclooxygenase-2, endothelin-1 and nitric oxide","Xie X, Shang K, Li X.","Cell Mol Biol (Noisy-le-grand). 2020 Sep 30;66(6):34-40.","Xie X","Cell Mol Biol (Noisy-le-grand)","2020","2020/10/12","","",""
"8846403","Clinical perspectives of calcitonin gene related peptide pharmacology","Feuerstein G, Willette R, Aiyar N.","Can J Physiol Pharmacol. 1995 Jul;73(7):1070-4. doi: 10.1139/y95-152.","Feuerstein G","Can J Physiol Pharmacol","1995","1995/07/01","","","10.1139/y95-152"
"15985111","Plasma cytokine levels in migraineurs and controls","Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, Bussone G, Toso V.","Headache. 2005 Jul-Aug;45(7):926-31. doi: 10.1111/j.1526-4610.2005.05135.x.","Perini F","Headache","2005","2005/06/30","","","10.1111/j.1526-4610.2005.05135.x"
"33594672","Erenumab patient characteristics, medication adherence, and treatment patterns in the United States","Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M.","Headache. 2021 Apr;61(4):590-602. doi: 10.1111/head.14068. Epub 2021 Feb 16.","Hines DM","Headache","2021","2021/02/17","","","10.1111/head.14068"
"26704993","Pharmacological characterization of a novel gastrodin derivative as a potential anti-migraine agent","Wang PH, Zhao LX, Wan JY, Zhang L, Mao XN, Long FY, Zhang S, Chen C, Du JR.","Fitoterapia. 2016 Mar;109:52-7. doi: 10.1016/j.fitote.2015.12.007. Epub 2015 Dec 17.","Wang PH","Fitoterapia","2016","2015/12/26","","","10.1016/j.fitote.2015.12.007"
"16412148","Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients","Bellamy JL, Cady RK, Durham PL.","Headache. 2006 Jan;46(1):24-33. doi: 10.1111/j.1526-4610.2006.00294.x.","Bellamy JL","Headache","2006","2006/01/18","","","10.1111/j.1526-4610.2006.00294.x"
"23671255","Pearls and pitfalls in neural CGRP immunohistochemistry","Warfvinge K, Edvinsson L.","Cephalalgia. 2013 Jun;33(8):593-603. doi: 10.1177/0333102412472072.","Warfvinge K","Cephalalgia","2013","2013/05/15","","","10.1177/0333102412472072"
"36739511","Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials","Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ.","Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686.","Lipton RB","Cephalalgia","2023","2023/02/05","","","10.1177/03331024221141686"
"29752991","Cerebrolysin attenuates hyperalgesia, photophobia, and neuroinflammation in a nitroglycerin-induced migraine model in rats","Mahmoudi J, Mohaddes G, Erfani M, Sadigh-Eteghad S, Karimi P, Rajabi M, Reyhani-Rad S, Farajdokht F.","Brain Res Bull. 2018 Jun;140:197-204. doi: 10.1016/j.brainresbull.2018.05.008. Epub 2018 May 9.","Mahmoudi J","Brain Res Bull","2018","2018/05/13","","","10.1016/j.brainresbull.2018.05.008"
"34115380","Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine","Ashina M, Cohen JM, Gandhi SK, Du E.","Headache. 2021 Jun;61(6):916-926. doi: 10.1111/head.14127. Epub 2021 Jun 11.","Ashina M","Headache","2021","2021/06/11","PMC8362007","","10.1111/head.14127"
"21195698","Association study of calcitonin gene-related polypeptide-alpha (CALCA) gene polymorphism with migraine","Menon S, Buteri J, Roy B, Murrell M, Quinlan S, Macmillan JC, Lea RA, Haupt LM, Griffiths LR.","Brain Res. 2011 Mar 10;1378:119-24. doi: 10.1016/j.brainres.2010.12.072. Epub 2010 Dec 31.","Menon S","Brain Res","2011","2011/01/04","","","10.1016/j.brainres.2010.12.072"
"11422450","Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats","Ma QP, Hill R, Sirinathsinghji D.","Eur J Neurosci. 2001 Jun;13(11):2099-104. doi: 10.1046/j.0953-816x.2001.01586.x.","Ma QP","Eur J Neurosci","2001","2001/06/26","","","10.1046/j.0953-816x.2001.01586.x"
"32209650","Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R.","Neurology. 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Epub 2020 Mar 24.","Lipton RB","Neurology","2020","2020/03/27","PMC7274916","","10.1212/WNL.0000000000009169"
"36510143","CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine","Chou TM, Lee ZF, Wang SJ, Lien CC, Chen SP.","J Headache Pain. 2022 Dec 12;23(1):157. doi: 10.1186/s10194-022-01531-8.","Chou TM","J Headache Pain","2022","2022/12/12","PMC9746101","","10.1186/s10194-022-01531-8"
"18991732","The tortuous road to an ideal CGRP function blocker for the treatment of migraine","Davis CD, Xu C.","Curr Top Med Chem. 2008;8(16):1468-79. doi: 10.2174/156802608786264218.","Davis CD","Curr Top Med Chem","2008","2008/11/11","","","10.2174/156802608786264218"
"18498397","Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo","Martino G, Perkins MN.","Cephalalgia. 2008 Jul;28(7):723-33. doi: 10.1111/j.1468-2982.2008.01582.x. Epub 2008 May 21.","Martino G","Cephalalgia","2008","2008/05/24","","","10.1111/j.1468-2982.2008.01582.x"
"29913472","Erenumab (Aimovig) for migraine prevention","","Med Lett Drugs Ther. 2018 Jun 18;60(1549):101-103.","","Med Lett Drugs Ther","2018","2018/06/19","","",""
"33382087","Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report","Spector AR, Kerkow JF, Collins TA.","Headache. 2021 Jan;61(1):216-217. doi: 10.1111/head.14055. Epub 2020 Dec 31.","Spector AR","Headache","2021","2020/12/31","","","10.1111/head.14055"
"37925645","Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review","Takizawa T, Ihara K, Uno S, Ohtani S, Watanabe N, Imai N, Nakahara J, Hori S, Garcia-Azorin D, Martelletti P.","Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):951-967. doi: 10.1080/17425255.2023.2280221. Epub 2024 Jan 12.","Takizawa T","Expert Opin Drug Metab Toxicol","2023","2023/11/05","","","10.1080/17425255.2023.2280221"
"21130807","Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects","Chan KY, Vermeersch S, de Hoon J, Villalón CM, Maassenvandenbrink A.","Pharmacol Ther. 2011 Mar;129(3):332-51. doi: 10.1016/j.pharmthera.2010.12.001. Epub 2010 Dec 2.","Chan KY","Pharmacol Ther","2011","2010/12/07","","","10.1016/j.pharmthera.2010.12.001"
"20937606","Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan","Dodick DW, Kost J, Assaid C, Lines C, Ho TW.","Cephalalgia. 2011 Feb;31(3):296-300. doi: 10.1177/0333102410385585. Epub 2010 Oct 11.","Dodick DW","Cephalalgia","2011","2010/10/13","","","10.1177/0333102410385585"
"20347391","TRPV1 in migraine pathophysiology","Meents JE, Neeb L, Reuter U.","Trends Mol Med. 2010 Apr;16(4):153-9. doi: 10.1016/j.molmed.2010.02.004. Epub 2010 Mar 27.","Meents JE","Trends Mol Med","2010","2010/03/30","","","10.1016/j.molmed.2010.02.004"
"31035923","The effect of orofacial complete Freund's adjuvant treatment on the expression of migraine-related molecules","Körtési T, Tuka B, Nyári A, Vécsei L, Tajti J.","J Headache Pain. 2019 Apr 29;20(1):43. doi: 10.1186/s10194-019-0999-7.","Körtési T","J Headache Pain","2019","2019/05/01","PMC6734445","","10.1186/s10194-019-0999-7"
"19467597","Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability","Degnan AP, Conway CM, Dalterio RA, Macci R, Mercer SE, Schartman R, Xu C, Dubowchik GM, Macor JE.","Bioorg Med Chem Lett. 2009 Jul 1;19(13):3555-8. doi: 10.1016/j.bmcl.2009.04.150. Epub 2009 May 8.","Degnan AP","Bioorg Med Chem Lett","2009","2009/05/27","","","10.1016/j.bmcl.2009.04.150"
"35896988","Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study","Hu B, Li G, Li X, Wu S, Yu T, Li X, Zhao H, Jia Z, Zhuang J, Yu S.","J Headache Pain. 2022 Jul 28;23(1):90. doi: 10.1186/s10194-022-01458-0.","Hu B","J Headache Pain","2022","2022/07/27","PMC9330971","","10.1186/s10194-022-01458-0"
"32557089","Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab","Frattale I, Ornello R, Pistoia F, Caponnetto V, Colangeli E, Sacco S.","Intern Emerg Med. 2021 Jan;16(1):227-228. doi: 10.1007/s11739-020-02407-y. Epub 2020 Jun 17.","Frattale I","Intern Emerg Med","2021","2020/06/20","","","10.1007/s11739-020-02407-y"
"30594122","Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","Förderreuther S, Zhang Q, Stauffer VL, Aurora SK, Láinez MJA.","J Headache Pain. 2018 Dec 29;19(1):121. doi: 10.1186/s10194-018-0951-2.","Förderreuther S","J Headache Pain","2018","2018/12/31","PMC6755564","","10.1186/s10194-018-0951-2"
"38311738","Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials","Deng X, Zhou L, Liang C, Shang X, Hui X, Liu W, Liang S, Wang Y, Xu M, Guo K, Yang K, Li X.","J Headache Pain. 2024 Feb 5;25(1):16. doi: 10.1186/s10194-024-01723-4.","Deng X","J Headache Pain","2024","2024/02/04","PMC10840250","","10.1186/s10194-024-01723-4"
"31297805","Erenumab Side Effects","Robbins L.","Headache. 2019 Jul;59(7):1088-1089. doi: 10.1111/head.13589.","Robbins L","Headache","2019","2019/07/13","","","10.1111/head.13589"
"21335365","Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?","Tfelt-Hansen P.","Cephalalgia. 2011 Aug;31(11):1240. doi: 10.1177/0333102411398154. Epub 2011 Feb 18.","Tfelt-Hansen P","Cephalalgia","2011","2011/02/22","","","10.1177/0333102411398154"
"20482328","Calcitonin gene-related peptide receptor antagonists for migraine","Fischer MJ.","Expert Opin Investig Drugs. 2010 Jul;19(7):815-23. doi: 10.1517/13543784.2010.490829.","Fischer MJ","Expert Opin Investig Drugs","2010","2010/05/21","","","10.1517/13543784.2010.490829"
"37550498","The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)","Filippi M, Messina R, Bartezaghi M, Cetta I, Colombo B, Grazzi L, Martinelli D, Ornello R, Pichiecchio A, Raimondi D, Russo A, Sacco S, Splendiani A, Tassorelli C, Turrini R, Valsasina P, Rocca MA; RESET BRAIN Study Group.","J Neurol. 2023 Nov;270(11):5600-5612. doi: 10.1007/s00415-023-11879-9. Epub 2023 Aug 8.","Filippi M","J Neurol","2023","2023/08/07","PMC10576673","","10.1007/s00415-023-11879-9"
"26432181","Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD.","Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.","Bigal ME","Lancet Neurol","2015","2015/10/04","","","10.1016/S1474-4422(15)00245-8"
"31043094","Fremanezumab as a preventive treatment for episodic and chronic migraine","Bigal ME, Walter S, Rapoport AM.","Expert Rev Neurother. 2019 Aug;19(8):719-728. doi: 10.1080/14737175.2019.1614742. Epub 2019 May 22.","Bigal ME","Expert Rev Neurother","2019","2019/05/03","","","10.1080/14737175.2019.1614742"
"30235976","Erenumab in the treatment of migraine","Jain S, Yuan H, Spare N, Silberstein SD.","Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21.","Jain S","Pain Manag","2018","2018/09/22","","","10.2217/pmt-2018-0037"
"36031609","Trends in utilization and costs of migraine medications, 2017-2020","Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, Good CB.","J Headache Pain. 2022 Aug 28;23(1):111. doi: 10.1186/s10194-022-01476-y.","Nguyen JL","J Headache Pain","2022","2022/08/28","PMC9420279","","10.1186/s10194-022-01476-y"
"20416945","New drugs in migraine treatment and prophylaxis: telcagepant and topiramate","Edvinsson L, Linde M.","Lancet. 2010 Aug 21;376(9741):645-55. doi: 10.1016/S0140-6736(10)60323-6. Epub 2010 Apr 21.","Edvinsson L","Lancet","2010","2010/04/27","","","10.1016/S0140-6736(10)60323-6"
"31752521","Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine","Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y.","Cephalalgia. 2020 Apr;40(5):470-477. doi: 10.1177/0333102419885905. Epub 2019 Nov 21.","Brandes JL","Cephalalgia","2020","2019/11/23","","","10.1177/0333102419885905"
"21331665","Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin","Zhu X, Han Y, Xiong W, Liu W, Lu S, Li J, Wang H, Fan Z.","Neurol Sci. 2011 Aug;32(4):589-94. doi: 10.1007/s10072-011-0486-7. Epub 2011 Feb 18.","Zhu X","Neurol Sci","2011","2011/02/19","","","10.1007/s10072-011-0486-7"
"30091544","[Effect of Manual Acupuncture Preconditioning on Behavior and Contents of Serum CGRP, SP, IL-1 β and TNF-α Levels in Migraine Rats]","Wang MM, Yu XH, Geng W, Cui HF, Wang CC, Han J, Yang DH.","Zhen Ci Yan Jiu. 2018 Jun 25;43(6):375-9. doi: 10.13702/j.1000-0607.170415.","Wang MM","Zhen Ci Yan Jiu","2018","2018/08/10","","","10.13702/j.1000-0607.170415"
"33594686","Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study","Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB.","Headache. 2021 Mar;61(3):438-454. doi: 10.1111/head.14053. Epub 2021 Feb 16.","Kawata AK","Headache","2021","2021/02/17","PMC8048891","","10.1111/head.14053"
"27175010","Inefficient constitutive inhibition of P2X3 receptors by brain natriuretic peptide system contributes to sensitization of trigeminal sensory neurons in a genetic mouse model of familial hemiplegic migraine","Marchenkova A, Vilotti S, Ntamati N, van den Maagdenberg AM, Nistri A.","Mol Pain. 2016 May 12;12:1744806916646110. doi: 10.1177/1744806916646110. Print 2016.","Marchenkova A","Mol Pain","2016","2016/05/14","PMC4955999","","10.1177/1744806916646110"
"36380284","Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study","Ehrlich M, Hentschke C, Sieder C, Maier-Peuschel M, Reuter U.","J Headache Pain. 2022 Nov 15;23(1):141. doi: 10.1186/s10194-022-01511-y.","Ehrlich M","J Headache Pain","2022","2022/11/15","PMC9664641","","10.1186/s10194-022-01511-y"
"38157876","The history and rationale of the development of new drugs for migraine treatment","Kowacs PA, Sampaio Rocha-Filho PA, Peres MFP, Edvinsson L.","Arq Neuropsiquiatr. 2023 Dec;81(12):1084-1097. doi: 10.1055/s-0043-1777723. Epub 2023 Dec 29.","Kowacs PA","Arq Neuropsiquiatr","2023","2023/12/29","PMC10756794","","10.1055/s-0043-1777723"
"31595600","Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies","Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK.","Eur J Neurol. 2020 Mar;27(3):542-549. doi: 10.1111/ene.14102. Epub 2019 Dec 10.","Ailani J","Eur J Neurol","2020","2019/10/10","PMC7028018","","10.1111/ene.14102"
"33749851","Meningeal CGRP-Prolactin Interaction Evokes Female-Specific Migraine Behavior","Avona A, Mason BN, Burgos-Vega C, Hovhannisyan AH, Belugin SN, Mecklenburg J, Goffin V, Wajahat N, Price TJ, Akopian AN, Dussor G.","Ann Neurol. 2021 Jun;89(6):1129-1144. doi: 10.1002/ana.26070. Epub 2021 Apr 22.","Avona A","Ann Neurol","2021","2021/03/22","PMC8195469","NIHMS1703764","10.1002/ana.26070"
"31310337","Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists","Evans RW.","Headache. 2019 Sep;59(8):1360-1364. doi: 10.1111/head.13596. Epub 2019 Jul 16.","Evans RW","Headache","2019","2019/07/17","","","10.1111/head.13596"
"35727536","Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects","Shen Q, Jin Y, Di X, Hu C, Liu R, Wang Y, Qi X, Wang Y, Wang Z.","Clin Drug Investig. 2022 Jul;42(7):623-630. doi: 10.1007/s40261-022-01171-5. Epub 2022 Jun 21.","Shen Q","Clin Drug Investig","2022","2022/06/21","","","10.1007/s40261-022-01171-5"
"33434187","Drugs for Migraine","","Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-160.","","Med Lett Drugs Ther","2020","2021/01/12","","",""
"29335794","Effect of a calcitonin gene-related peptide-binding L-RNA aptamer on neuronal activity in the rat spinal trigeminal nucleus","Fischer MJM, Schmidt J, Koulchitsky S, Klussmann S, Vater A, Messlinger K.","J Headache Pain. 2018 Jan 15;19(1):3. doi: 10.1186/s10194-018-0832-8.","Fischer MJM","J Headache Pain","2018","2018/01/17","PMC5768576","","10.1186/s10194-018-0832-8"
"29623444","Polygenic risk score: use in migraine research","Chalmer MA, Esserlind AL, Olesen J, Hansen TF.","J Headache Pain. 2018 Apr 5;19(1):29. doi: 10.1186/s10194-018-0856-0.","Chalmer MA","J Headache Pain","2018","2018/04/07","PMC5887014","","10.1186/s10194-018-0856-0"
"20958294","Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ.","Headache. 2010 Oct;50(9):1406-18. doi: 10.1111/j.1526-4610.2010.01766.x.","Blumenfeld A","Headache","2010","2010/10/21","","","10.1111/j.1526-4610.2010.01766.x"
"24668446","The TRPA1 channel in inflammatory and neuropathic pain and migraine","Nassini R, Materazzi S, Benemei S, Geppetti P.","Rev Physiol Biochem Pharmacol. 2014;167:1-43. doi: 10.1007/112_2014_18.","Nassini R","Rev Physiol Biochem Pharmacol","2014","2014/03/27","","","10.1007/112_2014_18"
"18384419","Comparison of CGRP and NO responses in the human peripheral microcirculation of migraine and control subjects","Edvinsson ML, Edvinsson L.","Cephalalgia. 2008 May;28(5):563-6. doi: 10.1111/j.1468-2982.2008.01558.x. Epub 2008 Mar 31.","Edvinsson ML","Cephalalgia","2008","2008/04/04","","","10.1111/j.1468-2982.2008.01558.x"
"36752584","Prolactin in headache and migraine: A systematic review of preclinical studies","Al-Karagholi MA, Kalatharan V, Ghanizada H, Dussor G, Ashina M.","Headache. 2023 May;63(5):577-584. doi: 10.1111/head.14412. Epub 2023 Feb 8.","Al-Karagholi MA","Headache","2023","2023/02/08","","","10.1111/head.14412"
"19438917","Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache","De Felice M, Porreca F.","Cephalalgia. 2009 Dec;29(12):1277-84. doi: 10.1111/j.1468-2982.2009.01873.x. Epub 2009 May 11.","De Felice M","Cephalalgia","2009","2009/05/15","PMC5693217","NIHMS918979","10.1111/j.1468-2982.2009.01873.x"
"31666008","The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal","Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S.","J Headache Pain. 2019 Oct 30;20(1):99. doi: 10.1186/s10194-019-1054-4.","Ornello R","J Headache Pain","2019","2019/11/01","PMC6822439","","10.1186/s10194-019-1054-4"
"29693578","A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats","Feng S, He X, Zhong P, Zhao J, Huang C, Hu Z.","Molecules. 2018 Apr 25;23(5):1004. doi: 10.3390/molecules23051004.","Feng S","Molecules","2018","2018/04/26","PMC6102536","","10.3390/molecules23051004"
"7715843","Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache","Knyihar-Csillik E, Tajti J, Mohtasham S, Sari G, Vecsei L.","Neurosci Lett. 1995 Jan 30;184(3):189-92. doi: 10.1016/0304-3940(94)11203-u.","Knyihar-Csillik E","Neurosci Lett","1995","1995/01/30","","","10.1016/0304-3940(94)11203-u"
"21818718","[Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine]","Messlinger K, Fischer MJ, Lennerz JK.","Schmerz. 2011 Aug;25(4):393-8, 400-1. doi: 10.1007/s00482-011-1069-5.","Messlinger K","Schmerz","2011","2011/08/06","","","10.1007/s00482-011-1069-5"
"17203873","[The modulatory effect of estrogen on the caudal trigeminal nucleus of the rat in an animal model of migraine]","Varga H, Párdutz A, Tajti J, Vécsei L, Schoenen J.","Ideggyogy Sz. 2006 Nov 20;59(11-12):389-95.","Varga H","Ideggyogy Sz","2006","2007/01/06","","",""
"31919565","Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis","Kokoti L, Drellia K, Papadopoulos D, Mitsikostas DD.","J Neurol. 2020 Apr;267(4):1158-1170. doi: 10.1007/s00415-019-09673-7. Epub 2020 Jan 9.","Kokoti L","J Neurol","2020","2020/01/11","","","10.1007/s00415-019-09673-7"
"29532195","The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system","Messlinger K.","J Headache Pain. 2018 Mar 12;19(1):22. doi: 10.1186/s10194-018-0848-0.","Messlinger K","J Headache Pain","2018","2018/03/14","PMC5847494","","10.1186/s10194-018-0848-0"
"30764776","Migraine-provoking substances evoke periorbital allodynia in mice","De Logu F, Landini L, Janal MN, Li Puma S, De Cesaris F, Geppetti P, Nassini R.","J Headache Pain. 2019 Feb 14;20(1):18. doi: 10.1186/s10194-019-0968-1.","De Logu F","J Headache Pain","2019","2019/02/16","PMC6734434","","10.1186/s10194-019-0968-1"
"31876735","Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials","Zhu C, Guan J, Xiao H, Luo W, Tong R.","Medicine (Baltimore). 2019 Dec;98(52):e18483. doi: 10.1097/MD.0000000000018483.","Zhu C","Medicine (Baltimore)","2019","2019/12/27","PMC6946432","","10.1097/MD.0000000000018483"
"20590623","Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model","Chan KY, Gupta S, de Vries R, Danser AH, Villalón CM, Muñoz-Islas E, Maassenvandenbrink A.","Br J Pharmacol. 2010 Jul;160(6):1316-25. doi: 10.1111/j.1476-5381.2010.00733.x.","Chan KY","Br J Pharmacol","2010","2010/07/02","PMC2938804","","10.1111/j.1476-5381.2010.00733.x"
"11251696","Deficiency of tumor necrosis factor alpha in a subclass of menstrual migraineurs","Mueller L, Gupta AK, Stein TP.","Headache. 2001 Feb;41(2):129-37. doi: 10.1046/j.1526-4610.2001.111006129.x.","Mueller L","Headache","2001","2001/03/17","","","10.1046/j.1526-4610.2001.111006129.x"
"34404250","Could erectile dysfunction be a side effect of CGRP inhibition? A case report","Al-Hassany L, Vries T, Carpay JA, MaassenVanDenBrink A.","Cephalalgia. 2022 Mar;42(3):257-261. doi: 10.1177/03331024211037304. Epub 2021 Aug 18.","Al-Hassany L","Cephalalgia","2022","2021/08/18","PMC8988460","","10.1177/03331024211037304"
"36604785","Temporal alterations of pituitary adenylate cyclase activating polypeptide and its receptors in a rat model induced by recurrent chemical stimulations: Relevant to chronic migraine","Wu H, Dong Z, Liu Y, Zhang Q, Zhang M, Hu G, Yu S, Han X.","Mol Pain. 2023 Jan-Dec;19:17448069231152129. doi: 10.1177/17448069231152129.","Wu H","Mol Pain","2023","2023/01/06","PMC9869212","","10.1177/17448069231152129"
"36946234","Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study","Russo CV, Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R.","Cephalalgia. 2023 Apr;43(4):3331024231161809. doi: 10.1177/03331024231161809.","Russo CV","Cephalalgia","2023","2023/03/22","","","10.1177/03331024231161809"
"34162645","Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial","Schmidt K, Kleine-Borgmann J, Holle-Lee D, Gaul C, Bingel U.","BMJ Open. 2021 Jun 23;11(6):e045969. doi: 10.1136/bmjopen-2020-045969.","Schmidt K","BMJ Open","2021","2021/06/24","PMC8230930","","10.1136/bmjopen-2020-045969"
"37979595","Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA","Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM.","Lancet. 2023 Dec 16;402(10419):2307-2316. doi: 10.1016/S0140-6736(23)01683-5. Epub 2023 Nov 15.","Dodick DW","Lancet","2023","2023/11/18","","","10.1016/S0140-6736(23)01683-5"
"29941531","FDA approves licensing of erenumab-aooe to prevent migraine","Traynor K.","Am J Health Syst Pharm. 2018 Jul 1;75(13):929-930. doi: 10.2146/news180044.","Traynor K","Am J Health Syst Pharm","2018","2018/06/27","","","10.2146/news180044"
"30917684","A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody","Kielbasa W, Helton DL.","Cephalalgia. 2019 Sep;39(10):1284-1297. doi: 10.1177/0333102419840780. Epub 2019 Mar 27.","Kielbasa W","Cephalalgia","2019","2019/03/29","PMC6710614","","10.1177/0333102419840780"
"29255900","Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial","Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW.","JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859.","Skljarevski V","JAMA Neurol","2018","2017/12/20","PMC5838630","","10.1001/jamaneurol.2017.3859"
"38223948","[New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants]","Mínguez-Olaondo A, López-Bravo A, Quintas S, Nieves-Castellanos C, Layos-Romero A, Belvís R, Irimia P, Díaz-Insa S.","Rev Neurol. 2024 Jan 16;78(2):47-57. doi: 10.33588/rn.7802.2023176.","Mínguez-Olaondo A","Rev Neurol","2024","2024/01/15","","","10.33588/rn.7802.2023176"
"30165876","Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation","Long T, He W, Pan Q, Zhang S, Zhang Y, Liu C, Liu Q, Qin G, Chen L, Zhou J.","J Neuroinflammation. 2018 Aug 30;15(1):245. doi: 10.1186/s12974-018-1285-3.","Long T","J Neuroinflammation","2018","2018/09/01","PMC6117935","","10.1186/s12974-018-1285-3"
"34830154","TRPA1-Mediated Src Family Kinases Activity Facilitates Cortical Spreading Depression Susceptibility and Trigeminovascular System Sensitization","Nie L, Jiang L, Quinn JP, Grubb BD, Wang M.","Int J Mol Sci. 2021 Nov 12;22(22):12273. doi: 10.3390/ijms222212273.","Nie L","Int J Mol Sci","2021","2021/11/27","PMC8620265","","10.3390/ijms222212273"
"12081660","Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen","Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J.","Eur J Neurosci. 2002 Jun;15(11):1803-9. doi: 10.1046/j.1460-9568.2002.02031.x.","Pardutz A","Eur J Neurosci","2002","2002/06/26","","","10.1046/j.1460-9568.2002.02031.x"
"27865545","Anti-CGRP antibodies block CGRP-induced diarrhea in mice","Kaiser EA, Rea BJ, Kuburas A, Kovacevich BR, Garcia-Martinez LF, Recober A, Russo AF.","Neuropeptides. 2017 Aug;64:95-99. doi: 10.1016/j.npep.2016.11.004. Epub 2016 Nov 14.","Kaiser EA","Neuropeptides","2017","2016/11/21","PMC5429995","NIHMS831884","10.1016/j.npep.2016.11.004"
"32061264","Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis","Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL, Tang ZP.","BMC Neurol. 2020 Feb 15;20(1):57. doi: 10.1186/s12883-020-01633-3.","Deng H","BMC Neurol","2020","2020/02/17","PMC7023812","","10.1186/s12883-020-01633-3"
"32985222","A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain","Kopruszinski CM, Navratilova E, Swiokla J, Dodick DW, Chessell IP, Porreca F.","Cephalalgia. 2021 Mar;41(3):305-317. doi: 10.1177/0333102420959794. Epub 2020 Sep 26.","Kopruszinski CM","Cephalalgia","2021","2020/09/28","PMC7995998","NIHMS1674948","10.1177/0333102420959794"
"32264820","Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S.","J Headache Pain. 2020 Apr 7;21(1):32. doi: 10.1186/s10194-020-01102-9.","Ornello R","J Headache Pain","2020","2020/04/09","PMC7137484","","10.1186/s10194-020-01102-9"
"19766109","Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs","Lynch JJ, Shen YT, Pittman TJ, Anderson KD, Koblan KS, Gould RJ, Regan CP, Kane SA.","Eur J Pharmacol. 2009 Nov 25;623(1-3):96-102. doi: 10.1016/j.ejphar.2009.09.018. Epub 2009 Sep 17.","Lynch JJ","Eur J Pharmacol","2009","2009/09/22","","","10.1016/j.ejphar.2009.09.018"
"19579177","Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine","Tepper SJ, Cleves C.","Curr Opin Investig Drugs. 2009 Jul;10(7):711-20.","Tepper SJ","Curr Opin Investig Drugs","2009","2009/07/07","","",""
"37757639","Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing","Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Takemura R, Hori S, Nakahara J, Takizawa T.","J Neurol Sci. 2023 Oct 15;453:120811. doi: 10.1016/j.jns.2023.120811. Epub 2023 Sep 16.","Ihara K","J Neurol Sci","2023","2023/09/27","","","10.1016/j.jns.2023.120811"
"37365293","[Clinical use of botulinum toxin type A in pain medicine]","Schwarzer A, Mäcken T, Enax-Krumova EK.","Schmerz. 2023 Aug;37(4):297-307. doi: 10.1007/s00482-023-00730-9. Epub 2023 Jun 26.","Schwarzer A","Schmerz","2023","2023/06/26","","","10.1007/s00482-023-00730-9"
"34000848","Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach","Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L.","Cephalalgia. 2021 Sep;41(10):1065-1074. doi: 10.1177/03331024211007789. Epub 2021 May 17.","Cohen-Barak O","Cephalalgia","2021","2021/05/18","","","10.1177/03331024211007789"
"19068510","Migraine, allodynia, and implications for treatment","Schürks M, Diener HC.","Eur J Neurol. 2008 Dec;15(12):1279-85. doi: 10.1111/j.1468-1331.2008.02343.x.","Schürks M","Eur J Neurol","2008","2008/12/11","","","10.1111/j.1468-1331.2008.02343.x"
"33529288","Migraine and adult-onset stuttering: A proposed autoimmune phenomenon","Wong SM, Kim JY, Maguire GA.","Ann Clin Psychiatry. 2021 Feb;33(1):56-57. doi: 10.12788/acp.0016.","Wong SM","Ann Clin Psychiatry","2021","2021/02/02","","","10.12788/acp.0016"
"30789292","Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials","Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y, Liu L.","Cephalalgia. 2019 Aug;39(9):1164-1179. doi: 10.1177/0333102419829007. Epub 2019 Feb 21.","Xu D","Cephalalgia","2019","2019/02/22","","","10.1177/0333102419829007"
"37009867","Shared and independent roles of CGRP and PACAP in migraine pathophysiology","Kuburas A, Russo AF.","J Headache Pain. 2023 Apr 3;24(1):34. doi: 10.1186/s10194-023-01569-2.","Kuburas A","J Headache Pain","2023","2023/04/03","PMC10069045","","10.1186/s10194-023-01569-2"
"29298622","Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers","Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M.","Nutr Neurosci. 2019 Sep;22(9):607-615. doi: 10.1080/1028415X.2017.1421039. Epub 2018 Jan 3.","Dahri M","Nutr Neurosci","2019","2018/01/05","","","10.1080/1028415X.2017.1421039"
"30220332","A new theory on GABA and Calcitonin Gene-Related Peptide involvement in Mal de Debarquement Syndrome predisposition factors and pathophysiology","Mucci V, Jacquemyn Y, Van Ombergen A, Van de Heyning PH, Browne CJ.","Med Hypotheses. 2018 Nov;120:128-134. doi: 10.1016/j.mehy.2018.08.024. Epub 2018 Aug 29.","Mucci V","Med Hypotheses","2018","2018/09/18","","","10.1016/j.mehy.2018.08.024"
"24391116","Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead","Ibrahimi K, Vermeersch S, Danser A, Villalón CM, van den Meiracker AH, de Hoon J, MaassenVanDenBrink A.","Cephalalgia. 2014 Jun;34(7):514-22. doi: 10.1177/0333102413517773. Epub 2014 Jan 3.","Ibrahimi K","Cephalalgia","2014","2014/01/07","","","10.1177/0333102413517773"
"33792938","Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review","Ala M, Ghasemi M, Mohammad Jafari R, Dehpour AR.","Drug Dev Res. 2021 Nov;82(7):896-906. doi: 10.1002/ddr.21819. Epub 2021 Apr 1.","Ala M","Drug Dev Res","2021","2021/04/01","","","10.1002/ddr.21819"
"7515329","Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura","Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J.","Cephalalgia. 1994 Feb;14(1):47-54. doi: 10.1046/j.1468-2982.1994.1401047.x.","Friberg L","Cephalalgia","1994","1994/02/01","","","10.1046/j.1468-2982.1994.1401047.x"
"19737844","Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus","Sixt ML, Messlinger K, Fischer MJ.","Brain. 2009 Nov;132(Pt 11):3134-41. doi: 10.1093/brain/awp168. Epub 2009 Sep 8.","Sixt ML","Brain","2009","2009/09/10","","","10.1093/brain/awp168"
"34153117","Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study","Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.","Headache. 2021 Jun;61(6):927-935. doi: 10.1111/head.14138. Epub 2021 Jun 21.","Takeshima T","Headache","2021","2021/06/21","PMC8361926","","10.1111/head.14138"
"32552657","The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms","González-Hernández A, Marichal-Cancino BA, García-Boll E, Villalón CM.","CNS Neurol Disord Drug Targets. 2020;19(5):344-359. doi: 10.2174/1871527319666200618144637.","González-Hernández A","CNS Neurol Disord Drug Targets","2020","2020/06/20","","","10.2174/1871527319666200618144637"
"18626630","Current and prospective pharmacological targets in relation to antimigraine action","Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, MaassenVanDenBrink A.","Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. doi: 10.1007/s00210-008-0322-7. Epub 2008 Jul 15.","Mehrotra S","Naunyn Schmiedebergs Arch Pharmacol","2008","2008/07/16","","","10.1007/s00210-008-0322-7"
"33314079","Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2","Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R.","Headache. 2021 Jan;61(1):125-136. doi: 10.1111/head.14036. Epub 2020 Dec 13.","Diener HC","Headache","2021","2020/12/14","","","10.1111/head.14036"
"28792272","Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice","Chan KY, Labastida-Ramírez A, Ramírez-Rosas MB, Labruijere S, Garrelds IM, Danser AH, van den Maagdenberg AM, MaassenVanDenBrink A.","J Cereb Blood Flow Metab. 2019 Apr;39(4):718-729. doi: 10.1177/0271678X17725673. Epub 2017 Aug 9.","Chan KY","J Cereb Blood Flow Metab","2019","2017/08/10","PMC6446415","","10.1177/0271678X17725673"
"24256609","The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion","Feistel S, Albrecht S, Messlinger K.","J Headache Pain. 2013 Nov 20;14(1):93. doi: 10.1186/1129-2377-14-93.","Feistel S","J Headache Pain","2013","2013/11/22","PMC3845525","","10.1186/1129-2377-14-93"
"31004075","Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis","Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.","J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.","Goadsby PJ","J Neurol Neurosurg Psychiatry","2019","2019/04/21","PMC6691875","","10.1136/jnnp-2018-320242"
"38308209","Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study","Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F.","J Headache Pain. 2024 Feb 2;25(1):14. doi: 10.1186/s10194-024-01721-6.","Grazzi L","J Headache Pain","2024","2024/02/02","PMC10836018","","10.1186/s10194-024-01721-6"
"21457238","Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine","Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R, Schaefer E, Lines C, Ho TW.","Headache. 2011 Apr;51(4):533-43. doi: 10.1111/j.1526-4610.2011.01860.x.","Hewitt DJ","Headache","2011","2011/04/05","","","10.1111/j.1526-4610.2011.01860.x"
"14659530","NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release","Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G.","Pain. 2003 Dec;106(3):461-470. doi: 10.1016/j.pain.2003.09.008.","Juhasz G","Pain","2003","2003/12/09","","","10.1016/j.pain.2003.09.008"
"34893074","MicroRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-induced chronic migraine mouse model","Wen Q, Wang Y, Pan Q, Tian R, Zhang D, Qin G, Zhou J, Chen L.","J Neuroinflammation. 2021 Dec 10;18(1):287. doi: 10.1186/s12974-021-02342-5.","Wen Q","J Neuroinflammation","2021","2021/12/11","PMC8665643","","10.1186/s12974-021-02342-5"
"14576330","Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX","Vater A, Jarosch F, Buchner K, Klussmann S.","Nucleic Acids Res. 2003 Nov 1;31(21):e130. doi: 10.1093/nar/gng130.","Vater A","Nucleic Acids Res","2003","2003/10/25","PMC275487","","10.1093/nar/gng130"
"15882801","The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes","Just S, Arndt K, Doods H.","Neurosci Lett. 2005 Jun 10-17;381(1-2):120-4. doi: 10.1016/j.neulet.2005.02.012. Epub 2005 Feb 25.","Just S","Neurosci Lett","2005","2005/05/11","","","10.1016/j.neulet.2005.02.012"
"32223300","No central action of CGRP antagonising drugs in the GTN mouse model of migraine","Christensen SL, Ernstsen C, Olesen J, Kristensen DM.","Cephalalgia. 2020 Aug;40(9):924-934. doi: 10.1177/0333102420914913. Epub 2020 Mar 29.","Christensen SL","Cephalalgia","2020","2020/04/01","","","10.1177/0333102420914913"
"26032833","CGRP as a neuropeptide in migraine: lessons from mice","Russo AF.","Br J Clin Pharmacol. 2015 Sep;80(3):403-14. doi: 10.1111/bcp.12686. Epub 2015 Jul 14.","Russo AF","Br J Clin Pharmacol","2015","2015/06/03","PMC4574826","","10.1111/bcp.12686"
"34324700","Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N.","Headache. 2021 Jul;61(7):1092-1101. doi: 10.1111/head.14169. Epub 2021 Jul 29.","Sakai F","Headache","2021","2021/07/29","PMC8456899","","10.1111/head.14169"
"33764538","Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine","Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.","Headache. 2021 Apr;61(4):653-661. doi: 10.1111/head.14096. Epub 2021 Mar 25.","Sakai F","Headache","2021","2021/03/25","PMC8251924","","10.1111/head.14096"
"33008506","OnabotulinumtoxinA injection in the treatment of chronic migraine","Wang YF.","Prog Brain Res. 2020;255:171-206. doi: 10.1016/bs.pbr.2020.05.013. Epub 2020 Jun 30.","Wang YF","Prog Brain Res","2020","2020/10/03","","","10.1016/bs.pbr.2020.05.013"
"32602955","Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF.","Headache. 2020 Jul;60(7):1259-1272. doi: 10.1111/head.13849. Epub 2020 Jun 30.","Burstein R","Headache","2020","2020/07/01","PMC7496564","","10.1111/head.13849"
"2664974","Pain mechanisms underlying vascular headaches. Progress Report 1989","Moskowitz MA, Buzzi MG, Sakas DE, Linnik MD.","Rev Neurol (Paris). 1989;145(3):181-93.","Moskowitz MA","Rev Neurol (Paris)","1989","1989/01/01","","",""
"33009665","No ""Wearing-Off Effect"" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study","Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B, Tepper SJ.","Headache. 2020 Nov;60(10):2431-2443. doi: 10.1111/head.13994. Epub 2020 Oct 28.","Blumenfeld AM","Headache","2020","2020/10/03","PMC7756709","","10.1111/head.13994"
"30446596","Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.","Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.","Detke HC","Neurology","2018","2018/11/18","PMC6329331","","10.1212/WNL.0000000000006640"
"22816019","ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974)","Hopkins CR.","ACS Chem Neurosci. 2011 Jul 20;2(7):334-5. doi: 10.1021/cn200059f.","Hopkins CR","ACS Chem Neurosci","2011","2012/07/21","PMC3369750","","10.1021/cn200059f"
"19330169","Molecule of the month. Telcagepant","","Drug News Perspect. 2009 Mar;22(2):115.","","Drug News Perspect","2009","2009/03/31","","",""
"34786968","Evaluation and treatment of headache associated with moyamoya disease - a narrative review","Chiang CC, Shahid AH, Harriott AM, Tietjen GE, Savastano LE, Klaas JP, Lanzino G.","Cephalalgia. 2022 May;42(6):542-552. doi: 10.1177/03331024211056250. Epub 2021 Nov 17.","Chiang CC","Cephalalgia","2022","2021/11/17","","","10.1177/03331024211056250"
"19126117","Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders","Petersen KA, Birk S, Kitamura K, Olesen J.","Cephalalgia. 2009 Jan;29(1):23-30. doi: 10.1111/j.1468-2982.2008.01695.x.","Petersen KA","Cephalalgia","2009","2009/01/08","","","10.1111/j.1468-2982.2008.01695.x"
"26432182","Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB.","Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30.","Bigal ME","Lancet Neurol","2015","2015/10/04","","","10.1016/S1474-4422(15)00249-5"
"38476099","Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study","Hershey AD, Paiva da Silva Lima G, Pannacciulli N, Mackowski M, Koukakis R, McVige JW.","Clin Transl Sci. 2024 Mar;17(3):e13755. doi: 10.1111/cts.13755.","Hershey AD","Clin Transl Sci","2024","2024/03/13","PMC10933636","","10.1111/cts.13755"
"29783863","Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers","de Hoon J, Van Hecken A, Vandermeulen C, Herbots M, Kubo Y, Lee E, Eisele O, Vargas G, Gabriel K.","Cephalalgia. 2019 Jan;39(1):100-110. doi: 10.1177/0333102418776017. Epub 2018 May 21.","de Hoon J","Cephalalgia","2019","2018/05/23","PMC6348461","","10.1177/0333102418776017"
"31022159","In brief: Erenumab (Aimovig) hypersensitivity","","Med Lett Drugs Ther. 2019 Mar 25;61(1568):48.","","Med Lett Drugs Ther","2019","2019/04/26","","",""
"32990364","Erenumab in Chronic Migraine: An Australian Experience","Cheng S, Jenkins B, Limberg N, Hutton E.","Headache. 2020 Nov;60(10):2555-2562. doi: 10.1111/head.13968. Epub 2020 Sep 29.","Cheng S","Headache","2020","2020/09/29","","","10.1111/head.13968"
"33202039","Erenumab-Induced Severe Nausea Leading to Smoking Cessation: A Retrospective Case Series","Mathew PG, Krivitski D, Sharon R.","Headache. 2020 Nov;60(10):2563-2569. doi: 10.1111/head.13979. Epub 2020 Nov 17.","Mathew PG","Headache","2020","2020/11/17","","","10.1111/head.13979"
"29352859","Is selective 5-HT(1F) receptor agonism an entity apart from that of the triptans in antimigraine therapy?","Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A.","Pharmacol Ther. 2018 Jun;186:88-97. doi: 10.1016/j.pharmthera.2018.01.005. Epub 2018 Jan 17.","Rubio-Beltrán E","Pharmacol Ther","2018","2018/01/22","","","10.1016/j.pharmthera.2018.01.005"
"21333611","Cervical sympathectomy reduces neurogenic vasodilation in dura mater of rats","Wei J, Yan L, Liu T, Xu W, Shi Z, Wu T, Wan Q.","Auton Neurosci. 2011 Jul 5;162(1-2):10-4. doi: 10.1016/j.autneu.2011.01.005. Epub 2011 Feb 18.","Wei J","Auton Neurosci","2011","2011/02/22","","","10.1016/j.autneu.2011.01.005"
"30502971","CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?","Majima M, Ito Y, Hosono K, Amano H.","Trends Pharmacol Sci. 2019 Jan;40(1):11-21. doi: 10.1016/j.tips.2018.11.003. Epub 2018 Nov 28.","Majima M","Trends Pharmacol Sci","2019","2018/12/04","","","10.1016/j.tips.2018.11.003"
"34845002","Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study","Ferrari MD, Reuter U, Goadsby PJ, Paiva da Silva Lima G, Mondal S, Wen S, Tenenbaum N, Pandhi S, Lanteri-Minet M, Stites T.","J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):254-262. doi: 10.1136/jnnp-2021-327480. Epub 2021 Nov 29.","Ferrari MD","J Neurol Neurosurg Psychiatry","2022","2021/11/30","PMC8862066","","10.1136/jnnp-2021-327480"
"11830255","CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine?","Brain SD, Poyner DR, Hill RG.","Trends Pharmacol Sci. 2002 Feb;23(2):51-3. doi: 10.1016/s0165-6147(02)01945-4.","Brain SD","Trends Pharmacol Sci","2002","2002/02/07","","","10.1016/s0165-6147(02)01945-4"
"34685523","Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine","Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C.","Cells. 2021 Sep 26;10(10):2543. doi: 10.3390/cells10102543.","Greco R","Cells","2021","2021/10/23","PMC8534238","","10.3390/cells10102543"
"35557046","Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy-migraine comorbid rats","Wang L, Fu LL, Deng ZR, Zhang J, Zu MD, Wu JC, Wang Y.","Brain Behav. 2022 Jun;12(6):e2594. doi: 10.1002/brb3.2594. Epub 2022 May 12.","Wang L","Brain Behav","2022","2022/05/13","PMC9226826","","10.1002/brb3.2594"
"35410121","Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study","Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R.","J Headache Pain. 2022 Apr 11;23(1):47. doi: 10.1186/s10194-022-01411-1.","Driessen MT","J Headache Pain","2022","2022/04/12","PMC9004075","","10.1186/s10194-022-01411-1"
"33249580","Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine","Ford JH, Kurth T, Starling AJ, Ayer DW, Wietecha LA, Port MD, Rettiganti M, Ruff DD.","Headache. 2020 Nov;60(10):2304-2319. doi: 10.1111/head.14013.","Ford JH","Headache","2020","2020/11/29","PMC7756324","","10.1111/head.14013"
"24783932","Effect of qilongtoutong granule on calcitonin gene-related peptide, beta-endorphin, serotonin, dopamine, and noradrenalin in migraine model rats and mice","Wu X, Zhang M, Huang H.","J Tradit Chin Med. 2014 Apr;34(2):188-93. doi: 10.1016/s0254-6272(14)60077-7.","Wu X","J Tradit Chin Med","2014","2014/05/03","","","10.1016/s0254-6272(14)60077-7"
"31427046","Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M.","Lancet. 2019 Sep 21;394(10203):1030-1040. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16.","Ferrari MD","Lancet","2019","2019/08/21","","","10.1016/S0140-6736(19)31946-4"
"31318457","Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk","Mathew PG, Klein BC.","Headache. 2019 Sep;59(8):1421-1426. doi: 10.1111/head.13601. Epub 2019 Jul 18.","Mathew PG","Headache","2019","2019/07/19","","","10.1111/head.13601"
"34363708","Timing and durability of response to erenumab in patients with chronic migraine","Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G.","Headache. 2021 Sep;61(8):1255-1263. doi: 10.1111/head.14193. Epub 2021 Aug 7.","Tepper SJ","Headache","2021","2021/08/07","PMC8519048","","10.1111/head.14193"
"29022756","Soluble guanylyl cyclase is a critical regulator of migraine-associated pain","Ben Aissa M, Tipton AF, Bertels Z, Gandhi R, Moye LS, Novack M, Bennett BM, Wang Y, Litosh V, Lee SH, Gaisina IN, Thatcher GR, Pradhan AA.","Cephalalgia. 2018 Jul;38(8):1471-1484. doi: 10.1177/0333102417737778. Epub 2017 Oct 12.","Ben Aissa M","Cephalalgia","2018","2017/10/13","PMC5916516","NIHMS959763","10.1177/0333102417737778"
"21383046","Possible site of action of CGRP antagonists in migraine","Tfelt-Hansen P, Olesen J.","Cephalalgia. 2011 Apr;31(6):748-50. doi: 10.1177/0333102411398403. Epub 2011 Mar 7.","Tfelt-Hansen P","Cephalalgia","2011","2011/03/09","","","10.1177/0333102411398403"
"30088106","PACAP38 and PAC(1) receptor blockade: a new target for headache?","Rubio-Beltrán E, Correnti E, Deen M, Kamm K, Kelderman T, Papetti L, Vigneri S, MaassenVanDenBrink A, Edvinsson L; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2018 Aug 7;19(1):64. doi: 10.1186/s10194-018-0893-8.","Rubio-Beltrán E","J Headache Pain","2018","2018/08/09","PMC6081277","","10.1186/s10194-018-0893-8"
"35738471","San Pian decoction can treat nitroglycerin-induced migraine in rats by inhibiting the PI3K/AKT and MAPK signaling pathways","Mao Q, Cui Y, Du H, Wu J, Zhou M, Ouyang H, Feng Y, Yang S.","J Ethnopharmacol. 2022 Oct 5;296:115470. doi: 10.1016/j.jep.2022.115470. Epub 2022 Jun 20.","Mao Q","J Ethnopharmacol","2022","2022/06/23","","","10.1016/j.jep.2022.115470"
"32073660","Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II","Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN.","Headache. 2020 Apr;60(4):686-700. doi: 10.1111/head.13766. Epub 2020 Feb 19.","Dodick DW","Headache","2020","2020/02/20","PMC7155006","","10.1111/head.13766"
"36585619","Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis","Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, Iba C, Shibata M, Takemura R, Hori S, Nakahara J.","BMC Neurol. 2022 Dec 31;22(1):512. doi: 10.1186/s12883-022-03041-1.","Takizawa T","BMC Neurol","2022","2022/12/30","PMC9805082","","10.1186/s12883-022-03041-1"
"35410497","Calcitonin receptor antibody validation and expression in the rodent brain","Hendrikse ER, Rees TA, Tasma Z, Le Foll C, Lutz TA, Siow A, Wookey PJ, Walker CS, Hay DL.","Cephalalgia. 2022 Aug;42(9):815-826. doi: 10.1177/03331024221084029. Epub 2022 Apr 11.","Hendrikse ER","Cephalalgia","2022","2022/04/12","PMC9441190","NIHMS1832488","10.1177/03331024221084029"
"28990289","Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin-treated Mice","Yi L, Wu Q, Chen N, Song G, Wang C, Zou Q, Zhang Z.","Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):310-316. doi: 10.1111/bcpt.12915. Epub 2017 Nov 12.","Yi L","Basic Clin Pharmacol Toxicol","2018","2017/10/10","","","10.1111/bcpt.12915"
"17448181","Migraine and adiponectin: is there a connection?","Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM.","Cephalalgia. 2007 May;27(5):435-46. doi: 10.1111/j.1468-2982.2007.01306.x.","Peterlin BL","Cephalalgia","2007","2007/04/24","","","10.1111/j.1468-2982.2007.01306.x"
"34215196","Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report","Cullum CK, Olsen MK, Kocadag HB, Ashina M, Amin FM.","BMC Neurol. 2021 Jul 2;21(1):257. doi: 10.1186/s12883-021-02294-6.","Cullum CK","BMC Neurol","2021","2021/07/03","PMC8252281","","10.1186/s12883-021-02294-6"
"36795624","Neuronal NLRP3 inflammasome mediates spreading depolarization-evoked trigeminovascular activation","Chen PY, Yen JC, Liu TT, Chen ST, Wang SJ, Chen SP.","Brain. 2023 Jul 3;146(7):2989-3002. doi: 10.1093/brain/awad045.","Chen PY","Brain","2023","2023/02/16","","","10.1093/brain/awad045"
"31150417","Development of chimeric and bifunctional antagonists for CLR/RAMP receptors","Chang CL, Hsu SYT.","PLoS One. 2019 May 31;14(5):e0216996. doi: 10.1371/journal.pone.0216996. eCollection 2019.","Chang CL","PLoS One","2019","2019/06/01","PMC6544337","","10.1371/journal.pone.0216996"
"34037500","Safety and tolerability evaluation of erenumab for the preventive treatment of migraine","Deligianni CI, Mitsikostas DD, Ashina M.","Expert Opin Drug Saf. 2021 Aug;20(8):867-876. doi: 10.1080/14740338.2021.1933941. Epub 2021 Jul 16.","Deligianni CI","Expert Opin Drug Saf","2021","2021/05/26","","","10.1080/14740338.2021.1933941"
"27465216","The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments","Villalón CM, VanDenBrink AM.","Mini Rev Med Chem. 2017;17(11):928-938. doi: 10.2174/1389557516666160728121050.","Villalón CM","Mini Rev Med Chem","2017","2016/07/29","","","10.2174/1389557516666160728121050"
"36597043","Role of ATP in migraine mechanisms: focus on P2X3 receptors","Giniatullin R, Nistri A.","J Headache Pain. 2023 Jan 3;24(1):1. doi: 10.1186/s10194-022-01535-4.","Giniatullin R","J Headache Pain","2023","2023/01/03","PMC9809127","","10.1186/s10194-022-01535-4"
"32522232","Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine","Zhang Y, Zhang Y, Tian K, Wang Y, Fan X, Pan Q, Qin G, Zhang D, Chen L, Zhou J.","J Headache Pain. 2020 Jun 10;21(1):72. doi: 10.1186/s10194-020-01145-y.","Zhang Y","J Headache Pain","2020","2020/06/12","PMC7288551","","10.1186/s10194-020-01145-y"
"36111429","A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist","Kudrow D, Nguyen L, Semler J, Stroud C, Samaan K, Hoban DB, Wietecha L, Hsu HA, Pearlman E.","Headache. 2022 Oct;62(9):1164-1176. doi: 10.1111/head.14390. Epub 2022 Sep 16.","Kudrow D","Headache","2022","2022/09/16","PMC9826055","","10.1111/head.14390"
"34323290","Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N.","Headache. 2021 Jul;61(7):1102-1111. doi: 10.1111/head.14178. Epub 2021 Jul 29.","Sakai F","Headache","2021","2021/07/29","PMC8457233","","10.1111/head.14178"
"12566974","Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow","Strecker T, Dux M, Messlinger K.","J Vasc Res. 2002 Nov-Dec;39(6):489-96. doi: 10.1159/000067206.","Strecker T","J Vasc Res","2002","2003/02/05","","","10.1159/000067206"
"33779998","Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report","Naegel S, Burow P, Holle D, Stoevesandt D, Heintz S, Thaele A, Zierz S, Kraya T.","Headache. 2021 Apr;61(4):694-696. doi: 10.1111/head.14101. Epub 2021 Mar 29.","Naegel S","Headache","2021","2021/03/29","","","10.1111/head.14101"
"28215304","Neurotrophins and Migraine","Martins LB, Teixeira AL, Domingues RB.","Vitam Horm. 2017;104:459-473. doi: 10.1016/bs.vh.2016.10.003. Epub 2016 Nov 29.","Martins LB","Vitam Horm","2017","2017/02/21","","","10.1016/bs.vh.2016.10.003"
"31389059","Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect","Tfelt-Hansen P, Messlinger K.","Br J Clin Pharmacol. 2019 Nov;85(11):2487-2498. doi: 10.1111/bcp.14090. Epub 2019 Sep 4.","Tfelt-Hansen P","Br J Clin Pharmacol","2019","2019/08/08","PMC6848898","","10.1111/bcp.14090"
"26114340","Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model","Buntinx L, Vermeersch S, de Hoon J.","Br J Clin Pharmacol. 2015 Nov;80(5):992-1000. doi: 10.1111/bcp.12704. Epub 2015 Oct 6.","Buntinx L","Br J Clin Pharmacol","2015","2015/06/27","PMC4631172","","10.1111/bcp.12704"
"32931071","Deficiency in the function of inhibitory interneurons contributes to glutamate-associated central sensitization through GABABR2-SynCAM1 signaling in chronic migraine rats","Zeng X, Niu Y, Qin G, Zhang D, Zhou J, Chen L.","FASEB J. 2020 Nov;34(11):14780-14798. doi: 10.1096/fj.202001561R. Epub 2020 Sep 15.","Zeng X","FASEB J","2020","2020/09/15","","","10.1096/fj.202001561R"
"14979881","Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","Durham PL, Cady R, Cady R.","Headache. 2004 Jan;44(1):35-42; discussion 42-3. doi: 10.1111/j.1526-4610.2004.04007.x.","Durham PL","Headache","2004","2004/02/26","","","10.1111/j.1526-4610.2004.04007.x"
"21070229","Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine","Tfelt-Hansen P.","Headache. 2011 Jan;51(1):118-23. doi: 10.1111/j.1526-4610.2010.01797.x. Epub 2010 Nov 10.","Tfelt-Hansen P","Headache","2011","2010/11/13","","","10.1111/j.1526-4610.2010.01797.x"
"17929795","Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974)","Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, Koblan KS, Salvatore CA, Mosser SD, Johnston VK, Wong BK, Miller-Stein CM, Hershey JC, Graham SL, Vacca JP, Williams TM.","J Med Chem. 2007 Nov 15;50(23):5564-7. doi: 10.1021/jm070668p. Epub 2007 Oct 11.","Paone DV","J Med Chem","2007","2007/10/13","","","10.1021/jm070668p"
"15196297","Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache","Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J.","Cephalalgia. 2004 Jul;24(7):547-53. doi: 10.1111/j.1468-2982.2003.00712.x.","Kruuse C","Cephalalgia","2004","2004/06/16","","","10.1111/j.1468-2982.2003.00712.x"
"32522164","Lasmiditan mechanism of action - review of a selective 5-HT(1F) agonist","Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM.","J Headache Pain. 2020 Jun 10;21(1):71. doi: 10.1186/s10194-020-01132-3.","Clemow DB","J Headache Pain","2020","2020/06/12","PMC7288483","","10.1186/s10194-020-01132-3"
"22406987","Management of acute and chronic migraine","Coppola G, Schoenen J.","Curr Opin Support Palliat Care. 2012 Jun;6(2):177-82. doi: 10.1097/SPC.0b013e3283521dc3.","Coppola G","Curr Opin Support Palliat Care","2012","2012/03/13","","","10.1097/SPC.0b013e3283521dc3"
"29571276","Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective","Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D.","J Med Econ. 2018 Jul;21(7):666-675. doi: 10.1080/13696998.2018.1457533. Epub 2018 Apr 3.","Lipton RB","J Med Econ","2018","2018/03/25","","","10.1080/13696998.2018.1457533"
"30841847","ROS/TRPA1/CGRP signaling mediates cortical spreading depression","Jiang L, Ma D, Grubb BD, Wang M.","J Headache Pain. 2019 Mar 6;20(1):25. doi: 10.1186/s10194-019-0978-z.","Jiang L","J Headache Pain","2019","2019/03/08","PMC6734415","","10.1186/s10194-019-0978-z"
"23975906","In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232","Hostetler ED, Joshi AD, Sanabria-Bohórquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, Van Laere K, Evelhoch JL.","J Pharmacol Exp Ther. 2013 Nov;347(2):478-86. doi: 10.1124/jpet.113.206458. Epub 2013 Aug 23.","Hostetler ED","J Pharmacol Exp Ther","2013","2013/08/27","","","10.1124/jpet.113.206458"
"32696077","[Headache in multiple sclerosis]","Gebhardt M, Kropp P, Hoffmann F, Zettl UK.","Nervenarzt. 2020 Oct;91(10):926-935. doi: 10.1007/s00115-020-00959-0.","Gebhardt M","Nervenarzt","2020","2020/07/23","","","10.1007/s00115-020-00959-0"
"9185668","Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model","Knyihár-Csillik E, Tajti J, Samsam M, Sáry G, Slezák S, Vécsei L.","J Neurosci Res. 1997 Jun 1;48(5):449-64.","Knyihár-Csillik E","J Neurosci Res","1997","1997/06/01","","",""
"25998753","Up-regulation of calcitonin gene-related peptide in trigeminal ganglion following chronic exposure to paracetamol in a CSD migraine animal model","Yisarakun W, Chantong C, Supornsilpchai W, Thongtan T, Srikiatkhachorn A, Reuangwechvorachai P, Maneesri-le Grand S.","Neuropeptides. 2015 Jun;51:9-16. doi: 10.1016/j.npep.2015.03.008. Epub 2015 Apr 23.","Yisarakun W","Neuropeptides","2015","2015/05/23","","","10.1016/j.npep.2015.03.008"
"33663087","Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis","Zhang Z, Shu Y, Diao Y, Du Y, Chen L, Liu Y, Du B.","Medicine (Baltimore). 2021 Feb 26;100(8):e24741. doi: 10.1097/MD.0000000000024741.","Zhang Z","Medicine (Baltimore)","2021","2021/03/05","PMC7909234","","10.1097/MD.0000000000024741"
"33337920","A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine","Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S, Al-Karagholi MA, Amin FM, Sessa M.","Expert Opin Drug Saf. 2021 Apr;20(4):467-474. doi: 10.1080/14740338.2021.1866537. Epub 2020 Dec 29.","Pellesi L","Expert Opin Drug Saf","2021","2020/12/18","","","10.1080/14740338.2021.1866537"
"33125303","Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis","Armanious M, Khalil N, Lu Y, Jimenez-Sanders R.","J Pain Palliat Care Pharmacother. 2021 Mar;35(1):1-6. doi: 10.1080/15360288.2020.1829249. Epub 2020 Oct 30.","Armanious M","J Pain Palliat Care Pharmacother","2021","2020/10/30","","","10.1080/15360288.2020.1829249"
"23958278","Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system","Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L.","J Pain. 2013 Nov;14(11):1289-303. doi: 10.1016/j.jpain.2013.03.010. Epub 2013 Aug 17.","Eftekhari S","J Pain","2013","2013/08/21","","","10.1016/j.jpain.2013.03.010"
"33250209","Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study","Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S, Smith J, Schaeffler B.","Clin Ther. 2020 Dec;42(12):2254-2265.e3. doi: 10.1016/j.clinthera.2020.11.007. Epub 2020 Nov 27.","Smith TR","Clin Ther","2020","2020/11/30","","","10.1016/j.clinthera.2020.11.007"
"17119542","Endocannabinoids in chronic migraine: CSF findings suggest a system failure","Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P.","Neuropsychopharmacology. 2007 Jun;32(6):1384-90. doi: 10.1038/sj.npp.1301246. Epub 2006 Nov 22.","Sarchielli P","Neuropsychopharmacology","2007","2006/11/23","","","10.1038/sj.npp.1301246"
"33165938","Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing","Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S.","Headache. 2020 Nov;60(10):2220-2231. doi: 10.1111/head.14007. Epub 2020 Nov 9.","Dodick DW","Headache","2020","2020/11/09","PMC7756794","","10.1111/head.14007"
"32838728","A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug","Naduchamy KP, Parthasarathy V.","Curr Mol Pharmacol. 2021;14(1):11-26. doi: 10.2174/1874467213999200824124532.","Naduchamy KP","Curr Mol Pharmacol","2021","2020/08/26","","","10.2174/1874467213999200824124532"
"33337544","Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F.","Headache. 2021 Feb;61(2):363-372. doi: 10.1111/head.14032. Epub 2020 Dec 18.","Barbanti P","Headache","2021","2020/12/18","","","10.1111/head.14032"
"36613527","A Single Episode of Cortical Spreading Depolarization Increases mRNA Levels of Proinflammatory Cytokines, Calcitonin Gene-Related Peptide and Pannexin-1 Channels in the Cerebral Cortex","Volobueva MN, Suleymanova EM, Smirnova MP, Bolshakov AP, Vinogradova LV.","Int J Mol Sci. 2022 Dec 21;24(1):85. doi: 10.3390/ijms24010085.","Volobueva MN","Int J Mol Sci","2022","2023/01/08","PMC9820231","","10.3390/ijms24010085"
"31721185","Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies","Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, Aurora SK, Camporeale A.","Headache. 2020 Jan;60(1):110-123. doi: 10.1111/head.13684. Epub 2019 Nov 13.","Oakes TM","Headache","2020","2019/11/14","","","10.1111/head.13684"
"34927700","[Clinical experience with erenumab during the first year of treatment]","Caso-González A, Leralta-González C, Sanz-Alonso V, Iturbe-Heras M, Hernando-de la Bárcena I, Obaldia-Alaña C.","Rev Neurol. 2022 Jan 1;74(1):8-14. doi: 10.33588/rn.7401.2021182.","Caso-González A","Rev Neurol","2022","2021/12/20","","","10.33588/rn.7401.2021182"
"21070230","Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial","Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, Massaad R, Williams-Diaz A, Lines C, Ho TW.","Headache. 2011 Jan;51(1):73-84. doi: 10.1111/j.1526-4610.2010.01799.x. Epub 2010 Nov 10.","Connor KM","Headache","2011","2010/11/13","","","10.1111/j.1526-4610.2010.01799.x"
"32028899","The distribution of oxytocin and the oxytocin receptor in rat brain: relation to regions active in migraine","Warfvinge K, Krause D, Edvinsson L.","J Headache Pain. 2020 Feb 7;21(1):10. doi: 10.1186/s10194-020-1079-8.","Warfvinge K","J Headache Pain","2020","2020/02/08","PMC7006173","","10.1186/s10194-020-1079-8"
"22445525","Pharmacological evidence that spinal α(2C)- and, to a lesser extent, α(2A)-adrenoceptors inhibit capsaicin-induced vasodilatation in the canine external carotid circulation","Villalón CM, Galicia-Carreón J, González-Hernández A, Marichal-Cancino BA, Manrique-Maldonado G, Centurión D.","Eur J Pharmacol. 2012 May 15;683(1-3):204-10. doi: 10.1016/j.ejphar.2012.03.002. Epub 2012 Mar 14.","Villalón CM","Eur J Pharmacol","2012","2012/03/27","","","10.1016/j.ejphar.2012.03.002"
"31311674","Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB.","Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13.","Croop R","Lancet","2019","2019/07/18","","","10.1016/S0140-6736(19)31606-X"
"33167864","Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects","Warfvinge K, Krause DN, Maddahi A, Edvinsson JCA, Edvinsson L, Haanes KA.","J Headache Pain. 2020 Nov 10;21(1):131. doi: 10.1186/s10194-020-01197-0.","Warfvinge K","J Headache Pain","2020","2020/11/10","PMC7653779","","10.1186/s10194-020-01197-0"
"33998825","Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States","Tepper SJ, Fang J, Zhou L, Shen Y, Vo P, Abdrabboh A, Glassberg MB, Ferraris M.","J Manag Care Spec Pharm. 2021 Sep;27(9):1157-1170. doi: 10.18553/jmcp.2021.21060. Epub 2021 May 17.","Tepper SJ","J Manag Care Spec Pharm","2021","2021/05/17","PMC10394219","","10.18553/jmcp.2021.21060"
"15361324","Post-triptan era for the treatment of acute migraine","Goadsby PJ.","Curr Pain Headache Rep. 2004 Oct;8(5):393-8. doi: 10.1007/s11916-996-0013-3.","Goadsby PJ","Curr Pain Headache Rep","2004","2004/09/14","","","10.1007/s11916-996-0013-3"
"36946245","Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model","Zhang L, Zhou Y, Wang Y, Yang L, Wang Y, Shan Z, Liang J, Xiao Z.","Cephalalgia. 2023 Apr;43(4):3331024231163131. doi: 10.1177/03331024231163131.","Zhang L","Cephalalgia","2023","2023/03/22","","","10.1177/03331024231163131"
"26193319","Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety","Szok D, Csáti A, Vécsei L, Tajti J.","Toxins (Basel). 2015 Jul 17;7(7):2659-73. doi: 10.3390/toxins7072659.","Szok D","Toxins (Basel)","2015","2015/07/21","PMC4516935","","10.3390/toxins7072659"
"15315527","Effects of sumatriptan on capsaicin-induced carotid haemodynamic changes and CGRP release in anaesthetized pigs","Arulmani U, Heiligers JP, Garrelds IM, Sánchez-López A, Willems EW, Villalón CM, Saxena PR.","Cephalalgia. 2004 Sep;24(9):717-27. doi: 10.1111/j.1468-2982.2004.00743.x.","Arulmani U","Cephalalgia","2004","2004/08/19","","","10.1111/j.1468-2982.2004.00743.x"
"20456192","Capsaicin jelly against migraine pain","Cianchetti C.","Int J Clin Pract. 2010 Mar;64(4):457-9. doi: 10.1111/j.1742-1241.2009.02294.x.","Cianchetti C","Int J Clin Pract","2010","2010/05/12","","","10.1111/j.1742-1241.2009.02294.x"
"32703784","Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway","Diel RJ, Mehra D, Kardon R, Buse DC, Moulton E, Galor A.","Br J Ophthalmol. 2021 Jun;105(6):751-760. doi: 10.1136/bjophthalmol-2020-316417. Epub 2020 Jul 23.","Diel RJ","Br J Ophthalmol","2021","2020/07/25","PMC8022288","NIHMS1678882","10.1136/bjophthalmol-2020-316417"
"35716692","Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.","Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5.","Ashina M","Lancet Neurol","2022","2022/06/18","","","10.1016/S1474-4422(22)00185-5"
"33241721","Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications","Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, M Adams A, Jakate A, Liu C, Szegedi A, Trugman JM.","Cephalalgia. 2021 Apr;41(5):546-560. doi: 10.1177/0333102420970523. Epub 2020 Nov 26.","Goadsby PJ","Cephalalgia","2021","2020/11/26","PMC8047719","","10.1177/0333102420970523"
"32418458","ATP sensitive potassium (K(ATP)) channel inhibition: A promising new drug target for migraine","Christensen SL, Munro G, Petersen S, Shabir A, Jansen-Olesen I, Kristensen DM, Olesen J.","Cephalalgia. 2020 Jun;40(7):650-664. doi: 10.1177/0333102420925513. Epub 2020 May 16.","Christensen SL","Cephalalgia","2020","2020/05/19","","","10.1177/0333102420925513"
"37531032","A Brief Review of Gepants","Li D, Abreu J, Tepper SJ.","Curr Pain Headache Rep. 2023 Sep;27(9):479-488. doi: 10.1007/s11916-023-01142-1. Epub 2023 Aug 2.","Li D","Curr Pain Headache Rep","2023","2023/08/02","","","10.1007/s11916-023-01142-1"
"22278333","A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina","Chaitman BR, Ho AP, Behm MO, Rowe JF, Palcza JS, Laethem T, Heirman I, Panebianco DL, Kobalava Z, Martsevich SY, Free AL, Bittar N, Chrysant SG, Ho TW, Chodakewitz JA, Murphy MG, Blanchard RL.","Clin Pharmacol Ther. 2012 Mar;91(3):459-66. doi: 10.1038/clpt.2011.246. Epub 2012 Jan 25.","Chaitman BR","Clin Pharmacol Ther","2012","2012/01/27","","","10.1038/clpt.2011.246"
"16161996","Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine","Rudolf K, Eberlein W, Engel W, Pieper H, Entzeroth M, Hallermayer G, Doods H.","J Med Chem. 2005 Sep 22;48(19):5921-31. doi: 10.1021/jm0490641.","Rudolf K","J Med Chem","2005","2005/09/16","","","10.1021/jm0490641"
"24512072","Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia","Raddant AC, Russo AF.","Headache. 2014 Mar;54(3):472-84. doi: 10.1111/head.12301. Epub 2014 Feb 11.","Raddant AC","Headache","2014","2014/02/12","PMC3947709","NIHMS545866","10.1111/head.12301"
"36137961","Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions","Raciti L, Raciti G, Militi D, Casella C, Calabrò RS.","J Integr Neurosci. 2022 Aug 10;21(5):141. doi: 10.31083/j.jin2105141.","Raciti L","J Integr Neurosci","2022","2022/09/22","","","10.31083/j.jin2105141"
"20974582","Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor","Dieterle A, Fischer MJ, Link AS, Neuhuber WL, Messlinger K.","Cephalalgia. 2011 Jan;31(1):31-42. doi: 10.1177/0333102410375725. Epub 2010 Jul 5.","Dieterle A","Cephalalgia","2011","2010/10/27","","","10.1177/0333102410375725"
"36108557","Role of endothelin in the pathophysiology of migraine: A new view on an old player","Yuasa GH, Costa NLVK, Lopes RV, Baggio DF, Rae GA, Chichorro JG.","Neuropeptides. 2022 Dec;96:102286. doi: 10.1016/j.npep.2022.102286. Epub 2022 Sep 7.","Yuasa GH","Neuropeptides","2022","2022/09/15","","","10.1016/j.npep.2022.102286"
"37638400","Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial","Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, Stokes J, Dabruzzo B, Gandhi P, Ashina M.","Cephalalgia. 2023 Aug;51(8):3331024231190296. doi: 10.1177/03331024231190296.","Lipton RB","Cephalalgia","2023","2023/08/28","","","10.1177/03331024231190296"
"33749826","Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis","Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A.","Headache. 2021 Mar;61(3):422-429. doi: 10.1111/head.14089. Epub 2021 Mar 22.","Blumenfeld AM","Headache","2021","2021/03/22","PMC8252782","","10.1111/head.14089"
"28835404","Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study","Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.","Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.","Ashina M","Neurology","2017","2017/08/25","","","10.1212/WNL.0000000000004391"
"28460892","Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.","Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.","Tepper S","Lancet Neurol","2017","2017/05/03","","","10.1016/S1474-4422(17)30083-2"
"27281531","TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points","Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ.","Neurology. 2016 Jul 5;87(1):41-8. doi: 10.1212/WNL.0000000000002801. Epub 2016 Jun 8.","Bigal ME","Neurology","2016","2016/06/10","PMC4932236","","10.1212/WNL.0000000000002801"
"33740902","Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial","Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA.","BMC Neurol. 2021 Mar 19;21(1):126. doi: 10.1186/s12883-021-02123-w.","Kudrow D","BMC Neurol","2021","2021/03/20","PMC7977171","","10.1186/s12883-021-02123-w"
"22584531","Brain-derived neurotrophic factor in primary headaches","Fischer M, Wille G, Klien S, Shanib H, Holle D, Gaul C, Broessner G.","J Headache Pain. 2012 Aug;13(6):469-75. doi: 10.1007/s10194-012-0454-5. Epub 2012 May 15.","Fischer M","J Headache Pain","2012","2012/05/16","PMC3464472","","10.1007/s10194-012-0454-5"
"30400767","NR2B-Tyr phosphorylation regulates synaptic plasticity in central sensitization in a chronic migraine rat model","Wang XY, Zhou HR, Wang S, Liu CY, Qin GC, Fu QQ, Zhou JY, Chen LX.","J Headache Pain. 2018 Nov 6;19(1):102. doi: 10.1186/s10194-018-0935-2.","Wang XY","J Headache Pain","2018","2018/11/08","PMC6755586","","10.1186/s10194-018-0935-2"
"8536297","Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally","Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R.","Cephalalgia. 1995 Oct;15(5):384-90. doi: 10.1046/j.1468-2982.1995.1505384.x.","Gallai V","Cephalalgia","1995","1995/10/01","","","10.1046/j.1468-2982.1995.1505384.x"
"17257240","An adenosine A2A receptor gene haplotype is associated with migraine with aura","Hohoff C, Marziniak M, Lesch KP, Deckert J, Sommer C, Mössner R.","Cephalalgia. 2007 Feb;27(2):177-81. doi: 10.1111/j.1468-2982.2007.01254.x.","Hohoff C","Cephalalgia","2007","2007/01/30","","","10.1111/j.1468-2982.2007.01254.x"
"27338837","Wiping Out CGRP: Potential Cardiovascular Risks","MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD.","Trends Pharmacol Sci. 2016 Sep;37(9):779-788. doi: 10.1016/j.tips.2016.06.002. Epub 2016 Jun 21.","MaassenVanDenBrink A","Trends Pharmacol Sci","2016","2016/06/25","","","10.1016/j.tips.2016.06.002"
"33525904","TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons","Lengyel M, Hajdu D, Dobolyi A, Rosta J, Czirják G, Dux M, Enyedi P.","Cephalalgia. 2021 Jun;41(7):827-838. doi: 10.1177/0333102421989261. Epub 2021 Feb 1.","Lengyel M","Cephalalgia","2021","2021/02/02","","","10.1177/0333102421989261"
"37999868","Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study","Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF; Italian Headache Registry (RICe) Study Group.","CNS Drugs. 2023 Dec;37(12):1069-1080. doi: 10.1007/s40263-023-01050-3. Epub 2023 Nov 24.","Caponnetto V","CNS Drugs","2023","2023/11/24","PMC10703741","","10.1007/s40263-023-01050-3"
"31534133","Maladaptive activation of Nav1.9 channels by nitric oxide causes triptan-induced medication overuse headache","Bonnet C, Hao J, Osorio N, Donnet A, Penalba V, Ruel J, Delmas P.","Nat Commun. 2019 Sep 18;10(1):4253. doi: 10.1038/s41467-019-12197-3.","Bonnet C","Nat Commun","2019","2019/09/20","PMC6751217","","10.1038/s41467-019-12197-3"
"21383045","Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW.","Cephalalgia. 2011 Apr;31(6):712-22. doi: 10.1177/0333102411398399. Epub 2011 Mar 7.","Hewitt DJ","Cephalalgia","2011","2011/03/09","","","10.1177/0333102411398399"
"34161797","Screen of anti-migraine active compounds from Duijinsan by spectrum-effect relationship analysis and molecular docking","Zheng G, Gan L, Jia LY, Zhou DC, Bi S, Meng ZQ, Guan GJ, Huang MM, He X, Zhang CF, Wang CZ, Yuan CS.","J Ethnopharmacol. 2021 Oct 28;279:114352. doi: 10.1016/j.jep.2021.114352. Epub 2021 Jun 20.","Zheng G","J Ethnopharmacol","2021","2021/06/23","","","10.1016/j.jep.2021.114352"
"32429851","Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine","Stauffer VL, Wang S, Bonner J, Kim B, Bhandari R, Day KA, Camporeale A.","BMC Neurol. 2020 May 19;20(1):194. doi: 10.1186/s12883-020-01775-4.","Stauffer VL","BMC Neurol","2020","2020/05/21","PMC7236916","","10.1186/s12883-020-01775-4"
"25127173","Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study","Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS.","Lancet Neurol. 2014 Sep;13(9):885-92. doi: 10.1016/S1474-4422(14)70128-0. Epub 2014 Aug 10.","Dodick DW","Lancet Neurol","2014","2014/08/16","","","10.1016/S1474-4422(14)70128-0"
"32011192","Ubrogepant for the treatment of migraine","Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L.","Expert Opin Pharmacother. 2020 May;21(7):755-759. doi: 10.1080/14656566.2020.1721462. Epub 2020 Feb 3.","Curto M","Expert Opin Pharmacother","2020","2020/02/04","","","10.1080/14656566.2020.1721462"
"23095108","Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment","Durham PL, Masterson CG.","Headache. 2013 Jan;53(1):67-80. doi: 10.1111/j.1526-4610.2012.02262.x. Epub 2012 Oct 23.","Durham PL","Headache","2013","2012/10/26","PMC3540191","NIHMS406471","10.1111/j.1526-4610.2012.02262.x"
"31234642","Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial","Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.","Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.","Dodick DW","Cephalalgia","2019","2019/06/26","","","10.1177/0333102419858355"
"24366981","Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia","Greco R, Mangione AS, Siani F, Blandini F, Vairetti M, Nappi G, Sandrini G, Buzzi MG, Tassorelli C.","Cephalalgia. 2014 Jul;34(8):594-604. doi: 10.1177/0333102413517776. Epub 2013 Dec 23.","Greco R","Cephalalgia","2014","2013/12/25","","","10.1177/0333102413517776"
"20173082","Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults","Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson K, Xu Y, Ermlich S, Boyle J, Lines C, Gutierrez M, Van Bortel L, Xiao AJ, Sinclair S, Hickey L, Panebianco D, Murphy MG.","J Clin Pharmacol. 2010 Dec;50(12):1367-76. doi: 10.1177/0091270010361741. Epub 2010 Feb 19.","Han TH","J Clin Pharmacol","2010","2010/02/23","","","10.1177/0091270010361741"
"21251825","Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918","Paone DV, Nguyen DN, Shaw AW, Burgey CS, Potteiger CM, Deng JZ, Mosser SD, Salvatore CA, Yu S, Roller S, Kane SA, Selnick HG, Vacca JP, Williams TM.","Bioorg Med Chem Lett. 2011 May 1;21(9):2683-6. doi: 10.1016/j.bmcl.2010.12.054. Epub 2010 Dec 30.","Paone DV","Bioorg Med Chem Lett","2011","2011/01/22","","","10.1016/j.bmcl.2010.12.054"
"8752390","[Autonomic nervous activity in migraine]","Araki N.","Rinsho Shinkeigaku. 1995 Dec;35(12):1336-8.","Araki N","Rinsho Shinkeigaku","1995","1995/12/01","","",""
"28053042","Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms","Mason BN, Kaiser EA, Kuburas A, Loomis MM, Latham JA, Garcia-Martinez LF, Russo AF.","J Neurosci. 2017 Jan 4;37(1):204-216. doi: 10.1523/JNEUROSCI.2967-16.2016.","Mason BN","J Neurosci","2017","2017/01/06","PMC5214631","","10.1523/JNEUROSCI.2967-16.2016"
"29171818","Fremanezumab for the Preventive Treatment of Chronic Migraine","Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.","N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.","Silberstein SD","N Engl J Med","2017","2017/11/25","","","10.1056/NEJMoa1709038"
"33871613","Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon","Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, Pittelkow MR, Mangold AR.","JAMA Netw Open. 2021 Apr 1;4(4):e217934. doi: 10.1001/jamanetworkopen.2021.7934.","Breen ID","JAMA Netw Open","2021","2021/04/19","PMC8056280","","10.1001/jamanetworkopen.2021.7934"
"38177990","Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model","Sun S, Fan Z, Liu X, Wang L, Ge Z.","J Headache Pain. 2024 Jan 5;25(1):3. doi: 10.1186/s10194-023-01707-w.","Sun S","J Headache Pain","2024","2024/01/04","PMC10768449","","10.1186/s10194-023-01707-w"
"29260608","Tonic regulation of middle meningeal artery diameter by ATP-sensitive potassium channels","Syed AU, Koide M, Brayden JE, Wellman GC.","J Cereb Blood Flow Metab. 2019 Apr;39(4):670-679. doi: 10.1177/0271678X17749392. Epub 2017 Dec 20.","Syed AU","J Cereb Blood Flow Metab","2019","2017/12/21","PMC6446425","","10.1177/0271678X17749392"
"29985973","TRPA1/NOX in the soma of trigeminal ganglion neurons mediates migraine-related pain of glyceryl trinitrate in mice","Marone IM, De Logu F, Nassini R, De Carvalho Goncalves M, Benemei S, Ferreira J, Jain P, Li Puma S, Bunnett NW, Geppetti P, Materazzi S.","Brain. 2018 Aug 1;141(8):2312-2328. doi: 10.1093/brain/awy177.","Marone IM","Brain","2018","2018/07/10","PMC6061846","","10.1093/brain/awy177"
"33567891","Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis","Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD.","Cephalalgia. 2021 Jun;41(7):851-864. doi: 10.1177/0333102421989601. Epub 2021 Feb 10.","Drellia K","Cephalalgia","2021","2021/02/11","","","10.1177/0333102421989601"
"35681463","The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow","Dux M, Vogler B, Kuhn A, Mackenzie KD, Stratton J, Messlinger K.","Cells. 2022 May 28;11(11):1768. doi: 10.3390/cells11111768.","Dux M","Cells","2022","2022/06/10","PMC9179471","","10.3390/cells11111768"
"30413151","A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL.","BMC Neurol. 2018 Nov 9;18(1):188. doi: 10.1186/s12883-018-1193-2.","Camporeale A","BMC Neurol","2018","2018/11/11","PMC6234796","","10.1186/s12883-018-1193-2"
"30971286","Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model","He W, Long T, Pan Q, Zhang S, Zhang Y, Zhang D, Qin G, Chen L, Zhou J.","J Neuroinflammation. 2019 Apr 10;16(1):78. doi: 10.1186/s12974-019-1459-7.","He W","J Neuroinflammation","2019","2019/04/12","PMC6456991","","10.1186/s12974-019-1459-7"
"23632269","Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery","Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N, Moench P, Denton R, Macci R, Schartman R, Whiterock V, Davis C, Macor JE, Dubowchik GM.","Bioorg Med Chem Lett. 2013 Jun 1;23(11):3157-61. doi: 10.1016/j.bmcl.2013.04.012. Epub 2013 Apr 12.","Chaturvedula PV","Bioorg Med Chem Lett","2013","2013/05/02","","","10.1016/j.bmcl.2013.04.012"
"31039731","Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking","Manoukian R, Sun H, Miller S, Shi D, Chan B, Xu C.","J Headache Pain. 2019 Apr 30;20(1):44. doi: 10.1186/s10194-019-0992-1.","Manoukian R","J Headache Pain","2019","2019/05/02","PMC6734291","","10.1186/s10194-019-0992-1"
"23602496","What's new in the migraine attack treatment","Lanteri-Minet M.","Rev Neurol (Paris). 2013 May;169(5):436-41. doi: 10.1016/j.neurol.2013.03.006. Epub 2013 Apr 18.","Lanteri-Minet M","Rev Neurol (Paris)","2013","2013/04/23","","","10.1016/j.neurol.2013.03.006"
"17064360","Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons","Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A.","J Neurochem. 2006 Dec;99(5):1338-50. doi: 10.1111/j.1471-4159.2006.04161.x. Epub 2006 Oct 25.","Buldyrev I","J Neurochem","2006","2006/10/27","PMC2440676","NIHMS54951","10.1111/j.1471-4159.2006.04161.x"
"18665579","Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure","Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM.","J Med Chem. 2008 Aug 28;51(16):4858-61. doi: 10.1021/jm800546t. Epub 2008 Jul 30.","Degnan AP","J Med Chem","2008","2008/07/31","","","10.1021/jm800546t"
"10711339","Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist","Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W.","Br J Pharmacol. 2000 Feb;129(3):420-3. doi: 10.1038/sj.bjp.0703110.","Doods H","Br J Pharmacol","2000","2000/03/11","PMC1571877","","10.1038/sj.bjp.0703110"
"32653068","Predicting erenumab adverse events with single-cell genomics","Vgontzas A, Renthal W.","Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.","Vgontzas A","Lancet","2020","2020/07/13","","","10.1016/S0140-6736(19)32952-6"
"33818780","Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study","Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB.","Headache. 2021 Apr;61(4):642-652. doi: 10.1111/head.14095. Epub 2021 Apr 5.","Jakate A","Headache","2021","2021/04/05","PMC8252052","","10.1111/head.14095"
"32640973","Neuropeptide FF receptor 2 inhibits capsaicin-induced CGRP Upregulation in mouse trigeminal ganglion","Lin YT, Yu Z, Tsai SC, Hsu PH, Chen JC.","J Headache Pain. 2020 Jul 8;21(1):87. doi: 10.1186/s10194-020-01152-z.","Lin YT","J Headache Pain","2020","2020/07/10","PMC7346335","","10.1186/s10194-020-01152-z"
"32276265","NO up-regulates migraine-related CGRP via activation of an Akt/GSK-3β/NF-κB signaling cascade in trigeminal ganglion neurons","Yao G, Man YH, Li AR, Guo Y, Dai Y, Wang P, Zhou YF.","Aging (Albany NY). 2020 Apr 10;12(7):6370-6384. doi: 10.18632/aging.103031. Epub 2020 Apr 10.","Yao G","Aging (Albany NY)","2020","2020/04/11","PMC7185139","","10.18632/aging.103031"
"34813050","Atogepant: First Approval","Deeks ED.","Drugs. 2022 Jan;82(1):65-70. doi: 10.1007/s40265-021-01644-5.","Deeks ED","Drugs","2022","2021/11/23","","","10.1007/s40265-021-01644-5"
"32079247","Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity","Zhu J, Pedersen MD, Ahmed LS, Abdolalizadeh B, Grell AS, Berg JO, Thulstrup PW, Franzyk H, Edvinsson L, Sams A, Sheykhzade M, Hansen PR.","Int J Mol Sci. 2020 Feb 17;21(4):1343. doi: 10.3390/ijms21041343.","Zhu J","Int J Mol Sci","2020","2020/02/22","PMC7072916","","10.3390/ijms21041343"
"30336190","Expression of Pituitary Adenylate Cyclase-activating Peptide, Calcitonin Gene-related Peptide and Headache Targets in the Trigeminal Ganglia of Rats and Humans","Frederiksen SD, Warfvinge K, Ohlsson L, Edvinsson L.","Neuroscience. 2018 Nov 21;393:319-332. doi: 10.1016/j.neuroscience.2018.10.004. Epub 2018 Oct 15.","Frederiksen SD","Neuroscience","2018","2018/10/19","","","10.1016/j.neuroscience.2018.10.004"
"11487512","The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs","Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ.","Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162.","Williamson DJ","Br J Pharmacol","2001","2001/08/07","PMC1572868","","10.1038/sj.bjp.0704162"
"34591982","Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data","Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B, Zhang F, Khodavirdi AC, Mann A, Abdrabboh A, Kalim J.","Headache. 2021 Oct;61(9):1411-1420. doi: 10.1111/head.14208. Epub 2021 Sep 30.","Dodick DW","Headache","2021","2021/09/30","PMC9293040","","10.1111/head.14208"
"21054362","Antimigraine efficacy of telcagepant based on patient's historical triptan response","Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD.","Headache. 2011 Jan;51(1):64-72. doi: 10.1111/j.1526-4610.2010.01790.x. Epub 2010 Nov 4.","Ho TW","Headache","2011","2010/11/09","","","10.1111/j.1526-4610.2010.01790.x"
"22221151","Pharmacological synergy: the next frontier on therapeutic advancement for migraine","Blumenfeld A, Gennings C, Cady R.","Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Epub 2012 Jan 6.","Blumenfeld A","Headache","2012","2012/01/07","","","10.1111/j.1526-4610.2011.02058.x"
"25524408","Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model","Yao G, Han X, Hao T, Huang Q, Yu T.","Neurosci Lett. 2015 Feb 5;587:29-34. doi: 10.1016/j.neulet.2014.12.021. Epub 2014 Dec 15.","Yao G","Neurosci Lett","2015","2014/12/20","","","10.1016/j.neulet.2014.12.021"
"31718551","C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system","Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson L, Haanes KA.","J Headache Pain. 2019 Nov 12;20(1):105. doi: 10.1186/s10194-019-1055-3.","Edvinsson JCA","J Headache Pain","2019","2019/11/14","PMC6852900","","10.1186/s10194-019-1055-3"
"27021026","Expression and function of calcitonin gene-related peptide (CGRP) receptors in trigeminal ganglia of R192Q Cacna1a knock-in mice","Vilotti S, Vana N, Van den Maagdenberg AM, Nistri A.","Neurosci Lett. 2016 May 4;620:104-10. doi: 10.1016/j.neulet.2016.03.046. Epub 2016 Mar 25.","Vilotti S","Neurosci Lett","2016","2016/03/30","","","10.1016/j.neulet.2016.03.046"
"22144717","K(ATP) channel openers in the trigeminovascular system","Ploug KB, Amrutkar DV, Baun M, Ramachandran R, Iversen A, Lund TM, Gupta S, Hay-Schmidt A, Olesen J, Jansen-Olesen I.","Cephalalgia. 2012 Jan;32(1):55-65. doi: 10.1177/0333102411430266. Epub 2011 Dec 5.","Ploug KB","Cephalalgia","2012","2011/12/07","","","10.1177/0333102411430266"
"17477918","Effect of two novel CGRP-binding compounds in a closed cranial window rat model","Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I.","Eur J Pharmacol. 2007 Jul 12;567(1-2):117-24. doi: 10.1016/j.ejphar.2007.04.004. Epub 2007 Apr 14.","Juhl L","Eur J Pharmacol","2007","2007/05/05","","","10.1016/j.ejphar.2007.04.004"
"28884307","The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model","Demartini C, Tassorelli C, Zanaboni AM, Tonsi G, Francesconi O, Nativi C, Greco R.","J Headache Pain. 2017 Sep 7;18(1):94. doi: 10.1186/s10194-017-0804-4.","Demartini C","J Headache Pain","2017","2017/09/09","PMC5589714","","10.1186/s10194-017-0804-4"
"25090640","Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety","Noseda R, Kainz V, Borsook D, Burstein R.","PLoS One. 2014 Aug 4;9(8):e103929. doi: 10.1371/journal.pone.0103929. eCollection 2014.","Noseda R","PLoS One","2014","2014/08/05","PMC4121288","","10.1371/journal.pone.0103929"
"29171821","A Controlled Trial of Erenumab for Episodic Migraine","Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.","N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.","Goadsby PJ","N Engl J Med","2017","2017/11/25","","","10.1056/NEJMoa1705848"
"27919017","Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms","Greco R, Demartini C, Zanaboni AM, Redavide E, Pampalone S, Toldi J, Fülöp F, Blandini F, Nappi G, Sandrini G, Vécsei L, Tassorelli C.","Cephalalgia. 2017 Nov;37(13):1272-1284. doi: 10.1177/0333102416678000. Epub 2016 Nov 16.","Greco R","Cephalalgia","2017","2016/12/06","","","10.1177/0333102416678000"
"33059243","Inhibition of NR2A reduces calcitonin gene-related peptide gene expression induced by cortical spreading depression in rat amygdala","Bu F, Yuan M, Ma D, Zhu Y, Wang M.","Neuropeptides. 2020 Dec;84:102097. doi: 10.1016/j.npep.2020.102097. Epub 2020 Oct 8.","Bu F","Neuropeptides","2020","2020/10/15","","","10.1016/j.npep.2020.102097"
"26559125","Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor","Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C.","J Pharmacol Exp Ther. 2016 Jan;356(1):223-31. doi: 10.1124/jpet.115.227793. Epub 2015 Nov 11.","Shi L","J Pharmacol Exp Ther","2016","2015/11/13","","","10.1124/jpet.115.227793"
"8989773","Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons","Russo AF, Clark MS, Durham PL.","Mol Neurobiol. 1996 Dec;13(3):257-76. doi: 10.1007/BF02740626.","Russo AF","Mol Neurobiol","1996","1996/12/01","","","10.1007/BF02740626"
"34807454","Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study","Gladstone J, Chhibber S, Minhas J, Neish CS, Power GS, Lan Z, Rochdi D, Lanthier-Martel J, Bastien N.","Headache. 2022 Jan;62(1):78-88. doi: 10.1111/head.14218. Epub 2021 Nov 22.","Gladstone J","Headache","2022","2021/11/22","PMC9298790","","10.1111/head.14218"
"26879279","Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R.","Lancet Neurol. 2016 Apr;15(4):382-90. doi: 10.1016/S1474-4422(16)00019-3. Epub 2016 Feb 12.","Sun H","Lancet Neurol","2016","2016/02/17","","","10.1016/S1474-4422(16)00019-3"
"27369815","Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions","Yegutkin GG, Guerrero-Toro C, Kilinc E, Koroleva K, Ishchenko Y, Abushik P, Giniatullina R, Fayuk D, Giniatullin R.","Purinergic Signal. 2016 Sep;12(3):561-74. doi: 10.1007/s11302-016-9521-8. Epub 2016 Jul 1.","Yegutkin GG","Purinergic Signal","2016","2016/07/03","PMC5023636","","10.1007/s11302-016-9521-8"
"20164785","Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries","Lynch JJ Jr, Regan CP, Edvinsson L, Hargreaves RJ, Kane SA.","J Cardiovasc Pharmacol. 2010 May;55(5):518-21. doi: 10.1097/FJC.0b013e3181d7665f.","Lynch JJ Jr","J Cardiovasc Pharmacol","2010","2010/02/19","","","10.1097/FJC.0b013e3181d7665f"
"16240341","Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine","Levy D, Burstein R, Strassman AM.","Ann Neurol. 2005 Nov;58(5):698-705. doi: 10.1002/ana.20619.","Levy D","Ann Neurol","2005","2005/10/22","","","10.1002/ana.20619"
"22528462","Mitogen-activated protein kinase pathways are involved in the upregulation of calcitonin gene-related peptide of rat trigeminal ganglion after organ culture","Lei L, Yuan X, Wang S, Zhang F, Han Y, Ning Q, Luo G, Lu S.","J Mol Neurosci. 2012 Sep;48(1):53-65. doi: 10.1007/s12031-012-9772-y. Epub 2012 Apr 20.","Lei L","J Mol Neurosci","2012","2012/04/25","","","10.1007/s12031-012-9772-y"
"29932027","Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine","Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, Egeo G, Guadagni F.","Curr Med Chem. 2019;26(34):6191-6206. doi: 10.2174/0929867325666180622122938.","Ferroni P","Curr Med Chem","2019","2018/06/23","","","10.2174/0929867325666180622122938"
"31482569","Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine","Kielbasa W, Quinlan T.","J Clin Pharmacol. 2020 Feb;60(2):229-239. doi: 10.1002/jcph.1511. Epub 2019 Sep 4.","Kielbasa W","J Clin Pharmacol","2020","2019/09/05","PMC6972493","","10.1002/jcph.1511"
"17059436","Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine","Gupta S, Akerman S, van den Maagdenberg AM, Saxena PR, Goadsby PJ, van den Brink AM.","Cephalalgia. 2006 Nov;26(11):1294-303. doi: 10.1111/j.1468-2982.2006.01219.x.","Gupta S","Cephalalgia","2006","2006/10/25","","","10.1111/j.1468-2982.2006.01219.x"
"11422090","Neuropeptide localization in the ""migraine generator"" region of the human brainstem","Tajti J, Uddman R, Edvinsson L.","Cephalalgia. 2001 Mar;21(2):96-101. doi: 10.1046/j.1468-2982.2001.00140.x.","Tajti J","Cephalalgia","2001","2001/06/26","","","10.1046/j.1468-2982.2001.00140.x"
"2431789","Multiple transmitter amines and peptides in cerebrovascular nerves: possible links in migraine pathophysiology","Owman C, Hardebo JE.","Cephalalgia. 1986;6 Suppl 4:49-62. doi: 10.1177/03331024860060S406.","Owman C","Cephalalgia","1986","1986/01/01","","","10.1177/03331024860060S406"
"35975575","Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study","Woods RH.","Pharmacotherapy. 2022 Oct;42(10):758-767. doi: 10.1002/phar.2725. Epub 2022 Aug 17.","Woods RH","Pharmacotherapy","2022","2022/08/17","","","10.1002/phar.2725"
"17103145","Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery","Mehrotra S, Gupta S, Garrelds IM, Villalón CM, Saxena PR, Bogers AJ, Maassenvandenbrink A.","Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):163-75. doi: 10.1007/s00210-006-0108-8. Epub 2006 Nov 14.","Mehrotra S","Naunyn Schmiedebergs Arch Pharmacol","2006","2006/11/15","","","10.1007/s00210-006-0108-8"
"1660351","Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine","Buzzi MG, Moskowitz MA.","Cephalalgia. 1991 Sep;11(4):165-8. doi: 10.1046/j.1468-2982.1991.1104165.x.","Buzzi MG","Cephalalgia","1991","1991/09/01","","","10.1046/j.1468-2982.1991.1104165.x"
"31104506","Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models","Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AH, Edvinsson L, MaassenVanDenBrink A.","Cephalalgia. 2019 Oct;39(11):1421-1434. doi: 10.1177/0333102419851810. Epub 2019 May 19.","Haanes KA","Cephalalgia","2019","2019/05/21","","","10.1177/0333102419851810"
"17665333","Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment","Recober A, Russo AF.","IDrugs. 2007 Aug;10(8):566-74.","Recober A","IDrugs","2007","2007/08/01","","",""
"16765548","Familial limb pain in childhood: unusual manifestation of migraine?","Saito Y, Fusayasu E, Iitsuka T, Takeshima T, Ohno K.","Brain Dev. 2006 Nov;28(10):660-2. doi: 10.1016/j.braindev.2006.04.009. Epub 2006 Jun 12.","Saito Y","Brain Dev","2006","2006/06/13","","","10.1016/j.braindev.2006.04.009"
"22607672","MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats","Bell IM, Stump CA, Gallicchio SN, Staas DD, Zartman CB, Moore EL, Sain N, Urban M, Bruno JG, Calamari A, Kemmerer AL, Mosser SD, Fandozzi C, White RB, Zrada MM, Selnick HG, Graham SL, Vacca JP, Kane SA, Salvatore CA.","Bioorg Med Chem Lett. 2012 Jun 15;22(12):3941-5. doi: 10.1016/j.bmcl.2012.04.105. Epub 2012 Apr 30.","Bell IM","Bioorg Med Chem Lett","2012","2012/05/22","","","10.1016/j.bmcl.2012.04.105"
"23965396","BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ.","Cephalalgia. 2014 Feb;34(2):114-25. doi: 10.1177/0333102413500727. Epub 2013 Aug 21.","Marcus R","Cephalalgia","2014","2013/08/23","","","10.1177/0333102413500727"
"22406417","The inhibitory action of the antimigraine nonsteroidal anti-inflammatory drug naproxen on P2X3 receptor-mediated responses in rat trigeminal neurons","Hautaniemi T, Petrenko N, Skorinkin A, Giniatullin R.","Neuroscience. 2012 May 3;209:32-8. doi: 10.1016/j.neuroscience.2012.02.023. Epub 2012 Feb 22.","Hautaniemi T","Neuroscience","2012","2012/03/13","","","10.1016/j.neuroscience.2012.02.023"
"34811955","Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium","Boinpally R, Lu K.","Clin Pharmacol Drug Dev. 2022 Feb;11(2):270-277. doi: 10.1002/cpdd.1034. Epub 2021 Nov 22.","Boinpally R","Clin Pharmacol Drug Dev","2022","2021/11/23","","","10.1002/cpdd.1034"
"20373344","Triptan-induced latent sensitization: a possible basis for medication overuse headache","De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, Dodick DW, Vanderah TW, Dussor G, Porreca F.","Ann Neurol. 2010 Mar;67(3):325-37. doi: 10.1002/ana.21897.","De Felice M","Ann Neurol","2010","2010/04/08","PMC5690477","NIHMS919009","10.1002/ana.21897"
"16106903","[Nitroglycerin-induced headaches]","Juhász G, Zsombók T, Gonda X, Bagdy G.","Orv Hetil. 2004 Nov 14;145(46):2323-8.","Juhász G","Orv Hetil","2004","2005/08/19","","",""
"35790906","Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings","Polavieja P, Belger M, Venkata SK, Wilhelm S, Johansson E.","J Headache Pain. 2022 Jul 6;23(1):76. doi: 10.1186/s10194-022-01440-w.","Polavieja P","J Headache Pain","2022","2022/07/05","PMC9258126","","10.1186/s10194-022-01440-w"
"21040789","Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat","Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K.","Mol Cell Neurosci. 2011 Jan;46(1):333-9. doi: 10.1016/j.mcn.2010.10.005. Epub 2010 Oct 30.","Edvinsson L","Mol Cell Neurosci","2011","2010/11/03","","","10.1016/j.mcn.2010.10.005"
"37085778","Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model","Zeng X, Mai J, Xie H, Yang L, Liu X.","J Headache Pain. 2023 Apr 21;24(1):44. doi: 10.1186/s10194-023-01580-7.","Zeng X","J Headache Pain","2023","2023/04/21","PMC10120244","","10.1186/s10194-023-01580-7"
"30378008","Galcanezumab: First Global Approval","Lamb YN.","Drugs. 2018 Nov;78(16):1769-1775. doi: 10.1007/s40265-018-1002-7.","Lamb YN","Drugs","2018","2018/11/01","","","10.1007/s40265-018-1002-7"
"22652383","Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF","Hoffmann J, Wecker S, Neeb L, Dirnagl U, Reuter U.","Cephalalgia. 2012 Jul;32(9):659-67. doi: 10.1177/0333102412447701. Epub 2012 May 30.","Hoffmann J","Cephalalgia","2012","2012/06/02","","","10.1177/0333102412447701"
"24032687","The role of caveolae in regulating calcitonin receptor-like receptor subcellular distribution in vascular smooth muscle cells","Tang JQ, Sun F, Wang YH, Chen LX, Yao CH, Fu XQ, Zhang L, Qin XP.","Biochem Cell Biol. 2013 Oct;91(5):357-60. doi: 10.1139/bcb-2013-0020. Epub 2013 Jun 5.","Tang JQ","Biochem Cell Biol","2013","2013/09/17","","","10.1139/bcb-2013-0020"
"31913519","Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial","Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM.","Headache. 2020 Jan;60(1):141-152. doi: 10.1111/head.13682.","Ailani J","Headache","2020","2020/01/09","PMC7004213","","10.1111/head.13682"
"32920850","Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine","Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.","Headache. 2020 Oct;60(9):2014-2025. doi: 10.1111/head.13951. Epub 2020 Sep 13.","Robblee J","Headache","2020","2020/09/13","","","10.1111/head.13951"
"36967387","Prolactin and oxytocin: potential targets for migraine treatment","Szewczyk AK, Ulutas S, Aktürk T, Al-Hassany L, Börner C, Cernigliaro F, Kodounis M, Lo Cascio S, Mikolajek D, Onan D, Ragaglini C, Ratti S, Rivera-Mancilla E, Tsanoula S, Villino R, Messlinger K, Maassen Van Den Brink A, de Vries T; European Headache Federation School of Advanced Studies (EHF-SAS).","J Headache Pain. 2023 Mar 27;24(1):31. doi: 10.1186/s10194-023-01557-6.","Szewczyk AK","J Headache Pain","2023","2023/03/26","PMC10041814","","10.1186/s10194-023-01557-6"
"24609082","Methylation of migraine-related genes in different tissues of the rat","Labruijere S, Stolk L, Verbiest M, de Vries R, Garrelds IM, Eilers PH, Danser AH, Uitterlinden AG, MaassenVanDenBrink A.","PLoS One. 2014 Mar 7;9(3):e87616. doi: 10.1371/journal.pone.0087616. eCollection 2014.","Labruijere S","PLoS One","2014","2014/03/11","PMC3946422","","10.1371/journal.pone.0087616"
"10199623","Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro","Ebersberger A, Averbeck B, Messlinger K, Reeh PW.","Neuroscience. 1999 Mar;89(3):901-7. doi: 10.1016/s0306-4522(98)00366-2.","Ebersberger A","Neuroscience","1999","1999/04/13","","","10.1016/s0306-4522(98)00366-2"
"31327684","Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report","Aradi S, Kaiser E, Cucchiara B.","J Stroke Cerebrovasc Dis. 2019 Oct;28(10):104286. doi: 10.1016/j.jstrokecerebrovasdis.2019.07.002. Epub 2019 Jul 18.","Aradi S","J Stroke Cerebrovasc Dis","2019","2019/07/23","","","10.1016/j.jstrokecerebrovasdis.2019.07.002"
"24508136","PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor","Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J.","Neuropeptides. 2014 Apr;48(2):53-64. doi: 10.1016/j.npep.2014.01.004. Epub 2014 Jan 25.","Jansen-Olesen I","Neuropeptides","2014","2014/02/11","","","10.1016/j.npep.2014.01.004"
"30324723","Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents","Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA.","Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15.","Szperka CL","Headache","2018","2018/10/17","PMC6258331","NIHMS989503","10.1111/head.13414"
"19812328","Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study","Charbit AR, Akerman S, Holland PR, Goadsby PJ.","J Neurosci. 2009 Oct 7;29(40):12532-41. doi: 10.1523/JNEUROSCI.2887-09.2009.","Charbit AR","J Neurosci","2009","2009/10/09","PMC6665099","","10.1523/JNEUROSCI.2887-09.2009"
"32969035","Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study","Alex A, Vaughn C, Rayhill M.","Headache. 2020 Nov;60(10):2454-2462. doi: 10.1111/head.13956. Epub 2020 Sep 23.","Alex A","Headache","2020","2020/09/24","","","10.1111/head.13956"
"36153693","2022 Taiwan Guidelines for Acute Treatment of Migraine","Lau CI, Wang YF; Treatment Guideline Subcommittee of the Taiwan Headache Society.","Acta Neurol Taiwan. 2022 Jun 30;31(2):89-113.","Lau CI","Acta Neurol Taiwan","2022","2022/09/25","","",""
"10524656","Effect of cortical spreading depression on activity of trigeminovascular sensory neurons","Lambert GA, Michalicek J, Storer RJ, Zagami AS.","Cephalalgia. 1999 Sep;19(7):631-8. doi: 10.1046/j.1468-2982.1999.019007631.x.","Lambert GA","Cephalalgia","1999","1999/10/19","","","10.1046/j.1468-2982.1999.019007631.x"
"18397647","[A new therapeutic principle for migraine]","Ashina M, Jensen RH.","Ugeskr Laeger. 2008 Mar 17;170(12):1029.","Ashina M","Ugeskr Laeger","2008","2008/04/10","","",""
"37957603","Progesterone distribution in the trigeminal system and its role to modulate sensory neurotransmission: influence of sex","Maddahi A, Warfvinge K, Holm A, Edvinsson JCA, Reducha PV, Kazantzi S, Haanes KA, Edvinsson L.","J Headache Pain. 2023 Nov 14;24(1):154. doi: 10.1186/s10194-023-01687-x.","Maddahi A","J Headache Pain","2023","2023/11/14","PMC10644471","","10.1186/s10194-023-01687-x"
"31889312","The Headache Pipeline: Excitement and Uncertainty","Rapoport AM, McAllister P.","Headache. 2020 Jan;60(1):190-199. doi: 10.1111/head.13728. Epub 2019 Dec 30.","Rapoport AM","Headache","2020","2020/01/01","","","10.1111/head.13728"
"16160082","Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception","Holland PR, Akerman S, Goadsby PJ.","J Pharmacol Exp Ther. 2005 Dec;315(3):1380-5. doi: 10.1124/jpet.105.090951. Epub 2005 Sep 13.","Holland PR","J Pharmacol Exp Ther","2005","2005/09/15","","","10.1124/jpet.105.090951"
"37101198","Acetaldehyde via CGRP receptor and TRPA1 in Schwann cells mediates ethanol-evoked periorbital mechanical allodynia in mice: relevance for migraine","Landini L, Souza Monteiro de Araujo D, Chieca M, De Siena G, Bellantoni E, Geppetti P, Nassini R, De Logu F.","J Biomed Sci. 2023 Apr 26;30(1):28. doi: 10.1186/s12929-023-00922-6.","Landini L","J Biomed Sci","2023","2023/04/26","PMC10131321","","10.1186/s12929-023-00922-6"
"30768945","Mechanosensitive meningeal nociception via Piezo channels: Implications for pulsatile pain in migraine?","Mikhailov N, Leskinen J, Fagerlund I, Poguzhelskaya E, Giniatullina R, Gafurov O, Malm T, Karjalainen T, Gröhn O, Giniatullin R.","Neuropharmacology. 2019 May 1;149:113-123. doi: 10.1016/j.neuropharm.2019.02.015. Epub 2019 Feb 13.","Mikhailov N","Neuropharmacology","2019","2019/02/16","","","10.1016/j.neuropharm.2019.02.015"
"32558564","Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine","Bucknell SJ, Ator MA, Brown AJH, Brown J, Cansfield AD, Cansfield JE, Christopher JA, Congreve M, Cseke G, Deflorian F, Jones CR, Mason JS, O'Brien MA, Ott GR, Pickworth M, Southall SM.","J Med Chem. 2020 Jul 23;63(14):7906-7920. doi: 10.1021/acs.jmedchem.0c01003. Epub 2020 Jul 8.","Bucknell SJ","J Med Chem","2020","2020/06/20","","","10.1021/acs.jmedchem.0c01003"
"33205382","Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine","Andreou AP, Leese C, Greco R, Demartini C, Corrie E, Simsek D, Zanaboni A, Koroleva K, Lloyd JO, Lambru G, Doran C, Gafurov O, Seward E, Giniatullin R, Tassorelli C, Davletov B.","Neurotherapeutics. 2021 Jan;18(1):556-568. doi: 10.1007/s13311-020-00967-7. Epub 2020 Nov 17.","Andreou AP","Neurotherapeutics","2021","2020/11/18","PMC8116399","","10.1007/s13311-020-00967-7"
"31985052","Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine","Riggins N, Ehrlich A, Sawhney H, Dapkus L, Levin M.","Headache. 2020 Mar;60(3):617-620. doi: 10.1111/head.13756. Epub 2020 Jan 27.","Riggins N","Headache","2020","2020/01/28","","","10.1111/head.13756"
"9203569","The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation","Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ.","Eur J Pharmacol. 1997 Jun 5;328(1):61-4. doi: 10.1016/s0014-2999(97)83028-2.","Williamson DJ","Eur J Pharmacol","1997","1997/06/05","","","10.1016/s0014-2999(97)83028-2"
"17300362","Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin","Gupta S, Villalón CM, Mehrotra S, de Vries R, Garrelds IM, Saxena PR, MaassenVanDenbrink A.","Headache. 2007 Feb;47(2):225-35. doi: 10.1111/j.1526-4610.2006.00526.x.","Gupta S","Headache","2007","2007/02/16","","","10.1111/j.1526-4610.2006.00526.x"
"24405707","Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists","Joshi P, Anderson C, Binch H, Hadida S, Yoo S, Bergeron D, Decker C, terHaar E, Moore J, Garcia-Guzman M, Termin A.","Bioorg Med Chem Lett. 2014 Feb 1;24(3):845-9. doi: 10.1016/j.bmcl.2013.12.089. Epub 2013 Dec 26.","Joshi P","Bioorg Med Chem Lett","2014","2014/01/11","","","10.1016/j.bmcl.2013.12.089"
"11075845","Intranasal civamide for the acute treatment of migraine headache","Diamond S, Freitag F, Phillips SB, Bernstein JE, Saper JR.","Cephalalgia. 2000 Jul;20(6):597-602. doi: 10.1046/j.1468-2982.2000.00088.x.","Diamond S","Cephalalgia","2000","2000/11/15","","","10.1046/j.1468-2982.2000.00088.x"
"34289083","Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors","Garelja ML, Bower RL, Brimble MA, Chand S, Harris PWR, Jamaluddin MA, Petersen J, Siow A, Walker CS, Hay DL.","Br J Pharmacol. 2022 Feb;179(3):416-434. doi: 10.1111/bph.15628. Epub 2021 Oct 15.","Garelja ML","Br J Pharmacol","2022","2021/07/21","PMC8776895","NIHMS1742484","10.1111/bph.15628"
"20188075","Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding","Moore EL, Gingell JJ, Kane SA, Hay DL, Salvatore CA.","Biochem Biophys Res Commun. 2010 Mar 26;394(1):141-5. doi: 10.1016/j.bbrc.2010.02.131. Epub 2010 Feb 24.","Moore EL","Biochem Biophys Res Commun","2010","2010/03/02","","","10.1016/j.bbrc.2010.02.131"
"28025094","Serotonergic mechanisms of trigeminal meningeal nociception: Implications for migraine pain","Kilinc E, Guerrero-Toro C, Zakharov A, Vitale C, Gubert-Olive M, Koroleva K, Timonina A, Luz LL, Shelukhina I, Giniatullina R, Tore F, Safronov BV, Giniatullin R.","Neuropharmacology. 2017 Apr;116:160-173. doi: 10.1016/j.neuropharm.2016.12.024. Epub 2016 Dec 23.","Kilinc E","Neuropharmacology","2017","2016/12/28","","","10.1016/j.neuropharm.2016.12.024"
"34526307","Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial","Ramsden CE, Zamora D, Faurot KR, MacIntosh B, Horowitz M, Keyes GS, Yuan ZX, Miller V, Lynch C, Honvoh G, Park J, Levy R, Domenichiello AF, Johnston A, Majchrzak-Hong S, Hibbeln JR, Barrow DA, Loewke J, Davis JM, Mannes A, Palsson OS, Suchindran CM, Gaylord SA, Mann JD.","BMJ. 2021 Jun 30;374:n1448. doi: 10.1136/bmj.n1448.","Ramsden CE","BMJ","2021","2021/09/16","PMC8244542","","10.1136/bmj.n1448"
"15546258","Chemokine levels in the jugular venous blood of migraine without aura patients during attacks","Sarchielli P, Alberti A, Vaianella L, Pierguidi L, Floridi A, Mazzotta G, Floridi A, Gallai V.","Headache. 2004 Nov-Dec;44(10):961-8. doi: 10.1111/j.1526-4610.2004.04189.x.","Sarchielli P","Headache","2004","2004/11/18","","","10.1111/j.1526-4610.2004.04189.x"
"32096556","Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis","Ornello R, Frattale I, Pistoia F, Sacco S, Notturno F.","Headache. 2020 Apr;60(4):787-788. doi: 10.1111/head.13779. Epub 2020 Feb 25.","Ornello R","Headache","2020","2020/02/26","","","10.1111/head.13779"
"29344989","Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats","Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G, Tore F.","Clin Exp Pharmacol Physiol. 2018 Jun;45(6):536-546. doi: 10.1111/1440-1681.12915. Epub 2018 Feb 13.","Kilinc E","Clin Exp Pharmacol Physiol","2018","2018/01/19","","","10.1111/1440-1681.12915"
"32651400","Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant","Tang C, Unekawa M, Kitagawa S, Takizawa T, Kayama Y, Nakahara J, Shibata M.","Sci Rep. 2020 Jul 10;10(1):11408. doi: 10.1038/s41598-020-67948-w.","Tang C","Sci Rep","2020","2020/07/12","PMC7351983","","10.1038/s41598-020-67948-w"
"34407343","Atogepant for the Preventive Treatment of Migraine","Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group.","N Engl J Med. 2021 Aug 19;385(8):695-706. doi: 10.1056/NEJMoa2035908.","Ailani J","N Engl J Med","2021","2021/08/18","","","10.1056/NEJMoa2035908"
"28430869","Inhibition of the P2X7-PANX1 complex suppresses spreading depolarization and neuroinflammation","Chen SP, Qin T, Seidel JL, Zheng Y, Eikermann M, Ferrari MD, van den Maagdenberg AMJM, Moskowitz MA, Ayata C, Eikermann-Haerter K.","Brain. 2017 Jun 1;140(6):1643-1656. doi: 10.1093/brain/awx085.","Chen SP","Brain","2017","2017/04/22","PMC7526725","","10.1093/brain/awx085"
"31742631","Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial","Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM.","JAMA. 2019 Nov 19;322(19):1887-1898. doi: 10.1001/jama.2019.16711.","Lipton RB","JAMA","2019","2019/11/20","PMC6865323","","10.1001/jama.2019.16711"
"10658626","Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells","Wotherspoon G, Priestley JV.","Neuroscience. 2000;95(2):465-71. doi: 10.1016/s0306-4522(99)00465-0.","Wotherspoon G","Neuroscience","2000","2000/02/05","","","10.1016/s0306-4522(99)00465-0"
"31899602","Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males","Ankrom W, Bondiskey P, Li CC, Palcza J, Liu W, Dockendorf MF, Matthews C, Panebianco D, Reynders T, Wagner JA, Jakate A, Mesens S, Kraft WK, Marcantonio EE.","Clin Transl Sci. 2020 May;13(3):462-472. doi: 10.1111/cts.12728. Epub 2020 Jan 3.","Ankrom W","Clin Transl Sci","2020","2020/01/04","PMC7214647","","10.1111/cts.12728"
"16702835","Are headache disorders caused by neurobiological mechanisms?","Olesen J.","Curr Opin Neurol. 2006 Jun;19(3):277-80. doi: 10.1097/01.wco.0000227038.77952.ed.","Olesen J","Curr Opin Neurol","2006","2006/05/17","","","10.1097/01.wco.0000227038.77952.ed"
"12574409","Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons","Durham PL, Russo AF.","J Neurosci. 2003 Feb 1;23(3):807-15. doi: 10.1523/JNEUROSCI.23-03-00807.2003.","Durham PL","J Neurosci","2003","2003/02/08","PMC6741928","","10.1523/JNEUROSCI.23-03-00807.2003"
"31722730","P2Y12 receptor mediates microglial activation via RhoA/ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine","Jing F, Zhang Y, Long T, He W, Qin G, Zhang D, Chen L, Zhou J.","J Neuroinflammation. 2019 Nov 13;16(1):217. doi: 10.1186/s12974-019-1603-4.","Jing F","J Neuroinflammation","2019","2019/11/15","PMC6854723","","10.1186/s12974-019-1603-4"
"12044622","ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE(2) release in isolated rat dura mater","Zimmermann K, Reeh PW, Averbeck B.","Pain. 2002 Jun;97(3):259-265. doi: 10.1016/S0304-3959(02)00027-1.","Zimmermann K","Pain","2002","2002/06/05","","","10.1016/S0304-3959(02)00027-1"
"27155150","Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies","Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C, Edvinsson L.","Neuroscience. 2016 Jul 22;328:165-83. doi: 10.1016/j.neuroscience.2016.04.046. Epub 2016 May 4.","Miller S","Neuroscience","2016","2016/05/08","","","10.1016/j.neuroscience.2016.04.046"
"18186028","Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution","Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K.","J Comp Neurol. 2008 Mar 20;507(3):1277-99. doi: 10.1002/cne.21607.","Lennerz JK","J Comp Neurol","2008","2008/01/11","","","10.1002/cne.21607"
"32990832","Chronic Cluster Headache Update and East-West Comparisons: Focusing on Clinical Features, Pathophysiology, and Management","Tsai CL, Lin GY, Wu SK, Yang FC, Wang SJ.","Curr Pain Headache Rep. 2020 Sep 29;24(11):68. doi: 10.1007/s11916-020-00902-7.","Tsai CL","Curr Pain Headache Rep","2020","2020/09/29","","","10.1007/s11916-020-00902-7"
"21389219","Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain","Ceruti S, Villa G, Fumagalli M, Colombo L, Magni G, Zanardelli M, Fabbretti E, Verderio C, van den Maagdenberg AM, Nistri A, Abbracchio MP.","J Neurosci. 2011 Mar 9;31(10):3638-49. doi: 10.1523/JNEUROSCI.6440-10.2011.","Ceruti S","J Neurosci","2011","2011/03/11","PMC6622774","","10.1523/JNEUROSCI.6440-10.2011"
"23798725","Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine","Depré M, Macleod C, Palcza J, Behm M, de Lepeleire I, Han T, Panebianco D, Smith W, Blanchard R, Chodakewitz J, Murphy M, de Hoon J.","Cephalalgia. 2013 Dec;33(16):1292-301. doi: 10.1177/0333102413494272. Epub 2013 Jun 24.","Depré M","Cephalalgia","2013","2013/06/27","","","10.1177/0333102413494272"
"33827963","Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine: A Randomized Crossover Study","Ghanizada H, Al-Karagholi MA, Arngrim N, Mørch-Rasmussen M, Walker CS, Hay DL, Ashina M.","Neurology. 2021 May 18;96(20):e2488-e2499. doi: 10.1212/WNL.0000000000011930. Epub 2021 Apr 7.","Ghanizada H","Neurology","2021","2021/04/08","","","10.1212/WNL.0000000000011930"
"33129939","Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine","Greco R, Demartini C, Zanaboni A, Casini I, De Icco R, Reggiani A, Misto A, Piomelli D, Tassorelli C.","Neurobiol Dis. 2021 Jan;147:105157. doi: 10.1016/j.nbd.2020.105157. Epub 2020 Oct 28.","Greco R","Neurobiol Dis","2021","2020/11/01","","","10.1016/j.nbd.2020.105157"
"11301492","Neurogenic inflammation in the context of migraine","Williamson DJ, Hargreaves RJ.","Microsc Res Tech. 2001 May 1;53(3):167-78. doi: 10.1002/jemt.1081.","Williamson DJ","Microsc Res Tech","2001","2001/04/13","","","10.1002/jemt.1081"
"28527051","New treatments for headache","Maasumi K, Tepper SJ, Rapoport AM.","Neurol Sci. 2017 May;38(Suppl 1):145-156. doi: 10.1007/s10072-017-2910-0.","Maasumi K","Neurol Sci","2017","2017/05/21","","","10.1007/s10072-017-2910-0"
"17635592","Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology","Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL.","Headache. 2007 Jul-Aug;47(7):1008-23; discussion 24-5. doi: 10.1111/j.1526-4610.2007.00854.x.","Thalakoti S","Headache","2007","2007/07/20","PMC2268711","NIHMS41593","10.1111/j.1526-4610.2007.00854.x"
"20627971","Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers","De Felice M, Ossipov MH, Wang R, Dussor G, Lai J, Meng ID, Chichorro J, Andrews JS, Rakhit S, Maddaford S, Dodick D, Porreca F.","Brain. 2010 Aug;133(Pt 8):2475-88. doi: 10.1093/brain/awq159. Epub 2010 Jul 13.","De Felice M","Brain","2010","2010/07/15","PMC3139937","","10.1093/brain/awq159"
"32573795","Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans","Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A.","Headache. 2020 Jul;60(7):1340-1350. doi: 10.1111/head.13862. Epub 2020 Jun 23.","Jakate A","Headache","2020","2020/06/24","PMC7496299","","10.1111/head.13862"
"30143795","Evidence mounts for anti-CGRP treatment in cluster headache","Leone M.","Nat Rev Neurol. 2018 Nov;14(11):636-637. doi: 10.1038/s41582-018-0063-2.","Leone M","Nat Rev Neurol","2018","2018/08/26","","","10.1038/s41582-018-0063-2"
"32304441","Posttraumatic headache: recent progress","Howard L, Schwedt TJ.","Curr Opin Neurol. 2020 Jun;33(3):316-322. doi: 10.1097/WCO.0000000000000815.","Howard L","Curr Opin Neurol","2020","2020/04/19","","","10.1097/WCO.0000000000000815"
"37632682","New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment","Sadeghpour M, Abdolizadeh A, Yousefi P, Rastegar-Kashkouli A, Chitsaz A.","Curr Pain Headache Rep. 2023 Oct;27(10):551-559. doi: 10.1007/s11916-023-01161-y. Epub 2023 Aug 26.","Sadeghpour M","Curr Pain Headache Rep","2023","2023/08/26","","","10.1007/s11916-023-01161-y"
"31852816","Vascular safety of erenumab for migraine prevention","Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, Hong F, Klatt J, Zhang F, Cheng S, Picard H, Eisele O, Wang J, Latham JN, Mikol DD.","Neurology. 2020 Feb 4;94(5):e497-e510. doi: 10.1212/WNL.0000000000008743. Epub 2019 Dec 18.","Kudrow D","Neurology","2020","2019/12/20","PMC7080286","","10.1212/WNL.0000000000008743"
"36648786","Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster: A Review","Diener HC, Tassorelli C, Dodick DW.","JAMA Neurol. 2023 Mar 1;80(3):308-319. doi: 10.1001/jamaneurol.2022.4804.","Diener HC","JAMA Neurol","2023","2023/01/17","","","10.1001/jamaneurol.2022.4804"
"26763044","Laboratory tests of headache disorders - dawn of a new era?","Schytz HW, Olesen J.","Cephalalgia. 2016 Nov;36(13):1268-1290. doi: 10.1177/0333102415612585. Epub 2016 Jul 11.","Schytz HW","Cephalalgia","2016","2016/01/15","","","10.1177/0333102415612585"
"32867531","Refractory short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing responsive to anti-calcitonin gene-related peptide monoclonal antibodies: A case report","Bsteh G, Bsteh C, Broessner G.","Cephalalgia. 2021 Jan;41(1):127-130. doi: 10.1177/0333102420954558. Epub 2020 Aug 31.","Bsteh G","Cephalalgia","2021","2020/09/02","","","10.1177/0333102420954558"
"31266456","Emerging evidence of occipital nerve compression in unremitting head and neck pain","Blake P, Burstein R.","J Headache Pain. 2019 Jul 2;20(1):76. doi: 10.1186/s10194-019-1023-y.","Blake P","J Headache Pain","2019","2019/07/04","PMC6734343","","10.1186/s10194-019-1023-y"
"32297990","Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants","Ankrom W, Xu J, Vallee MH, Dockendorf MF, Armas D, Boinpally R, Min KC.","J Clin Pharmacol. 2020 Sep;60(9):1157-1165. doi: 10.1002/jcph.1610. Epub 2020 Apr 16.","Ankrom W","J Clin Pharmacol","2020","2020/04/17","PMC7496689","","10.1002/jcph.1610"
"38111226","Biomarkers in cluster headache: A systematic review","Søborg MK, Jensen RH, Barloese M, Petersen AS.","Headache. 2024 Jan;64(1):98-116. doi: 10.1111/head.14641. Epub 2023 Dec 18.","Søborg MK","Headache","2024","2023/12/19","","","10.1111/head.14641"
"9344563","Plasma protein extravasation induced in the rat dura mater by stimulation of the parasympathetic sphenopalatine ganglion","Delépine L, Aubineau P.","Exp Neurol. 1997 Oct;147(2):389-400. doi: 10.1006/exnr.1997.6614.","Delépine L","Exp Neurol","1997","1997/11/05","","","10.1006/exnr.1997.6614"
"27786243","New strategies for the treatment and prevention of primary headache disorders","Schuster NM, Rapoport AM.","Nat Rev Neurol. 2016 Oct 27;12(11):635-650. doi: 10.1038/nrneurol.2016.143.","Schuster NM","Nat Rev Neurol","2016","2016/10/28","","","10.1038/nrneurol.2016.143"
"16688612","Novel therapeutic targets","Geppetti P, Trevisani M, Nicoletti P, Capone JG.","Neurol Sci. 2006 May;27 Suppl 2:S111-4. doi: 10.1007/s10072-006-0583-1.","Geppetti P","Neurol Sci","2006","2006/05/12","","","10.1007/s10072-006-0583-1"
"34125320","Models for Treating Post-traumatic Headache","Kamins J.","Curr Pain Headache Rep. 2021 Jun 14;25(8):52. doi: 10.1007/s11916-021-00970-3.","Kamins J","Curr Pain Headache Rep","2021","2021/06/14","PMC8203551","","10.1007/s11916-021-00970-3"
"33142014","Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults","Min KC, Kraft WK, Bondiskey P, Colón-González F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R.","Clin Transl Sci. 2021 Mar;14(2):599-605. doi: 10.1111/cts.12917. Epub 2020 Nov 24.","Min KC","Clin Transl Sci","2021","2020/11/03","PMC7993278","","10.1111/cts.12917"
"18973738","Advances in the pharmacologic treatment of tension-type headache","Bigal ME, Rapoport AM, Hargreaves R.","Curr Pain Headache Rep. 2008 Dec;12(6):442-6. doi: 10.1007/s11916-008-0075-5.","Bigal ME","Curr Pain Headache Rep","2008","2008/11/01","","","10.1007/s11916-008-0075-5"
"33709972","Medication overuse headache","Green MW.","Curr Opin Neurol. 2021 Jun 1;34(3):378-383. doi: 10.1097/WCO.0000000000000925.","Green MW","Curr Opin Neurol","2021","2021/03/12","","","10.1097/WCO.0000000000000925"
"33448373","Peptides, MAbs, Molecules, Mechanisms, and More: Taking a Stab at Cluster Headache","Joshi S.","Headache. 2020 Sep;60(8):1871-1877. doi: 10.1111/head.13909. Epub 2020 Jul 23.","Joshi S","Headache","2020","2021/01/15","","","10.1111/head.13909"
"11301495","Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model","Knyihár-Csillik E, Tajti J, Chadaide Z, Csillik B, Vécsei L.","Microsc Res Tech. 2001 May 1;53(3):193-211. doi: 10.1002/jemt.1084.","Knyihár-Csillik E","Microsc Res Tech","2001","2001/04/13","","","10.1002/jemt.1084"
"21893556","Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse","Mathew R, Andreou AP, Chami L, Bergerot A, van den Maagdenberg AM, Ferrari MD, Goadsby PJ.","Cephalalgia. 2011 Oct;31(13):1368-80. doi: 10.1177/0333102411418847. Epub 2011 Sep 5.","Mathew R","Cephalalgia","2011","2011/09/07","","","10.1177/0333102411418847"
"27454989","Advances in the understanding of cluster headache","Leone M, Proietti Cecchini A.","Expert Rev Neurother. 2017 Feb;17(2):165-172. doi: 10.1080/14737175.2016.1216796. Epub 2016 Aug 8.","Leone M","Expert Rev Neurother","2017","2016/07/26","","","10.1080/14737175.2016.1216796"
"18494989","Biological markers of cervicogenic headache","Frese A, Evers S.","Cephalalgia. 2008 Jul;28 Suppl 1:21-3. doi: 10.1111/j.1468-2982.2008.01613.x.","Frese A","Cephalalgia","2008","2008/06/14","","","10.1111/j.1468-2982.2008.01613.x"
"15853622","Nerve growth factor and chronic daily headache: a potential implication for therapy","Sarchielli P, Gallai V.","Expert Rev Neurother. 2004 Jan;4(1):115-27. doi: 10.1586/14737175.4.1.115.","Sarchielli P","Expert Rev Neurother","2004","2005/04/28","","","10.1586/14737175.4.1.115"
"33206562","Drug profile: galcanezumab for prevention of cluster headache","Mudugal D, Monteith TS.","Expert Rev Neurother. 2021 Feb;21(2):145-155. doi: 10.1080/14737175.2021.1852931. Epub 2020 Dec 8.","Mudugal D","Expert Rev Neurother","2021","2020/11/18","","","10.1080/14737175.2021.1852931"
"36792216","Clinical Profile of Chronic Cluster Headaches in a Regional Headache Center in Japan","Kikui S, Danno D, Takeshima T.","Intern Med. 2023;62(4):519-525. doi: 10.2169/internalmedicine.9557-22. Epub 2023 Feb 15.","Kikui S","Intern Med","2023","2023/02/15","PMC10017249","","10.2169/internalmedicine.9557-22"
"16109051","Calcitonin gene-related peptide in cervicogenic headache","Frese A, Schilgen M, Edvinsson L, Frandsen E, Evers S.","Cephalalgia. 2005 Sep;25(9):700-3. doi: 10.1111/j.1468-2982.2004.00940.x.","Frese A","Cephalalgia","2005","2005/08/20","","","10.1111/j.1468-2982.2004.00940.x"
"15914251","Neurobiology in primary headaches","Edvinsson L, Uddman R.","Brain Res Brain Res Rev. 2005 Jun;48(3):438-56. doi: 10.1016/j.brainresrev.2004.09.007. Epub 2004 Nov 18.","Edvinsson L","Brain Res Brain Res Rev","2005","2005/05/26","","","10.1016/j.brainresrev.2004.09.007"
"32077327","Enhanced post-traumatic headache-like behaviors and diminished contribution of peripheral CGRP in female rats following a mild closed head injury","Bree D, Mackenzie K, Stratton J, Levy D.","Cephalalgia. 2020 Jun;40(7):748-760. doi: 10.1177/0333102420907597. Epub 2020 Feb 20.","Bree D","Cephalalgia","2020","2020/02/21","PMC7525829","NIHMS1631747","10.1177/0333102420907597"
"26590611","Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders","Tzabazis A, Mechanic J, Miller J, Klukinov M, Pascual C, Manering N, Carson DS, Jacobs A, Qiao Y, Cuellar J, Frey WH 2nd, Jacobs D, Angst M, Yeomans DC.","Cephalalgia. 2016 Sep;36(10):943-50. doi: 10.1177/0333102415618615. Epub 2015 Nov 20.","Tzabazis A","Cephalalgia","2016","2015/11/23","","","10.1177/0333102415618615"
"33199891","Making headway - a role for CGRP in post-traumatic headache","Mitsikostas DD, Moskowitz MA.","Nat Rev Neurol. 2021 Mar;17(3):133-134. doi: 10.1038/s41582-020-00431-2.","Mitsikostas DD","Nat Rev Neurol","2021","2020/11/17","","","10.1038/s41582-020-00431-2"
"24117004","Pathophysiology of medication overuse headache--an update","Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ.","Headache. 2014 Jan;54(1):204-10. doi: 10.1111/head.12224. Epub 2013 Oct 3.","Srikiatkhachorn A","Headache","2014","2013/10/15","","","10.1111/head.12224"
"33340486","Headache research in 2020: disrupting and improving practice","Goadsby PJ.","Lancet Neurol. 2021 Jan;20(1):7-8. doi: 10.1016/S1474-4422(20)30457-9.","Goadsby PJ","Lancet Neurol","2021","2020/12/19","","","10.1016/S1474-4422(20)30457-9"
"32600065","Increased severity of closed head injury or repetitive subconcussive head impacts enhances post-traumatic headache-like behaviors in a rat model","Bree D, Stratton J, Levy D.","Cephalalgia. 2020 Oct;40(11):1224-1239. doi: 10.1177/0333102420937664. Epub 2020 Jun 29.","Bree D","Cephalalgia","2020","2020/07/01","PMC7541737","NIHMS1631743","10.1177/0333102420937664"
"35315067","Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature","Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B.","Headache. 2022 Mar;62(3):329-362. doi: 10.1111/head.14284.","Medrea I","Headache","2022","2022/03/22","","","10.1111/head.14284"
"28281109","Neuropeptides as a Marker for Chronic Headache","Riesco N, Cernuda-Morollón E, Pascual J.","Curr Pain Headache Rep. 2017 Apr;21(4):18. doi: 10.1007/s11916-017-0618-8.","Riesco N","Curr Pain Headache Rep","2017","2017/03/11","","","10.1007/s11916-017-0618-8"
"9117375","Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients","Fanciullacci M, Alessandri M, Sicuteri R, Marabini S.","Brain. 1997 Feb;120 ( Pt 2):283-8. doi: 10.1093/brain/120.2.283.","Fanciullacci M","Brain","1997","1997/02/01","","","10.1093/brain/120.2.283"
"29516437","Therapeutic Approaches for the Management of Trigeminal Autonomic Cephalalgias","Wei DY, Jensen RH.","Neurotherapeutics. 2018 Apr;15(2):346-360. doi: 10.1007/s13311-018-0618-3.","Wei DY","Neurotherapeutics","2018","2018/03/09","PMC5935647","","10.1007/s13311-018-0618-3"
"26017524","Emerging treatments for the primary headache disorders","Schuster NM, Vollbracht S, Rapoport AM.","Neurol Sci. 2015 May;36 Suppl 1:109-13. doi: 10.1007/s10072-015-2133-1.","Schuster NM","Neurol Sci","2015","2015/05/29","","","10.1007/s10072-015-2133-1"
"12806133","Calcitonin gene-related peptide in tension-type headache","Ashina M.","ScientificWorldJournal. 2002 Jun 7;2:1527-31. doi: 10.1100/tsw.2002.808.","Ashina M","ScientificWorldJournal","2002","2003/06/14","PMC6009354","","10.1100/tsw.2002.808"
"22644186","The therapeutic future in headache","Rapoport AM.","Neurol Sci. 2012 May;33 Suppl 1:S119-25. doi: 10.1007/s10072-012-1056-3.","Rapoport AM","Neurol Sci","2012","2012/05/31","","","10.1007/s10072-012-1056-3"
"32209808","Evolving options for the treatment of cluster headache","Villar-Martinez MD, Chan C, Goadsby PJ.","Curr Opin Neurol. 2020 Jun;33(3):323-328. doi: 10.1097/WCO.0000000000000808.","Villar-Martinez MD","Curr Opin Neurol","2020","2020/03/27","","","10.1097/WCO.0000000000000808"
"29904827","A new era in headache treatment","Vikelis M, Spingos KC, Rapoport AM.","Neurol Sci. 2018 Jun;39(Suppl 1):47-58. doi: 10.1007/s10072-018-3337-y.","Vikelis M","Neurol Sci","2018","2018/06/16","","","10.1007/s10072-018-3337-y"
"28527055","Cluster headache: present and future therapy","Leone M, Giustiniani A, Cecchini AP.","Neurol Sci. 2017 May;38(Suppl 1):45-50. doi: 10.1007/s10072-017-2924-7.","Leone M","Neurol Sci","2017","2017/05/21","","","10.1007/s10072-017-2924-7"
"36323303","Refractory Headaches","Begasse de Dhaem O, Rizzoli P.","Semin Neurol. 2022 Aug;42(4):512-522. doi: 10.1055/s-0042-1757925. Epub 2022 Nov 2.","Begasse de Dhaem O","Semin Neurol","2022","2022/11/02","","","10.1055/s-0042-1757925"
"32511056","Cluster headache therapies: pharmacology and mode of action","Mecklenburg J, Sanchez Del Rio M, Reuter U.","Expert Rev Clin Pharmacol. 2020 Jun;13(6):641-654. doi: 10.1080/17512433.2020.1774361. Epub 2020 Jun 8.","Mecklenburg J","Expert Rev Clin Pharmacol","2020","2020/06/09","","","10.1080/17512433.2020.1774361"
"31595486","Circulating CGRP levels in medication-overuse headache","Pascual J.","Acta Neurol Scand. 2020 Apr;141(4):355-356. doi: 10.1111/ane.13176. Epub 2019 Oct 28.","Pascual J","Acta Neurol Scand","2020","2019/10/10","","","10.1111/ane.13176"
"7540279","Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack","Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S.","Pain. 1995 Feb;60(2):119-123. doi: 10.1016/0304-3959(94)00097-X.","Fanciullacci M","Pain","1995","1995/02/01","","","10.1016/0304-3959(94)00097-X"
"29987329","Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial","Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, Ashina M.","JAMA Neurol. 2018 Oct 1;75(10):1187-1197. doi: 10.1001/jamaneurol.2018.1675.","Vollesen ALH","JAMA Neurol","2018","2018/07/11","PMC6233850","","10.1001/jamaneurol.2018.1675"
"30457160","Circulating nociceptin and CGRP in medication-overuse headache","Munksgaard SB, Ertsey C, Frandsen E, Bendtsen L, Tekes K, Jensen RH.","Acta Neurol Scand. 2019 Mar;139(3):269-275. doi: 10.1111/ane.13053. Epub 2018 Dec 11.","Munksgaard SB","Acta Neurol Scand","2019","2018/11/21","","","10.1111/ane.13053"
"32689824","Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury","Ashina H, Al-Khazali HM, Iljazi A, Ashina S, Jørgensen NR, Amin FM, Ashina M, Schytz HW.","Cephalalgia. 2020 Oct;40(12):1276-1282. doi: 10.1177/0333102420941115. Epub 2020 Jul 20.","Ashina H","Cephalalgia","2020","2020/07/22","","","10.1177/0333102420941115"
"31550910","CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice","Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F.","Cephalalgia. 2019 Dec;39(14):1762-1775. doi: 10.1177/0333102419877662. Epub 2019 Sep 24.","Navratilova E","Cephalalgia","2019","2019/09/26","","","10.1177/0333102419877662"
"32847402","Baseline tear fluid CGRP is elevated in active cluster headache patients as long as they have not taken attack abortive medication","Kamm K, Straube A, Ruscheweyh R.","Cephalalgia. 2021 Jan;41(1):69-77. doi: 10.1177/0333102420949858. Epub 2020 Aug 26.","Kamm K","Cephalalgia","2021","2020/08/28","","","10.1177/0333102420949858"
"25790126","Photophobia in primary headaches","Rossi HL, Recober A.","Headache. 2015 Apr;55(4):600-4. doi: 10.1111/head.12532. Epub 2015 Mar 19.","Rossi HL","Headache","2015","2015/03/20","PMC4459705","NIHMS655844","10.1111/head.12532"
"32689825","The analysis of calcitonin gene-related peptide - a narrow path between useful and misleading findings","Hoffmann J.","Cephalalgia. 2020 Oct;40(12):1271-1273. doi: 10.1177/0333102420941114. Epub 2020 Jul 20.","Hoffmann J","Cephalalgia","2020","2020/07/22","PMC7605040","","10.1177/0333102420941114"
"28856479","Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment","Ashina H, Newman L, Ashina S.","Neurol Sci. 2017 Dec;38(12):2089-2093. doi: 10.1007/s10072-017-3101-8. Epub 2017 Aug 30.","Ashina H","Neurol Sci","2017","2017/09/01","","","10.1007/s10072-017-3101-8"
"38436282","Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study","Petersen AS, Lund N, Meßlinger K, Christensen SL, Barloese M, Jørgensen NR, Kogelman L, Jensen RH.","Cephalalgia. 2024 Mar;44(3):3331024231223970. doi: 10.1177/03331024231223970.","Petersen AS","Cephalalgia","2024","2024/03/04","","","10.1177/03331024231223970"
"32790533","Use of CGRP receptor blocker erenumab in the management of post-traumatic headache: a case series of 5 women","VanderEnde J, Bateman EA, MacKenzie HM, Sequeira K.","Brain Inj. 2020 Aug 23;34(10):1431-1434. doi: 10.1080/02699052.2020.1807052. Epub 2020 Aug 13.","VanderEnde J","Brain Inj","2020","2020/08/14","","","10.1080/02699052.2020.1807052"
"30820761","Anti-CGRP in cluster headache therapy","Giani L, Proietti Cecchini A, Leone M.","Neurol Sci. 2019 May;40(Suppl 1):129-135. doi: 10.1007/s10072-019-03786-7.","Giani L","Neurol Sci","2019","2019/03/02","","","10.1007/s10072-019-03786-7"
"34390103","Type of headache at onset and risk for complications in reversible cerebral vasoconstriction syndrome","Lange KS, Forster O, Mawet J, Tuloup G, Burcin C, Corti L, Duflos C, Roos C, Ducros A.","Eur J Neurol. 2022 Jan;29(1):130-137. doi: 10.1111/ene.15064. Epub 2021 Aug 24.","Lange KS","Eur J Neurol","2022","2021/08/14","","","10.1111/ene.15064"
"29174963","Diagnosis, pathophysiology, and management of cluster headache","Hoffmann J, May A.","Lancet Neurol. 2018 Jan;17(1):75-83. doi: 10.1016/S1474-4422(17)30405-2. Epub 2017 Nov 23.","Hoffmann J","Lancet Neurol","2018","2017/11/28","","","10.1016/S1474-4422(17)30405-2"
"31339562","Verapamil and Cluster Headache: Still a Mystery. A Narrative Review of Efficacy, Mechanisms and Perspectives","Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH.","Headache. 2019 Sep;59(8):1198-1211. doi: 10.1111/head.13603. Epub 2019 Jul 24.","Petersen AS","Headache","2019","2019/07/25","","","10.1111/head.13603"
"33243037","Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion","Argyriou AA, Vikelis M, Mantovani E, Litsardopoulos P, Tamburin S.","Expert Rev Neurother. 2021 Feb;21(2):235-248. doi: 10.1080/14737175.2021.1857240. Epub 2020 Dec 17.","Argyriou AA","Expert Rev Neurother","2021","2020/11/27","","","10.1080/14737175.2021.1857240"
"12421159","Hyperbaric oxygen treatment of active cluster headache: a double-blind placebo-controlled cross-over study","Nilsson Remahl AI, Ansjön R, Lind F, Waldenlind E.","Cephalalgia. 2002 Nov;22(9):730-9. doi: 10.1046/j.1468-2982.2002.00450.x.","Nilsson Remahl AI","Cephalalgia","2002","2002/11/08","","","10.1046/j.1468-2982.2002.00450.x"
"32806953","Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts","Ruscheweyh R, Broessner G, Goßrau G, Heinze-Kuhn K, Jürgens TP, Kaltseis K, Kamm K, Peikert A, Raffaelli B, Rimmele F, Evers S.","Cephalalgia. 2020 Dec;40(14):1574-1584. doi: 10.1177/0333102420949866. Epub 2020 Aug 17.","Ruscheweyh R","Cephalalgia","2020","2020/08/19","PMC7691634","","10.1177/0333102420949866"
"27206958","Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents","Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F.","Cephalalgia. 2017 May;37(6):560-570. doi: 10.1177/0333102416650702. Epub 2016 May 19.","Kopruszinski CM","Cephalalgia","2017","2016/05/22","","","10.1177/0333102416650702"
"31053055","Therapeutic strategies that act on the peripheral nervous system in primary headache disorders","Tajti J, Szok D, Nyári A, Vécsei L.","Expert Rev Neurother. 2019 Jun;19(6):509-533. doi: 10.1080/14737175.2019.1615447. Epub 2019 May 13.","Tajti J","Expert Rev Neurother","2019","2019/05/05","","","10.1080/14737175.2019.1615447"
"32504377","Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache","Scott LJ.","Drugs. 2020 Jun;80(9):893-904. doi: 10.1007/s40265-020-01329-5.","Scott LJ","Drugs","2020","2020/06/07","","","10.1007/s40265-020-01329-5"
"37431108","2022 Taiwan Guidelines for Acute and Preventive Treatment of Cluster Headaches","Yang FC, Tsai CL, Lin GY; Treatment Guidelines Subcommittee of the Taiwan Headache Society.","Acta Neurol Taiwan. 2022 Dec 30;31(4):254-273.","Yang FC","Acta Neurol Taiwan","2022","2023/07/11","","",""
"34266608","The neurobiology of cluster headache","Leone M, Ferraro S, Proietti Cecchini A.","Handb Clin Neurol. 2021;182:401-414. doi: 10.1016/B978-0-12-819973-2.00027-7.","Leone M","Handb Clin Neurol","2021","2021/07/16","","","10.1016/B978-0-12-819973-2.00027-7"
"32548854","S100B and NSE in Cluster Headache - Evidence for Glial Cell Activation?","Snoer AH, Vollesen ALH, Beske RP, Guo S, Hoffmann J, Jørgensen NR, Martinussen T, Ashina M, Jensen RH.","Headache. 2020 Sep;60(8):1569-1580. doi: 10.1111/head.13864. Epub 2020 Jun 16.","Snoer AH","Headache","2020","2020/06/18","","","10.1111/head.13864"
"31724752","Headache and Methemoglobinemia","Khan FA, McIntyre C, Khan AM, Maslov A.","Headache. 2020 Jan;60(1):291-297. doi: 10.1111/head.13696. Epub 2019 Nov 14.","Khan FA","Headache","2020","2019/11/15","","","10.1111/head.13696"
"12662182","Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid","Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P.","Cephalalgia. 2003 Apr;23(3):166-74. doi: 10.1046/j.1468-2982.2003.00552.x.","Gallai V","Cephalalgia","2003","2003/03/29","","","10.1046/j.1468-2982.2003.00552.x"
"7518321","Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies","Goadsby PJ, Edvinsson L.","Brain. 1994 Jun;117 ( Pt 3):427-34. doi: 10.1093/brain/117.3.427.","Goadsby PJ","Brain","1994","1994/06/01","","","10.1093/brain/117.3.427"
"32493206","Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study","Ashina H, Iljazi A, Al-Khazali HM, Eigenbrodt AK, Larsen EL, Andersen AM, Hansen KJ, Bräuner KB, Mørch-Jessen T, Chaudhry B, Antic S, Christensen CE, Ashina M, Amin FM, Schytz HW.","J Headache Pain. 2020 Jun 3;21(1):62. doi: 10.1186/s10194-020-01136-z.","Ashina H","J Headache Pain","2020","2020/06/05","PMC7271543","","10.1186/s10194-020-01136-z"
"32845493","Anti-CGRP monoclonal antibodies in cluster headache: what can we learn from recent clinical trials","Giani L, Proietti Cecchini A, Leone M.","Neurol Sci. 2020 Dec;41(Suppl 2):485-486. doi: 10.1007/s10072-020-04668-z.","Giani L","Neurol Sci","2020","2020/08/27","","","10.1007/s10072-020-04668-z"
"33782592","Cluster headache pathophysiology - insights from current and emerging treatments","Wei DY, Goadsby PJ.","Nat Rev Neurol. 2021 May;17(5):308-324. doi: 10.1038/s41582-021-00477-w. Epub 2021 Mar 29.","Wei DY","Nat Rev Neurol","2021","2021/03/30","","","10.1038/s41582-021-00477-w"
"24958681","Corticosteroids alter CGRP and melatonin release in cluster headache episodes","Neeb L, Anders L, Euskirchen P, Hoffmann J, Israel H, Reuter U.","Cephalalgia. 2015 Apr;35(4):317-26. doi: 10.1177/0333102414539057. Epub 2014 Jun 23.","Neeb L","Cephalalgia","2015","2014/06/25","","","10.1177/0333102414539057"
"34822741","PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation","Pellesi L, Chaudhry BA, Vollesen ALH, Snoer AH, Baumann K, Skov PS, Jensen RH, Ashina M.","Cephalalgia. 2022 Jul;42(8):687-695. doi: 10.1177/03331024211056248. Epub 2021 Nov 25.","Pellesi L","Cephalalgia","2022","2021/11/25","","","10.1177/03331024211056248"
"34919214","Drug Treatment of Cluster Headache","Diener HC, May A.","Drugs. 2022 Jan;82(1):33-42. doi: 10.1007/s40265-021-01658-z. Epub 2021 Dec 17.","Diener HC","Drugs","2022","2021/12/17","PMC8748342","","10.1007/s40265-021-01658-z"
"1689282","Substance P theory: a unique focus on the painful and painless phenomena of cluster headache","Sicuteri F, Fanciullacci M, Nicolodi M, Geppetti P, Fusco BM, Marabini S, Alessandri M, Campagnolo V.","Headache. 1990 Jan;30(2):69-79. doi: 10.1111/j.1526-4610.1990.hed3002069.x.","Sicuteri F","Headache","1990","1990/01/01","","","10.1111/j.1526-4610.1990.hed3002069.x"
"29794878","Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns","Buonvicino D, Urru M, Muzzi M, Ranieri G, Luceri C, Oteri C, Lapucci A, Chiarugi A.","Pain. 2018 Oct;159(10):1980-1988. doi: 10.1097/j.pain.0000000000001291.","Buonvicino D","Pain","2018","2018/05/26","","","10.1097/j.pain.0000000000001291"
"37796114","Plasma calcitonin gene-related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion","Scher AI, McGinley JS, VanDam LR, Campbell AM, Chai X, Collins B, Klimp SA, Finkel AG, Schwab K, Lipton RB, Johnson KW.","Headache. 2023 Oct;63(9):1240-1250. doi: 10.1111/head.14635. Epub 2023 Oct 5.","Scher AI","Headache","2023","2023/10/05","","","10.1111/head.14635"
"33316102","Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation","Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z, Grech O, Lavery GG, Mollan SP, Sinclair AJ.","Headache. 2021 Jan;61(1):157-169. doi: 10.1111/head.14026. Epub 2020 Dec 14.","Yiangou A","Headache","2021","2020/12/14","PMC7898289","","10.1111/head.14026"
"7585922","Neuropeptides in the cerebral circulation: relevance to headache","Edvinsson L, Goadsby PJ.","Cephalalgia. 1995;15(4):272-6. doi: 10.1046/j.1468-2982.1995.1504272.x.","Edvinsson L","Cephalalgia","1995","1995/01/01","","","10.1046/j.1468-2982.1995.1504272.x"
"19259966","Medullary pain facilitating neurons mediate allodynia in headache-related pain","Edelmayer RM, Vanderah TW, Majuta L, Zhang ET, Fioravanti B, De Felice M, Chichorro JG, Ossipov MH, King T, Lai J, Kori SH, Nelsen AC, Cannon KE, Heinricher MM, Porreca F.","Ann Neurol. 2009 Feb;65(2):184-93. doi: 10.1002/ana.21537.","Edelmayer RM","Ann Neurol","2009","2009/03/05","PMC2772103","NIHMS74709","10.1002/ana.21537"
"32959458","Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache","Ashina H, Iljazi A, Al-Khazali HM, Christensen CE, Amin FM, Ashina M, Schytz HW.","Ann Neurol. 2020 Dec;88(6):1220-1228. doi: 10.1002/ana.25915. Epub 2020 Oct 6.","Ashina H","Ann Neurol","2020","2020/09/22","","","10.1002/ana.25915"
"11087777","Plasma levels of calcitonin gene-related peptide in chronic tension-type headache","Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J.","Neurology. 2000 Nov 14;55(9):1335-40. doi: 10.1212/wnl.55.9.1335.","Ashina M","Neurology","2000","2000/11/23","","","10.1212/wnl.55.9.1335"
"27054429","An Analysis of Neuropeptides at Nasal Contact Points of Patients With Secondary Headache","Demir D, Cengiz N, Güven M, Bulduk O.","J Craniofac Surg. 2016 May;27(3):e305-9. doi: 10.1097/SCS.0000000000002553.","Demir D","J Craniofac Surg","2016","2016/04/08","","","10.1097/SCS.0000000000002553"
"37940864","Medication overuse headache is associated with elevated lipopolysaccharide binding protein and pro-inflammatory molecules in the bloodstream","Dağıdır HG, Topa E, Vuralli D, Bolay H.","J Headache Pain. 2023 Nov 8;24(1):150. doi: 10.1186/s10194-023-01672-4.","Dağıdır HG","J Headache Pain","2023","2023/11/08","PMC10631084","","10.1186/s10194-023-01672-4"
"7520365","Nostril capsaicin application as a model of trigeminal primary sensory neuronal activation","Nicolodi M.","Cephalalgia. 1994 Apr;14(2):134-8. doi: 10.1046/j.1468-2982.1994.1402134.x.","Nicolodi M","Cephalalgia","1994","1994/04/01","","","10.1046/j.1468-2982.1994.1402134.x"
"23065481","A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization","Akerman S, Holland PR, Summ O, Lasalandra MP, Goadsby PJ.","Brain. 2012 Dec;135(Pt 12):3664-75. doi: 10.1093/brain/aws249. Epub 2012 Oct 11.","Akerman S","Brain","2012","2012/10/16","","","10.1093/brain/aws249"
"22076674","Pathophysiology of medication-overuse headache: implications from animal studies","Bongsebandhu-phubhakdi S, Srikiatkhachorn A.","Curr Pain Headache Rep. 2012 Feb;16(1):110-5. doi: 10.1007/s11916-011-0234-y.","Bongsebandhu-phubhakdi S","Curr Pain Headache Rep","2012","2011/11/15","","","10.1007/s11916-011-0234-y"
"35674077","From basic mechanisms to therapeutic perspectives in cluster headache","Moreno-Ajona D, Hoffmann J.","Curr Opin Neurol. 2022 Jun 1;35(3):336-342. doi: 10.1097/WCO.0000000000001055.","Moreno-Ajona D","Curr Opin Neurol","2022","2022/06/08","","","10.1097/WCO.0000000000001055"
"27301459","Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses","Marics B, Peitl B, Varga A, Pázmándi K, Bácsi A, Németh J, Szilvássy Z, Jancsó G, Dux M.","Cephalalgia. 2017 May;37(6):581-591. doi: 10.1177/0333102416654883. Epub 2016 Jun 14.","Marics B","Cephalalgia","2017","2016/06/16","","","10.1177/0333102416654883"
"29523978","PACAP and its role in primary headaches","Edvinsson L, Tajti J, Szalárdy L, Vécsei L.","J Headache Pain. 2018 Mar 9;19(1):21. doi: 10.1186/s10194-018-0852-4.","Edvinsson L","J Headache Pain","2018","2018/03/11","PMC5845082","","10.1186/s10194-018-0852-4"
"7991067","Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache","Bach FW, Langemark M, Ekman R, Rehfeld JF, Schifter S, Olesen J.","Neuropeptides. 1994 Aug;27(2):129-36. doi: 10.1016/0143-4179(94)90053-1.","Bach FW","Neuropeptides","1994","1994/08/01","","","10.1016/0143-4179(94)90053-1"
"15030536","Circulating nociceptin levels during the cluster headache period","Ertsey C, Hantos M, Bozsik G, Tekes K.","Cephalalgia. 2004 Apr;24(4):280-3. doi: 10.1111/j.1468-2982.2004.00664.x.","Ertsey C","Cephalalgia","2004","2004/03/20","","","10.1111/j.1468-2982.2004.00664.x"
"7515383","""Capsaicin-sensitive"" sensory neurons in cluster headache: pathophysiological aspects and therapeutic indication","Fusco BM, Fiore G, Gallo F, Martelletti P, Giacovazzo M.","Headache. 1994 Mar;34(3):132-7. doi: 10.1111/j.1526-4610.1994.hed3403132.x.","Fusco BM","Headache","1994","1994/03/01","","","10.1111/j.1526-4610.1994.hed3403132.x"
"32050782","Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment","Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T.","Cephalalgia. 2020 Aug;40(9):935-948. doi: 10.1177/0333102420905321. Epub 2020 Feb 12.","Dodick DW","Cephalalgia","2020","2020/02/14","PMC7787002","","10.1177/0333102420905321"
"27300190","[Botulinum toxin type A in headache treatment : Established and experimental indications]","Gaul C, Holle-Lee D, Straube A.","Nervenarzt. 2016 Aug;87(8):853-9. doi: 10.1007/s00115-016-0138-5.","Gaul C","Nervenarzt","2016","2016/06/15","","","10.1007/s00115-016-0138-5"
"35700873","Histone Deacetylase Inhibitors Counteract CGRP Signaling and Pronociceptive Sensitization in a Rat Model of Medication Overuse Headache","Urru M, Buonvicino D, Pistolesi A, Paccosi S, Chiarugi A.","J Pain. 2022 Nov;23(11):1874-1884. doi: 10.1016/j.jpain.2022.05.007. Epub 2022 Jun 11.","Urru M","J Pain","2022","2022/06/14","","","10.1016/j.jpain.2022.05.007"
"11284996","Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache","Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J.","Eur J Neurol. 2001 Mar;8(2):173-8. doi: 10.1046/j.1468-1331.2001.00191.x.","Ashina M","Eur J Neurol","2001","2001/04/04","","","10.1046/j.1468-1331.2001.00191.x"
"21352213","5-HT(1D) receptor immunoreactivity in the sphenopalatine ganglion: implications for the efficacy of triptans in the treatment of autonomic signs associated with cluster headache","Ivanusic JJ, Kwok MMK, Ahn AH, Jennings EA.","Headache. 2011 Mar;51(3):392-402. doi: 10.1111/j.1526-4610.2011.01843.x.","Ivanusic JJ","Headache","2011","2011/03/01","PMC3073163","NIHMS267318","10.1111/j.1526-4610.2011.01843.x"
"33290608","Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives","Courault P, Demarquay G, Zimmer L, Lancelot S.","Fundam Clin Pharmacol. 2021 Jun;35(3):595-619. doi: 10.1111/fcp.12636. Epub 2020 Dec 24.","Courault P","Fundam Clin Pharmacol","2021","2020/12/08","","","10.1111/fcp.12636"
"1722915","[Neurogenic malregulation of microcirculation as a cause of chronic pain]","Zimmermann M.","Vasa Suppl. 1991;32:572-88.","Zimmermann M","Vasa Suppl","1991","1991/01/01","","",""
"30854880","Calcitonin-gene related peptide and disease activity in cluster headache","Snoer A, Vollesen ALH, Beske RP, Guo S, Hoffmann J, Fahrenkrug J, Jørgensen NR, Martinussen T, Jensen RH, Ashina M.","Cephalalgia. 2019 Apr;39(5):575-584. doi: 10.1177/0333102419837154. Epub 2019 Mar 9.","Snoer A","Cephalalgia","2019","2019/03/12","","","10.1177/0333102419837154"
"7697703","Spontaneous and 5HT-induced cyclic contractions in superficial temporal arteries from chronic and episodic cluster headache patients","Mathiau P, Brochet B, Boulan P, Henry P, Aubineau P.","Cephalalgia. 1994 Dec;14(6):419-29; discussion 393. doi: 10.1046/j.1468-2982.1994.1406419.x.","Mathiau P","Cephalalgia","1994","1994/12/01","","","10.1046/j.1468-2982.1994.1406419.x"
"33615840","CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache","Kopruszinski CM, Turnes JM, Swiokla J, Weinstein TJ, Schwedt TJ, Dodick DW, Anderson T, Navratilova E, Porreca F.","Cephalalgia. 2021 May;41(6):749-759. doi: 10.1177/0333102420981688. Epub 2021 Feb 20.","Kopruszinski CM","Cephalalgia","2021","2021/02/22","","","10.1177/0333102420981688"
"32615788","Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache","Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F.","Cephalalgia. 2020 Aug;40(9):892-902. doi: 10.1177/0333102420938652. Epub 2020 Jul 2.","Navratilova E","Cephalalgia","2020","2020/07/04","PMC7412872","","10.1177/0333102420938652"
"27899434","Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache","Bree D, Levy D.","Cephalalgia. 2018 Feb;38(2):246-258. doi: 10.1177/0333102416681571. Epub 2016 Dec 7.","Bree D","Cephalalgia","2018","2016/12/01","PMC6454269","NIHMS1021325","10.1177/0333102416681571"
"34030566","Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs","Piccinni C, Cevoli S, Ronconi G, Dondi L, Calabria S, Pedrini A, Maggioni AP, Esposito I, Addesi A, Favoni V, Pierangeli G, Cortelli P, Martini N.","Expert Rev Clin Pharmacol. 2021 Sep;14(9):1165-1171. doi: 10.1080/17512433.2021.1934448. Epub 2021 May 31.","Piccinni C","Expert Rev Clin Pharmacol","2021","2021/05/25","","","10.1080/17512433.2021.1934448"
"34806783","Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment","Láinez MJA, Schoenen J, Stroud C, Bardos J, Bangs M, Kemmer P, Wenzel R, Kuruppu DK, Martinez JM, Oakes TM.","Headache. 2022 Jan;62(1):65-77. doi: 10.1111/head.14234. Epub 2021 Nov 22.","Láinez MJA","Headache","2022","2021/11/22","PMC9299588","","10.1111/head.14234"
"1717660","Anatomical basis for a parasympathetic and sensory innervation of the intracranial segment of the internal carotid artery in man. Possible implication for vascular headache","Suzuki N, Hardebo JE.","J Neurol Sci. 1991 Jul;104(1):19-31. doi: 10.1016/0022-510x(91)90211-o.","Suzuki N","J Neurol Sci","1991","1991/07/01","","","10.1016/0022-510x(91)90211-o"
"26751129","Challenges in developing drugs for primary headaches","Schytz HW, Hargreaves R, Ashina M.","Prog Neurobiol. 2017 May;152:70-88. doi: 10.1016/j.pneurobio.2015.12.005. Epub 2016 Jan 2.","Schytz HW","Prog Neurobiol","2017","2016/01/12","","","10.1016/j.pneurobio.2015.12.005"
"31291515","Trial of Galcanezumab in Prevention of Episodic Cluster Headache","Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.","N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.","Goadsby PJ","N Engl J Med","2019","2019/07/11","","","10.1056/NEJMoa1813440"
